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Abstract 
Nuclear medicine is a functional imaging modality involving the administration of 
a radioactive material and the imaging of its distribution within the body.  
Planar nuclear medicine imaging has been used for many years in the evaluation 
of patients with disorders of the parathyroid and thyroid glands.  Single photon 
emission computed tomography (SPECT) can also be carried out.  This is a three-
dimensional nuclear medicine imaging technique that gives both increased image 
contrast due to the separation of overlying structures and improved information 
on lesion localisation. 
Currently, there is no definitive procedure for parathyroid imaging, which is 
primarily used for localisation of adenomas or hyperplastic glands in patients 
with hyperparathyroidism.  This information can be used to assist during surgery 
to remove the overactive glands.  Some centres use a single-isotope, dual-phase 
technique with 99mTc-Sestamibi, whilst others use a dual-isotope subtraction 
technique with either 99mTc-pertechnetate or 123I-iodide to outline the thyroid.  
Single-isotope SPECT is used in some institutions but there is little information 
on the use of dual-isotope subtraction SPECT. 
Thyroid imaging with either 99mTc-pertechnetate or 123I-iodide is used to 
characterise thyroid disorders.  The thyroid uptake can also be calculated using 
planar images, which can assist in clinical decision making for patients with 
hyper- or hypothyroidism.  SPECT is not commonly used in thyroid imaging at 
present. 
This study was carried out in the Department of Nuclear Medicine, Glasgow 
Royal Infirmary (GRI) and was split into two distinct sections, the first being an 
assessment of the utility of dual-isotope subtraction SPECT for localisation of 
parathyroid adenomas and the second being an evaluation of the use of SPECT 
imaging for calculating thyroid uptake.  A custom designed and built phantom 
was used to assess the feasibility of parathyroid and thyroid SPECT imaging and 
to establish suitable acquisition parameters.  The results from the phantom work 
demonstrated that the techniques were viable and so patient SPECT data 
collection was commenced. 
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A total of 32 patients with hyperparathyroidism underwent dual-isotope SPECT 
imaging in addition to routine planar imaging.  The SPECT images were then 
reconstructed and a subtraction SPECT data set was produced.  An observer 
study was then carried out with 5 experienced observers independently 
reviewing the images in 4 phases.  In phase 1, only the dual-isotope subtraction 
planar images were available for review.  Phase 2 was comprised of only dual-
isotope subtraction SPECT images, whilst phase 3 involved review of single-
isotope 99mTc-Sestamibi planar and SPECT images in the absence of 123I-iodide 
thyroid images.  Finally, in phase 4, all of the acquired planar and SPECT images 
were available for review. 
The patients’ case notes were interrogated to obtain information on the surgical 
and histological reports of excised glands.  A total of 17 of the 32 patients had 
surgery and the results were compared to the findings from the observer study 
to determine which type of images provided the most useful clinical 
information.  The results of any ultrasound imaging were also obtained to 
compare with the surgical findings. 
The total number of lesions seen by the observers was higher when dual-isotope 
subtraction SPECT images were part of the review than when they were not, 
with totals in phases 1-4 of 89, 183, 89 and 155, respectively.  The calculated 
sensitivities relative to the surgical gold standard for phases 1-4 were 49%, 77%, 
45% & 64%, respectively, with ultrasound having a sensitivity of 72% for 
comparison.  Dual-isotope subtraction SPECT therefore has a clear advantage 
over planar imaging for detection and localisation of parathyroid adenomas.  The 
specificities for phases 1-4 were calculated as 61%, 31%, 29% & 27%, with the 
specificity for ultrasound being 33%.  These specificities are, however, 
unreliable due to the fact that only 2 true negatives were recorded from 
surgery. 
This study showed a clear improvement in the sensitivity of dual-isotope 
subtraction SPECT imaging over planar imaging for the detection and localisation 
of parathyroid adenomas, as well as more detailed localisation information being 
available from the 3D images.  As a result, clinical practice in the department 
has been changed and all patients now routinely undergo dual-isotope 
subtraction SPECT imaging. 
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SPECT imaging with 99mTc-pertechnetate was carried out on 57 patients with 
thyroid disorders.  The images were reconstructed with and without the 
inclusion of attenuation correction and the thyroid uptake was calculated by 
drawing a region of interest on each slice and summing the counts within each 
region.  A standard acquisition was also carried out to allow accurate 
quantification to be performed.  These uptake values were compared to those 
from planar imaging.  Similar analysis was performed on images of a phantom to 
determine the accuracy of the patient uptake measurements. 
The various uptake values calculated from the phantom images were all similar 
and were slightly lower than the “true” uptake value.  However, there were 
significant differences demonstrated between the SPECT and planar uptake 
values from the patient images with the SPECT uptake tending to be higher.  The 
reasons for this are not immediately clear but are most likely related to the 
difference in time between injection and imaging for the planar and SPECT 
acquisitions at 24.5 ± 8.0 minutes (mean ± 1SD) and 71.5 ± 17.5 minutes 
respectively. 
Significant differences seen between the calculated uptake values from SPECT 
and planar images in the patient data sets were not evident in the phantom 
work, indicating that some physiological effect resulting in changing thyroid 
uptake over time was not taken into account.  Further work could be undertaken 
to characterise this effect, but the method used to calculate the uptake from 
SPECT images is too cumbersome to be used routinely.  Therefore, no change in 
clinical practice is anticipated for the calculation of thyroid uptake. 
This study has therefore resulted in a change of clinical practice for parathyroid 
imaging at GRI, with the introduction of dual-isotope subtraction SPECT 
routinely.  Thyroid imaging remains unchanged, however, with the thyroid 
uptake being calculated from planar images. 
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Chapter 1 – Introduction 
1.1 The Thyroid and Parathyroid Glands – Anatomy and 
Physiology 
The thyroid and parathyroid glands form part of the body’s endocrine system and 
produce hormones that provide important regulatory functions.  Both types of 
gland are subject to disorders that can lead to either an increase or decrease in 
hormone levels within the body, and hence an imbalance in the regulatory 
function.  Nuclear medicine imaging can be used to visualise the function of the 
thyroid and parathyroid glands in an attempt to assist in diagnosis, 
characterisation or localisation of such disorders. 
1.1.1 The Thyroid Gland 
The thyroid gland is located in the anterior aspect of the neck, lying over the 
anterior surface of the trachea (Martini, 2001).  Figure 1.1 shows the typical 
size, shape and position of the gland, which is composed of two lobes – left and 
right – which are connected via a thin central isthmus.  The thyroid gland 
produces thyroid hormones which are active in the regulation of overall 
metabolic rate within the cells of the body and so are vital for growth and 
mental development (Berne & Levy, 1993, Martini, 2001, Longmore et al., 2007).  
The function of the thyroid gland is itself regulated by the secretion of thyroid 
stimulating hormone (TSH) from the pituitary gland, which is situated in the 
brain (Moore & Agur, 2007). 
The thyroid is composed of a large number of follicles, consisting of rings of cells 
enclosing a follicular cavity, as shown in Figure 1.2.  Thyroid hormones are 
synthesised and then stored in a colloid within the follicular cavities.  When 
stimulated by TSH, the hormones are released into the blood stream and 
transported around the body, where they bind with receptors within cells (Berne 
& Levy, 1993, Martini, 2001).  This then results in a variety of different 
metabolic actions depending on the target tissue. 
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Figure 1.1 - Normal location of the thyroid gland 
Diagrammatic view of the typical size, shape and position of the thyroid gland in the neck. 
There are two main hormones produced and secreted by the thyroid gland – 
thyroxine (also known as T4) and triiodothyronine (or T3).  T4 accounts for 
approximately 90% of thyroid hormone production, with the remaining 10% being 
T3 (Martini, 2001).  Iodine is a key component of both T3 and T4 and so the 
thyroid actively concentrates around one-third of dietary iodine (Sharp et al., 
1998), although the exact proportion will vary depending on the amount of 
 
Figure 1.2 - Structure of the thyroid gland 
Magnified diagrammatic view of the thyroid gland showing follicle cells surrounding the 
follicular cavities, within which thyroid hormones are synthesised and stored. 
iodine in the diet.  The thyroid will typically utilise 70µg - 80µg of iodine in the 
production of T3 and T4 on a daily basis (Berne & Levy, 1993).  Production of 
thyroid hormones can be affected if there is a deficiency of dietary iodine, 
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although this is uncommon in developed countries.  Excess iodine is primarily 
excreted in the urine via the kidneys (Martini, 2001). 
Thyroid tissue may also be present in ectopic locations and can be found at any 
point between the anterior mediastinum and the base of the tongue (Sharp et 
al., 1998), as shown in Figure 1.3.  In most cases, normally functioning ectopic 
thyroid tissue causes no problems but it may on occasion be responsible for 
constriction of other tissues (e.g. the trachea) or difficulty in swallowing. 
 
Figure 1.3 - Some potential ectopic locations for thyroid tissue 
Thyroid tissue can be present throughout the neck and upper mediastinum. 
Disorders of the thyroid gland related to increased or decreased production and 
secretion of thyroid hormones are discussed in Section 1.2.1 below. 
1.1.2 The Parathyroid Glands 
The parathyroid glands are very small and are usually located on the posterior 
surface of the thyroid, as shown in Figure 1.4.  There are normally four glands in 
total, with two behind each thyroid lobe, one superior and one inferior (Moore & 
Agur, 2007) with a combined total mass of around 1.6g (Martini, 2001). 
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Figure 1.4 - Typical location of the parathyroid glands 
Posterior view of the thyroid gland showing the normal positions of the four parathyroid 
glands – superior and inferior relative to each of the thyroid lobes. 
However, it is relatively common for there to be any number between 2 and 6 
glands (Moore & Agur, 2007) and for one or more to be located ectopically, away 
from the thyroid (Thomas & Wishart, 2003).  Like the thyroid, parathyroid tissue 
can be found anywhere from the base of the tongue to the mediastinum, with 
the most common ectopic location being around the thymus (Sharp et al., 1998).  
Some typical ectopic locations are shown in Figure 1.5. 
The glands are composed of two types of cells: oxyphils and chief cells, the 
latter of which produce and secrete parathyroid hormone or parathormone 
(PTH).  PTH is responsible for controlling the levels of calcium and phosphorus in 
the blood (Moore & Agur, 2007) and therefore helps to regulate serum calcium 
levels and maintain calcium and vitamin D homeostasis (Hindié et al., 2009). 
PTH is secreted by the parathyroids via a feedback mechanism in response to 
low serum Ca2+ levels.  It acts by increasing osteoclast activity in the bones to 
increase release of Ca2+ and PO4
3- from the bones to the bloodstream and 
increases reabsorption of Ca2+ in the kidney (Longmore et al., 2007).  Osteoblast 
activity within the bones is also inhibited, meaning that the rate of calcium 
deposition in bone is reduced (Martini, 2001). 
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Figure 1.5 - Normal and ectopic locations of parathyroid glands 
Typical locations of ectopic parathyroid glands in the sub-lingual region, around the thymus 
and retrosternally in the mediastinum. 
Increased or decreased production and secretion of PTH by the parathyroid 
glands will therefore lead to an imbalance in serum calcium levels.  Such 
disorders and their resultant effects are discussed further in Section 1.2.2 
below. 
1.2 Disorders of the Thyroid and Parathyroid Glands 
1.2.1 Disorders of the Thyroid Gland 
There are a number of disorders that can affect the thyroid gland and the 
production of thyroid hormones.  Such disorders are only rarely caused by the 
pituitary gland and its production of TSH and are almost exclusively due to 
problems within the thyroid gland itself (Longmore et al., 2007).  The result can 
be either underproduction (hypothyroidism) or overproduction (hyperthyroidism) 
of hormones. 
Hypothyroidism can either be due to a developmental deficiency in the thyroid 
gland, which occurs in 1 in 4000-5000 live births (Robin, 1996), or acquired as 
the result of an autoimmune disorder (Besser et al., 1994, Longmore et al., 
2007).  The latter is common, occurring in 2-4% of the population as a whole 
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with an annual incidence of 2 per 1000 population (Besser et al., 1994).  The 
condition is a factor of 10 more common in middle aged women than in the rest 
of the population (Besser et al., 1994).  Other causes of hypothyroidism include 
a drug induced reduction in hormone levels or iodine deficiency (Berne & Levy, 
1993, Longmore et al., 2007).  Secondary hypothyroidism as the result of other 
conditions also exists, although this is less common (Longmore et al., 2007). 
The lower than normal metabolic rate that occurs as a result of hypothyroidism 
results in weight gain, a lowering of body temperature, tiredness, lethargy and a 
dislike of cold, amongst other symptoms (Berne & Levy, 1993, Longmore et al., 
2007).  Significant retardation in growth and rate of development occur in 
infants suffering from untreated hypothyroidism (Berne & Levy, 1993). 
Hypothyroidism is easy to treat and is normally treated medically with thyroxine 
(T4), which ensures an adequate supply of thyroid hormone within the body 
(Berne & Levy, 1993, Longmore et al., 2007).  Symptoms can quickly resolve 
with adequate treatment.   
Hyperthyroidism has a similar incidence in the adult population as 
hypothyroidism at 1.8% and is again around 10 times more common in middle-
aged women (Besser et al., 1994).  There are several possible causes of 
hyperthyroidism, with the most common being Graves’ disease, which is 
hyperplasia (an increase in the total number of cells) of the entire gland as a 
result of an autoimmune disorder.  Benign tumours or adenomas within the 
thyroid can also result in an oversecretion of thyroid hormones, whilst 
inflammation of the gland is much less common but can, on occasion, lead to 
hyperactivity of the gland (Berne & Levy, 1993).  Toxic multinodular goitre is a 
condition characterised by thyroid nodules that secrete active thyroid hormones 
and is most commonly seen in the elderly and in people with iodine-deficient 
diets.  Thyrotoxicosis is the clinical and biochemical effect of excess thyroid 
hormone due to hyperthyroidism (Longmore et al., 2007). 
Symptoms of hyperthyroidism include weight loss despite increased appetite, 
heat intolerance, sweating, irritability, frenetic activity & psychosis, amongst 
others.  Protruding eyes and goitre (swelling of the thyroid) are also common in 
Graves’ disease (Berne & Levy, 1993, Martini, 2001, Longmore et al., 2007). 
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Hyperthyroidism can be treated medically with drugs to block the synthesis of 
thyroid hormones, but is most effectively treated by surgery (partial or total 
thyroidectomy) or radionuclide therapy with iodine-131 (Berne & Levy, 1993).  
The last option makes use of the iodine concentrating properties of the thyroid 
and the beta emissions from the radioactive iodine-131, resulting in cellular 
damage and a corresponding reduction in the total number of active thyroid 
cells, leading to a reduction in thyroid hormone synthesis and secretion (Sharp 
et al., 1998).  There is no evidence of increased cancer risk in patients who 
undergo iodine-131 therapy, although patients commonly experience post-
treatment hypothyroidism, which can be treated in the same way as other forms 
of hypothyroidism, which is discussed above (Longmore et al., 2007). 
1.2.2 Disorders of the Parathyroid Glands 
In the same way as for the thyroid gland, disorders of the parathyroids can lead 
to either under- or overproduction of PTH and hence hypo- or 
hyperparathyroidism.  Diagnosis of a parathyroid disorder is biochemical 
(Coakley, 2003, Hindié et al., 2009), in that levels of calcium and PTH in the 
blood are increased or decreased abnormally. 
Hypoparathyroidism is by far the less common of the two and results in low 
serum calcium levels.  In many cases the cause is uncertain, but the condition 
can be primary, in which case it is an autoimmune disorder (Longmore et al., 
2007), or secondary in that it develops after thyroidectomy if the parathyroid 
glands are removed with the thyroid or have their blood supply restricted.  The 
main symptoms involve the muscles and the nervous system, which become more 
excitable in response to the low calcium levels and this can lead to dangerous 
spasms (Martini, 2001).  Due to the lack of availability of parathyroid hormone, 
treatment for hypoparathyroidism tends to be via calcium supplements in 
conjunction with vitamin D to promote calcium absorption (Berne & Levy, 1993, 
Martini, 2001). 
Much more prevalent is hyperparathyroidism which is characterised by high 
levels of PTH and calcium in the blood.  There are two main and distinct forms 
of hyperparathyroidism.  Primary hyperparathyroidism is the result of a benign 
or malignant tumour of one or more glands.  Involvement of one gland in benign 
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disease is usually known as an adenoma, whilst if multiple glands are involved, 
the patient is said to have parathyroid hyperplasia.  The rare malignant disease 
is termed parathyroid carcinoma (Sathe et al., 2009).  Secondary 
hyperparathyroidism occurs in patients with chronic renal failure when the 
amount of PTH secreted by the parathyroids is increased in response to the 
failure of the hormonal regulation provided by the kidneys.  Another commonly 
acknowledged form of hyperparathyroidism is tertiary hyperparathyroidism.  This 
occurs after prolonged secondary hyperparathyroidism, when the hormone 
feedback mechanism fails and the parathyroid glands begin to act autonomously 
(Longmore et al., 2007). 
The prevalence of primary hyperparathyroidism within the population is ~1 in 
1000 which increases with age and the condition is 3 times more common in 
women than in men (Robin, 1996).  Approximately 85% of patients with 
hyperparathyroidism have an adenoma, 12% have hyperplasia and 3% have 
carcinoma (Hall & Evered, 1990, Thomas & Wishart, 2003, Longmore et al., 
2007).  Primary hyperparathyroidism is often asymptomatic, with raised serum 
Ca2+ being noted on routine blood tests for other pre-existing conditions.  
Symptoms can include weakness, tiredness, depression, renal stones and 
osteoporosis. 
The only curative treatment for hyperparathyroidism is surgical excision of the 
adenoma or hyperplastic glands (Thomas & Wishart, 2003).  However, in mild 
and asymptomatic cases, surgery may not be merited and patients can be 
medically managed (Longmore et al., 2007).  Parathyroidectomy surgery offers a 
long-term cure in more than 95% of cases (Rodgers et al., 2008) but 
complications include hypoparathyroidism and damage to the recurrent 
laryngeal nerve in the neck (Longmore et al., 2007).  Surgery for hyperplasia 
often requires complete removal of the parathyroid glands from the neck 
followed by autotransplantation of a small amount of tissue, normally in the 
lower arm (Sathe et al., 2009) or, as is the case in Glasgow, the thigh. 
The standard surgical technique used by endocrine surgeons for many years was 
to perform bilateral surgery, whereby the entire thyroid area was exposed and 
all parathyroid glands were located.  Those glands visually suggestive of 
adenoma or hyperplasia were then removed. 
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However, in recent years it has been noted that bilateral surgery may not be 
necessary in all cases due to the high incidence of single gland disease (Russell 
et al., 2006).  There has therefore been a trend away from bilateral exploration 
towards unilateral and minimally invasive techniques (Greene et al., 2009).  In 
order to successfully perform such techniques, some localisation of the 
parathyroid adenoma or hyperplastic glands is necessary.  This can be performed 
using pre-operative imaging, which is discussed in detail in Section 1.3.2 below, 
or by radioguided surgery with a gamma probe in theatre (Cayo & Chen, 2008) 
after intravenous injection of a radioactive substance which localises in 
parathyroid tissue.  Intra-operative PTH assay can then be used to confirm 
removal of the overactive parathyroid tissue (Longmore et al., 2007) by 
detecting the rapid reduction in serum PTH levels.  Post-surgical follow-up for 
patients then includes regular biochemical analysis of blood samples to ensure 
that PTH and calcium levels revert to being within the normal range. 
1.3 Imaging of the Thyroid and Parathyroid Glands 
1.3.1 Thyroid Imaging 
Imaging is frequently used in the assessment of thyroid disorders in order to 
provide more detailed information on the type of disease and to assist the 
clinician in deciding the most appropriate course of treatment.  The thyroid is 
most commonly imaged with ultrasound (US) or nuclear medicine scintigraphy 
(NM), although X-ray computed tomography (CT) and magnetic resonance 
imaging (MRI) are occasionally used for anatomical thyroid imaging (Meller & 
Becker, 2002).  US provides anatomical imaging, showing the overall morphology 
of the gland and any nodules or cysts present.  In contrast, NM allows the 
acquisition of functional images, showing the parts of the thyroid that are more 
or less active than others. 
The main use of US is to determine the presence and type of thyroid nodules.  It 
can distinguish between cystic and solid nodules, the former of which are usually 
benign and the latter of which may be malignant (Longmore et al., 2007).  
However, US cannot be used in the assessment of retrosternal or mediastinal 
thyroid tissue due to its inability to image through bone.  Further assessment can 
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then be undertaken using fine needle aspiration (FNA) of any suspicious nodules, 
giving a definitive diagnosis of benign or malignant disease. 
Early NM studies of the thyroid took advantage of the known fact that the 
thyroid concentrates iodine, by utilising the radioactive isotope 131I as an 
intravenous injection of 131I-iodode.  However, the high energy gamma emission 
of 131I (364keV) is not ideal for gamma camera imaging and the coexisting beta 
emissions result in a high radiation dose (Sharp et al., 1998, Meller & Becker, 
2002).  The main use of 131I was in determining the uptake of the thyroid gland – 
that is, the percentage of injected iodine present in the thyroid after a set 
period of time, giving an indication of the overall activity of the thyroid – rather 
than for imaging.  Further details of the process of calculating thyroid uptake 
are given in Chapter 8 of this thesis and no further discussion will be included 
here. 
An alternative isotope of iodine, 123I, has a more suitable gamma emission energy 
for imaging at 159keV and has no beta emission, meaning that the radiation dose 
is considerably reduced and image quality is markedly improved.  Images using 
123I-iodide are of good quality with low background and an assessment of thyroid 
uptake can be made from the images.  The main drawback of using 123I is the 
considerable cost due to the isotope being cyclotron produced. 
It has been discovered, however, that the pertechnetate ion (TcO4
-) is also 
concentrated by the thyroid in much the same way as iodine – a very useful fact 
given that the isotope 99mTc is the most commonly used radionuclide for NM 
imaging, meaning that good quality images can be obtained at relatively low 
cost.  Indeed, pertechnetate seems to have a very similar distribution 
throughout the body as iodine, although the quantitative uptake in tissue is 
lower (Andros et al., 1965, Hays & Berman, 1977).  The thyroid to background 
ratio is therefore lower than with isotopes of iodine (Shimmins et al., 1969) but 
is sufficiently good to provide useful clinical information for the management of 
patients with thyroid disease. 
Pertechnetate images can also be used for the calculation of thyroid uptake.  
However, since pertechnetate is not organified by the thyroid – that is, 
pertechnetate is not incorporated into thyroid hormones – the measurement 
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does not give a true indication of thyroid uptake.  Nevertheless, pertechnetate 
uptakes can still be useful in determining the presence of hypo- or 
hyperthyroidism if a normal range for the population under consideration is 
established (Shimmins et al., 1968, Esser et al., 1973). 
NM scanning with either 99mTc-pertechnetate or 123I-iodide is useful for 
determining the causes of hyperthyroidism and the status of nodules as “hot” or 
“cold” in reference to the relative accumulation of radiopharmaceutical.   
Around 20% of cold nodules are malignant whereas few neutral and almost no 
hot nodules are malignant so the uptake status of a suspicious nodule is very 
important (Longmore et al., 2007).  Retrosternal goitre, ectopic thyroid tissue 
and thyroid metastases can also be detected using NM imaging, although 123I-
iodide imaging is often more useful than 99mTc-pertechnetate in these 
circumstances due to the higher thyroid to background ratio.  However, most 
nuclear medicine departments primarily use 99mTc-pertechnetate routinely for 
thyroid imaging and uptake measurements as it is cheaper and more readily 
available than 123I-iodide, which can normally only be obtained on certain days 
of the week whilst 99mTc-pertechnetate will be available on a daily basis. 
NM functional imaging normally takes the form of planar imaging with an uptake 
measurement, although 3-dimensional SPECT imaging can sometimes be used, as 
discussed in detail in Section 1.5.1 below.  Planar images can be acquired using 
either a pinhole collimator, which produces a magnified image of the gland but 
is subject to geometrical distortions due to the effects of parallax, or a parallel 
hole collimator with software zoom, which gives a better sensitivity in terms of 
counts/s/MBq.  The exact technique employed is a matter of preference for the 
imaging centre. 
1.3.2 Parathyroid Imaging 
Imaging of the parathyroids is not used to diagnose disease as this is performed 
using biochemical analysis of blood samples.  However, imaging can be used to 
assist the endocrine surgeon in localising the abnormal gland or glands prior to 
surgery (Coakley, 2003, Hindié et al., 2009) in patients with 
hyperparathyroidism.  In general, parathyroid glands of normal size are too small 
to be resolved on imaging and only adenomas or hyperplastic glands can be 
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visualised (Sandler & Patton, 1987).  For this reason, imaging is not routinely 
carried out in cases of hypoparathyroidism, as no further useful clinical 
information can be gained. 
As for the thyroid, various imaging modalities can be utilised for parathyroid 
localisation including US, NM, CT and MRI, although once again US and NM are 
most commonly used.  CT tends to have a lower sensitivity for detection of 
normally located parathyroid adenomas than the other modalities (Moinuddin & 
Whynott, 1996, Peeler et al., 1997), although it can be useful for detecting 
ectopic mediastinal adenomas (Sandler & Patton, 1987, Beierwaltes, 1991).  MRI 
is particularly useful for mediastinal imaging (Sandler & Patton, 1987) and has 
been demonstrated to have a sensitivity similar to or slightly lower than US and 
NM at between 55% and 80% (Moinuddin & Whynott, 1996, Peeler et al., 1997, 
Ishibashi et al., 1998, Hänninen et al., 2000, Wakamatsu et al., 2001, Saeed et 
al., 2006) but is limited by high cost and low specificity due to being unable to 
differentiate between parathyroid adenomas and thyroid disorders (Beierwaltes, 
1991). 
Enlarged parathyroid glands can be readily visualised on US as they tend to be 
hypoechoic with respect to the surrounding tissues (Sandler & Patton, 1987) and 
the technique has the advantages of being low cost and not using ionising 
radiation (Mariani et al., 2003).  However, the sensitivity of US varies due to the 
fact that it is very operator dependent (Rodgers et al., 2008) and it is 
particularly ineffective at detecting ectopic glands in the mediastinum 
(Beierwaltes, 1991, Carlier et al., 2008).  Despite this, the sensitivity of US 
imaging by an experienced operator can be high, with values around 75% being 
quoted in the literature (e.g. Ishibashi et al., 1998, Tublin et al., 2009), 
although values as low as 38-45% have been found (Hewin et al., 1997, Peeler et 
al., 1997), clearly demonstrating the high operator dependence of the 
technique. 
The main advantage of NM imaging over the other modalities is that it represents 
the function of the parathyroid tissue, rather than the visual anatomy, meaning 
that hyperactive glands can be distinguished from normally functioning tissue.  
However, no single radiopharmaceutical exists that is localised only to 
parathyroid tissue – in every case there is simultaneous uptake in the thyroid 
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gland so a variety of different techniques have been employed to visualise and 
localise parathyroid adenomas and hyperplastic glands. 
Early attempts at parathyroid imaging in NM involved the use of methionine, 
which had been shown to concentrate in the parathyroid glands (DiGiulio & 
Beierwaltes, 1964).  The methionine was labelled with the radioisotope 75Se and 
the neck was scanned using a scintillation detector or gamma camera to 
determine any areas of increased uptake (DiGiulio & Beierwaltes, 1964, Haynie 
et al., 1964, Ashkar et al., 1971).  Although the results were encouraging with 
several successful localisations reported, the high radiation dose due to the long 
half-life of 75Se (119.8 days) (ICRP, 1988, Delacroix et al., 2002) meant that only 
small activities could be administered to patients, resulting in poor image 
quality and the technique was soon superseded. 
Attempts were then made to localise parathyroid adenomas using 67Ga-citrate, 
with some level of success (Bekerman et al., 1977, Cann & Prussin, 1980), but 
the first technique used widely was that of 201Tl-thallous chloride/99mTc-
pertechnetate subtraction imaging (Sharp et al., 1998).  The 201Tc-thallous 
chloride is taken up in both the thyroid and parathyroid tissues, whilst the 99mTc-
pertechnetate is only taken up in the thyroid, meaning that subtraction imaging 
can be performed to visualise only the uptake in the parathyroids.  The method 
commonly used was to inject the 201Tc-thallous chloride and acquire an image of 
the neck area.  The 99mTc-pertechnetate would then be injected and a 
corresponding image of its distribution acquired.  This second image could then 
be subtracted digitally from the first, removing the thyroid from the image and 
leaving only the activity in the parathyroid glands.  In order to ensure correct 
image registration and prevent artefacts in the subtraction image, however, it 
was necessary to immobilise the patient throughout the imaging procedure 
(Sharp et al., 1998).  A slight variation on this method involved the use of 123I-
iodide as the thyroid imaging agent, giving a better thyroid to background ratio, 
although the overall procedure did not vary significantly from that described 
above (Pattou et al., 1998, O’Doherty & Kettle, 2003). 
In the early 1990s, a new cardiac imaging agent called 99mTc-Sestamibi (MIBI) 
was introduced which was soon demonstrated have a similar distribution in man 
to thallous chloride and therefore to concentrate in the thyroid and parathyroid 
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glands (Bristol-Myers Squibb, 2005).  The uptake mechanisms of MIBI remain 
uncertain (Hung et al., 2003) but the fact that it is labelled with 99mTc makes it 
more attractive for imaging studies than 201Tl.  At present, there is no definitive 
protocol for imaging of parathyroids using 99mTc-Sestamibi, with two main 
methods commonly employed (Hindié et al., 2009). 
The first of these methods takes advantage of the fact that MIBI has been shown 
to demonstrate differential washout from the parathyroids with respect to the 
thyroid gland (Taillefer et al., 1992) and is named the dual-phase technique.  
Images are taken at around 15 minutes and 2 hours post-injection of MIBI, with a 
parathyroid adenoma or hyperplastic gland being more easily visualised on the 
later image due to the delayed MIBI washout.  This technique has been employed 
successfully by a number of groups, showing increased sensitivity over imaging 
with 201Tl (Rauth et al., 1996, Peeler et al., 1997, Wakamatsu et al., 2001, Erbil 
et al., 2006).  However, problems have also been demonstrated in that the 
differential washout does not appear to be universal (Bénard et al., 1995, 
Calendini-Viallet, 1997, Krausz et al., 2001) and some thyroid adenomas can 
preferentially retain MIBI relative to the rest of the thyroid, giving false-positive 
results (Kresnik et al., 1997). 
The second method in widespread use utilises dual-isotope subtraction imaging 
in much the same way as with 201Tl with either 99mTc-pertechnetate or 123I-iodide 
used as the thyroid imaging agent.  MIBI/pertechnetate subtraction requires 
consecutive imaging of the two agents as the same radionuclide is used in both.  
The 99mTc-pertechnetate is administered first, followed by imaging of the 
thyroid.  An administration of perchlorate can be used to wash the 
pertechnetate out of the thyroid prior to injection of the 99mTc-Sestamibi 
(Gallowitsch et al., 1997, Rubello et al., 2000).  The MIBI distribution is then 
imaged, with the patient requiring to be immobilised throughout the procedure 
to prevent misregistration artefacts in the subsequent subtraction image.  In 
contrast, the MIBI/iodide subtraction technique uses two different radionuclides 
with different gamma emission energies (140keV and 159keV respectively).  
Dual-isotope image acquisition is therefore possible resulting in reduced imaging 
time (Hindié et al., 1998).  However, there is a significant cost implication in 
using 123I, as has been discussed for thyroid imaging above, and so the cheaper 
pertechnetate subtraction remains common. 
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Comparisons have been carried out between the dual-phase and dual-isotope 
techniques, with a better sensitivity in correctly localising parathyroid lesions 
with dual-isotope imaging reported by several groups (Hindié et al., 1998, Leslie 
et al., 2002, Wakamatsu et al., 2003).  Also, one of the most common reasons 
for failed localisation and hence the requirement for bilateral neck exploration 
is the presence of concomitant thyroid disease, such as multinodular goitre 
(Gallowitsch et al., 1997, Casara et al., 2001, Gates et al., 2009), meaning that 
an assessment of the thyroid can be very useful for the surgeon.  However, the 
dual-phase technique remains popular with many centres finding satisfactory 
results with the method. 
Another cardiac imaging agent that has been investigated for use in parathyroid 
imaging is 99mTc-Tetrofosmin.  This agent has similar characteristics to 99mTc-
Sestamibi but does not display differential washout and so subtraction imaging is 
required (Fjeld et al., 1997, Gallowitsch et al., 1997 & 2000, Fröberg et al., 
2003).  Its use in parathyroid imaging is, however, not widespread and the 
product is not licensed for parathyroid imaging in the UK (personal 
communication, Dot Robinson, GE Healthcare). 
As is the case for thyroid imaging (see Section 1.3.1 above), most NM parathyroid 
imaging is carried out using planar techniques.  Also, there is the option to use 
either a pinhole or parallel hole collimator.  Some groups have found an 
increased sensitivity for detecting parathyroid adenomas with a pinhole 
collimator (Takamiya et al., 2004, Tomas et al., 2008), but its use remains a 
matter of preference for the imaging centre.  Three-dimensional SPECT imaging 
with 99mTc-Sestamibi has also been investigated in an attempt to increase both 
the sensitivity and the spatial information provided for preoperative localisation, 
and this is discussed in detail in Section 1.5.2 below. 
One final imaging method is available for the localisation of parathyroid 
adenomas and hyperplastic glands.  Positron emission tomography (PET) is 
becoming more widely available and it provides an opportunity to once again 
image the parathyroid glands with methionine, although for PET it is labelled 
with 11C rather than with 75Se.  Several studies have been carried out to assess 
the clinical utility of 11C-methionine, finding sensitivities of between 50% and 
85% (Sundin, et al., 1996, Otto et al., 2004, Beggs & Hain, 2005, Rubello et al., 
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2006, Herrmann et al., 2009).  However, standard NM techniques with 99mTc-
Sestamibi remain in more common usage due to the wider availability of gamma 
cameras. 
1.4 Nuclear Medicine SPECT Imaging 
Traditionally, nuclear medicine imaging has been a planar technique, producing 
images that are a 2-dimensional projection of the 3-dimensional distribution of 
radiopharmaceutical within the patient.  Single photon emission computed 
tomography (SPECT) is a technique that allows reconstruction of images in 
multiple planes.  The gamma camera rotates around the patient, acquiring a 
number of frames at different projection angles.  A computer is then used to 
reconstruct these frames to produce a full 3-dimensional image data set (Sharp 
et al., 1998).  Theoretically, an infinite number of projections are required to 
reconstruct the true distribution of activity within the patient, but a good 
estimate can still be obtained with a limited number of projections (Bruyant, 
2002). 
SPECT does not give improved resolution over planar imaging.  However, the 
contrast is markedly improved due to the separation of activity in overlying and 
underlying structures which is not possible in planar imaging (Sharp et al., 1998, 
Wagner et al., 1999, Bruyant, 2002).  Theoretically, acquisition of projection 
data over only 180o is required as opposing projections contain the same image 
information.  However, due to the fact that there is an inherent loss of 
resolution with depth in nuclear medicine imaging and that the gamma photons 
may be differentially attenuated by different sides of the body, opposing 
projections are in reality different, which means that 360o of data is often 
acquired.  For imaging of structures close to one surface of the body, the use of 
360o of projection data in reconstructing SPECT images can simply lead to an 
unacceptable increase in the noise level.  For example, the thyroid lies close to 
the anterior surface of the neck and will be poorly visualised in the posterior 
projections, which would add noise and little useful information to the 
reconstructed images.  In these cases, 180o of acquired projection data is 
sufficient to produce an acceptable SPECT reconstruction of the activity 
distribution in the structure of interest (Wagner et al., 1999). 
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There are various possible mathematical methods of reconstructing the 3-
dimensional images from the projection data.  For many years, the most 
commonly used technique was filtered back projection (FBP), the mathematics 
of which was first described in the 1960s (Bracewell & Riddle, 1967).  This 
method is described in detail elsewhere (e.g. Sharp et al., 1998) and so no 
further discussion will be given here.  FBP is computationally relatively simple 
and hence reconstruction times are fast, but significant artefacts can be 
introduced to the images, particularly around areas of very high or low count 
densities where streaks occur.  The reconstructed images also require to be 
filtered in order to reduce blurring artefacts and high background noise levels, 
but this leads to a compromise between spatial resolution and noise, as noise is 
represented by high spatial frequencies (Sharp et al., 1998, Bruyant, 2002). 
The last 10 years or so has seen a significant improvement in the processing 
capabilities of computers, meaning that other more computationally demanding 
reconstruction methods have become viable.  The most commonly implemented 
of these are the iterative methods, such as Maximum Likelihood Expectation 
Maximisation (MLEM) or the related Ordered Subsets Expectation Maximisation 
(OSEM) (Sharp et al., 1998, Bruyant, 2002, Takahashi et al., 2003).  These 
methods involve beginning with an assumed activity distribution (such as a 
uniform distribution with all pixels having the same value) which would give a 
certain estimated set of projection images.  The actual acquired projection data 
are compared to the estimated values by taking the ratio of measured to 
estimated counts and the original estimate is then updated to account for these 
differences.  The whole process is then repeated and the estimated activity 
distribution becomes closer to the true activity distribution with each iteration.  
The process converges to a solution whereby the change in the estimated 
activity between successive iterations is minimal (Bruyant, 2002). 
Iterative techniques tend to result in fewer image artefacts and can give 
accurate estimates of the true activity distribution with a smaller number of 
projection images than are required for filtered back projection (Takahashi et 
al., 2003).  Improved spatial resolution and increased lesion detection over FBP 
images have also been reported (Shepp & Vardi, 1982, Tourassi et al., 1991, 
Moka et al., 2000a, Brambilla et al., 2005). 
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Various corrections can be made to SPECT data either before, during or after 
reconstruction in order to increase the accuracy of the final image data set.  
These include scatter correction, cross-talk correction, distortion corrections 
and, most commonly, attenuation correction (AC).  Performing AC aims to 
reduce the dependency of the number of counts recorded on the depth of the 
origin of the photons within the patient.  There are several different AC methods 
available (Walters et al., 1981, Webb et al., 1983, Sharp et al., 1998), which 
range from a linear correction method which assumes that the attenuation 
throughout the patient volume is entirely uniform, to the acquisition of an X-ray 
computed tomography (CT) image, which is used to produce a map of the actual 
attenuation at all points in the image.  All of these corrections can be 
incorporated into an iterative reconstruction algorithm, whereas FBP requires 
the various corrections to be made either pre- or post-reconstruction (Bruyant, 
2002). 
SPECT studies are most often acquired using a parallel hole collimator, but it is 
possible to perform pinhole SPECT.  The main difficulty with the use of the 
pinhole collimator is the introduction of geometrical distortions in the projection 
images due to parallax (Mavai & Caride, 1996).  Standard reconstruction 
algorithms are not designed to deal with such cone beam data and so special 
algorithms must be used (Wanet et al., 1996, Vanhove et al., 2000).  Slight 
changes in the relative angle of the collimator to the area of interest have been 
shown to result in significant distortions in the final reconstructed images (Mavai 
& Caride, 1996).  The method is therefore not commonly used in routine 
practice. 
Over the last few years, there has been an increase in the use of SPECT/CT 
systems, which allow the acquisition of fully registered SPECT and X-ray CT 
images.  A single gantry supports both a double headed gamma camera and a CT 
scanner.  The patient first undergoes a SPECT scan and then, without the patient 
moving, the imaging couch is moved into the CT scanner and an X-ray CT of the 
same area is taken.  Registered functional and anatomical images can therefore 
be acquired together as well as allowing CT attenuation maps to be used in the 
attenuation correction of the SPECT images. 
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1.5 SPECT of the Thyroid and Parathyroid Glands 
1.5.1 Thyroid SPECT 
SPECT imaging is not commonly used in the assessment of thyroid disorders, 
although it has been shown to be useful on occasion (Chen et al., 1988, Wanet 
et al., 1996, Krausz et al., 1997).  In particular, SPECT has been shown to allow 
visualisation of cold nodules which are not seen on planar imaging due to high 
levels of surrounding activity (Chen et al., 1988, Krausz et al., 1997).  However, 
ultrasound imaging offers good visualisation of thyroid nodules without the use 
of ionising radiation and so is often the preferred imaging tool for clinicians. 
Thyroid SPECT has most often been used in the estimation of thyroid volume 
(e.g. Chen et al., 1988, Wanet et al., 1996, Zaidi, 1996, van Isselt et al., 2003, 
Pant et al., 2003), which is useful as an aid to determining a suitable 
therapeutic 131I-iodide activity to administer to a patient with hyperthyroidism.  
SPECT has been shown to be considerably superior to planar imaging for volume 
measurements, but shows no significant improvement over ultrasound methods 
(Zaidi, 1996, van Isselt et al., 2003, Pant et al., 2003). 
In summary, thyroid SPECT can be useful in certain circumstances but is not used 
routinely in many imaging centres. 
1.5.2 Parathyroid SPECT 
The use of SPECT in parathyroid imaging is becoming more widespread, although 
it is by no means a universally accepted technique (Pattou et al., 1998, Hindié 
et. al., 2009).  There is a large amount of published data relating to the use of 
single-isotope 99mTc-Sestamibi SPECT (Billotey et al., 1996a & 1996b, Torres et 
al., 1996, Chen et al., 1997, Moka et al., 2000b, Lorberboym et al., 2003, 
Schachter et al., 2004, Spanu et al., 2004, Slater & Gleeson, 2005, Ansquer et 
al., 2008, Carlier et al., 2008, Ho Shon et al., 2008, Nichols et al., 2008, Thomas 
et al., 2009) with most studies demonstrating an increase in sensitivity in the 
detection and localisation of parathyroid adenomas over planar imaging.  MIBI 
SPECT has been shown to be particularly effective in localising ectopic 
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parathyroid adenomas (Billotey et al., 1996a, Lorberboym et al., 2003) as well 
as being more sensitive than ultrasound imaging (Quiros et al., 2004). 
Despite the widespread use of planar subtraction imaging, only one group, led by 
Donald R. Neumann and based in Cleveland, Ohio, has published data on the use 
of dual-isotope subtraction SPECT for localising parathyroid adenomas.  The 
group’s various papers on the topic (Neumann et al., 1997b, 1998, 2000, 2008) 
have demonstrated that dual-isotope subtraction SPECT is superior to single-
isotope 99mTc-Sestamibi SPECT and is a clinically useful imaging technique. 
In the same way as for thyroid imaging, it is possible to carry out pinhole SPECT 
for parathyroid disorders, which has been shown to give increased sensitivity 
over planar imaging (Profanter et al., 2003).  However, the same issues with 
geometric distortions in the images and the requirement to use cone beam 
reconstruction algorithms affect parathyroid pinhole SPECT as they do for 
thyroid pinhole SPECT (see Section 1.5.1 above). 
SPECT/CT is not yet commonly used for either thyroid or parathyroid imaging.  
However, the literature suggests (Even-Sapir et al., 2001, Gayed, et al., 2005, 
Krausz, et al., 2006, Lavely et al., 2007, Neumann et al., 2008, Papathanassiou 
et al., 2008, Akram et al., 2009) that it may be particularly useful in parathyroid 
imaging for patients who have had previous neck surgery or have one or more 
ectopically located parathyroid adenomas. 
1.6 Study Aims 
The aims of this study involve the assessment of the use of SPECT imaging in 
thyroid and parathyroid disorders using both phantom and patient data. 
Firstly, it aims to assess the clinical utility of 99mTc-Sestamibi/123I-iodide dual-
isotope subtraction SPECT imaging for localisation of hyperactive parathyroid 
glands.  This will be achieved by performing dual-isotope scans using a custom 
designed and built thyroid/parathyroid phantom to determine suitable imaging 
and SPECT reconstruction and analysis parameters followed by an observer study 
reviewing dual-isotope subtraction SPECT patient data sets. 
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Secondly, this study aims to assess the possibility of performing thyroid uptake 
measurements from 99mTc-pertechnetate SPECT acquisitions.  As for the 
parathyroid study, the new thyroid/parathyroid phantom will be used to 
determine appropriate imaging and SPECT reconstruction parameters as well as 
a method for calculating the uptake from these images.  These methods will 
then be applied to patient data and the results compared with those for the 
standard uptake measurement from planar images. 
A detailed description of the phantom custom designed and built for this study 
and the work carried out using it is given in Chapter 2 of this thesis.  Chapters 3 
– 7 then describe the parathyroid observer study and discuss the findings in 
relation to work carried out by other groups.  Finally, Chapters 8 & 9 describe 
the work on calculation of thyroid uptake from SPECT images using both patient 
and phantom image data. 
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Chapter 2 – Design, Construction and Use of a 
Dedicated Thyroid and Parathyroid Phantom 
2.1 Introduction 
Phantoms have been used in nuclear medicine imaging for many years to 
simulate a patient during image acquisition.  A phantom is generally made of a 
tissue-equivalent material and can be filled with a radioactive substance 
repeatedly to test imaging or analysis parameters without the need to expose a 
person to radiation via intravenous injection, inhalation or ingestion.  They also 
provide consistent imaging conditions in terms of their attenuation properties 
and the relative distances between particular points, which are difficult to 
obtain reproducibly with human subjects.  The resultant reproducibility of 
acquired images means that phantoms are particularly useful in quality 
assurance of imaging systems. 
Information on the attenuation and scatter properties of various human tissues 
and tissue substitutes can be found in a report by the International Commission 
on Radiation Units and Measurements (ICRU, 1989). 
This study concentrated on the use of single photon emission computed 
tomography (SPECT) imaging of the thyroid and parathyroid glands, which has 
not been routine practice in the Nuclear Medicine department at Glasgow Royal 
Infirmary (GRI).  In order to ensure that suitable acquisition parameters for the 
SPECT data were in place prior to any participants undergoing imaging, it was 
decided that a new thyroid/parathyroid phantom would be created so that 
different parameters could be tested and a suitable protocol established.  The 
phantom would simulate the neck area and would be capable of providing 
imaging conditions similar to those of patient thyroid and parathyroid studies. 
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2.2 Materials and Methods 
2.2.1 Design and Construction of a Thyroid/Parathyroid Phantom 
In 1975, the International Commission on Radiological Protection (ICRP) 
published a report giving information on “Reference Man” (ICRP, 1975).  This 
report brought together large quantities of published data on the typical 
anatomy, physiology and metabolism of humans.  It then defined the various 
characteristics of a “Reference Man” that can be used for calculations of 
radiation dose to a reference individual such that comparisons of results from 
different types of exposure can easily be made.  The information in this report 
was used as the basis for the design of the thyroid/parathyroid phantom for this 
study such that the phantom would give a good representation of a standard 
patient. 
The phantom was designed so that it could be manufactured from Perspex 
(polymethylmethacrylate) and filled with water, both of which have attenuation 
properties similar to soft tissue for the 140keV gamma photons of 99mTc and the 
159keV gamma photons of 123I (ICRU, 1989), which were the isotopes to be used 
for this study.  At 140keV, the linear attenuation coefficient (µ) of soft tissue is 
0.159cm-1 (ICRU, 1989), whilst for water µ=0.155cm-1, and for Perspex 
µ=0.178cm-1 (Hubbell & Seltzer, 1996).  At the 159keV photon energy of 123I, the 
linear attenuation coefficients of soft tissue, water and Perspex are  
µ=0.153cm-1, µ=0.148cm-1 and µ=0.171cm-1, respectively.  It was also important 
that the phantom could easily be opened and closed with a watertight seal so 
that radioactive liquids could be introduced to the water chambers repeatedly 
without significant risk of a spillage of radioactive material. 
The main body of the phantom was designed to be a hollow cylinder of diameter 
15cm to simulate the neck.  It was necessary that the chamber could be filled 
with water, which may or may not contain a small amount of radioactive liquid 
to act as a background activity, and sealed.  Two interchangeable inserts were 
then designed to be used for simulating thyroid and parathyroid imaging 
respectively.  Each insert was to consist of a hollow thyroid-shaped chamber of 
the same internal dimensions, which are shown in Figure 2.1.  The dimensions 
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were taken as the approximate mean value of the range given in the ICRP report 
(ICRP, 1975) for the thyroid gland.  Each insert was to be mounted at a 
maximum depth of 2cm from the face of the outer cylinder, as this is the 
maximum thickness of tissue overlying the thyroid specified in the ICRP report 
(ICRP, 1975). 
 
Figure 2.1 - Dimensions of thyroid for phantom inserts 
 
The thyroid insert was also to include features within the thyroid that could be 
used to simulate hot and cold nodules of various sizes.  Visualisation of the 
different sized “nodules” could help give an indication of the contrast and 
resolution of the images acquired with the phantom.  Three pairs of nodules 
were to be included, with diameters of 15mm, 10mm and 5mm respectively.  
The cold nodules were to be simulated by solid rods running through the depth 
of the thyroid insert (anterior-posterior) where no radioactivity could be 
present.  The hot nodules were designed as chambers also running through the 
depth of the thyroid insert but which could be filled and sealed separately from 
the main chamber.  This would allow liquid to be added to these chambers 
which had a higher concentration of radioactivity (MBq/ml) than the liquid in the 
main chamber.  These chambers would then appear hotter than the main body 
of the thyroid on the final acquired image.  The specification for these 
“nodules” is shown in Figure 2.2. 
width height depth 
lobes 
isthmus 
Front Side View 
Thyroid chamber 
dimensions: 
Height – 65mm 
Width – 30mm 
Depth – 17.5mm 
 
 
Isthmus dimensions: 
Height – 20mm 
Width – 20mm 
Depth – 4mm 
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Figure 2.2 - Specification for phantom thyroid insert 
 
The parathyroid insert was to have four small chambers of varying volume on its 
posterior surface which could be independently filled and sealed to represent 
the parathyroid glands.  Parathyroid glands are very small and are typically 
spherical or ovoid with a combined weight for all four glands of around 1.3g 
(ICRP, 1975).  The ICRP report gives suggested dimensions for each gland, but 
these are very small (1-15mm) and would be difficult to manufacture.  It was 
instead decided that the size of each chamber would be defined by its individual 
volume.  Small volumes of <1ml were used because of the small dimensions of 
true parathyroid glands.  The resulting specification for the insert is shown in 
Figure 2.3.  A typical parathyroid adenoma is around 100mg – 1500mg in weight, 
corresponding to a volume of 0.1ml – 1.5ml.  The chambers in the phantom 
ranged in volume from 0.11ml – 0.46ml to simulate a variety of adenoma sizes. 
 
Figure 2.3 - Specification for phantom parathyroid insert 
 
Rear surface of 
parathyroid insert 
4 sealed 
chamber 
attachments 
Front view of thyroid 
insert 
Side view of 
thyroid insert 
Hot nodules 
(chambers) 
Cold nodules 
(solid rods) 
Chambers/rod
s 
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The final specification for the phantom was passed to the Department of Clinical 
Physics and Bio-engineering Mechanical Workshop at the Western Infirmary, 
Glasgow for manufacture.  The workshop mounted each insert on its own lid so 
that the position of the insert relative to the sides of the cylinder could be 
maintained.  The main cylinder and lids were constructed of 6mm thick Perspex, 
whilst the inserts were made from 3mm thick Perspex.  The exception to this 
was the cold nodules, which were made of solid rods of Perspex.  All the 
chambers were sealed with Perspex screws, a washer and an “o”-ring.  
Photographs of the completed phantom are shown in Figure 2.4. 
 
Figure 2.4 - Photographs of completed phantom 
Photographs showing the phantom with the thyroid insert in place and the parathyroid 
insert alongside. 
Once the manufacture and leak testing was completed by the workshop, the 
phantom was filled with water and the exact volume of each chamber in both 
inserts was ascertained.  These measured volumes are shown in Table 2.1.  
Knowing the relative volumes of the different chambers made it possible to test 
different relative activity concentrations (MBq/ml) accurately. 
Thyroid Insert Parathyroid Insert 
Chamber Volume (ml) Chamber Volume (ml) 
Thyroid 41.5 Thyroid 55.0 
Hot nodule 1 3.30 Parathyroid 1 0.46 
Hot nodule 2 1.75 Parathyroid 2 0.28 
Hot nodule 3 0.35 Parathyroid 3 0.18 
  Parathyroid 4 0.11 
Total Nodules 5.40 Total Parathyroids 1.03 
Table 2.1 - Volume of each chamber within the two phantom inserts 
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Each time the phantom was filled for imaging, a small volume of water was 
removed from each chamber using a syringe and needle in order to create an air 
bubble.  The required activity of radioisotope was then injected into the 
chamber and mixed thoroughly to ensure uniform activity throughout the 
chamber.  The remaining air bubble was then removed by injecting more water 
into the chamber before sealing it.  Once each chamber was filled, the phantom 
was ready to be imaged as described in Section 2.2.2 below. 
The thyroid insert was filled only with 99mTc as thyroid imaging at GRI is a single 
isotope procedure.  The activity was introduced into the thyroid chamber, the 3 
hot nodule chambers and the main phantom cylinder to simulate physiological 
uptake of 99mTc-pertechnetate in the neck region.  In contrast, both 99mTc and 
123I were used for the parathyroid insert as the imaging procedure for this type 
of investigation at GRI is dual-isotope.  The thyroid had both 99mTc and 123I 
introduced into it whilst the parathyroid chambers and main cylinder only 
contained 99mTc, again in order to best simulate physiological uptake. 
2.2.2 Image Acquisitions using the Phantom 
The first images acquired of the new phantom were planar views in an anterior 
orientation, as is the case for standard thyroid and parathyroid imaging at GRI. 
The images of the phantom could therefore be directly compared with patient 
images acquired using the standard protocol to determine how well it simulated 
the physiological distribution of radiopharmaceutical.  A variety of SPECT image 
data acquisitions were then obtained in order to assess the potential usefulness 
of the phantom for determining suitable SPECT acquisition parameters for both 
thyroid and parathyroid imaging and the feasibility of performing dual-isotope 
subtraction SPECT on parathyroid images.   
2.2.2.1 Thyroid Insert Planar Acquisitions 
The thyroid insert was filled to give a simulated total thyroid uptake of around 
2%, which lies within the normal range for a patient study.  It was then imaged 
using both a pinhole collimator and a parallel hole low energy, high resolution 
(LEHR) collimator.  The geometry of the pinhole gives an inherently zoomed 
image, meaning that a small organ such as the thyroid can be imaged in greater 
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detail.  The use of a pinhole collimator does, however, introduce geometric 
distortions to the images, as shown in Figure 2.5.  Modern gamma cameras now 
have the facility to produce a software zoom when using a standard parallel hole 
collimator.  Software zoom involves selecting the central area of the image 
acquisition matrix and rebinning the acquired counts into a larger matrix, 
resulting in the image of the area of interest filling a larger area of the final 
image matrix.  This gives a distortion-free image whilst still giving good 
resolution detail of a small area.  However, the use of software zoom results in a 
reduction in resolution due to the fact that the area of interest comprises a 
larger part of the final image matrix without any increase in acquisition 
resolution. 
When this study began, the department at GRI was moving from pinhole to 
parallel hole imaging due to the replacement of the gamma camera that had a 
pinhole collimator.  For all planar imaging, an energy window of ±10% centred 
on 140keV was used along with a 1282 image matrix, which are the standard 
acquisition parameters used at GRI. 
 
Figure 2.5 - Geometry of the pinhole collimator of a gamma camera 
Diagram showing the position on the gamma camera detector of counts originating from 
three identical points with the pinhole collimator (a) centred over the thyroid and (b) centred 
over the sternal notch.  In the projected images, distance AB is approximately equal but the 
distance BC is shorter in the first image, demonstrating the significant effect of acquisition 
geometry on the final image when using a pinhole collimator. 
Example images of the thyroid insert obtained using a pinhole collimator are 
shown in Figure 2.6.  The image on the left shows a 60 second (s) acquisition 
with a total of 54,000 counts whilst that on the right shows an acquisition with a 
total number of counts in the image of 200,000.  The two lobes of the thyroid 
insert are clearly seen, as are all three “hot” nodules and 2 of the 3 cold 
A B C A B C 
(a) (b) 
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nodules.  The smallest cold nodule (5mm diameter) is not visible on this image 
due to the limiting low contrast resolution of the gamma camera.  The length of 
time to acquire the 200,000 count image (around 4 minutes) was similar to that 
required for acquisition of a 200,000 count patient image. 
 
Figure 2.6 - Planar images of phantom with thyroid insert acquired using a pinhole 
collimator 
Image on left was acquired for 60s and image on right was acquired to a total of 200,000 
counts. 
Figure 2.7 shows images of the thyroid insert in the phantom acquired using a 
parallel hole low energy high resolution (LEHR) collimator.  The images were 
acquired on the same day as those in Figure 2.6 and so the relative activity 
concentrations in the different chambers were identical.  The first two images 
were acquired with the same stopping conditions as those in Figure 2.6 with no 
software zoom applied.  The 60s image had a total of 117,000 counts and the 
time taken to acquire the 200,000 count image was around 2 minutes, 
demonstrating the improved sensitivity of the parallel hole collimator relative to 
the pinhole.  The final image, on the right, shows a 200,000 count acquisition 
with an applied software zoom of 1.33, which was found to result in the thyroid 
insert being approximately the same size on the final image as was seen on the 
pinhole images.  Again, the time taken to acquire the 200,000 count image 
(approximately 2 minutes) was similar to that for a patient study using this 
collimator. 
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A visual comparison of the images in Figure 2.6 and Figure 2.7 clearly 
demonstrates the geometric distortions in the images acquired using the pinhole 
collimator.  The upper and lower edges of the main phantom cylinder are very 
flat in the LEHR images, but are rounded in the pinhole views.  The images 
acquired with the LEHR collimator also show all three “hot” nodules and two of 
the “cold” nodules, suggesting that the resolution is not significantly degraded. 
 
Figure 2.7 - Planar images of phantom with thyroid insert acquired using parallel hole LEHR 
collimator 
Image on left was acquired for 60s, image in centre was acquired to a total of 200,000 
counts and the image on the right was acquired to a total of 200,000 counts with an applied 
software zoom factor of 1.33. 
The images from the phantom acquisitions were then compared to patient data 
sets to assess their usefulness in simulating true physiological uptake in the 
thyroid.  Example patient images demonstrating a normal thyroid gland and a 
multinodular gland are shown in Figure 2.8.  The upper images were acquired 
using the pinhole collimator and the lower images with a parallel hole LEHR 
collimator.  The difference in zoom factor is due to the different positioning 
geometries that were used in the image acquisition.  It was felt that the 
phantom, whilst not totally physiologically accurate, was suitable for use in 
assessing SPECT acquisition parameters. 
2.2.2.2 Parathyroid Insert Planar Acquisitions 
Planar images were also acquired of the parathyroid phantom insert using both 
available collimators.  A dual-isotope acquisition lasting 10 minutes was 
performed, according to the standard departmental protocol.  The images were 
then processed to produce a subtraction image in an attempt to show only the 
parathyroid chambers.  As with the thyroid insert, physiological activities 
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simulating thyroid and parathyroid uptake were added to the phantom.  In this 
case, a thyroid uptake of 123I-iodide of 5-10% was assumed, along with an uptake 
of 99mTc in the thyroid of around 0.1%.  The activity concentration in the 
parathyroid chambers was then varied such that it was between 2 and 6 times 
greater than that in the thyroid chamber for each separate acquisition, 
 
Figure 2.8 - Example planar patient thyroid studies 
Images of two patients with a normal thyroid acquired with a pinhole collimator (top) and 
multinodular gland acquired with a parallel hole LEHR collimator (bottom).  Left hand 
images are 60s acquisitions and right hand views are to 200,000 total counts. 
simulating different levels of uptake in a parathyroid adenoma.  The dual-
isotope acquisitions were performed using a 1282 image matrix and energy 
windows of 135keV ± 10% for 99mTc and 165keV ± 10% for 123I respectively, which 
are the standard parameters used for parathyroid acquisitions at GRI.  An 
example energy spectrum from the gamma camera for a dual-isotope 99mTc/123I 
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acquisition showing both the acquisition energy windows and the photopeaks 
from the two isotopes is shown in Figure 2.9. 
 
Figure 2.9 - Spectrum of dual-isotope 99mTc/123I acquisition showing offset energy windows 
Spectrum captured from a gamma camera showing the overlapping photopeaks of the 99mTc 
(left) and 123I (right).  The acquisition energy windows are shown as red box A (99mTc) and 
blue box B (123I), respectively. 
Example images of a planar acquisition using the pinhole collimator are shown in 
Figure 2.10.  The left hand image shows 99mTc distribution, the centre image is 
of 123I distribution and the view on the right is the subtraction image, created 
using the scaling method described in Section 4.5.  As with the thyroid insert, 
the geometric distortion produced by the use of the pinhole collimator is clearly 
visible.  This particular acquisition was taken with a 99mTc activity concentration 
in the parathyroids of around 4x that in the thyroid.  It is clear that none of the 
parathyroid chambers are visible on the subtraction image and indeed this was 
the case up to 6x relative concentration. 
A similar acquisition was performed on the same day using the LEHR collimator 
and the resultant images, with an applied software zoom of 1.33, are shown in 
Figure 2.11.  Again, there is poor visualisation of the parathyroid chambers on 
the subtraction image, although the largest is just visible at the upper left pole 
of the thyroid chamber.  The visualisation of the parathyroid chambers was 
therefore slightly better with the parallel hole collimator than with the pinhole.  
This is principally due to the fact that the sensitivity of the LEHR collimator is 
significantly higher than the pinhole – at around 2.5:1 for 99mTc – and so more 
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counts were registered over the 10 minute acquisition period and the image 
statistics were considerably improved. 
 
Figure 2.10 - Planar images of phantom with parathyroid insert acquired using a pinhole 
collimator 
Image on left is of 99mTc distribution, image in centre is 123I distribution and image on right is 
subtraction. 
 
Figure 2.11 - Planar images of phantom with parathyroid insert acquired using a parallel 
hole LEHR collimator 
Image on left is of 99mTc distribution, image in centre is 123I distribution and image on right is 
subtraction. 
As with the images of the thyroid insert, a comparison with patient images was 
carried out to assess how accurately the phantom simulated the patient 
situation.  Example patient images are shown in Figure 2.12. 
The phantom was felt to simulate patient acquisitions reasonably well, although 
there was some concern over the inability to clearly see the parathyroid 
chambers on subtraction images.  It was felt that the two most likely reasons for 
this were that the parathyroid chambers were too small and therefore could 
contain an activity too small to be perceived on subtraction, or that the anterior 
orientation of the planar images was masking the presence of the chambers on 
Chapter 2  53 
the posterior surface of the phantom thyroid.  In order to determine which of 
these was the reason for the poor parathyroid visibility, SPECT images of the 
phantom were acquired to remove the possibility of anterior masking before a 
re-design of the phantom was considered. 
 
Figure 2.12 - Example planar patient parathyroid studies 
Top row shows negative study, bottom row shows study positive for parathyroid adenoma 
at right lower pole.  Left hand images are 99mTc-Sestamibi distribution, centre images are 
123I-iodide distribution and right hand views are subtraction images. 
2.2.2.3 Thyroid Insert SPECT Acquisitions 
The parameters for the SPECT acquisitions were chosen in order to give good 
image quality in terms of the number of counts acquired in each SPECT frame 
whilst keeping the overall imaging time low enough to be tolerated by a patient.  
The parameters that had been chosen by a number of other groups performing 
similar acquisitions were taken into account (Chen et al., 1988, Neumann, 1992, 
Torres et al., 1996, Wanet et al., 1996, Chen et al., 1997, Moka et al., 2000b, 
van Isselt et al., 2003, Pant et al., 2003, Lorberboym et al., 2003, Schachter et 
al., 2004, Spanu et al., 2004), as were the standard SPECT acquisition 
parameters used at GRI for other types of imaging investigation. 
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The final chosen parameters were as follows: LEHR collimators on the double-
headed Philips Forte gamma camera with the heads in the 90o orientation, 180o 
anterior circular acquisition, 60x40s frames with a 3o rotation between frames, 
giving a total acquisition time of 20 minutes and a 30cm square roving zoom 
applied.  The 180o anterior acquisition was chosen due to the fact that the areas 
of interest (thyroid and parathyroid glands) lie anterior in the neck and so the 
posterior image information would be of poorer quality and would not contribute 
an increase in the final image quality.  For acquisitions using the thyroid insert, 
a 10% energy window centred on 140keV was used whilst for those with the 
parathyroid insert, a dual-isotope acquisition was performed with energy 
windows of 135keV ± 10% for 99mTc and 165keV ± 10% for 123I.  These are the 
same energy windows as were used for the planar acquisitions. 
The SPECT data was reconstructed on the department’s HERMES imaging 
computer system (Nuclear Diagnostics Ltd.) using the Ordered Subsets 
Expectation Maximisation (OSEM) iterative method.  The reconstructions were 
carried out with 15 subsets and 4 iterations, upon the recommendation of 
Nuclear Diagnostics staff.  A post-reconstruction filter was then applied to 
smooth the images to maximise image quality.  The chosen filter for the 
reconstruction of phantom images was not necessarily the same as that used 
later for the reconstruction of patient image data (see Sections 5.3 & 8.3.2). 
Figure 2.13 shows an example of the reconstructed images produced after a 
SPECT acquisition of the thyroid insert.  The images represent a simulated total 
thyroid uptake of around 2% (which lies in the normal range at GRI) with 3 hot 
and 3 cold nodules present.  The two lobes of thyroid can clearly be seen, as can 
the hot and cold nodules.  However, as was the case for the planar images of the 
phantom, the smallest hot nodule cannot be resolved on these images.  In these 
images, the hot nodules contain an activity concentration (MBq/ml) of 
approximately 4x that in the thyroid chamber.  Other acquisitions carried out 
with different relative concentrations up to 7x confirmed that the smallest hot 
nodule is not visible on the SPECT images.  Higher relative concentrations were 
not tested as they were felt to be physiologically unlikely. 
The findings from the SPECT acquisitions of the phantom demonstrated that the 
overall resolution of the SPECT images was not significantly different from that 
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of the planar images.  However, the low contrast resolution was slightly 
improved in that the smallest cold chamber was visible on the reconstructed 
SPECT images.  They also showed that the chosen parameters for the SPECT 
acquisition were reasonable in order to obtain reconstructed SPECT images of 
acceptable quality clinically in terms of the target: background ratio and 
resolution. 
 
Figure 2.13 - Reconstructed SPECT images of thyroid phantom insert 
Top line shows transverse slices, middle line is coronal slices and bottom line is sagittal 
slices through the phantom. 
2.2.2.4 Parathyroid Insert SPECT Acquisitions 
The process of SPECT acquisition was then repeated using the parathyroid insert 
filled with physiologically appropriate activities of 99mTc and 123I and a dual-
isotope SPECT acquisition.  Once again, uptakes in the thyroid of 0.1% for 99mTc-
Sestamibi and 10% 123I-iodide were assumed.  Various ratios of 99mTc activity 
concentration between the parathyroid chambers and the main thyroid chamber 
were imaged, in the same way as for planar imaging.  An example of the 
reconstructed dual-isotope SPECT images is shown in Figure 2.14 with the 99mTc 
images on the left and the registered 123I images on the right.  On this occasion, 
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the activity concentration in the parathyroids was approximately 4x that in the 
thyroid. 
 
Figure 2.14 - Reconstructed SPECT images of parathyroid phantom insert 
Left hand images are 99mTc distribution and right are co-registered 123I images.  Within each 
image set, top row is transverse, middle row is coronal and bottom row is sagittal slices. 
The images show that the acquisition parameters are reasonable in order to 
acquire enough counts in each SPECT frame to produce reconstructed images of 
sufficiently good quality to be used clinically.  The two lobes of thyroid are also 
clearly defined on both sets of images. 
The HERMES computer system was then used to produce subtraction SPECT 
images in order to remove the image of the thyroid so that only the signal from 
the parathyroids remains.  The exact method used to achieve this is described in 
depth in Chapter 4 and will not be discussed further here.  However, an example 
of a subtraction SPECT data set produced from the 99mTc and 123I images in 
Figure 2.14 is shown in Figure 2.15. 
In these images, the signal from the thyroid chamber has been almost 
completely removed, leaving a void in the image.  The images also clearly show 
residual activity in all 4 of the parathyroid chambers, demonstrating that the 
subtraction technique used is sound.  At lower ratios of activity concentration in 
the parathyroids to that in the thyroid, the smallest chamber (volume 0.11ml) 
was not visible, but the other 3 were always visible on the subtraction images.  
This is in contrast to the situation with planar imaging, where visualisation of 
the parathyroid chambers on subtraction was always poor. 
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Figure 2.15 - Subtraction SPECT images of parathyroid phantom insert 
Subtracted images of same data set shown in Figure 2.14, showing residual activity in areas 
of parathyroid chambers.  Top row is transverse, middle row is coronal and bottom row is 
sagittal slices. 
2.3 Discussion and Conclusions 
The phantom designed and built for the purposes of this study was imaged under 
a variety of conditions in order to test its ease of use, physiological accuracy and 
usefulness in determining SPECT imaging parameters for thyroid and parathyroid 
SPECT.  The planar images acquired using both the thyroid and parathyroid 
inserts were of good quality and replicated patient studies sufficiently well to be 
used to assist in determining appropriate acquisition parameters for SPECT.  The 
known geometrical distortions present when using a pinhole collimator were 
clearly demonstrated, as was the good imaging resolution. 
The activities of radioisotopes used in the phantom were chosen to be similar to 
those found in the clinical setting in order to simulate the true physiological 
uptake of the relevant radiopharmaceuticals in the neck.  The count rates 
obtained on planar imaging were similar to those found in patient studies, 
demonstrating that the physiological accuracy of the phantom was sufficiently 
good for the purposes of determining suitable SPECT acquisition parameters for 
patient studies. 
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The relative resolution of the planar and SPECT images was similar, with the 
smallest nodules on the thyroid phantom being difficult to visualise on both 
types of image.  The use of SPECT imaging for patient studies would therefore 
not significantly degrade image resolution. 
The lack of visualisation of the parathyroid chambers on planar subtraction 
imaging which were then visible on SPECT imaging with a similar activity 
distribution demonstrates the problems with an anterior-only planar acquisition 
for parathyroid imaging.  Since the parathyroid glands tend to sit on the 
posterior surface of the thyroid, there is a risk that an anterior image will result 
in masking of the signal from the parathyroids and images in which a parathyroid 
adenoma is present could be reported as normal.  These results were 
encouraging in that they demonstrated the possible increased accuracy that may 
be obtained with dual-isotope subtraction SPECT parathyroid imaging for 
patients.  This is discussed in more detail in Chapters 3 - 7 of this thesis. 
The phantom with its two interchangeable inserts was felt to represent a good 
simulation of patient studies.  The phantom was therefore used to good effect in 
determining suitable SPECT acquisition parameters for patient parathyroid and 
thyroid studies as well as for work on thyroid uptake measurements, which is 
discussed in Chapters 8 & 9. 
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Chapter 3 – Parathyroid Study – Introduction 
3.1 Parathyroid Imaging at Glasgow Royal Infirmary 
3.1.1 Referrals 
Patients are referred to the Nuclear Medicine department at Glasgow Royal 
Infirmary (GRI) from a number of different hospitals in the Greater Glasgow & 
Clyde and Lanarkshire Health Board areas.  Referrals normally come from 
physicians in endocrine clinics which patients have been attending after high 
levels of calcium (Ca2+) and parathyroid hormone (PTH) have been found in blood 
samples.  The physician will request imaging to confirm the presence of a 
parathyroid adenoma and to give its location with respect to the thyroid gland.  
The information from the nuclear medicine study is then often combined with 
the complementary anatomical information from an ultrasound (US) scan to give 
a full account of the patient’s condition. 
The patient may then be referred to an endocrine surgeon for the adenoma to 
be removed.  The surgeon will use the information from the imaging studies to 
allow a minimally invasive unilateral neck exploration to be carried out, which 
results in a shorter operating time and carries a lower morbidity rate than the 
more traditional bilateral neck exploration, whilst providing equivalent curative 
results (Bergenfelz et al., 2002, Russell et al., 2006, Westerdahl & Bergenfelz, 
2007, Adler et al., 2008 & 2009).  In some cases, a patient may not undergo 
surgery for a number of possible reasons, which include no adenoma being 
visualised on imaging, another condition being present that could account for 
the high Ca2+ and PTH levels, the patient being asymptomatic or the patient 
simply refusing surgery. 
It should be noted that the standard patient pathway and referral process used 
at GRI is different from that used at other institutions.  The literature suggests 
that most other centres refer patients for localisation imaging only after the 
decision is made to perform surgery (e.g. Billotey et al., 1996a, Hindié et al., 
1998, Sidhu et al., 2003).  The information required from the imaging study by 
the referring clinician will therefore differ depending on the type of referral. 
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If surgery is definitely to take place, the imaging study is used simply to guide 
the surgeon to the most likely site of the parathyroid adenoma so that minimally 
invasive surgery can be performed.  Should the surgeon fail to find a suspicious 
lesion at the suggested position, further investigation can be carried out to 
locate the parathyroid adenoma or hyperplastic glands responsible for the 
patient’s hyperparathyroidism.  The sensitivity of the imaging technique is 
therefore important in order to best locate lesions, but the specificity is less so 
as the patient will undergo surgery regardless of whether or not a lesion is 
identified on imaging. 
In contrast, the requirements from a parathyroid imaging study at GRI are very 
different.  The patient will only undergo surgery if a suspicious lesion is 
identified on imaging and the patient’s symptoms suggest a significant 
improvement in quality of life will result from the removal of the overactive 
gland(s).  It is therefore important that the clinicians reviewing the nuclear 
medicine studies are certain of the presence of a suspicious lesion before 
reporting its presence so that a patient will not undergo unnecessary surgery.  In 
this case, high specificity of the imaging technique is important to ensure that 
false positive reports are kept to a minimum. 
The standard patient pathway at GRI is therefore likely to lead to a tendency for 
the nuclear medicine clinicians to under-report suspicious lesions to prevent 
false positive results.  A larger number of negative and equivocal reports would 
therefore be expected in comparison to an institution that uses the other 
referral pattern. 
3.1.2 Standard Parathyroid Imaging Procedure at GRI 
There are a number of different methods available for the detection of 
parathyroid adenomas using functional nuclear medicine imaging, as has been 
described in detail in Section 1.3.2 of this thesis.  The standard procedure used 
in the Nuclear Medicine department at GRI is a combination of two of these 
options, washout and subtraction imaging. 
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3.1.2.1 Injection and Imaging Procedure 
When the patient attends the department, the test is first described in detail to 
ensure the patient is comfortable with the procedure before receiving any 
radiopharmaceuticals.  An intravenous injection of 20MBq of 123I-sodium iodide, 
which represents the ARSAC limit for this type of imaging, is then given to the 
patient.  The iodine is taken up by the thyroid gland only.  After a period of at 
least 20 minutes, a further intravenous injection of 99mTc-Sestamibi is given.  At 
the beginning of the study period, the standard activity ordered for use was 
750MBq - although the ARSAC limit is 900MBq - which was felt to give sufficient 
image quality for diagnosis whilst keeping radiation dose to the patient to a 
minimum.  The 99mTc-Sestamibi will be taken up by both the thyroid and 
parathyroid glands.  The activity in the syringe prior to each injection is 
measured using a Capintec isotope calibrator and is printed on the patient 
request card so that a full record of the administrations is kept. 
After a further wait of 15 minutes to allow uptake of the 99mTc-Sestamibi in the 
thyroid and parathyroid glands, the patient is seated in front of a gamma camera 
fitted with a low energy high resolution (LEHR) collimator, and a series of planar 
anterior images is acquired.  The first acquisition is a view of the neck area and 
consists of 10x60s frames, which are then summed to give a single planar image 
of 10 minutes duration.  The dynamic acquisition allows motion correction to be 
carried out prior to the images being summed in the event of the patient 
changing position during the 10 minutes of the acquisition.  A further short 
acquisition lasting 1-2 minutes is then performed with a marker placed over the 
sternal notch to give positional information for the reporting clinician.  Finally, a 
3 minute acquisition of the chest area is performed to allow visualisation of any 
ectopic parathyroid glands lying inferior to the thyroid gland. 
The patient is then asked to wait within the department and a second set of 
images, consisting of the same three acquisitions as described above, is acquired 
at 2 hours post-injection of Sestamibi.  A comparison of the relative washout of 
Sestamibi between the early (15 minutes post-injection of Sestamibi) and late (2 
hours post-Sestamibi) acquisitions can then be used to demonstrate the presence 
of a parathyroid adenoma (see Section 1.3.2). 
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3.1.2.2 Energy Windows and Image Processing 
Since the gamma emissions of the 123I and 99mTc have different energies (159keV 
and 140keV, respectively), it is possible to acquire dual-isotope images, giving 
fully registered images showing the distribution of the different 
radiopharmaceuticals.  Since the iodine is taken up only by the thyroid gland and 
the Sestamibi is taken up by both thyroid and parathyroids, subtracting the 
iodine image from the Sestamibi image should remove the thyroid from the 
resultant image and allow direct visualisation of a parathyroid adenoma, if one is 
present.  Subtraction is therefore performed on the summed 10-minute neck 
acquisitions from both the early and late sets of images. 
When imaging the distribution of a single radioisotope within the body, the 
energy window of the gamma camera is usually set up to include the whole of 
the photopeak of the spectrum of gamma photon energies incident upon the 
crystal.  A gamma camera is unable to precisely quantify the energy of each 
incident photon and so a slight spread is seen in the spectrum from a 
radioisotope producing mono-energetic gamma radiation (e.g. 99mTc at 140keV).  
The energy resolution of a gamma camera system is defined as the full width 
half maximum (FWHM) of the photopeak of 99mTc expressed as a percentage of 
the 140keV gamma emission photon energy (Bolster & Waddington, 1996).  
Values for energy resolution of <10% are typical (Dr G Gardner, personal 
communication). 
The energies of the principal gamma ray emissions from 123I and 99mTc are, 
however, very close together, meaning that the photopeaks overlap somewhat, 
and the photopeak of 123I lies partially within the standard 99mTc 10% window 
centred on 140keV, as shown in Figure 3.1.  The dual energy acquisition 
parameters are therefore set such that the window for each isotope is narrower 
than normal and is centred slightly away from the maximum of the peak, as 
shown in Figure 3.2.  This results in poorer sensitivity (counts/s/MBq) in each 
window but provides sufficient discrimination between the photopeaks to allow 
accurate images of the relative distributions of the two radioisotopes to be 
obtained with minimal cross-talk between the acquired energy windows (Hindié 
et al., 1998).  The energy windows used at GRI are 148.5keV – 181.5keV for 123I 
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(±10% window centred on 165keV) and 121.5keV – 148.5keV for 99mTc (±10% 
window centred on 135keV), as shown in Figure 3.2. 
 
Figure 3.1 - Dual-isotope 99mTc/123I acquisition spectrum showing overlapping photopeaks 
and standard 99mTc energy window 
Energy spectrum acquired using a gamma camera showing the overlapping 99mTc (left) and 
123I (right) photopeaks.  The standard acquisition energy window for 99mTc, centred on 
140keV, is shown as the red box A, which contains some of the 123I photopeak. 
 
Figure 3.2 - Spectrum of dual-isotope 99mTc/123I acquisition showing offset energy windows 
Spectrum captured from a gamma camera showing the overlapping photopeaks of the 99mTc 
(left) and 123I (right).  The acquisition energy windows are shown as red box A (99mTc) and 
blue box B (123I), respectively. 
As the images for the two isotopes are acquired simultaneously using the 
different energy windows, they are inherently registered.  This means that there 
is no need to use anatomical markers or any other method to allow registration 
to be performed after acquisition, making the subtraction processing 
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considerably easier than it would be if the two sets of data were acquired 
consecutively. 
Direct subtraction of the iodine image would not give an acceptable result since 
the relative counts in the two images will be different.  A scaling factor must 
therefore be applied to the iodine image before performing the subtraction.  To 
obtain an appropriate scaling factor, a region of interest (ROI) is drawn around 
the thyroid gland on the iodine image.  The ROI is then also applied to the 
registered Sestamibi image and the total number of counts within the ROI on 
each image is noted.  The counts in the Sestamibi ROI are divided by those in the 
iodine ROI to give the scaling factor.  The counts in every pixel of the iodine 
image are then multiplied by this scaling factor and the iodine image is 
subtracted, pixel by pixel, from the Sestamibi image. 
An example of typical summed 10-minute anterior planar parathyroid images is 
shown in Figure 3.3.  The early and late 99mTc and 123I neck images are 
demonstrated, along with the resultant subtraction images.  On the subtraction, 
a residual area of activity is seen at the lower pole of the right lobe of thyroid, 
which strongly suggests the presence of a parathyroid adenoma at this site.  The 
washout study involving only the early and late 99mTc images is less clear, but 
also suggests an area of relatively increased activity in the late image, which is 
further evidence of the presence of a parathyroid adenoma. 
3.1.3 SPECT Imaging of the Parathyroid Glands 
Prior to the commencement of this study, the department at GRI had no 
experience of performing SPECT parathyroid studies.  However, it was 
recognised by both the medical and scientific staff in the department that the 
standard anterior planar imaging procedure may not allow sufficient visualisation 
of parathyroid adenomas lying posterior to the thyroid.  One alternative 
procedure could have been to acquire lateral or anterior oblique planar images 
to give a more direct line-of-sight to the posterior of the thyroid gland, as has 
been performed by other groups (Krausz et al., 1995, Billotey et al., 1996a, 
Hindié et al., 2000 & 2009, Arveschoug et al., 2007).  It was agreed, however, 
that a study on SPECT acquisition would provide an interesting assessment of the 
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extra information available to the reporting clinician from the three-dimensional 
images. 
 
Figure 3.3 - Example of typical planar parathyroid images from GRI 
The top row shows the early neck area images (15 minutes post-injection of Sestamibi) and 
the bottom row shows the late images (2 hours post-Sestamibi).  The left-hand images are 
of 99mTc-Sestamibi distribution, in the middle are the 123I-iodide images and the subtraction 
is shown on the right. 
Many groups have published data on single-isotope parathyroid SPECT using 
99mTc-Sestamibi alone (Billotey et al., 1996a & 1996b, Torres et al., 1996, Chen 
et al., 1997, Neumann et al., 1997a, Moka et al., 2000b, Lorberboym et al., 
2003, Schachter et al., 2004, Spanu et al., 2004, Slater & Gleeson, 2005, 
Ansquer et al., 2008, Carlier et al., 2008, Ho Shon et al., 2008, Nichols et al., 
2008, Thomas et al., 2009) but at the time of the study being set up (2004), only 
one group had published results in the literature relating to the use of dual-
isotope subtraction SPECT for parathyroid localisation (Neumann et al., 1997b, 
1998 & 2000).  Since the standard procedure at GRI involves subtraction imaging, 
it was decided that the study should look into the use of dual-isotope 
subtraction SPECT parathyroid imaging.  In the event that the method proved 
useful in providing extra relevant clinical information to the reporting clinician, 
one of the sets of planar images in the standard GRI procedure could be replaced 
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by a SPECT acquisition with little or no increase in the total imaging time.  This 
study commenced in early 2006 and the following chapters describe the study 
and results in detail. 
3.1.3.1 Ethics Approval 
Approval for the study was sought from the local research ethics committee 
(LREC) at GRI.  An application was submitted on the basis of patients receiving 
an extra scan but no other intervention, with particular emphasis placed on the 
fact that no administration of a radiopharmaceutical was required beyond that 
necessary for the scan for which the patient had been referred to the 
department.  A copy of the approval notice from the LREC is included in 
Appendix A. 
In order to gain ethics approval, it was necessary to create a patient information 
sheet and consent form that could be given to potential participants in advance 
of their attendance at the department.  The information sheet had to explain 
the aims of the research as well as any potential benefits and/or risks to 
participants.  The consent form had to be completed by each participant and a 
member of departmental staff (usually the lead researcher) prior to any 
additional imaging taking place.  A copy of the information sheet and consent 
form is included in Appendix B. 
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Chapter 4 – Parathyroid Study – Materials and 
Methods 
4.1 Study Participants 
All patients referred to the Nuclear Medicine department at Glasgow Royal 
Infirmary (GRI) for a parathyroid study between February 2006 and October 2008 
were sent a copy of the patient information sheet and consent form for this 
study (see Appendix B) with their appointment letter.  These letters are usually 
sent to patients around 2 weeks prior to the appointment date.  Patients who 
expressed an interest in participating were given the opportunity to speak 
privately to either the principal researcher or another member of staff familiar 
with the aims and requirements of the study.  Those willing to take part were 
then asked to sign the consent form, which was also signed by the staff member 
seeking the consent.  There were no particular exclusion criteria, although 
claustrophobic patients tended to decline the opportunity to take part.  Patients 
on anti-thyroid medications may have presented a problem in that the uptake of 
123I-iodide in the thyroid gland would have been considerably reduced, leading to 
potential difficulties in the subtraction process, but none referred for 
parathyroid imaging during the study period were taking such medications.  On 
occasion, time constraints on the clinical service in the department meant that 
it was not possible to carry out the SPECT acquisition for this study, in which 
case the patient was informed of the situation and did not complete the consent 
form.  A total of 32 participants were recruited over the 33-month period of the 
study. 
4.2 Injected Activities 
The pre-injection activity of each radiopharmaceutical (99mTc-Sestamibi and 123I-
iodide) in the syringe was measured using the departmental Capintec and was 
recorded on the request card, as per standard departmental procedure.  The 
residual activity in each syringe was also measured and recorded post-injection 
to allow an accurate assessment of the total injected activity to be made for 
each patient. 
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4.3 SPECT Acquisition 
The SPECT acquisition was carried out between the two sets of planar images 
that are acquired according to the department’s standard protocol (see Section 
3.1.2 for details).  This meant that the participants were not required to remain 
in the department beyond the normal requirements for parathyroid imaging.  
The timing of the SPECT acquisition post-injection was not fixed but varied due 
to the requirements of the clinical service.  However, in most cases the SPECT 
images were acquired immediately after the first set of planar images and so 
commenced at around 35 minutes post-injection of 99mTc-Sestamibi. 
The parameters for the SPECT acquisition were determined using the parathyroid 
phantom designed and constructed especially for this study (see Chapter 2 for 
further details).  All acquisitions were performed on a double headed Philips 
ADAC Forte gamma camera with the patient lying supine and using a head rest to 
ensure the head and neck remained still throughout the acquisition.  For a SPECT 
acquisition, acquisition data covering 180o is sufficient to accurately reconstruct 
the distribution of radiopharmaceutical within a patient (Wagner et al., 1999).  
Since the area of interest for this study – the thyroid and parathyroid glands – 
lies close to the anterior surface of the neck, it was felt that there was no need 
to collect posterior image frames.  The parathyroid phantom described in 
Chapter 2 was used to acquire image data sets with both 180o and 360o rotations 
and these confirmed that a 180o acquisition arc produced satisfactory 
reconstructed images.  The acquisition was therefore carried out over a 180o 
anterior arc with the gamma camera heads at a relative angle of 90o. 
The remaining acquisition parameters were as follows: 1282 acquisition matrix, 
energy windows of 135keV ± 10% for 99mTc and 165keV ± 10% for 123I, parallel 
hole high resolution (VXHR) collimators, 180o anterior circular rotation, 60 
frames, 30s acquisition time per frame.  A roving zoom of a 30cm square centred 
on the thyroid gland was also applied to the acquired frames.  The patient was 
positioned as close as possible to each of the gamma camera heads consistent 
with their comfort and the need for the circular rotation of the gantry.  The 
simultaneous dual-isotope acquisition ensured that the two sets of reconstructed 
SPECT images from the two energy windows would be inherently registered with 
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no need for anatomical markers or other means of registering the images after 
acquisition. 
The total imaging time for this protocol was therefore 15 minutes.  This was felt 
to be short enough to prevent significant discomfort for the patient resulting in 
movement but long enough that an acceptable number of counts would be 
collected in each acquisition frame in order to produce reconstructed SPECT 
images of diagnostic quality. 
4.4 SPECT Image Reconstruction 
For each patient, the two sets of SPECT images – from the dual-isotope 
acquisition – were reconstructed using the iterative Ordered Subsets Expectation 
Maximisation (OSEM) algorithm on the department’s HERMES imaging computer 
system (Nuclear Diagnostics Ltd.).  In accordance with recommendations from 
the software writers at Nuclear Diagnostics, the reconstruction for both isotopes 
was performed using 15 subsets and 4 iterations in order to obtain good quality 
images that accurately represented the isotope distribution in the body whilst 
keeping reconstruction time acceptably short.  The reconstruction for each data 
set took around 1 minute.  The reconstruction included no correction for 
attenuation, since the area of interest lies so close to the anterior surface of the 
neck, or for scatter. 
A post-reconstruction filter was then applied to smooth the SPECT images.  The 
final choice of filter was reached after a process of trial-and-error using both 
patient and phantom data.  The chosen filter had to provide the best 
compromise between sharpness and excessive image noise.  It was hoped that a 
single filter could be used for both the 99mTc and 123I data sets to simplify the 
image processing procedure, but it was realised that this would be unlikely due 
to the differences in the levels of background tissue activity and uptake in the 
thyroid gland for the different isotopes. 
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4.5 SPECT Subtraction 
As with the SPECT image reconstruction, the SPECT subtraction was performed 
on the HERMES computer system.  The two sets of inherently registered 
transverse image slices were loaded side-by-side into the “Multimodality” 
display program, as shown in Figure 4.1.  An image slice giving a clear view of 
the thyroid gland was selected.  The “ROI Analysis” option was then chosen in 
order to draw a free-hand region of interest (ROI) around the thyroid gland on 
the 123I image and the Multimodality program automatically applied the same 
ROI to the 99mTc.  The counts within the ROI on each image were noted and the 
ratio of 99mTc counts to 123I counts was calculated to produce a scaling factor, k. 
 
Figure 4.1 - Parathyroid SPECT image data in "Multimodality" display program 
Example of patient image data showing a single transverse SPECT slice with 99mTc-
Sestamibi image on the left, the 123I-iodide on the right and the hand-drawn thyroid ROI in 
red.  The ROI was defined using the 123I image.  The images are inherently co-registered due 
to the dual-isotope acquisition. 
The “Volume Math” option within Multimodality was then used to multiply the 
counts in each pixel in the 123I image by the scaling factor and then subtract the 
full 123I SPECT data set from the 99mTc data set.  The formula used in the 
subtraction was therefore: 
( )ITcsub IkII ×−=  
Equation 4.1 
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where Isub is the resultant subtracted image data set, ITc is the reconstructed 
99mTc SPECT data set, k is the scaling factor described above and II is the 
123I 
SPECT image data set. 
An example of the resultant Multimodality display is shown in Figure 4.2.  The 
display shows the original 99mTc SPECT on the left and the subtraction SPECT 
data set on the right.  The area from which the thyroid gland has been 
subtracted out of the image is clearly visible as an area of little or zero counts, 
whilst a residual area of activity is seen posterior to the left lobe of thyroid, 
strongly suggesting the presence of a parathyroid adenoma in this case. 
 
Figure 4.2 - Resultant subtraction image from "Multimodality" program 
Images show the original 99mTc-Sestamibi SPECT data on the left and the co-registered 
subtraction image on the right.  An area of residual activity posterior to the left lobe of 
thyroid can be seen on the subtraction image. 
4.6 Observer Image Reviews 
In order to assess the relative clinical utility of the various different sets of 
planar and SPECT images acquired for this study, a number of observer reviews 
were carried out.  The results from the various reviews could then be compared 
with each other and with the surgical results to assess the relative clinical utility 
of different sets of image data. 
A total of 5 observers took part in the study.  Two of the observers were 
consultant nuclear medicine physicians, one was a consultant radiologist and the 
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final two were experienced nuclear medicine clinical scientists.  Each observer 
was asked to review the images independently of the other observers.  There 
was also a time gap of a minimum of several weeks between different phases of 
the study for each observer.  This was to ensure that the risk of the observer 
remembering particular patient images and giving answers based upon a previous 
review was minimised. 
Prior to the reviews commencing, all the image data was anonymised to prevent 
both issues of confidentiality and also to prevent observers recalling specific 
individuals at any time.  Each image set was given the generic patient name 
“Patient X”, where X was a number between 1 and 32.  The order of the 
individual patients was based on the image acquisition date for some reviews 
and on the alphabetical listing of the participant surname for others to ensure 
that the observers could not recall the order of the data sets between reviews. 
The observers were asked to review images in 4 phases, with each phase 
involving different sets of images from all 32 study participants.  The first review 
included only the planar image data, consisting of 99mTc-Sestamibi, 123I-iodide 
and subtraction images acquired at 15 minutes and 2 hours post-injection of 
Sestamibi.  The second review involved only the reconstructed SPECT image data 
at a single time point, but again showing 99mTc, 123I and subtraction images.  The 
third review was of the planar and SPECT image data acquired in the 99mTc 
energy window only, which simulated the conditions under which many 
departments perform single-isotope parathyroid studies.  The fourth and final 
review included all the available planar and SPECT images.  A summary of the 4 
phases and the images included for review in each is given in Table 4.1. 
Phase Images included for review 
1 Planar only – both 99mTc-Sestamibi & 123I-iodide 
2 SPECT only – both 99mTc-Sestamibi & 123I-iodide 
3 99mTc-Sestamibi only – both planar & SPECT 
4 All images – both planar & SPECT and both 99mTc-Sestamibi & 123I-iodide 
Table 4.1 - Summary of parathyroid observer study phases 
 
For each patient in each phase of the reviews, the observers were asked to give 
information on any lesions they could see in the displayed images.  Scoring 
sheets were used to record their answers, and these were completed by the 
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principal investigator who attended every review session.  The number of lesions 
seen, their location(s) and the observer’s confidence that each lesion 
represented a true parathyroid adenoma (as opposed to image artefact or some 
other pathology) were recorded.  The location was specified in relation to the 
thyroid gland and classed as left or right, upper or lower, anterior or posterior 
and medial or lateral or as ectopic.  The confidence of the observer was classed 
on a 4-point scale as definite, suggestive, equivocal or negative, with the first 
two being taken as a positive report for parathyroid adenoma and the latter two 
as a negative report.  A score from 1-5 was also given for the quality of each set 
of image data, where 1 equates to poor and 5 to excellent. 
The scoring sheets varied slightly between the phases due to the different 
information available in the images – for example, the position of a lesion in the 
antero-posterior direction cannot be obtained from an anterior planar image – 
and the sheets are shown in Appendix C. 
The results from each phase of the review were then entered into a Microsoft 
Excel spreadsheet for analysis.  As there were 5 observers and 32 patients, there 
were a total of 160 reviews in each phase.  Therefore, there were a total of 640 
reviews over the 4 phases of the observer study.  Comparisons were made 
between the results for the same observer and same patient for the different 
study phases.  A total of 6 comparisons for each of the 5 observers for each of 
the 32 patients were therefore carried out.  The difference in number of lesions 
seen was calculated along with the difference in confidence level.  Also, the 
given location of any lesions seen was compared to determine if the same lesion 
was being observed on different sets of images for the same patient.  The 
comparison data was then transferred into the Minitab software package so that 
statistical analyses could be performed on the results and any statistically 
significant trends could be identified. 
4.7 Surgical and Ultrasound Results 
The gold standard and only definitive method for determining the presence or 
otherwise of a parathyroid adenoma or hyperplasia of the parathyroid glands is 
pathology analysis via a frozen section of the gland(s) resected at surgery.  The 
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results of the observer image reviews therefore needed to be correlated to 
surgical findings to determine the true clinical utility of the various types of 
available planar and SPECT images. 
In order to carry out a comparison of the image reviews and surgical findings, 
the case notes for each patient were examined to establish both the clinical 
diagnosis given prior to imaging and/or surgery and also the pathology results 
post-surgery.  The endocrine surgeon records the location of any resected 
samples relative to the thyroid gland or other anatomical structures on the 
surgical notes, which are then included in the case notes.  The pathology 
analysis results are also included in the case notes.  All locations of resected 
parathyroid glands and the results of the pathology analysis were noted for each 
patient. 
It was soon discovered, however, that not all of the patients had undergone 
parathyroidectomy surgery after nuclear medicine imaging.  This could be for a 
number of reasons, such as the lack of a visualised lesion on imaging, the 
presence of another condition which could lead to the symptoms and blood 
analysis results seen in the patient, the patient being asymptomatic or the 
patient refusing to undergo surgery. 
Unfortunately, when the individual participants agreed to take part in the study, 
there was no possible way of knowing which would or would not have surgery.  In 
the case of those patients who did not have surgery, another standard for 
comparison was required to evaluate the relative clinical utility of the different 
nuclear medicine images available from this study.  After discussion with various 
clinicians, the decision was made to use the findings of anatomical ultrasound 
(US) imaging as the standard.  All the patient case notes were therefore re-
examined and the results of any US imaging were noted.  The location of any 
lesions observed during US was noted, along with the certainty expressed by the 
US reporter that the any lesion represented a true parathyroid adenoma.  It was 
recognised, however, that ultrasound imaging is not a true gold standard in that 
it cannot absolutely confirm or deny the presence of a parathyroid adenoma and 
must be subject to a comparison with surgical findings in the same way as 
nuclear medicine imaging.  Nevertheless, in the absence of gold standard 
surgical information, a comparison of the findings of the observer study with 
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ultrasound findings should give an indication of the relative merits of the 
different types of nuclear medicine image being evaluated. 
The results from each of the 4 phases of observer image reviews were then 
compared to the surgical or US findings using a spreadsheet, in a similar fashion 
to the comparisons from the different image reviews discussed in Section 4.6.  
The Minitab package was also used again to carry out statistical analyses on the 
findings.  The clinical utility of the various sets of available images could 
therefore be assessed in the presence of the gold standard information. 
The percentage sensitivity and specificity of adenoma detection relative to the 
surgical results for each observer were then calculated separately for each phase 
of the study.  Only the positive/negative result and the given left/right location 
were considered in the calculations, since these are the most important pieces 
of information for the endocrine surgeon prior to carrying out minimally invasive 
surgery (Anderson et al., 2008).  The sensitivity was taken to be: 
%100×
+
=
FNTP
TPySensitivit  
Equation 4.2 
 
where TP is the number of true positive results and FN is the number of false 
negative results.  The specificity was calculated as: 
%100×
+
=
FPTN
TNySpecificit  
Equation 4.3 
 
where TN is the number of true negative results and FP is the number of false 
positive results.  The results for all 5 observers were then combined to give an 
overall measure of sensitivity and specificity for each study phase.  The 
sensitivity and specificity of the ultrasound results relative to the surgical results 
was also calculated. 
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Since a significant number of the study participants did not undergo surgery, the 
sensitivity and specificity of the observers reviewing the images was also 
calculated relative to the results of ultrasound scanning to provide an 
alternative measure of accuracy of the nuclear medicine imaging.  In this case, 
the ultrasound result was taken to be the gold standard and the sensitivity and 
specificity of the nuclear medicine imaging were calculated using Equation 4.2 
and Equation 4.3.
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Chapter 5 – Parathyroid Study – Results of 
Observer Study 
5.1 Patient Demographics 
 A total of 32 patients took part in the study, with 13 males (41%) and 19 females 
(59%).  The average age of the participants was 56.7±12.9 years (mean ± 1SD) 
with a range of 28 to 83 years.  All patients were referred with high blood serum 
levels of parathyroid hormone (PTH) and calcium and all referrals asked for 
confirmation of the presence of a parathyroid adenoma to explain these results 
and any other symptoms the patient may have been experiencing.  Primary 
hyperparathyroidism had been diagnosed in 29 of the participants, whilst the 
remaining 3 had secondary hyperparathyroidism as a result of chronic renal 
failure.  In general, hyperplastic glands in secondary hyperparathyroidism are 
smaller than the parathyroid adenomas seen in primary disease and so are likely 
to be less easily visualised on imaging. 
5.2 Injected Activities 
The recorded activities in the syringes pre- and post-injection were used to 
calculate the mean, maximum and minimum administered activities of 99mTc-
Sestamibi and 123I-iodide for the 32 patients.  The distribution of administered 
activities is shown in Figure 5.1 and shows that the activity of 99mTc-Sestamibi 
administered to the patients was relatively variable and often well below the 
intended activity of 700MBq.  The main reason for this is that Sestamibi has a 
tendency to stick to the walls of the glass vial and plastic syringe, meaning that 
not all of the available activity is administered to the patient.  Also, the 
administered activity of 99mTc-Sestamibi for patients 29-32 can be seen to be 
generally higher than for the preceding patients.  This is due to the fact that 
standard departmental procedure was modified at the time these patients 
attended the department and the activity ordered for administration was 
increased to the ARSAC limit of 900MBq in order to provide better image quality 
for diagnostic purposes. 
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Table 5.1 shows the mean, maximum and minimum administered activities of 
99mTc-Sestamibi and 123I-iodide for the 32 patients.  It is immediately clear from 
the table that the maximum and minimum values for administered activity of 
123I-iodide are considerably different to the intended 20MBq activity.  The 
maximum occurred due to an error by the operator in drawing up the  
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Figure 5.1 - Distribution of administered activities 
Column chart showing the administered activity in MBq of 99mTc-Sestamibi (blue) and 123I-
iodide (brown) for each of the 32 study participants 
radiopharmaceutical from the syringe.  The minimum occurred when there was a 
shortage of available 123I-iodide.  The ARSAC certificate holder felt, however, 
that in this instance, the test should continue as valuable clinical information 
could still be gained even with a low administered activity. 
 Administered Activity (MBq) 
 Intended Mean Maximum Minimum 
99mTc-Sestamibi 700 621.9 852.8 386.5 
123I-iodide 20 20.8 48.8 3.4 
Table 5.1 - Administered activities of radiopharmaceutical 
Intended, mean, maximum and minimum administered activities of 99mTc-Sestamibi and 123I-
iodide for the 32 study participants 
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5.3 SPECT Reconstruction 
The primary aim in reconstructing the SPECT image data was to produce 
clinically acceptable images.  It was therefore important to achieve a good 
balance between excessive smoothing, which can lead to blurring and a loss of 
resolution, and excessive sharpness, when the noise level in the image becomes 
unacceptably high.  Due to the different count density in the two acquisition 
energy windows (99mTc and 123I), the same reconstruction parameters applied to 
both data sets may not provide suitable image quality in both cases.  Some trial 
and error was therefore required to find the parameters giving acceptable image 
quality for the two sets of images. 
The superior-inferior extent of the reconstruction for all the SPECT data sets was 
selected to ensure that both the salivary glands and heart were visible in the 
99mTc-Sestamibi images.  This was in order to provide some useful anatomical 
location information for the observers reviewing the images.  The 123I-iodide 
images were then reconstructed with the same superior-inferior extent so that 
the inherent registration of the two sets of image data was maintained. 
As discussed in the previous chapter (Section 4.4), the number of subsets and 
iterations used in the Ordered Subsets Expectation Maximisation (OSEM) 
reconstruction on the department’s HERMES computer system (Nuclear 
Diagnostics Ltd.) were set to 15 and 4 respectively for both the 99mTc and 123I 
image data, which gave rapid convergence to the physiological distribution of 
activity.  The resultant images from this reconstruction were felt to be too sharp 
and contained too much noise.  An example of unfiltered 99mTc and 123I 
reconstructed images for a single patient is shown in Figure 5.2, clearly 
demonstrating the need for some post-reconstruction smoothing. 
The following filters, with the option to vary certain parameters (given in 
brackets for each), are available from the HERMES system: Butterworth (cutoff 
frequency in cycles/cm and order), Hanning (cutoff frequency in cycles/cm), 
Low Pass (cutoff frequency in cycles/cm), Metz (Metz factor and MTF resolution 
from very low to very high) and 3x3x3 smoothing (no variable parameters).  All 
the filters were tested on a number of patient data sets using the data acquired 
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in both the 99mTc and 123I energy windows.  For each type of filter, a number of 
different image data sets were produced after varying the optional parameters.  
The goal was to produce images with the best compromise between sharpness 
and excessive image noise. 
 
Figure 5.2 - Unfiltered reconstructed parathyroid SPECT images 
Example of reconstructed patient parathyroid images without post-reconstruction filter 
applied.  On the left are the 99mTc-Sestamibi images and on the right are the co-registered 
123I-iodide images.  On each, the top row is transverse slices, the middle row is coronal 
slices and the bottom row is sagittal slices. 
An example of a reconstructed dual-isotope SPECT data set is shown in Figure 
5.3.  In this case, the filter applied post-reconstruction has resulted in excessive 
image smoothing, meaning that the structure of the thyroid gland cannot be 
discerned. 
 
Figure 5.3 - Overly smoothed parathyroid SPECT images 
Example of patient parathyroid SPECT data that has been excessively smoothed by the post 
reconstruction filter.  Figure shows the same slices in the same layout as in Figure 5.2. 
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In contrast, the images shown in Figure 5.4 have been insufficiently filtered and 
so are too sharp and noisy.  The images in Figure 5.4 represent the same slices 
from the same patient data set as shown in Figure 5.2 and Figure 5.3. 
The images shown in Figure 5.5 are the same slices from the same patient data 
set as shown in Figure 5.2, Figure 5.3 & Figure 5.4, but in this case, the post-
reconstruction filter applied gives a much better compromise between 
smoothing and noise.  These images represent an example of the final choice of 
post-reconstruction filter, which was decided upon by asking experienced 
physicians and clinical scientists to view a number of SPECT image data sets, to 
which different post-reconstruction filters had been applied, for several 
different patient acquisitions.  Each reviewer was asked to nominate the images 
they felt produced the best compromise between smoothing and noise and the 
consensus view was taken as the most appropriate filter to use for this study.  
Although objective measures – such as resolution, contrast or signal-to-noise 
ratio (SNR) – can be used to compare images to which different post-
reconstruction filters have been applied, the subjective method used here is the 
most commonly applied.  This is due to the fact that human observers will report 
from the final images and so they must be subjectively acceptable to the 
observer. 
 
Figure 5.4 - Overly sharp parathyroid SPECT images 
Example of patient parathyroid SPECT data that remains too sharp after the application of 
the post-reconstruction filter.  Figure shows the same slices in the same layout as in Figure 
5.2. 
Unexpectedly, the same Hanning filter with a cutoff frequency of 3 cycles/cm 
gave acceptable image quality for both the reconstructed 99mTc and 123I image 
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data for a number of different patient data sets.  This filter was therefore 
applied to all the reconstructed data prior to performing image subtraction. 
 
Figure 5.5 - Parathyroid images acceptably filtered 
Example of patient parathyroid SPECT data that has been filtered to give the best 
compromise between smoothing and excessive image noise.  Figure shows the same slices 
in the same layout as in Figure 5.2. 
Subtraction SPECT images were then created for each patient data set and all 
images were anonymised before being shown to the observers.  An example of a 
subtraction SPECT data set demonstrating an area of residual activity consistent 
with a parathyroid adenoma is shown in Figure 5.6. 
 
Figure 5.6 - Subtraction SPECT images 
Example of patient parathyroid subtraction SPECT images with area of residual activity 
seen posterior to the left lobe of thyroid, indicating the presence of a parathyroid adenoma.  
The same slices are shown in the same layout as in Figure 5.2. 
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5.4 Observer Study Results 
5.4.1 General Comments 
All five observers took part in all 4 phases of the observer study (see Table 4.1 
for list of phases), each reviewing the 32 patient image data sets in each phase.  
Detailed feedback was provided for each image data set reviewed, but the 
observers were also asked for general comments during the process.  An 
overview of these comments will now be given. 
All the observers were comfortable reviewing the images shown during the first 
phase of the study, which were the planar images acquired according to the 
department’s standard protocol.  The second phase gave the observers the 
opportunity to review the SPECT images (including the subtraction images) in the 
absence of the planar images.  This brought a mixture of feedback with general 
agreement that the anterior-posterior information available from the SPECT 
images was useful but that the amount of available data meant that the process 
of review was sometimes more complicated than with the planar images.  Most 
of the observers also commented that by the time they were reviewing the last 
few sets of patient data, they were more comfortable with the SPECT data than 
they had been at the start of this phase, when viewing parathyroid SPECT data 
was entirely new to them.  This may have affected the image quality scores 
given for this phase of the study. 
All the observers felt that not enough clinical information was available to them 
during the third phase of reviewing the 99mTc-Sestamibi images only, even 
though both planar and SPECT images were shown.  The lack of specific image 
information delineating the thyroid gland meant that the observers were often 
unsure if a possible lesion was thyroid tissue or was indeed a parathyroid 
adenoma.  Although this feedback was essentially negative, the fact that all the 
observers are used to seeing the 123I thyroid images in their normal practice may 
have been a significant factor. 
The final phase of the review process involved the observers reviewing all the 
planar and SPECT images together.  The comments received for this phase were 
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almost all positive with the observers feeling that the SPECT images often 
helped to confirm or deny a possible lesion seen on the planar images.  They also 
commented that there were a number of lesions seen only on the SPECT images 
that were not visualised on the planar images.  One of the observers also 
consistently commented that SPECT/CT data would be even more useful than 
just SPECT as it would give more anatomical detail to aid in the localisation of 
any lesions.  The other observers did not share this feeling, however, and felt 
that only in the case of an obviously ectopic parathyroid adenoma would CT data 
provide any significant localisation information. 
In all the results presented in the remainder of this chapter and in Chapter 6, 
the observers are numbered 1-5 in the same order each time.  Observers 1 & 3 
were consultant nuclear medicine physicians, observer 2 was a consultant 
radiologist (all ARSAC certificate holders), and observers 4 & 5 were experienced 
clinical scientists in nuclear medicine physics. 
5.4.2 Phase 1 – Planar Images 
5.4.2.1 Lesions Seen 
When reviewing the planar images only, the 5 observers noted a total of 89 
lesions.  Of these, 42 (47%) were deemed to definitely represent a parathyroid 
adenoma, 19 (21%) were suggestive for parathyroid adenoma and the remaining 
28 (32%) were classed as equivocal lesions.  The observers therefore saw a total 
of 61 lesions that they felt positively demonstrated the presence of a 
parathyroid adenoma as equivocal reports were taken as negative in this study.  
Of the 160 reviews in this phase (32 patients each reviewed by 5 observers), 80 
(50%) were classed as negative for the presence of any lesions. 
5.4.2.2 Image Quality and Usefulness Scores 
Scores were also given for the quality of the 99mTc-Sestamibi images, the 123I-
iodide images and the subtraction images for each patient.  The scoring scale 
was from 1 to 5 with 1 representing poor and 5 excellent image quality.  The 
observers were also asked to give a score on the same scale for the relative 
usefulness of the subtraction images.  Average values of these scores were taken 
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for each patient and then the average of these results taken over the 32 patients 
to assess the relative quality of the different images.  Average scores were also 
calculated for each observer and compared. 
The variation in the given scores was wide between patients but less so between 
different observers.  The average scores for each of the individual observers and 
overall are shown in Table 5.2.  The results show that all observers gave higher 
scores for image quality to the 123I-iodide images than to the 99mTc-Sestamibi 
images.  Indeed, the observers commented that the lack of background activity 
on the 123I-iodide images tends to automatically lead to better image quality 
than is seen for the 99mTc-Sestamibi or subtraction images.  The usefulness of 
subtraction results show that, in general, the observers found these images more 
useful than not, in that the mean scores are above 3 (the median of the scoring 
scale) for each observer. 
Observer 99mTc-Sestamibi 123I-Iodide Subtraction Usefulness of 
Subtraction 
1 3.0 3.3 3.2 3.1 
2 3.4 3.6 3.7 3.8 
3 3.3 3.7 3.5 3.5 
4 3.4 3.7 3.4 3.3 
5 2.6 3.8 3.4 3.7 
Overall 3.2 3.6 3.4 3.5 
Table 5.2 - Image quality scoring for planar images in observer study phase 1 
Average image quality scores given by each observer and for all observers together on a 
scale of 1 (poor) to 5 (excellent). 
The information on the location of any lesions seen by the observers will not be 
discussed in detail here.  Instead, the findings will be compared with those from 
the other phases of the observer study in Section 5.5. 
5.4.3 Phase 2 – SPECT Images 
5.4.3.1 Lesions Seen 
The observers commented on the presence of a total of 183 lesions whilst 
reviewing the SPECT image data in isolation from the planar views.  In 89 (49%) 
cases, the observers were confident that the lesion definitely represented a 
parathyroid adenoma, in 45 (24%) instances they felt the lesion was suggestive 
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for a parathyroid adenoma, whilst in the remaining 49 (27%) cases they classed 
the lesion as equivocal.  A total of 24 (15%) of the 160 reviews in this phase were 
reported as negative by the observers.  There were therefore a total of 134 
lesions reported as positive for parathyroid adenoma, which is a significant 
increase on the 61 positive lesions seen on the planar image in phase 1 of the 
review. 
5.4.3.2 Image Quality and Usefulness Scores 
As for phase 1 of this review, the observers were asked to give scores for the 
quality and usefulness of the images shown for each patient data set.  The same 
scale was used and, once again, scores were given for the quality of the 99mTc-
Sestamibi, 123I-iodide and subtraction SPECT images.  A score was also given for 
the overall usefulness of the subtraction SPECT data set for assisting the 
observer in determining the presence or otherwise of a parathyroid adenoma. 
The average scores for each individual observer and for all the observers 
together were again calculated and these are shown in Table 5.3.  As for the 
planar image reviews, the scores given to the 123I-iodide images were 
consistently higher than those given for the 99mTc-Sestamibi images.  Most of the 
scores given in this phase were lower than those in phase 1, which may in part 
be attributed to the fact that the observers had not seen parathyroid SPECT 
image data prior to this phase of the study and so were not used to reviewing 
the images.  However, the observers still generally found the subtraction images 
useful, with only observer 4 giving an average score of less than 3. 
Observer 99mTc-Sestamibi 123I-Iodide Subtraction Usefulness of 
Subtraction 
1 2.7 3.3 3.3 3.4 
2 3.2 3.5 3.6 3.4 
3 2.6 3.0 2.7 3.3 
4 3.1 3.5 3.0 2.9 
5 2.7 3.3 2.9 3.4 
Overall 2.8 3.3 3.1 3.3 
Table 5.3 - Image quality scoring for SPECT images in observer study phase 2 
Average image quality scores given by each observer and for all observers together on a 
scale of 1 (poor) to 5 (excellent). 
Chapter 5  87 
Once again, the detail of the location of the lesions seen will not be discussed 
here but comparisons with the results from other phases of the observer study 
are discussed in Section 5.5. 
5.4.4 Phase 3 – 99mTc-Sestamibi Planar and SPECT Images 
5.4.4.1 Lesions Seen 
For the third phase of the observer study, the observers were asked to review 
the image data collected in the 99mTc energy window only – that is, the images 
demonstrating the distribution of 99mTc-Sestamibi within the patient.  Both 
planar and SPECT images acquired in the 99mTc energy window were shown but 
no 123I-iodide or subtraction images were included in this phase.  The observers 
reported seeing a total of 116 lesions, which is more than were on the planar 
dual-isotope and subtraction planar scans shown in phase 1 but fewer than when 
the observers reviewed the SPECT images in phase 2.  Of these 116 lesions, 25 
(22%) were classed by the observers as definitely parathyroid adenoma, 37 (32%) 
were judged to be suggestive for parathyroid adenoma and the final 54 (46%) 
were said to be equivocal.  In total 57 (36%) of the reviews in this phase were 
reported as negative by the observers.  Therefore, there were a total of 62 
lesions deemed positive for the presence of parathyroid adenoma seen in this 
phase of the study, which is similar to the number given as positive in phase 1. 
5.4.4.2 Image Quality and Usefulness Scores 
On this occasion, scores were given for the quality of the planar and SPECT 
images and for the usefulness of the SPECT image in determining the presence or 
absence of a parathyroid adenoma and the results are shown in Table 5.4.  
Interestingly, the scores given for planar image quality are generally lower than 
those given for the 99mTc-Sestamibi planar images in phase 1, even though the 
images shown were exactly the same.  Similarly, the scores given for the SPECT 
images in phase 3 were generally lower than those given for the 99mTc-Sestamibi 
SPECT images in phase 2.  These findings indicate that the presence of the 123I-
iodide images showing uptake only in the thyroid gland has a bearing on the 
perceived quality of the much noisier 99mTc-Sestamibi images.  The observers 
gave a mixed response to the usefulness of the SPECT images for the review, 
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with three (observers 1, 3 and 5) giving average scores of greater than 3, whilst 
the others (observers 2 and 4) gave average scores of less than 3. 
Observer Planar SPECT Usefulness of SPECT 
1 2.9 3.1 3.8 
2 3.2 2.9 2.5 
3 3.4 2.8 3.2 
4 3.3 3.2 2.9 
5 2.4 3.0 3.3 
Overall 3.0 3.0 3.1 
Table 5.4 – Image quality scoring for 99mTc-Sestamibi images in observer study phase 3 
Average image quality scores given by each observer and for all observers together on a 
scale of 1 (poor) to 5 (excellent). 
The comparisons between the results from this phase of the study with those 
from the other phases are discussed in Section 5.5 and so no further details will 
be given here. 
5.4.5 Phase 4 – All Planar and SPECT Images 
5.4.5.1 Lesions Seen 
The fourth and final phase of the observer study involved asking the observers to 
review all the available image data for each patient together.  That is, the 
observers were shown the planar and SPECT images from both the 99mTc and 123I 
acquisition energy windows as well as the planar and SPECT subtraction images.  
The observers reported a total of 155 lesions in this phase of the study, which is 
lower than the total number seen in phase 2 but higher than in either phase 1 or 
phase 3.  In 70 (45%) cases the observers felt that the lesion seen was definitely 
a parathyroid adenoma, whilst in 33 (21%) they felt that the lesion was 
suggestive for the presence of a parathyroid adenoma and in the remaining 52 
(34%) the lesion was classed as equivocal.  Negative results were reported in 33 
(21%) of the 160 reviews.  There were therefore 103 lesions positively identified 
as parathyroid adenoma in this phase of the study, which is a higher number 
than seen in phases 1 and 3 but considerably fewer than seen in phase 2. 
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5.4.5.2 Image Quality and Usefulness Scores 
As was the case in phase 3, the observers were asked to give scores for the 
quality of the planar and SPECT images as well as giving a score for the 
usefulness of the SPECT images in reaching a final conclusion.  The results are 
shown in Table 5.5 and indicate that the observers generally found the quality of 
the SPECT and planar images to be similar.  The scores given for the usefulness 
of the SPECT images indicate that all the observers generally found the SPECT 
data helpful in reaching a conclusion as to the presence or otherwise of a 
parathyroid adenoma.  Observer 5, in particular, gave high scores for the 
usefulness of SPECT resulting in an average score of greater than 4. 
As was the case for the previous phases, the detail of the lesions seen will not be 
discussed here but instead will be commented upon in Section 5.5 where the 
results from this phase of the study are compared with those from the preceding 
three phases. 
Observer Planar SPECT Usefulness of SPECT 
1 3.2 3.0 3.6 
2 3.7 3.3 3.3 
3 3.3 3.0 3.2 
4 3.1 3.4 3.7 
5 3.1 3.2 4.3 
Overall 3.3 3.2 3.6 
Table 5.5 - Image quality scoring for all planar and SPECT images in observer study phase 4 
Average image quality scores given by each observer and for all observers together on a 
scale of 1 (poor) to 5 (excellent). 
5.4.6 Summary of Lesions Seen 
Figure 5.7 shows the total number of lesions seen by the 5 observers on each 
phase of the observer study.  It also shows the number of lesions on each phase 
that the observers felt were “definite”, “suggestive”, “equivocal” or “negative” 
for parathyroid adenoma.  It is immediately clear that the highest number of 
lesions were seen in phases 2 & 4 of the study, which are those phases that 
included the review of the dual-isotope subtraction SPECT images.  The phase 
with the fewest lesions seen in total, as well as the highest number of negative 
reports, was phase 1, in which only planar images were available for review.  
The numbers of equivocal and negative reports for phase 3 were also high, 
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confirming that the observers were not confident reviewing images in the 
absence of the 123I-iodide thyroid images. 
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Figure 5.7 - Bar chart of number of lesions seen 
Bar chart showing the total number of lesions seen by the 5 observers on each phase of the 
observer study as well as the numbers given in each category of confidence. 
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Figure 5.8 - Bar chart of lesions seen by each observer 
Bar chart showing the number of lesions seen by each of the 5 observers individually on 
each of the 4 phases of the observer study 
Chapter 5  91 
A bar chart showing the number of lesions that was seen by each individual 
observer on each of the 4 study phases is shown in Figure 5.8.  Observer 5 has a 
clear tendency to see more lesions on the images than any of the other 
observers.  In contrast, observer 2 saw fewer lesions than all other observers on 
all 4 phases of the study.  The chart also confirms the fact that more lesions 
were seen on phases 2 & 4 of the study, when the dual-isotope subtraction 
SPECT images were available for review, than on the other phases. 
5.5 Comparisons of Results of Observer Study 
The information provided by the observers from each phase of the study was 
compared to that from each of the other phases to assess the differences 
between the number of lesions seen, the certainty that the lesions seen 
represented true parathyroid adenomas and the locations of the lesions.  The 
reported information from each individual observer for each patient was 
compared directly to determine any differences.  In cases where multiple lesions 
were seen in one or other of the phases being compared, comparisons were 
made between each individual lesion seen in one phase with each individual 
lesion seen in the other phase.  That is, if an observer saw 2 lesions in one phase 
of the study and 3 in another, a total of 6 comparisons were carried out. 
The difference in the number of lesions seen in the different phases was 
calculated and then the Wilcoxon Signed Ranks test was applied using the 
Minitab software (Minitab Inc.) to establish if any statistical differences existed.  
The number of instances for each observer of the number of lesions seen in one 
phase being higher, lower and the same as seen in the other phase was also 
determined.  The comparison of the observers’ certainty that a given lesion 
represented a true parathyroid adenoma yielded a result of “more”, “same” or 
“less” certain.  Reviews classed as negative were placed at the bottom of the 
certainty scale.  For each patient, an overall certainty comparison was made by 
summing the number of “more”, “same” and “less” results and determining the 
class with the highest total.  The Wilcoxon Signed Ranks test was also applied to 
the results from each observer and to the combined results for all observers by 
giving each “more” result a value of 1, “same” a value of 0 and “less” a value of 
-1. 
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Finally, the location of lesions reported in the different phases was compared.  
The given location was classed as “same” or “different” for left versus right, 
upper versus lower, anterior versus posterior and medial versus lateral.  The left 
versus right and upper versus lower results were then combined using the logical 
“AND” function to give a “same” or “different” result for establishing if the 
same lesion was seen in the different phases.  For comparisons involving only 
phases 2, 3 and 4, the anterior versus posterior information was also added.  In 
comparisons involving phase 1, no anterior/posterior data was included as it is 
not possible to determine the position of a lesion in this plane from anterior 
planar images only.  The given medial/lateral information was not included in 
the comparison because the observers often felt that it was not appropriate to 
report on this aspect of the location of an observed lesion.  Statistical testing 
was not applied to the location information due to the fact that the comparisons 
of different phases were not necessarily of the same lesion.  This means that the 
data are not truly paired and applying the Wilcoxon Signed Ranks test could give 
misleading and inaccurate results. 
In the following sections, the differences between the number of lesions seen 
are always quoted as the later phase minus the earlier phase.  Also, a letter has 
been used to designate the number of lesions seen in each phase of the study as 
follows: P for phase 1 (dual-isotope planar images), S for phase 2 (dual-isotope 
SPECT images), M for phase 3 (Sestamibi SPECT and planar images) and A for 
phase 4 (all planar and SPECT images).  A category described as “M>S”, for 
example, therefore means that the number of lesions seen on phase 3 was 
greater than the number seen on phase 2 of the study. 
5.5.1 Phase 2 versus Phase 1 Reviews 
5.5.1.1 Number of Lesions Seen 
The number of lesions seen in phase 1 (planar only) was subtracted from the 
number seen in phase 2 (SPECT only).  Table 5.6 summarises the number of 
times each observer saw more, the same or fewer lesions on the SPECT images.  
It shows that in most cases, the number of lesions seen on reviewing the SPECT 
images is the same as the number seen on the planar images.  However, there 
are more cases of the number of lesions seen being greater on the SPECT than on 
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the planar images.  Observer 5 has the highest number in the “S>P” category 
whilst observer 1 has the fewest. 
Observer S > P S < P S = P Total 
1 9 3 20 32 
2 11 1 20 32 
3 14 2 16 32 
4 15 0 17 32 
5 21 0 11 32 
Total 70 6 84 160 
Table 5.6 - Comparison of number of lesions seen in phase 1 (planar only) and phase 2 
(SPECT only) 
S>P = number of times more lesions were seen on SPECT than planar, S<P = number of 
times fewer lesions were seen on SPECT than on planar, S=P = number of times same 
number of lesions were seen on SPECT as on planar. 
The Wilcoxon Signed Ranks non-parametric statistical test was applied to the 
differences in the number of lesions seen for each observer individually as well 
as for all the reviews in total.  Each application of the test gave a p-value of 
statistical significance, an estimated median and a 95% confidence interval (CI).  
A p-value of less than 0.05 was taken to indicate a statistically significant result.  
The results are shown in Table 5.7.  It should be noted that the lowest p-value 
the software will define is 0.001 so any value lower than this is stated as <0.001. 
Observer p-value Estimated median 95% CI 
1 0.108 0.0 (0.0, 0.5) 
2 0.011 0.5 (0.0, 0.5) 
3 0.006 0.5 (0.0, 0.5) 
4 0.001 0.5 (0.5, 1.0) 
5 <0.001 1.0 (1.0, 1.5) 
Overall <0.001 0.5 (0.5, 0.5) 
Table 5.7 - Results from Wilcoxon Signed Ranks test on differences in number of lesions 
seen (phase 2 vs phase 1) 
Output from Minitab software applied to the differences in the number of lesions seen 
between the SPECT and planar images. 
These results clearly show that for 4 of the 5 observers and for the data from all 
the observers combined, there is a statistically significant difference in the 
number of lesions seen with p<0.05.  However, for the other observer (observer 
1), the result of p=0.108 indicates that no such statistically significant difference 
exists.  This is in keeping with the results in Table 5.6 where this observer had 
the lowest number in the “S>P” category.  In contrast, observer 5 has both the 
lowest p-value and highest estimated median of all the observers, which again 
supports the results shown in Table 5.6.  The estimated median values from the 
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test are all ≥0, indicating that, in general, more lesions are seen on the SPECT 
than on the planar images. 
5.5.1.2 Confidence of Lesions Representing True Adenoma 
A total of 224 comparisons were carried out between the confidence level 
expressed by the observer from the review of the SPECT images and the 
confidence scores from the planar images.  The number of comparisons falling 
into each of the “more”, “same” and “less” categories from each observer and 
the combined numbers overall are shown in Table 5.8.  It can be seen that 
observers 1-4 all have more than 50% of the comparisons in the “more” category, 
with observer 3 having the highest proportion at 60%, meaning that the 
observers are all more confident that they are seeing true lesions on SPECT 
images more than half of the time.  Although observer 5 had slightly less than 
50% in this category, it still represented the highest proportion for this observer.  
Observer 5 also had the highest number of comparisons carried out in total, 
meaning that this observer tended to see more lesions than the others. 
Observer No. More (%) No. Same (%) No. Less (%) Total 
1 18 (53%) 13 (38%) 3 (9%) 34 
2 18 (51%) 14 (40%) 3 (9%) 35 
3 25 (60%) 14 (33%) 3 (7%) 42 
4 23 (57%) 13 (32%) 4 (10%) 40 
5 36 (49%) 27 (36%) 11 (15%) 74 
Overall 119 (53%) 81 (36%) 24 (11%) 224 
Table 5.8 - Results from comparison of confidence levels expressed (phase 2 vs phase 1) 
Number of comparisons between expressed confidence levels that showed observers as 
more, same or less confident looking at the SPECT images as compared to the planar.  
Percentages of the total in each category for each observer and overall are given in 
brackets. 
For 19 (59%) of the 32 patients, the observers were generally more confident 
that the lesions they saw in the SPECT were true lesions when compared to their 
confidence reviewing the planar images, whilst for 12 (38%) patients they 
expressed the same level of confidence.  Therefore, they were generally less 
confident for only 1 (3%) patient, indicating that the SPECT images give a 
significant increase in the confidence level.  The results of the Wilcoxon Signed 
Ranks test applied to the comparisons for each observer and for the results for 
all the observers combined are shown in Table 5.9.  Again, a p-value of <0.05 
was taken to be statistically significant. 
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The results clearly show that a statistically significant difference exists for all 
the observers with p<<0.05 in all cases.  The fact that the estimated median 
values are all >0 and the 95% CIs are all positive is as expected, given that the 
observers are more confident when reporting from the SPECT images than from 
the planar. 
Observer p-value Estimated median 95% CI 
1 0.004 0.5 (0.0, 0.5) 
2 0.004 0.5 (0.0, 0.5) 
3 <0.001 0.5 (0.5, 1.0) 
4 0.001 0.5 (0.5, 1.0) 
5 0.002 0.5 (0.0, 0.5) 
Overall <0.001 0.5 (0.5, 0.5) 
Table 5.9 - Results from Wilcoxon Signed Ranks test on differences in expressed 
confidence level (phase 2 vs phase 1) 
Output from Minitab software applied to the comparison of confidence level expressed by 
the observers between the SPECT and planar images. 
5.5.1.3 Location of Observed Lesions 
The given locations of any lesions reported by the observers were compared 
between the two phases of the review.  The left/right locations were compared 
separately from the upper/lower results, all locations being relative to the 
thyroid gland.  The findings were then combined using the logical AND function 
to determine how many lesions were seen at the same location on both sets of 
images.  As discussed in Section 5.5, no comparison of the anterior/posterior 
locations was possible due to the lack of information in this plane on the planar 
images. 
Table 5.10 gives the results of the left/right comparison, showing the number 
(and percentage) of lesions seen in the same and different locations for each 
observer.  The results show that there are roughly equal proportions in each 
category for each of the observers individually and for all observers combined.  
Observer 1 has the highest proportion of lesion to which the same left/right 
location was given at 57% whilst observer 5 has the lowest fraction at 43%. 
The findings from the comparison of the given upper/lower locations are 
summarised in Table 5.11.  Again, the proportions in the two categories are 
similar, but there is a tendency for the number of lesions given different 
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locations to be slightly higher.  Once again, observer 5 had the lowest proportion 
of lesions reported at the same location on the two sets of images. 
Observer No. Same (%) No. Different (%) Total 
1 20 (57%) 15 (43%) 35 
2 19 (56%) 15 (44%) 34 
3 21 (50%) 21 (50%) 42 
4 19 (48%) 21 (52%) 40 
5 32 (43%) 42 (57%) 74 
Overall 111 (49%) 114 (51%) 225 
Table 5.10 - Results of comparison in left/right location between lesions seen on SPECT and 
planar images 
Number and percentage of lesions seen in the same and different left/right location for each 
observer and for the combined for all observers. 
Observer No. Same (%) No. Different (%) Total 
1 18 (51%) 17 (49%) 35 
2 16 (47%) 18 (53%) 34 
3 19 (45%) 23 (55%) 42 
4 18 (45%) 22 (55%) 40 
5 29 (39%) 45 (61%) 74 
Overall 100 (44%) 125 (56%) 225 
Table 5.11 - Results of comparison in upper/lower location between lesions seen on SPECT 
and planar images 
Number and percentage of lesions seen in the same and different upper/lower location for 
each observer and for the combined for all observers. 
A summary of the results from combining the data on differences in location is 
given in Table 5.12.  The data shows that for each observer, the number of 
lesions seen at different overall locations was greater than the number seen at 
the same location.  This will be partly explained by the fact that more lesions 
were seen on the SPECT images than the planar but it is interesting to note that 
it was not necessarily the same lesion that was seen on both planar and SPECT 
images for an individual patient. 
Observer No. Same (%) No. Different (%) Total 
1 16 (46%) 19 (54%) 35 
2 16 (47%) 18 (53%) 34 
3 18 (43%) 24 (57%) 42 
4 18 (45%) 22 (55%) 40 
5 24 (32%) 50 (68%) 74 
Overall 91 (41%) 133 (59%) 225 
Table 5.12 - Results of combined left/right and upper/lower location comparisons between 
lesions seen on SPECT and planar images 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
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5.5.2 Phase 3 versus Phase 1 Reviews 
5.5.2.1 Number of Lesions Seen 
The number of lesions seen in phase 1 (planar only) was subtracted from the 
number seen in phase 3 (Sestamibi only, planar + SPECT).  A summary of these 
results is shown in Table 5.13.  As was the case for the phase 1 vs phase 2 
comparison, an identical number of lesions were seen on the two sets of images 
more often than not.  Observer 2 has the lowest number in the “M>P” category 
whilst observer 5 has the highest. 
Observer M > P M < P M = P Total 
1 10 6 16 32 
2 5 7 20 32 
3 9 4 19 32 
4 11 5 16 32 
5 15 4 13 32 
Total 50 26 84 160 
Table 5.13 - Comparison of number of lesions seen in phase 1 (planar only) and phase 3 
(Sestamibi only) 
M>P = number of times more lesions were seen on Sestamibi (MIBI) than planar, M<P = 
number of times fewer lesions were seen on Sestamibi than on planar, M=P = number of 
times same number of lesions were seen on Sestamibi as on planar. 
The Wilcoxon Signed Ranks test was applied to the data from this comparison in 
the same way as discussed in Section 5.5.1.1.  The results are shown in Table 
5.14. 
Observer p-value Estimated median 95% CI 
1 0.394 0.0 (0.0, 0.5) 
2 0.638 0.0 (-0.5, 0.0) 
3 0.382 0.0 (0.0, 0.5) 
4 0.155 0.0 (0.0, 0.5) 
5 0.009 0.5 (0.0, 1.0) 
Overall 0.008 0.0 (0.0, 0.5) 
Table 5.14 - Results from Wilcoxon Signed Ranks test on differences in number of lesions 
seen (phase 3 vs phase 1) 
Output from Minitab software applied to the differences in the number of lesions seen 
between the Sestamibi only and planar images. 
In this instance, for 4 of the 5 observers (observers 1-4), no statistically 
significant difference existed between the number of lesions seen in the two 
phases of the study.  Only the results for observer 5 and the combined data from 
all the observers shows statistical significance with p<0.05.  The estimated 
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median of 0.5 for observer 5 indicates that this observer tended to see more 
lesions on the Sestamibi only images than on the planar, which supports the 
results shown in Table 5.13. 
5.5.2.2 Confidence of Lesions Representing True Adenoma 
There were a total of 185 comparisons carried out on the confidence level 
differences expressed by the observers in the two phases.  The results are shown 
in Table 5.15.  On this occasion, the spread of results is much more even, with 
the highest number falling into the “same” category.  Once again, however, 
observer 5 had the highest total number of comparisons, meaning that this 
observer tends to see more lesions in the images than do the other observers. 
Observer No. More (%) No. Same (%) No. Less (%) Total 
1 10 (30%) 12 (35%) 12 (35%) 34 
2 6 (19%) 17 (53%) 9 (28%) 32 
3 11 (32%) 12 (35%) 11 (32%) 34 
4 13 (37%) 13 (37%) 9 (26%) 35 
5 19 (38%) 14 (28%) 17 (34%) 50 
Overall 59 (32%) 68 (37%) 58 (31%) 285 
Table 5.15 - Results from comparison of confidence levels expressed (phase 3 vs phase 1) 
Number of comparisons between expressed confidence levels that showed observers as 
more, same or less confident looking at the Sestamibi only images as compared to the 
planar.  Percentages of the total in each category for each observer and overall are given in 
brackets. 
The observers were generally more confident that they were seeing true lesions 
on the Sestamibi planar + SPECT images in 10 (31%) of the 32 patients, less 
confident in 9 (28%) and they expressed similar levels of confidence in 13 (41%) 
patients.  This suggests that there is no significant difference in the level of 
confidence derived by the observers from reviewing planar images alone or the 
Sestamibi planar + SPECT images.  The results of the comparison were subjected 
to a Wilcoxon Signed Ranks test, the results of which are given in Table 5.16. 
There are clearly no statistically significant differences demonstrated by the 
Wilcoxon Signed Ranks test, supporting the conclusions from the data in Table 
5.15.  There is therefore no evidence to support the possibility of increased 
confidence being gained from reviewing Sestamibi planar + SPECT images in 
comparison to planar 99mTc-Sestamibi + 123I-iodide images. 
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Observer p-value Estimated median 95% CI 
1 0.721 0.0 (-0.5, 0.0) 
2 0.514 0.0 (-0.5, 0.0) 
3 1.000 0.0 (-0.5, 0.5) 
4 0.465 0.0 (0.0, 0.5) 
5 0.777 0.0 (0.0, 0.5) 
Overall 0.873 0.0 (0.0, 0.0) 
Table 5.16 - Results from Wilcoxon Signed Ranks test on differences in expressed 
confidence level (phase 3 vs phase 1) 
Output from Minitab software applied to the comparison of confidence level expressed by 
the observers between the Sestamibi and planar images. 
5.5.2.3 Location of Observed Lesions 
Once again, the left/right and upper/lower location results were compared 
separately first and then combined.  As in Section 5.5.1.3, no anterior/posterior 
information was included in the comparison due to the lack of information in this 
plane on the planar images. 
The results of the left/right comparison are given in Table 5.17.  Once again, the 
proportions in each category are similar, but with the number of lesions given in 
the same left/right comparison being slightly higher than those given in different 
positions.  Observer 2 has the highest proportion of lesions given the same 
left/right location at 66%, whilst observer 1 has the lowest at 50%. 
Observer No. Same (%) No. Different (%) Total 
1 17 (50%) 17 (50%) 34 
2 21 (66%) 11 (34%) 32 
3 19 (56%) 15 (44%) 34 
4 19 (54%) 16 (46%) 35 
5 26 (52%) 24 (48%) 50 
Overall 102 (55%) 83 (45%) 185 
Table 5.17 - Results of comparison in left/right location between lesions seen on Sestamibi 
only and planar images 
Number and percentage of lesions seen in the same and different left/right location for each 
observer and for the combined for all observers. 
Table 5.18 gives the results of the comparison of the upper/lower locations 
reported by the observers.  Once more, the proportions in the two categories 
overall are similar but there are significant differences between the individual 
observers with observer 2 having the highest number of lesions reported at the 
same location at 63% whilst observer 1 had the lowest at 41%. 
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Observer No. Same (%) No. Different (%) Total 
1 14 (41%) 20 (59%) 34 
2 20 (63%) 12 (37%) 32 
3 17 (50%) 17 (50%) 34 
4 16 (46%) 19 (54%) 35 
5 21 (42%) 29 (58%) 50 
Overall 88 (48%) 97 (52%) 185 
Table 5.18 - Results of comparison in upper/lower location between lesions seen on 
Sestamibi only and planar images 
Number and percentage of lesions seen in the same and different upper/lower location for 
each observer and for the combined for all observers. 
The results of the left/right and upper/lower given location comparisons were 
then combined and the results are given in Table 5.19.  The data confirms the 
differences between observers with observer 2 seeing 63% of lesions in the same 
overall location whilst observer 1 only reported 35% of lesions at the same 
location.  The overall results show similar proportions in the “same” and 
“different” categories, once again suggesting that it may not always be the same 
lesion seen on both planar and Sestamibi only (planar + SPECT) images for an 
individual patient. 
Observer No. Same (%) No. Different (%) Total 
1 12 (35%) 22 (65%) 34 
2 20 (63%) 12 (37%) 32 
3 17 (50%) 17 (50%) 34 
4 16 (46%) 19 (54%) 35 
5 20 (40%) 30 (60%) 50 
Overall 85 (46%) 100 (54%) 185 
Table 5.19 - Results of combined left/right and upper/lower location comparisons between 
lesions seen on Sestamibi only and planar images 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
5.5.3 Phase 4 versus Phase 1 Reviews 
5.5.3.1 Number of Lesions Seen 
The difference between the number of lesions seen in phase 4 (all planar and 
SPECT images) and phase 1 (planar only) was obtained for each observer for each 
of the 32 patients.  Table 5.20 summarises the results.  It is immediately clear 
that the number of times fewer lesions were seen on review of all available 
images than on the planar only views is very small.  Three of the observers and 
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the combined results have most entries in the “A=P” category, suggesting that in 
general there is no difference in the number of lesions seen. 
As discussed in Section 5.5.1.1, a Wilcoxon Signed Ranks test was applied to the 
difference data and the results are shown in Table 5.21. 
Observer A > P A < P A = P Total 
1 10 1 21 32 
2 8 1 23 32 
3 7 2 23 32 
4 18 1 13 32 
5 16 1 15 32 
Total 59 6 95 160 
Table 5.20 - Comparison of number of lesions seen in phase 1 (planar only) and phase 4 (all 
images) 
A>P = number of times more lesions were seen on review of all images than planar, A<P = 
number of times fewer lesions were seen on all images than on planar, A=P = number of 
times same number of lesions were seen on all images as on planar. 
The statistical test shows that 4 of the 5 observers saw a statistically different 
(p≤0.05) number of lesions on reviewing all the images together than on 
reviewing only the planar images.  Only the reports of observer 3 showed no 
statistically significant difference.  The estimated medians of ≥0 for all 
observers individually as well as the combined results indicates that there is a 
tendency for more lesions to be seen when all images are reviewed together as 
compared to review of only the planar images. 
Observer p-value Estimated median 95% CI 
1 0.050 0.5 (0.0, 0.5) 
2 0.044 0.0 (0.0, 0.5) 
3 0.124 0.0 (0.0, 0.5) 
4 <0.001 0.5 (0.5, 1.0) 
5 0.001 0.5 (0.5, 1.0) 
Overall <0.001 0.5 (0.0, 0.5) 
Table 5.21 - Results from Wilcoxon Signed Ranks test on differences in number of lesions 
seen (phase 4 vs phase 1) 
Output from Minitab software applied to the differences in the number of lesions seen 
between all images and planar views. 
5.5.3.2 Confidence of Lesions Representing True Adenoma 
A total of 204 comparisons were made between the confidence level expressed 
by the observers when reviewing all the available images together and that given 
when looking at the planar images only.  Table 5.22 shows the results of the 
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comparison, which demonstrate that there are similar proportions in the “more” 
and “same” categories and significantly fewer in the “less” category.  As was the 
case for the previous 2 comparisons, observer 5 had the highest total number of 
comparisons, meaning that this observer tends to see more lesions in the images 
than do the other observers. 
Observer No. More (%) No. Same (%) No. Less (%) Total 
1 17 (43%) 19 (49%) 3 (8%) 39 
2 13 (41%) 17 (53%) 2 (6%) 32 
3 19 (50%) 18 (47%) 1 (3%) 38 
4 25 (62%) 12 (30%) 3 (8%) 40 
5 24 (44%) 22 (40%) 9 (16%) 55 
Overall 98 (48%) 88 (43%) 18 (9%) 204 
Table 5.22 - Results from comparison of confidence levels expressed (phase 4 vs phase 1) 
Number of comparisons between expressed confidence levels that showed observers as 
more, same or less confident looking at all the images as compared to the planar.  
Percentages of the total in each category for each observer and overall are given in 
brackets. 
For 15 (47%) of the 32 patients, the observers were generally more confident 
when reviewing all the images as compared to the planar views.  They expressed 
similar levels of confidence in 17 (53%) patients and lower confidence in none 
(0%).  This indicates that reviewing all the images together is either more helpful 
or similarly helpful to reviewing the planar images alone but it is not less 
helpful.  The results of applying the Wilcoxon Signed Ranks test to the 
confidence data are shown in Table 5.23. 
Observer p-value Estimated median 95% CI 
1 0.006 0.5 (0.0, 0.5) 
2 0.013 0.5 (0.0, 0.5) 
3 0.001 0.5 (0.5, 0.5) 
4 <0.001 0.5 (0.5, 1.0) 
5 0.023 0.5 (0.0, 0.5) 
Overall <0.001 0.5 (0.5, 0.5) 
Table 5.23 - Results from Wilcoxon Signed Ranks test on differences in expressed 
confidence level (phase 4 vs phase 1) 
Output from Minitab software applied to the comparison of confidence level expressed by 
the observers between all images and planar images. 
Statistically significant differences (p<0.05) are demonstrated for all the 
observers and the estimated median and 95% CI values indicate that the 
observers are more confident that they are seeing a true lesion when all the 
images are viewed together than when they are reviewing the planar images 
only.  
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5.5.3.3 Location of Observed Lesions 
As previously, the left/right and upper/lower location results were compared 
separately first and then combined and no anterior/posterior information was 
included in the comparison. 
The results of the comparison of the given left/right location are shown in Table 
5.24.  For observers 1-3, there were a significantly higher proportion of lesions 
given in the same left/right location as in a different location.  Observers 4-5 
had similar proportions in each category.  Observers 2 & 3 reported the highest 
fraction in the same location at 66%, whilst observer 4 gave the lowest at 48%. 
Observer No. Same (%) No. Different (%) Total 
1 24 (61%) 15 (39%) 39 
2 21 (66%) 11 (34%) 32 
3 25 (66%) 13 (34%) 38 
4 19 (48%) 21 (52%) 40 
5 27 (49%) 28 (51%) 55 
Overall 116 (57%) 88 (43%) 204 
Table 5.24 - Results of comparison in left/right location between lesions seen on all images 
and planar only 
Number and percentage of lesions seen in the same and different left/right location for each 
observer and for the combined for all observers. 
A summary of the results of the upper/lower locations is given in Table 5.25.  
The overall numbers in the two categories are similar but the different observers 
have significantly different results.  Observer 2 has the highest proportion of 
lesions given at the same upper/lower location at 62%, whereas observer 4 gave 
the lowest fraction at 43%. 
Observer No. Same (%) No. Different (%) Total 
1 20 (51%) 19 (49%) 39 
2 20 (62%) 12 (38%) 32 
3 23 (60%) 15 (40%) 38 
4 17 (43%) 23 (57%) 40 
5 25 (46%) 30 (54%) 55 
Overall 105 (51%) 99 (49%) 204 
Table 5.25 - Results of comparison in upper/lower location between lesions seen on all 
images and planar only 
Number and percentage of lesions seen in the same and different upper/lower location for 
each observer and for the combined for all observers. 
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The combined results from the left/right and upper/lower comparisons are 
shown in Table 5.26.  Once again, the overall results show no difference with a 
50%:50% split between the two categories, but there are differences 
demonstrated between the observers.  Observer 2 gave more lesions at the same 
overall location than any of the others at 62%, whilst observer 4 gave the lowest 
proportion at the same location with just 40%. 
Observer No. Same (%) No. Different (%) Total 
1 20 (51%) 19 (49%) 39 
2 20 (62%) 12 (38%) 32 
3 23 (60%) 15 (40%) 38 
4 16 (40%) 24 (60%) 40 
5 23 (42%) 32 (58%) 55 
Overall 102 (50%) 102 (50%) 204 
Table 5.26 - Results of combined left/right and upper/lower location comparisons between 
lesions seen on all images and planar only 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
5.5.4 Phase 3 versus Phase 2 Reviews 
5.5.4.1 Number of Lesions Seen 
Table 5.27 gives a summary of the difference in the number of lesions seen by 
each observer in phase 3 (Sestamibi only, planar + SPECT) as compared to those 
seen in phase 2 (SPECT, 99mTc-Sestamibi + 123I-iodide + subtraction).  The results 
clearly show that there are significantly fewer occasions on which more lesions 
were seen on the Sestamibi only images than on the SPECT when compared to 
the number of times fewer lesions were seen.  For observers 1-4 and the 
combined results, the highest number was in the “M=S” category, whereas 
observer 5 had the highest number in “M<S”.  There were no instances of “M>S” 
being the largest category, indicating that there are generally the same number 
or fewer lesions seen on the Sestamibi only images than on the planar. 
The results of the Wilcoxon Signed Ranks test applied to this data are shown in 
Table 5.28.  Of the 5 observers, only 1 – observer 1 – failed to demonstrate a 
statistically significant difference (i.e. p<0.05) between the number of lesions 
seen in these two phases of the study.  Of the others, all had an estimated 
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median of <1, indicating that they were seeing fewer lesions on the Sestamibi 
only than on the SPECT images. 
Observer M > S M < S M = S Total 
1 3 7 22 32 
2 1 13 18 32 
3 2 11 19 32 
4 3 12 17 32 
5 2 21 9 32 
Total 11 64 85 160 
Table 5.27 - Comparison of number of lesions seen in phase 2 (SPECT) and phase 3 
(Sestamibi only) 
M>S = number of times more lesions were seen on Sestamibi only images than on SPECT, 
M<S = number of times fewer lesions were seen on Sestamibi only than on SPECT, M=S = 
number of times same number of lesions were seen on Sestamibi only images as on 
SPECT. 
Observer p-value Estimated median 95% CI 
1 0.285 0.0 (-0.5, 0.0) 
2 0.005 -0.5 (-0.5, 0.0) 
3 0.017 -0.5 (-0.5, 0.0) 
4 0.036 -0.5 (-0.5, 0.0) 
5 <0.001 -1.0 (-1.0, -0.5) 
Overall <0.001 -0.5 (-0.5, -0.5) 
Table 5.28 - Results from Wilcoxon Signed Ranks test on differences in number of lesions 
seen (phase 3 vs phase 2) 
Output from Minitab software applied to the differences in the number of lesions seen 
between Sestamibi only and SPECT images. 
5.5.4.2 Confidence of Lesions Representing True Adenoma 
There were 236 comparisons of the confidence level indicated by the observers 
during the different phases of the review.  A summary of the results is shown in 
Table 5.29.  For each observer and for the combined results, over half of the 
results fall into the “less” category, meaning that the observers are less 
confident when reviewing the Sestamibi only images than when they are 
reporting from the SPECT image data.  The lowest number for each observer was 
in the “more” category.  As before, observer 5 had the highest total number of 
comparisons, meaning that this observer tends to see more lesions in the images 
than do the other observers. 
The observers were generally more confident on reviewing the Sestamibi images 
as compared to the SPECT data for 2 (6%) of the 32 patients and had similar 
confidence levels for 9 (28%) patients.  They were therefore less confident for 21 
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(66%) of the patients, indicating that they generally preferred reporting from the 
SPECT images that included the 123I-iodide images than from the Sestamibi only 
images, even though both planar and SPECT images were available.  The 
Wilcoxon Signed Ranks test was then applied to the data, and the results are 
shown in Table 5.30. 
Observer No. More (%) No. Same (%) No. Less (%) Total 
1 3 (9%) 10 (30%) 20 (61%) 33 
2 5 (13%) 11 (32%) 18 (53%) 34 
3 5 (13%) 9 (24%) 24 (63%) 38 
4 5 (12%) 13 (32%) 23 (56%) 41 
5 18 (20%) 26 (29%) 46 (51%) 90 
Overall 36 (15%) 69 (29%) 131 (56%) 236 
Table 5.29 - Results from comparison of confidence levels expressed (phase 3 vs phase 2) 
Number of comparisons between expressed confidence levels that showed observers as 
more, same or less confident reviewing the Sestamibi only images as compared to the 
SPECT.  Percentages of the total in each category for each observer and overall are given in 
brackets. 
Observer p-value Estimated median 95% CI 
1 0.002 -0.5 (-1.0, -0.5) 
2 0.018 -0.5 (-0.5, 0.0) 
3 0.002 -0.5 (-1.0, -0.5) 
4 0.003 -0.5 (-0.5, 0.0) 
5 0.002 -0.5 (-0.5, 0.0) 
Overall <0.001 -0.5 (-0.5, -0.5) 
Table 5.30 - Results from Wilcoxon Signed Ranks test on differences in expressed 
confidence level (phase 3 vs phase 2) 
Output from Minitab software applied to the comparison of confidence level expressed by 
the observers between Sestamibi only and SPECT images. 
The results clearly show that statistically significant differences (p<0.05) exist 
between the confidence levels expressed by every observer between the two 
phases of the study.  The negative estimated median and 95% CI values show 
that the observers are less confident on reviewing the Sestamibi images than the 
SPECT. 
5.5.4.3 Location of Observed Lesions 
As previously, the left/right and upper/lower location results were compared 
separately first and then combined.  However, because SPECT images were 
included in both phases of this comparison, anterior/posterior information was 
also analysed, at first separately and then in combination with both the 
left/right and upper/lower results. 
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Table 5.31 gives a summary of the results of comparing the left/right location 
given by each observer for each lesion.  All the observers reported more lesions 
at the same site than at a different site.  The lowest proportion at the same site 
was given by observer 5 at 52%. 
Observer No. Same (%) No. Different (%) Total 
1 19 (58%) 14 (42%) 33 
2 18 (53%) 16 (47%) 34 
3 22 (58%) 16 (42%) 38 
4 24 (58%) 17 (42%) 41 
5 47 (52%) 43 (48%) 90 
Overall 130 (55%) 106 (45%) 236 
Table 5.31 - Results of comparison in left/right location between lesions seen on Sestamibi 
only and SPECT images 
Number and percentage of lesions seen in the same and different left/right location for each 
observer and for the combined for all observers. 
The results of the comparison in the given upper/lower locations are shown in 
Table 5.32.  There are generally more lesions reported at a different location 
than at the same, although observer 2 gave 56% of lesions at the same location. 
Observer No. Same (%) No. Different (%) Total 
1 17 (51%) 16 (49%) 33 
2 19 (56%) 15 (44%) 34 
3 18 (47%) 20 (53%) 38 
4 16 (39%) 25 (61%) 41 
5 32 (36%) 58 (64%) 90 
Overall 102 (43%) 134 (57%) 236 
Table 5.32 - Results of comparison in upper/lower location between lesions seen on 
Sestamibi only and SPECT images 
Number and percentage of lesions seen in the same and different upper/lower location for 
each observer and for the combined for all observers. 
Table 5.33 shows the combined results of the comparison of the left/right and 
upper/lower locations.  The overall tendency is for a different location to be 
given for a lesion seen on each of the two study phases, with observer 5 seeing 
only 23% of lesions at the same site.  Observer 2 saw 50% each at the same and 
different sites.  Once again, this indicates that it is not always the same lesion 
that is being seen on the two phases of the study or that there is some difficulty 
in giving accurate location information from one or other set of images. 
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Observer No. Same (%) No. Different (%) Total 
1 14 (42%) 19 (58%) 33 
2 17 (50%) 17 (50%) 34 
3 17 (45%) 21 (55%) 38 
4 16 (39%) 25 (61%) 41 
5 21 (23%) 69 (77%) 90 
Overall 85 (36%) 151 (64%) 236 
Table 5.33 - Results of combined left/right and upper/lower location comparisons between 
lesions seen on Sestamibi only and SPECT images 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
The anterior/posterior comparison results are shown in Table 5.34.  There is a 
wide variation between the observers with observer 1 giving 64% of lesions at the 
same site but observer 4 giving a similar fraction of 66% at different sites. 
Observer No. Same (%) No. Different (%) Total 
1 21 (64%) 12 (36%) 33 
2 15 (44%) 19 (56%) 34 
3 20 (53%) 18 (47%) 38 
4 14 (34%) 27 (66%) 41 
5 35 (39%) 55 (61%) 90 
Overall 105 (45%) 131 (55%) 236 
Table 5.34 - Results of comparison in anterior/posterior location between lesions seen on 
Sestamibi only and SPECT images 
Number and percentage of lesions seen in the same and different anterior/posterior location 
for each observer and for the combined for all observers. 
Table 5.35 shows the results of combining all the comparisons in location to 
determine if the same or a different overall location was given for each lesion 
seen on the Sestamibi only and SPECT images.  None of the observers have a 
greater proportion of lesions given at the same location than at a different 
location.  Indeed, observers 4 and 5 have very small proportion in the “same”  
Observer No. Same (%) No. Different (%) Total 
1 12 (36%) 21 (64%) 33 
2 13 (38%) 21 (62%) 34 
3 16 (42%) 22 (58%) 38 
4 8 (20%) 33 (80%) 41 
5 12 (13%) 78 (87%) 90 
Overall 61 (26%) 175 (74%) 236 
Table 5.35 - Results of combined left/right, upper/lower and anterior/posterior location 
comparisons between lesions seen on Sestamibi only and SPECT images 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
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category at 20% and 13% respectively.  Again, this suggests that either different 
lesions were observed on the two phases or that the different image data 
available to the observers in some way affected the reported location of the 
lesions. 
5.5.5 Phase 4 versus Phase 2 Reviews 
5.5.5.1 Number of Lesions Seen 
The difference between the number of lesions seen by each observer for each of 
the 32 patients in phase 4 (all images together) and the number seen in phase 2 
(SPECT) was calculated.  A summary of the results is shown in Table 5.36.  It is 
clear that on most occasions, the same number of lesions were seen in the two 
phases of the study.  However, observer 5 has a higher number in the “A<S” 
category than in “A=S”, indicating that this observer tended to see fewer lesions 
when reviewing all images together than when looking at the SPECT images in 
isolation from the planar. 
Observer A > S A < S A = S Total 
1 6 5 21 32 
2 2 6 24 32 
3 2 8 22 32 
4 8 6 18 32 
5 3 18 11 32 
Total 21 43 96 160 
Table 5.36 - Comparison of number of lesions seen in phase 2 (SPECT) and phase 4 (all 
images) 
A>S = number of times more lesions were seen on all images than on SPECT, A<S = number 
of times fewer lesions were seen on all images than on SPECT, A=S = number of times 
same number of lesions were seen on all images as on SPECT. 
The Wilcoxon Signed Ranks test was then applied to the difference values and 
the results are shown in Table 5.37.  Only observer 5 and the overall combined 
results show a statistically significant difference (p<0.05).  The estimated 
median and 95% CI for observer 5 are negative, indicating that this observer did 
indeed tend to see fewer lesions in phase 4 than phase 2, as was suggested from 
the data in Table 5.36. 
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5.5.5.2 Confidence of Lesions Representing True Adenoma 
Table 5.38 summarises the results of the comparison of the confidence level 
expressed by the observers as they reviewed the images.  There were a total of 
255 comparisons and it can be seen from the results that there is a wide 
variation between the observers.  Overall, the highest number of comparisons 
fell into the “same” category with the fewest in “more”, indicating that the 
Observer p-value Estimated median 95% CI 
1 0.657 0.0 (0.0, 0.0) 
2 0.234 0.0 (-0.5, 0.0) 
3 0.053 0.0 (-0.5, 0.0) 
4 0.530 0.0 (0.0, 0.5) 
5 0.012 -0.5 (-1.0, -0.5) 
Overall 0.017 0.0 (0.0, 0.0) 
Table 5.37 - Results from Wilcoxon Signed Ranks test on differences in number of lesions 
seen (phase 4 vs phase 2) 
Output from Minitab software applied to the differences in the number of lesions seen 
between all images and SPECT only. 
observers generally expressed a similar or lower level of confidence when 
reviewing all the images together than when looking at the SPECT alone.  Once 
again, observer 5 had the highest total number of comparisons, meaning that 
this observer saw more lesions on reviewing the images than did the others. 
Observer No. More (%) No. Same (%) No. Less (%) Total 
1 6 (16%) 22 (60%) 9 (24%) 37 
2 5 (15%) 21 (62%) 8 (23%) 34 
3 7 (17%) 15 (37%) 19 (46%) 41 
4 12 (26%) 24 (51%) 11 (23%) 47 
5 18 (18%) 39 (41%) 39 (41%) 96 
Overall 48 (19%) 121 (47%) 86 (34%) 255 
Table 5.38 - Results from comparison of confidence levels expressed (phase 4 vs phase 2) 
Number of comparisons between expressed confidence levels that showed observers as 
more, same or less confident reviewing all images together as compared to the SPECT.  
Percentages of the total in each category for each observer and overall are given in 
brackets. 
In general, the observers were more confident on reviewing all the images 
together than looking at the SPECT alone for 1 (3%) of the 32 patients.  They 
were equally confident for 20 (63%) of the patients and less confident in 11 
(34%).  This indicates that there is a tendency for the observers to be more 
confident that they are seeing true lesions when looking at the SPECT data alone 
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than when looking at the SPECT and planar images together.  The results of the 
Wilcoxon Signed Ranks test applied to the data are shown in Table 5.39. 
Statistically significant differences (p<0.05) are seen for observers 3 and 5 as 
well as the combined results.  Although the data for the other observers was not 
statistically significant, the estimate median and 95% CI values show that there 
is a tendency for the observers to be less confident when looking at all the 
images together than they are when reviewing the SPECT data in isolation. 
Observer p-value Estimated median 95% CI 
1 0.514 0.0 (-0.5, 0.0) 
2 0.363 0.0 (-0.5, 0.0) 
3 0.041 -0.5 (-0.5, 0.0) 
4 0.867 0.0 (0.0, 0.0) 
5 0.016 0.0 (-0.5, 0.0) 
Overall 0.004 0.0 (-0.5, 0.0) 
Table 5.39 - Results from Wilcoxon Signed Ranks test on differences in expressed 
confidence level (phase 4 vs phase 2) 
Output from Minitab software applied to the comparison of confidence level expressed by 
the observers between all images and SPECT alone. 
5.5.5.3 Location of Observed Lesions 
The given left/right, upper/lower and anterior/posterior locations were then 
compared and combined in the same way as in Section 5.5.4.3. 
The results of the left/right location comparison are given in Table 5.40.  For 4 
of the 5 observers and for the combined results, there were more lesions given 
at the same site than at a different location with observer 2 having the highest 
proportion at the same left/right location at 76%.  Observer 5 gave similar 
numbers at the same and different sites. 
Observer No. Same (%) No. Different (%) Total 
1 25 (68%) 12 (32%) 37 
2 26 (76%) 8 (24%) 34 
3 25 (61%) 16 (39%) 41 
4 30 (64%) 17 (36%) 47 
5 47 (49%) 49 (51%) 96 
Overall 153 (60%) 102 (40%) 255 
Table 5.40 - Results of comparison in left/right location between lesions seen on all images 
and SPECT only 
Number and percentage of lesions seen in the same and different left/right location for each 
observer and for the combined for all observers. 
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The upper/lower locations were also compared and the results are shown in 
Table 5.41.  It can clearly be seen that all observers saw more lesions at the 
same location than at a different site, with observers 1 and 2 having the highest 
proportion at 65%. 
Observer No. Same (%) No. Different (%) Total 
1 24 (65%) 13 (35%) 37 
2 22 (65%) 12 (35%) 34 
3 22 (54%) 19 (46%) 41 
4 24 (51%) 23 (49%) 47 
5 50 (52%) 46 (48%) 96 
Overall 142 (56%) 113 (44%) 255 
Table 5.41 - Results of comparison in upper/lower location between lesions seen on all 
images and SPECT only 
Number and percentage of lesions seen in the same and different upper/lower location for 
each observer and for the combined for all observers. 
The comparisons of the left/right and upper/lower locations were then 
combined and the results are shown in Table 5.42.  There are significant 
differences between the results for the different observers with observers 1 and 
2 having the highest fraction (62%) of lesions at the same overall location, while 
observer 5 gave only 34% at the same site.  The combined totals for all the 
observers can be seen to be similar. 
Observer No. Same (%) No. Different (%) Total 
1 23 (62%) 14 (38%) 37 
2 21 (62%) 13 (38%) 34 
3 21 (51%) 20 (49%) 41 
4 22 (47%) 25 (53%) 47 
5 33 (34%) 63 (66%) 96 
Overall 120 (47%) 135 (53%) 255 
Table 5.42 - Results of combined left/right and upper/lower location comparisons between 
lesions seen on all images and SPECT only 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
Table 5.43 gives the results of the anterior/posterior location comparison.  
Again, there is a wide variation between the results for the different observers 
with observer 2 seeing 65% of lesions at the same site but observer 5 seeing only 
47% at the same location. 
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Observer No. Same (%) No. Different (%) Total 
1 23 (62%) 14 (38%) 37 
2 22 (65%) 12 (35%) 34 
3 23 (56%) 18 (44%) 41 
4 23 (49%) 24 (51%) 47 
5 45 (47%) 51 (53%) 96 
Overall 136 (53%) 119 (47%) 255 
Table 5.43 - Results of comparison in anterior/posterior location between lesions seen on all 
images and SPECT alone 
Number and percentage of lesions seen in the same and different anterior/posterior location 
for each observer and for the combined for all observers. 
All the comparisons in the given location of lesions between phase 2 and phase 4 
of the study were then combined and the results are shown in Table 5.44.  
Observers 1, 2 and 3 gave similar numbers at the same overall location as at a 
different location, whilst observers 4 and 5 saw only a small proportion – 38% 
and 26% respectively – at the same site.  Once more, these results suggest that 
either different lesions were observed on the two phases or that the different 
image data available to the observers in some way affected the reported 
location of the lesions. 
Observer No. Same (%) No. Different (%) Total 
1 20 (54%) 17 (46%) 37 
2 17 (50%) 17 (50%) 34 
3 20 (49%) 21 (51%) 41 
4 18 (38%) 29 (62%) 47 
5 25 (26%) 71 (74%) 96 
Overall 100 (39%) 155 (61%) 255 
Table 5.44 - Results of combined left/right, upper/lower and anterior/posterior location 
comparisons between lesions seen on all images and SPECT only 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
5.5.6 Phase 4 versus Phase 3 Reviews 
5.5.6.1 Number of Lesions Seen 
The final comparison between the results of different phases of the observer 
study was between phase 3 (Sestamibi only) and phase 4 (all images).  A 
summary of the difference between the number of lesions seen in the two 
phases is shown in Table 5.45. 
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The data show that there is a tendency to see the same number or more lesions 
when reviewing all the available images than when reporting from the Sestamibi 
images only.  The category with the highest number for each observer is that for 
the same number of lesions seen in the two phases whilst that with the lowest 
number for all observers is when there were fewer lesions seen on phase 4 than 
on phase 3. 
Observer A > M A < M A = M Total 
1 11 7 14 32 
2 10 2 20 32 
3 6 4 22 32 
4 13 2 17 32 
5 8 6 18 32 
Total 48 21 91 160 
Table 5.45 - Comparison of number of lesions seen in phase 3 (Sestamibi only) and phase 4 
(all images) 
A>M = number of times more lesions were seen on all images than on Sestamibi only, A<M 
= number of times fewer lesions were seen on all images than on Sestamibi only, A=M = 
number of times same number of lesions were seen on all images as on Sestamibi only. 
Table 5.46 shows the results of the Wilcoxon Signed Ranks test being applied to 
the differences in the number of lesions seen on the two phases.  The results for 
observers 2 and 4 as well as the all the data combined are statistically 
significant (p<0.05) whilst for the other observers, no statistically significant 
difference is demonstrated.  The 95% CI results do, however, suggest that there 
is a tendency to see more lesions on review of all the images than when viewing 
the Sestamibi images only as they are weighted above 0. 
Observer p-value Estimated median 95% CI 
1 0.338 0.0 (0.0, 0.5) 
2 0.045 0.0 (0.0, 0.5) 
3 0.610 0.0 (0.0, 0.0) 
4 0.008 0.5 (0.0, 0.5) 
5 0.414 0.0 (0.0, 0.5) 
Overall 0.001 0.0 (0.0, 0.5) 
Table 5.46 - Results from Wilcoxon Signed Ranks test on differences in number of lesions 
seen (phase 4 vs phase 3) 
Output from Minitab software applied to the differences in the number of lesions seen 
between all images and Sestamibi only. 
5.5.6.2 Confidence of Lesions Representing True Adenoma 
The comparisons between the confidence level expressed by the observer during 
the two phases of the study numbered 209 in total and a summary of the results 
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is shown in Table 5.47.  The observers were altogether more confident when 
reviewing all the available images than when reporting from the Sestamibi 
images alone.  Observer 4 had the highest proportion in this category at 55%, 
whereas observer 3 had the lowest at 38% and did, in fact, have a higher 
proportion at the same confidence level (44%).  As was the case for all other 
comparisons, observer 5 had the highest total number of comparisons, once 
more indicating that this observer tended to see more lesions than the others. 
Observer No. More (%) No. Same (%) No. Less (%) Total 
1 19 (53%) 9 (25%) 8 (22%) 36 
2 15 (47%) 13 (41%) 4 (12%) 32 
3 13 (38%) 15 (44%) 6 (18%) 34 
4 23 (55%) 13 (31%) 6 (14%) 42 
5 29 (45%) 19 (29%) 17 (26%) 65 
Overall 99 (47%) 69 (33%) 41 (20%) 209 
Table 5.47 - Results from comparison of confidence levels expressed (phase 4 vs phase 3) 
Number of comparisons between expressed confidence levels that showed observers as 
more, same or less confident reviewing all images together as compared to the Sestamibi 
only.  Percentages of the total in each category for each observer and overall are given in 
brackets. 
In 17 (53%) of the 32 patients, the observers were generally more confident 
when reviewing all the images as compared to the Sestamibi only views and 
expressed similar levels of confidence in 11 (34%).  Therefore, they were less 
confident for only 4 (13%) of the 32 patients.  The results of Wilcoxon Signed 
Ranks test being applied to this data are shown in Table 5.48. 
Observer p-value Estimated median 95% CI 
1 0.066 0.5 (0.0, 0.5) 
2 0.028 0.5 (0.0, 0.5) 
3 0.165 0.0 (0.0, 0.5) 
4 0.006 0.5 (0.0, 0.5) 
5 0.125 0.0 (0.0, 0.5) 
Overall <0.001 0.5 (0.0, 0.5) 
Table 5.48 - Results from Wilcoxon Signed Ranks test on differences in expressed 
confidence level (phase 4 vs phase 3) 
Output from Minitab software applied to the comparison of confidence level expressed by 
the observers between all images and Sestamibi only. 
Statistically significant differences (p<0.05) exist between the levels of 
confidence expressed in the two phases of the study by observers 2 and 4 and for 
the overall combined results from all the observers.  The estimated median and 
95% CI values are all ≥0, indicating that the observers are generally more 
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confident when reporting from all the images together than from the Sestamibi 
only images, as was suggested in Table 5.47. 
5.5.6.3 Location of Observed Lesions 
The same comparisons of given location were carried out as in Sections 5.5.4.3 
and 5.5.5.3 and the results of the left/right comparison are shown in Table 5.49.  
The numbers of lesions given at the same and different locations are similar 
overall, although there was a tendency for more to be seen at the same 
location.  However, observer 1 saw less than half of the lesions (47%) at the 
same site. 
Observer No. Same (%) No. Different (%) Total 
1 17 (47%) 19 (53%) 36 
2 19 (59%) 13 (41%) 32 
3 20 (59%) 14 (41%) 34 
4 24 (57%) 18 (43%) 42 
5 38 (58%) 27 (42%) 65 
Overall 118 (56%) 91 (44%) 209 
Table 5.49 - Results of comparison in left/right location between lesions seen on all images 
and Sestamibi only 
Number and percentage of lesions seen in the same and different left/right location for each 
observer and for the combined for all observers. 
A summary of the upper/lower comparison is given in Table 5.50.  There were 
generally more occasions when a lesion was given at a different location, 
although observers 2 & 3 gave 59% and 56% of lesions at the same site, 
respectively. 
Observer No. Same (%) No. Different (%) Total 
1 16 (44%) 20 (56%) 36 
2 19 (59%) 13 (41%) 32 
3 19 (56%) 15 (44%) 34 
4 17 (41%) 25 (59%) 42 
5 27 (42%) 38 (58%) 65 
Overall 98 (47%) 111 (53%) 209 
Table 5.50 - Results of comparison in upper/lower location between lesions seen on all 
images and Sestamibi only 
Number and percentage of lesions seen in the same and different upper/lower location for 
each observer and for the combined for all observers. 
The combined results from comparing the left/right and upper/lower locations 
are shown in Table 5.51.  There are significant differences between the results 
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for the different observers with observer 2 seeing as many as 56% at the same 
overall location whilst observer 4 saw only 36% of lesions at the same site. 
Observer No. Same (%) No. Different (%) Total 
1 14 (39%) 22 (61%) 36 
2 18 (56%) 14 (44%) 32 
3 18 (53%) 16 (47%) 34 
4 15 (36%) 27 (64%) 42 
5 25 (39%) 40 (61%) 65 
Overall 90 (43%) 119 (57%) 209 
Table 5.51 - Results of combined left/right and upper/lower location comparisons between 
lesions seen on all images and Sestamibi only 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
Table 5.52 shows the results of the anterior/posterior comparison.  Once again, 
the results for the different observers are varied with observer 3 giving 56% of 
lesions at the same site and observer 4 seeing only 36% of lesions at the same 
location. 
Observer No. Same (%) No. Different (%) Total 
1 19 (53%) 17 (47%) 36 
2 17 (53%) 15 (47%) 32 
3 19 (56%) 15 (44%) 34 
4 15 (36%) 27 (64%) 42 
5 30 (46%) 35 (56%) 65 
Overall 100 (48%) 109 (52%) 209 
Table 5.52 - Results of comparison in anterior/posterior location between lesions seen on all 
images and Sestamibi alone 
Number and percentage of lesions seen in the same and different anterior/posterior location 
for each observer and for the combined for all observers. 
All the location comparisons were then combined and the results are shown in 
Table 5.53.  It can clearly be seen that for each observer, fewer lesions were 
seen at the same overall location as were seen in a different place.  Observer 4  
Observer No. Same (%) No. Different (%) Total 
1 13 (36%) 23 (64%) 36 
2 15 (47%) 17 (53%) 32 
3 16 (47%) 18 (53%) 34 
4 8 (19%) 34 (81%) 42 
5 16 (25%) 49 (75%) 65 
Overall 68 (33%) 141 (67%) 209 
Table 5.53 - Results of combined left/right, upper/lower and anterior/posterior location 
comparisons between lesions seen on all images and Sestamibi only 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
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gave only 19% of lesions at the same overall location, which is a very small 
proportion.  Once more, this suggests that either different lesions were observed 
on the two phases or that the different image data available to the observers in 
some way affected the reported location of the lesions. 
5.5.7 Summary of Comparison Results 
This section gives graphical summaries of the above results, allowing more direct 
assessments of the comparisons between the different phases of the observer 
study.  As above, when comparisons between phases are being described, the 
differences are always taken as the later phase minus the earlier phase. 
Figure 5.9 shows the frequency of “more”, “same” or “less” findings for the 
number of lesions seen when each of the phases of the observer study was 
compared against each of the others. 
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Figure 5.9 - Bar chart of comparisons in number of lesions seen 
Frequency of “more”, “same” and “less” findings for comparison of number of lesions seen 
in each phase of the study.  2vs1 = lesions seen on phase 2 minus lesions seen on phase 1 
(similar for comparisons of other phases) 
It is immediately clear that the “same” category is the highest for all of the 
phase comparisons, indicating that the observers reported the same number of 
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lesions on two phases of the study more frequently than giving a different 
number. 
The “more” category is higher than “less” for all of the comparisons involving 
phase 1 (planar images only), indicating that generally fewer lesions were seen 
on phase 1 than on the other phases.  In contrast, the “less” category is higher 
than “more” for the 3vs2 and 4vs2 comparisons.  All of these findings indicate 
that the observers were seeing more lesions on the dual-isotope subtraction 
SPECT images of phase 2 than on the other phases, which is most pronounced in 
the 2vs1 and 3vs2 comparisons. 
A similar plot showing the differences in the confidence level expressed by the 
observers when reviewing the images in each phase is shown in Figure 5.10.  In 
this case, the “same” category is often not the highest, meaning that there was 
often a significant difference in the level of confidence that a true parathyroid 
adenoma was visible in the image between different phases of the observer 
study. 
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Figure 5.10 - Bar chart of comparisons in expressed confidence level 
Frequency of “more”, “same” and “less” findings for comparison of confidence level 
expressed in each phase of the study.  2vs1 = confidence expressed on phase 2 versus 
confidence expressed on phase 1 (similar for comparisons of other phases) 
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The most striking differences are seen in the 2vs1 and 3vs2 comparisons.  In both 
instances, the level of confidence expressed by the observers from the review of 
the SPECT-only images (phase 2) is considerably higher than on the other phase 
being compared (phases 1 & 3 respectively).  In contrast, the highest category in 
the 4vs2 comparison is “same”, indicating that there are fewer differences in 
confidence level between the two phases in which the dual-isotope subtraction 
SPECT images were available than between the others.  This suggests that the 
inclusion of dual-isotope subtraction SPECT images increases the confidence of 
the reporting observer but the combination of planar and SPECT subtraction 
images does not lead to a further increase in confidence. 
A plot of the number of times the same or different left/right location was given 
for lesions in each of the phases of the observer study if shown in Figure 5.11.  It 
can clearly be seen that in all but one case (2vs1), the number of times the same 
left/right location was given in the two different phases exceeded the number 
of times a different site was reported.  This demonstrates that, more often than 
not, potential parathyroid lesions are being seen on the same side of the neck 
(relative to the thyroid gland) than on the contra-lateral side regardless of the 
type of images being reviewed. 
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Figure 5.11 - Bar chart of comparisons in given left/right lesion location 
Frequency of “same” and “different” findings for comparison of given left/right location of 
each lesion in each phase of the study.  2vs1 = lesions seen on phase 2 versus lesions seen 
on phase 1 (similar for comparisons of other phases) 
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The most likely reason for the difference demonstrated in the 2vs1 comparison is 
the fact that far more lesions in total were seen on phase 2 than on phase 1 (see 
Figure 5.7 above).  This means that several lesions seen on the dual-isotope 
subtraction SPECT images (phase 2) were being compared to each single lesion 
seen on the planar images (phase 1), resulting in many comparisons that were 
not like-for-like and hence a significant number of lesions were at a different 
left/right site on the comparison. 
Figure 5.12 is similar to Figure 5.11, but in this case the comparisons shown are 
of the overall given location of the lesions seen, taking into account the 
left/right, upper/lower and anterior/posterior position specified by the 
observer.  It should be noted that, as in the discussions in Sections 5.5.1 - 5.5.3 
above, no anterior/posterior information was included for any comparisons 
involving phase 1 as it is not possible to determine the anterior/posterior 
location of a lesion from an anterior planar image.  These comparisons therefore 
only take into account the combination of the given left/right and upper/lower 
locations. 
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Figure 5.12 - Bar chart of comparisons in given overall lesion location 
Frequency of “same” and “different” findings for comparison of given overall location of 
each lesion in each phase of the study.  2vs1 = lesions seen on phase 2 versus lesions seen 
on phase 1 (similar for comparisons of other phases) 
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It can clearly be seen from the chart that in all cases, the number of 
comparisons given a “different” overall location is greater than the number 
given at the “same” overall locations, with the exception of the comparison of 
phases 1 & 4, where the relative numbers in the two categories are equal.  All of 
the comparisons involving phase 2 (SPECT only) have a high proportion in the 
“different” category.  This is most likely due to the fact that more lesions were 
seen on phase 2 than any other, meaning that each lesion seen on the other 
three phases was being compared to several lesions seen on phase 2, resulting in 
a significant number of “different” location findings. 
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Chapter 6 – Parathyroid Study – Comparison of 
Observer Study with Surgical and US Findings 
6.1 Surgical and Ultrasound Results 
6.1.1 Participants Having Surgery and/or Ultrasound 
The results of any parathyroid surgery and/or ultrasound scanning of the neck 
performed on each patient were obtained from the patient case notes.  Of the 
32 patients who took part in this study, 17 (53%) have since undergone 
parathyroidectomy surgery and 13 of these patients also had an ultrasound scan.  
Of the remaining 15 (47%) patients, 12 (38%) have had further imaging using 
ultrasound.  There were therefore 25 (78%) patients who had ultrasound 
scanning.  The remaining 3 (9%) patients have had follow-up that has included 
neither surgery nor ultrasound and their symptoms are currently being managed 
clinically.  A full list of the surgical findings for the patients who underwent 
parathyroidectomy is given in Table 6.1. 
The histological results were examined for each patient who underwent 
parathyroidectomy to determine the presence or otherwise of a parathyroid 
adenoma or hyperplastic parathyroid glands in each case.  A total of 20 samples 
suspected of being parathyroid adenomas were resected, 18 of which were 
positive for either parathyroid adenoma or hyperplasia.  Of the 17 patients who 
had surgery, 16 (94%) results were positive for parathyroid adenoma or 
hyperplasia, with 14 cases of single adenoma and 2 of hyperplasia.  The 
parathyroid sample from the remaining patient was found to be histologically 
normal.  Three of the patients who had surgery had an ectopic parathyroid 
adenoma removed, with 2 being in the thymic tract and one in a retrosternal 
location. 
The surgical results show only 2 normal glands were resected, which means that 
there are only 2 true negative results in total.  The specificity depends heavily 
upon the true negative rate (see Equation 4.3) and so the small rate may 
strongly affect the calculated specificity for the observer study.  It is also an 
Chapter 6  124 
indication of the role the experience of the endocrine surgeon plays in selecting 
lesions for resection that are most likely to be hyperplastic glands or adenomas. 
Patient 
No. 
No. Lesions 
Resected 
Position Histological 
Findings 
1 1 Left     posterior    lower     lateral Adenoma 
2 1 Left     posterior    lower     lateral Normal 
3 1 Ectopic – right thymic tract Adenoma 
4 1 Right                   upper Adenoma 
5 1 Left     posterior    lower Adenoma 
7 1 Ectopic - intrathymic Adenoma 
8 1 Left     posterior    lower Adenoma 
9 1 Right   posterior    lower     lateral Adenoma 
11 1 Right   posterior    upper     lateral Adenoma 
12 1 Left     posterior    lower Adenoma 
17 1 Right   posterior    upper Adenoma 
20 2 Right   posterior    upper 
Right   posterior    lower 
Hyperplasia 
21 2 Left     posterior    upper 
Left     posterior    lower 
Hyperplasia 
(mild) 
22 2 Ectopic – retrosternal 
Right   posterior    lower 
Adenoma 
Normal 
23 1 Right    posterior   lower     lateral Adenoma 
26 1 Right    posterior   lower     lateral Adenoma 
31 1 Left     posterior    upper Adenoma 
Table 6.1 - Surgical findings for patients undergoing parathyroidectomy 
Full list of results from surgery for all 17 patients who had surgery after nuclear medicine 
parathyroid imaging.  Position is given as either relative to the thyroid gland or ectopic. 
Of the 25 patients who had a neck ultrasound scan, 14 (56%) had a positive 
report for parathyroid adenoma, with the remaining 11 having a negative 
ultrasound result.  And of the 13 patients who had both surgery and ultrasound, 
there were a total of 10 (77%) cases where the same result was given.  In all 
these cases, a positive report was given from both surgery and ultrasound.  The 
remaining 3 (23%) patients all had positive surgical results following a negative 
ultrasound scan.  There were no cases of negative surgery after a positive report 
from ultrasound.  The ultrasound report results for the 13 patients who had both 
ultrasound and surgery are given in Table 6.2, whilst Table 6.3 shows the 
ultrasound results for the 12 patients who had ultrasound imaging but did not 
have surgery. 
When the results in Table 6.2 are compared to those for the same patients in 
Table 6.1, it can clearly be seen that 7 of the surgical and ultrasound reports 
(patients 5, 8, 11, 12, 17, 23 & 26) give the same left/right location for a 
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positively identified adenoma or hyperplastic parathyroid gland.  The three 
negative ultrasound reports (patients 9, 20 & 21) were all given for patients who 
had positive samples resected at surgery.  Two of the three remaining patients 
(patients 4 & 31) had suspicious lesions noted on ultrasound imaging that were at 
a different left/right location to the histologically positive parathyroid adenomas 
at surgery.  The remaining one patient (patient 22) had an ectopic retrosternal 
adenoma removed at surgery which was not identified on ultrasound imaging.  
However, another sample was removed at surgery from a location corresponding 
to that reported as suspicious on the ultrasound scan but which was proven to be 
normal parathyroid tissue on histological examination. 
Patient 
No. 
No. Lesions 
Seen on US 
Position Positive/Negative 
4 1 Left     posterior    upper Positive 
5 1 Left     posterior    lower Positive 
8 1 Left     posterior    lower Positive 
9 0 N/A Negative 
11 1 Right   posterior Positive 
12 1 Left     posterior    lower Positive 
17 1 Right   posterior    lower Positive 
20 0 N/A Negative 
21 0 N/A Negative 
22 1 Right   posterior    lower Positive 
23 1 Right   posterior    lower   lateral Positive 
26 1 Right   posterior    lower Positive 
31 1 Right   posterior    lower   lateral Positive 
Table 6.2 - Ultrasound (US) findings for patients who had parathyroid surgery 
Full list of ultrasound results for the patients who had both ultrasound imaging and 
parathyroidectomy after nuclear medicine parathyroid imaging.  Position is given relative to 
the thyroid gland. 
The information contained in Table 6.1 and Table 6.2 was then used to calculate 
the sensitivity and specificity of ultrasound scanning relative to the gold 
standard of surgery in the study participants using Equation 4.2 and Equation 
4.3.  The sensitivity and specificity were calculated based on the given 
positive/negative and left/right findings only (see Section 4.7) and were found 
to be 72% and 33%, respectively.  These calculated values could then be 
compared to those from the 4 phases of the observer study, detailed in Chapter 
5, to determine the relative sensitivity and specificity from review of different 
types of images. 
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The relatively low sensitivity and specificity for ultrasound in comparison to 
surgery demonstrates that ultrasound imaging cannot be used as a true gold 
standard for comparison of the findings of the nuclear medicine observer study.  
However, it was felt that a comparison could still provide valuable information 
on the comparative merits of the planar and SPECT images in order to determine 
if routine SPECT imaging would be preferable to the current use of planar scans 
for parathyroid adenoma detection and localisation. 
Patient 
No. 
No. Lesions 
Seen on US 
Position Positive/Negative 
6 1 Right   posterior    lower Positive 
10 1 Right   posterior    upper    lateral Positive 
14 0 N/A Negative 
15 1 Left     posterior    upper Positive 
18 0 N/A Negative 
19 0 N/A Negative 
24 0 N/A Negative 
25 0 N/A Negative 
27 0 N/A Negative 
28 0 N/A Negative 
30 1 Right   posterior    upper    medial Positive 
32 0 N/A Negative 
Table 6.3 - Ultrasound (US) findings for patients who did not have parathyroid surgery 
Full list of ultrasound results for the patients who had only ultrasound imaging but not 
parathyroidectomy after nuclear medicine parathyroid imaging.  Position is given relative to 
the thyroid gland. 
The data in Table 6.3 show that the majority of patients (8 of 12) who had 
ultrasound imaging but did not undergo parathyroid surgery had a negative 
report from the ultrasound scan.  This highlights the way that referrals for 
surgery are carried out at Glasgow Royal Infirmary (GRI) – normally only after 
positive localisation imaging will a patient be referred to the endocrine 
surgeons.  Negative imaging results are often followed by medical management 
rather than surgery.  Of the 4 patients with positive ultrasound findings, 2 were 
deemed to be asymptomatic and therefore not in need of surgery and the other 
two were both keen to avoid surgery and to be managed medically if possible.  
The possibility of these patients having surgery in future exists, but none have 
elected to do so to date. 
There were different reasons for a lack of follow-up in each of the 3 patients 
who had neither surgery nor ultrasound imaging.  All 3 had negative reports from 
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planar nuclear medicine imaging.  One of the patients had known sarcoidosis and 
it was felt that the high blood calcium level was most likely due to disease 
activity rather than a parathyroid adenoma.  This patient’s PTH level was only 
borderline elevated and the blood calcium level was easily controlled by diet 
and so it was felt that no further investigations were required.  The second of 
the three patients had known Paget’s disease with only mildly elevated calcium 
and PTH levels.  These were attributed to the active Paget’s by the endocrine 
physicians and so, again, no further investigation was deemed necessary.  The 
final patient in this group was asymptomatic, with no renal stones or other 
symptoms of high calcium levels.  The decision was made to continue monitoring 
of blood calcium and PTH levels and to manage the patient clinically with no 
surgery planned. 
6.2 Comparison of Observer Study with Surgical and 
Ultrasound Findings 
6.2.1 Phase 1 versus Surgical and US Findings Comparison 
6.2.1.1 Surgical Results Comparison 
The difference in the number of suspected parathyroid adenoma samples 
resected at surgery and the number of lesions seen on the planar images in 
phase 1 of the observer study was calculated for each of the 17 patients for the 
5 observers separately.  The results were then categorised as in Section 5.5 and 
the results are shown in Table 6.4. 
Observer Sur > P Sur < P Sur = P Total 
1 4 1 12 17 
2 8 0 9 17 
3 6 1 10 17 
4 7 1 9 17 
5 6 2 9 17 
Total 31 5 49 85 
Table 6.4 - Comparison of number of samples resected at surgery and number of lesions 
seen in phase 1 (planar) 
Sur>P = number of times more lesions were resected than were seen on planar images, 
Sur<P = number of times fewer lesions were resected than were seen on planar images, 
Sur=P = number of times same number of lesions were resected as were seen on planar 
images. 
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It can clearly be seen that there are very few occasions when fewer lesions were 
resected than were seen on the planar images and that the situation which 
occurred most frequently was that when the same number of samples were 
resected as were seen on the planar images.  However, in more than one third of 
cases (36%), more lesions were resected than had been seen on the planar 
images.  This indicates that there are a significant number of cases in which 
positive lesions are not seen on planar imaging alone. 
The non-parametric Wilcoxon Signed Ranks statistical test was then applied to 
the data and the results of this are shown in Table 6.5.  As previously, a result 
was taken to be statistically significant if p<0.05. 
Observer p-value Estimated Median 95% CI 
1 0.225 0.0 (0.0, 0.5) 
2 0.014 0.5 (0.0, 1.0) 
3 0.205 0.5 (0.0, 1.0) 
4 0.050 0.5 (0.0, 1.0) 
5 0.294 0.5 (0.0, 1.0) 
Overall <0.001 0.5 (0.0, 0.5) 
Table 6.5 - Results from Wilcoxon Signed Ranks test on differences in number of lesions 
seen (surgery vs phase 1) 
Output from Minitab software applied to the differences in the number of lesions resected at 
surgery and the number seen on planar imaging. 
The results indicate that for only one observer (observer 2) and for the combined 
overall values, there was a statistically significant difference between the 
number of lesions they saw on the planar images and the number resected at 
surgery.  All other results showed no statistical significance.  The Wilcoxon 
Signed Ranks test applied to the combined data will be considerably more 
powerful than when applied to the data for individual observers due to the 
larger sample size and so a statistically significant result is more likely.  For all 
the observers individually and combined, the estimated median and 95% CI were 
≥0, indicating that there is a tendency for more lesions to have been resected at 
surgery than were seen on the planar images, which is as expected, given the 
results in Table 6.4. 
A comparison was then made between the reported positive/negative result for 
each lesion resected and each lesion seen on phase 1 of the observer study.  The 
results for each observer as well as the overall combined values are shown in 
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Table 6.6.  These results indicate that around half of the lesions are being given 
a different positive/negative report by the observers individually and overall 
when compared to the surgical results.  Observer 5 has the highest number in 
the “same” category at 61%.  Since 18 of the 20 lesions resected at surgery were 
found to be positive for adenoma or hyperplasia, these results suggest that the 
observers are either not seeing some lesions on planar imaging that are in fact 
true adenomas or are not confident that a lesion they see is a true adenoma and 
so are giving an equivocal report. 
Observer No. Same +/- (%) No. Different +/- (%) Total 
1 11 (48%) 12 (52%) 23 
2 10 (50%) 10 (50%) 20 
3 10 (46%) 12 (54%) 22 
4 10 (48%) 11 (52%) 21 
5 14 (61%) 9 (39%) 23 
Overall 55 (51%) 54 (49%) 109 
Table 6.6 - Results from comparison of positive/negative findings (surgery vs phase 1) 
Number of comparisons between the overall given positive/negative report for a lesion that 
were the same and different between the surgically resected lesions and those seen on the 
planar images.  Percentages of the total in each category for each observer and overall are 
given in brackets. 
The Wilcoxon Signed Ranks test was then applied to the results of the 
positive/negative comparisons by giving each “same” result a value of 1 and 
each “different” result a value of -1.  Table 6.7 gives the results of the 
statistical test and there are no statistically significant differences demonstrated 
which is as expected from the results in Table 6.6. 
Observer p-value Estimated Median 95% CI 
1 0.867 0.0 (-1.0, 0.0) 
2 1.000 0.0 (-1.0, 1.0) 
3 0.721 0.0 (-1.0, 0.0) 
4 0.862 0.0 (-1.0, 0.0) 
5 0.370 0.0 (0.0, 1.0) 
Overall 0.935 0.0 (0.0, 0.0) 
Table 6.7 - Results from Wilcoxon Signed Ranks Test on positive/negative comparison 
(surgery vs phase 1) 
Output from statistical test applied to comparison between the positive/negative report 
findings for surgical results and those given from review of the planar images. 
A comparison was then made of the given location of each lesion, with the 
surgical report compared to the positions given by the observers on review of 
the planar images.  The comparison was carried out in the same way as in 
Section 5.5 and no anterior/posterior information was included since this cannot 
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be gained from anterior planar imaging.  The results of the left/right location 
comparison are shown in Table 6.8 and it should be noted that lesions reported 
as being in an ectopic location were not included in this analysis. 
Observer No. Same (%) No. Different (%) Total 
1 13 (68%) 6 (32%) 19 
2 7 (41%) 10 (59%) 17 
3 10 (59%) 7 (41%) 17 
4 9 (53%) 8 (47%) 17 
5 11 (61%) 7 (39%) 18 
Overall 50 (57%) 38 (43%) 88 
Table 6.8 - Results of comparison in left/right location between lesions resected at surgery 
and those seen on planar images 
Number and percentage of lesions seen in the same and different left/right location for each 
observer and combined for all observers. 
The results show that, in general, more of the lesions were seen by the 
observers at the same left/right location as those that were resected at surgery.  
However, observer 2 saw fewer than half (41%) of the lesions at the same 
left/right location. 
The results of a similar comparison carried out on the upper/lower location 
information are shown in Table 6.9.  On this occasion, it is immediately clear 
that for each observer individually as well as for the combined results, fewer 
than half of the lesions are being seen at the same upper/lower location on 
planar images as those that are being resected during surgery.  Again, observer 2 
has the fewest number in the “same” category at just 35%. 
Observer No. Same (%) No. Different (%) Total 
1 9 (47%) 10 (53%) 19 
2 6 (35%) 11 (65%) 17 
3 7 (41%) 10 (59%) 17 
4 7 (41%) 10 (59%) 17 
5 7 (39%) 11 (61%) 18 
Overall 36 (41%) 52 (59%) 88 
Table 6.9 - Results of comparison in upper/lower location between lesions resected at 
surgery and those seen on planar images 
Number and percentage of lesions seen in the same and different upper/lower location for 
each observer and combined for all observers. 
The results of the left/right and upper/lower location comparisons were then 
combined to give a comparison of the overall location of each lesion.  The 
results of this analysis are shown in Table 6.10. 
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Observer No. Same (%) No. Different (%) Total 
1 9 (47%) 10 (53%) 19 
2 6 (35%) 11 (65%) 17 
3 7 (41%) 10 (59%) 17 
4 7 (41%) 10 (59%) 17 
5 7 (39%) 11 (61%) 18 
Overall 36 (41%) 52 (59%) 88 
Table 6.10 - Results of combined left/right and upper/lower location comparisons between 
lesions resected at surgery and those seen on planar images 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
A comparison of the results in Table 6.9 and Table 6.10 shows that the values 
given in each category are identical.  This indicates that on every occasion when 
the correct upper/lower location was given by the observer reviewing the planar 
images, the correct left/right location was also given.  There were therefore 
also other occasions on which the correct left/right position was reported by the 
observer but the upper/lower result was incorrect.  It should be noted, however, 
that the given left/right and upper/lower locations from the nuclear medicine 
images are always with respect to the location of the thyroid gland, whereas the 
locations given by the surgeon may be with respect to a variety of other 
anatomical landmarks.  It is therefore the case that the location definitions may 
be different and the same lesion may appear to be given at a different location. 
The sensitivity and specificity taking into account the given positive/negative 
result and left/right location were then calculated for each observer and for all 
the observers combined.  The results are shown in Table 6.11. 
Observer Sensitivity (%) Specificity (%) 
1 50 67 
2 46 67 
3 47 75 
4 47 67 
5 60 40 
Overall 49 61 
US 72 33 
Table 6.11- Calculated sensitivity and specificity values for comparison of surgical and 
planar imaging results 
Percentage sensitivity and specificity values are given for each observer and for the 
combined results of all observers as well as for US imaging to provide a comparison 
The results in Table 6.11 show clearly that the planar dual-isotope subtraction 
nuclear medicine imaging technique is considerably less sensitive than 
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ultrasound imaging for detecting parathyroid adenomas.  However, the 
specificity is generally higher, indicating that the observers are reporting fewer 
false positive results than were indicated by US imaging.  A combination of 
planar nuclear medicine and US imaging could therefore provide more accurate 
localisation overall than each independently.  For example, performing an US 
study first would take advantage of the higher sensitivity of that modality.  In 
instances where an equivocal or uncertain result is reported, carrying out planar 
nuclear medicine imaging with its higher specificity could help to confirm or 
deny the presence of an adenoma or hyperplastic gland.  This would have the 
advantage of using a non-ionising imaging technique first, therefore potentially 
removing the need for patients to receive a radiation dose.  However, the two 
imaging studies would not be truly independent and the results of the planar 
nuclear medicine imaging could be heavily influenced by the report from US.  
Also, US is not a functional imaging technique and can therefore not determine 
for certain the presence of a functionally overactive gland.  The high sensitivity 
demonstrated here may be partly attributed to the fact that at GRI, US normally 
takes place after nuclear medicine imaging, and so the operator could be 
influenced by the pre-existing nuclear medicine report. 
From the results in Table 6.11, it can be seen that observer 5 has both the 
highest sensitivity and lowest specificity values at 60% and 40%, respectively.  
This suggests that this observer tends to report more positive lesions from the 
images than the others, leading to the correct identification of more true 
positive lesions but also more false positive results.  Throughout the observer 
study, observer 5 was seen to report more lesions than the other observers and 
so this is not a surprising result. 
6.2.1.2 Ultrasound Results Comparison 
The results of the comparison between ultrasound imaging and phase 1 of the 
observer study were subjected to the same analysis as in Section 6.2.1.1.  The 
results of the comparison in the number of lesions seen on ultrasound imaging 
and planar nuclear medicine imaging for each of the 25 patients who had 
ultrasound are shown in Table 6.12 and the results from applying the Wilcoxon 
Signed Ranks test to this data are shown in Table 6.13. 
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Observer US > P US < P US = P Total 
1 3 4 18 25 
2 7 3 15 25 
3 4 4 17 25 
4 6 3 16 25 
5 3 5 17 25 
Total 23 19 83 125 
Table 6.12 - Comparison of number of lesions seen on ultrasound and in phase 1 (planar) 
US>P = number of times more lesions were seen on ultrasound than on planar images, 
US<P = number of times fewer lesions were seen on ultrasound than on planar images, 
US=P = number of times same number of lesions were seen on ultrasound than on planar 
images. 
Observer p-value Estimated Median 95% CI 
1 0.225 0.0 (0.0, 0.5) 
2 0.014 0.5 (0.0, 1.0) 
3 0.205 0.5 (0.0, 1.0) 
4 0.050 0.5 (0.0, 1.0) 
5 0.294 0.5 (0.0, 1.0) 
Overall <0.001 0.5 (0.0, 0.5) 
Table 6.13 - Results from Wilcoxon Signed Ranks test on differences in number of lesions 
seen (ultrasound vs phase 1) 
Output from Minitab software applied to the differences in the number of lesions seen on 
ultrasound and those seen on planar imaging. 
On this occasion, it is clear that there are more instances where the same 
number of lesions was seen on the ultrasound and nuclear medicine planar 
images than in either of the other two categories.  The Wilcoxon Signed Ranks 
test supported this finding for 4 of the 5 observers, with p>0.05.  However, 
observer 2 had a statistically significant difference demonstrated between the 
number of lesions seen on each time of imaging.  The estimated median and 95% 
CI values being >0 indicates that there is a tendency for more lesions to be 
reported from ultrasound imaging than from the planar images. 
The results of the comparison of positive/negative reports between the 
ultrasound and planar imaging are shown in Table 6.14.  When these results are 
compared with those in Table 6.6, it can be seen that the comparison of 
positive/negative reports between the ultrasound and planar images gives more 
results that are the same than when the comparison is between resected lesions 
at surgery and planar imaging. 
The results of applying the Wilcoxon Signed Ranks test to these data are shown 
in Table 6.15, with the level of statistical significance once again taken to be 
p<0.05.  The only result demonstrating statistical significance is the combined 
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overall data from all 5 observers, which is most likely to be because of the 
increased power of the test calculation due to the larger sample involved.  The 
95% CI values for each observer are, however, ≥0 which indicates that the 
observers tend to give more reports with the same positive/negative result than 
they do different. 
Observer No. Same +/- (%) No. Different +/- (%) Total 
1 17 (68%) 8 (32%) 25 
2 14 (56%) 11 (44%) 25 
3 15 (60%) 10 (40%) 25 
4 15 (60%) 10 (40%) 25 
5 17 (65%) 9 (35%) 26 
Overall 78 (62%) 48 (38%) 126 
Table 6.14 - Results from comparison of positive/negative findings (ultrasound vs phase 1) 
Number of comparisons between the overall given positive/negative report for a lesion that 
were the same and different between those seen on ultrasound imaging and those seen on 
the planar images.  Percentages of the total in each category for each observer and overall 
are given in brackets. 
Observer p-value Estimated Median 95% CI 
1 0.119 0.0 (0.0, 1.0) 
2 0.609 0.0 (0.0, 1.0) 
3 0.389 0.0 (0.0, 1.0) 
4 0.389 0.0 (0.0, 1.0) 
5 0.174 0.0 (0.0, 1.0) 
Overall 0.020 0.0 (0.0, 0.0) 
Table 6.15 - Results from Wilcoxon Signed Ranks Test on positive/negative comparison 
(ultrasound vs phase 1) 
Output from statistical test applied to comparison between the positive/negative report 
findings from ultrasound and those given from review of the planar images. 
The results of the comparison between the given left/right locations relative to 
the thyroid gland are given in Table 6.16.  As was seen in Table 6.8, observer 2 
tends to see the lowest proportion of lesions at the same left/right location as  
Observer No. Same (%) No. Different (%) Total 
1 10 (71%) 4 (29%) 14 
2 5 (36%) 9 (64%) 14 
3 9 (64%) 5 (36%) 14 
4 7 (50%) 7 (50%) 14 
5 10 (67%) 5 (33%) 15 
Overall 41 (58%) 30 (42%) 71 
Table 6.16 - Results of comparison in left/right location between lesions seen on ultrasound 
and those seen on planar images 
Number and percentage of lesions seen in the same and different left/right location for each 
observer and combined for all observers. 
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they are seen on ultrasound whilst the others all see the same or more lesions on 
the same side. 
Table 6.17 shows the results of the comparison of the given upper/lower 
location.  It should be noted that for one of the lesions seen on ultrasound, no 
upper/lower location information was reported, meaning that this lesion has not 
been included in this analysis.  There is a wide variation between the results for  
Observer No. Same (%) No. Different (%) Total 
1 6 (46%) 7 (54%) 13 
2 4 (31%) 9 (69%) 13 
3 7 (54%) 6 (46%) 13 
4 6 (46%) 7 (54%) 13 
5 8 (57%) 6 (43%) 14 
Overall 31 (47%) 35 (53%) 66 
Table 6.17 - Results of comparison in upper/lower location between lesions seen on 
ultrasound and those seen on planar images 
Number and percentage of lesions seen in the same and different upper/lower location for 
each observer and combined for all observers. 
different observers, with observer 4 seeing only 31% of the lesions in the same 
upper/lower location as was reported from ultrasound, whilst observer 5 sees 
57% in the same place.  The combined results for all the observers show similar 
proportions given as being at the same and different sites. 
A comparison of the overall location given for each lesion was then obtained by 
combining the results of the left/right and upper/lower analyses and the results 
are given in Table 6.18. 
Observer No. Same (%) No. Different (%) Total 
1 7 (50%) 7 (50%) 14 
2 5 (36%) 9 (64%) 14 
3 8 (57%) 6 (43%) 14 
4 7 (50%) 7 (50%) 14 
5 8 (53%) 7 (47%) 15 
Overall 35 (49%) 36 (51%) 71 
Table 6.18 - Results of combined left/right and upper/lower location comparisons between 
lesions seen on ultrasound and those seen on planar images 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
Each of the observers reported a similar proportion of lesions at the same and 
different overall location from the planar images as were seen on the ultrasound 
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scan.  The exception is observer 2, who gave only 36% of lesions at the same 
overall location. 
Taking the result from the ultrasound scan as the comparison standard, the 
sensitivity and specificity were calculated for each observer and for all the 
observers combined and the results are shown in Table 6.19. 
Observer Sensitivity (%) Specificity (%) 
1 54 77 
2 27 71 
3 38 69 
4 45 75 
5 62 69 
Overall 46 72 
Table 6.19 - Calculated sensitivity and specificity values for comparison of US and planar 
imaging results 
Percentage sensitivity and specificity values are given for each observer and for the 
combined results of all observers 
The results indicate that the specificity is relatively good for all the observers as 
well as the combined value.  However, the sensitivity is less so, with three of 
the observers and the overall result having values of <50%.  This demonstrates 
that there are a significant number of occasions when a lesion observed on 
ultrasound imaging is not observed on planar dual-isotope subtraction imaging 
but that a negative ultrasound result is often accompanied by a negative nuclear 
medicine result. 
6.2.2 Phase 2 versus Surgical and US Findings Comparison 
6.2.2.1 Surgical Results Comparison 
The number of suspected parathyroid adenomas seen in phase 2 (SPECT images) 
of the observer study was then compared to the number of samples resected at 
surgery.  The difference in the number of lesions was calculated for the 5 
observers independently for each of the 17 patients.  The results were 
categorised as before and are shown in Table 6.20. 
In this case, the largest category is that where the number of lesions resected at 
surgery was equal to the number seen on SPECT imaging.  For 4 of the 5 
observers, this was the largest category.  However, observer 5 tended to see 
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more lesions on the SPECT images than were sampled by the surgeon.  In only 14 
(16%) of the comparisons were more lesions resected than had been observed 
from the SPECT images, indicating that fewer lesions are missed when reviewing 
SPECT images than planar (compare with results in Section 6.2.1.1). 
Observer Sur > S Sur < S Sur = S Total 
1 3 0 14 17 
2 5 1 11 17 
3 3 4 10 17 
4 3 4 10 17 
5 0 10 7 17 
Total 14 19 52 85 
Table 6.20 - Comparison of number of samples resected at surgery and number of lesions 
seen in phase 2 (SPECT) 
Sur>S = number of times more lesions were resected than were seen on SPECT images, 
Sur<S = number of times fewer lesions were resected than were seen on SPECT images, 
Sur=S = number of times same number of lesions were resected as were seen on SPECT 
images. 
The data were then subjected to the Wilcoxon Signed Ranks test, for which a 
result of p<0.05 was again taken to be significant.  The results are shown in 
Table 6.21. 
Observer p-value Estimated Median 95% CI 
1 0.181 0.0 (0.0, 0.5) 
2 0.142 0.0 (0.0, 0.5) 
3 0.800 0.0 (-0.5, 0.5) 
4 0.866 0.0 (-0.5, 0.5) 
5 0.006 -1.0 (-1.5, -0.5) 
Overall 0.292 0.0 (0.0, 0.0) 
Table 6.21 - Results from Wilcoxon Signed Ranks test on differences in number of lesions 
seen (surgery vs phase 2) 
Output from Minitab software applied to the differences in the number of lesions resected at 
surgery and the number seen on SPECT imaging. 
It can be seen from the table that only the data from observer 5 demonstrated a 
statistically significant difference (p<0.05) between the number of lesions 
resected and those reported from the SPECT images.  The fact that the 
estimated median and 95% CI are <0 shows that this observer tended to see more 
lesions on the SPECT images than the surgeon sampled, which is as expected, 
given the results in Table 6.20. 
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Table 6.22 gives the results of the comparison between the positive/negative 
result reported for each lesion sampled and each lesion reported by the 
observers from the SPECT images. 
Observer No. Same +/- (%) No. Different +/- (%) Total 
1 14 (70%) 6 (30%) 20 
2 12 (57%) 9 (43%) 21 
3 18 (75%) 6 (25%) 24 
4 19 (76%) 6 (24%) 25 
5 31 (72%) 12 (28%) 43 
Overall 94 (71%) 39 (29%) 133 
Table 6.22 - Results from comparison of positive/negative findings (surgery vs phase 2) 
Number of comparisons between the overall given positive/negative report for a lesion that 
were the same and different between the surgically resected lesions and those seen on the 
SPECT images.  Percentages of the total in each category for each observer and overall are 
given in brackets. 
For all observers, the number reported with the same result is higher than that 
given a different result, with observer 4 having the highest proportion as the 
same at 76% and observer 2 having the lowest fraction the same at 57%.  These 
results are considerably better than those from Table 6.6 when the lesions 
observed on planar images were considered.  This indicates that the SPECT 
images do provide some improvement in reporting of possible adenomas. 
The results of the application of the Wilcoxon Signed Ranks test to this data are 
shown in Table 6.23.  Three of the 5 observers and the overall combined data 
show statistically significant differences with p<0.05.  Only observers 1 & 2 do 
not have p<0.05, which is to be expected if the results in Table 6.22 are 
considered since these were the two observers with the lowest proportion in the 
“same” category. 
Observer p-value Estimated Median 95% CI 
1 0.121 0.5 (0.0, 1.0) 
2 0.578 0.0 (0.0, 1.0) 
3 0.033 1.0 (0.0, 1.0) 
4 0.024 1.0 (0.0, 1.0) 
5 0.012 1.0 (0.0, 1.0) 
Overall <0.001 1.0 (0.0, 1.0) 
Table 6.23 - Results from Wilcoxon Signed Ranks Test on positive/negative comparison 
(surgery vs phase 2) 
Output from statistical test applied to comparison between the positive/negative report 
findings for surgical results and those given from review of the SPECT images. 
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The location of each resected sample and lesion seen on the SPECT images was 
then compared.  Since an indication of the anterior/posterior position of a lesion 
can be gained from SPECT images, this information was included in the overall 
comparison. 
Table 6.24 gives the results of the left/right location comparison.  Once again, 
lesions reported by the observers as being in an ectopic location were not 
included in this analysis. 
Observer No. Same (%) No. Different (%) Total 
1 14 (82%) 3 (18%) 17 
2 11 (65%) 6 (35%) 17 
3 16 (80%) 4 (20%) 20 
4 15 (79%) 4 (21%) 19 
5 21 (62%) 13 (38%) 34 
Overall 77 (72%) 30 (28%) 107 
Table 6.24 - Results of comparison in left/right location between lesions resected at surgery 
and those seen on SPECT images 
Number and percentage of lesions seen in the same and different left/right location for each 
observer and combined for all observers. 
For each observer, well over 50% of the lesions were seen on the same side 
(left/right) as those samples taken at surgery, with observer 5 demonstrating the 
lowest proportion at 62%.  It should also be noted that observer 5 has the highest 
total number of comparisons, meaning that this observer tended to see more 
lesions than the others, as has already been remarked upon in Section 5.4.6. 
The given upper/lower locations were then compared and the results are shown 
in Table 6.25.  It can be seen that the results for each observer vary 
considerably with observer 1 seeing as many as 76% of lesions in the same  
Observer No. Same (%) No. Different (%) Total 
1 13 (76%) 4 (24%) 17 
2 7 (41%) 10 (59%) 17 
3 10 (50%) 10 (50%) 20 
4 10 (53%) 9 (47%) 19 
5 16 (47%) 18 (53%) 34 
Overall 56 (52%) 51 (48%) 107 
Table 6.25 - Results of comparison in upper/lower location between lesions resected at 
surgery and those seen on SPECT images 
Number and percentage of lesions seen in the same and different upper/lower location for 
each observer and combined for all observers. 
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upper/lower position as the lesions resected at surgery whilst observer 2 saw 
only 41% at the same site. 
The results of the combined analysis of the left/right and upper/lower 
comparisons to give an assessment of any differences in the overall given 
location for each lesion are shown in Table 6.26. 
Observer No. Same (%) No. Different (%) Total 
1 11 (65%) 6 (35%) 17 
2 6 (35%) 11 (65%) 17 
3 8 (40%) 12 (60%) 20 
4 9 (47%) 10 (53%) 19 
5 11 (32%) 23 (68%) 34 
Overall 45 (42%) 62 (58%) 107 
Table 6.26 - Results of combined left/right and upper/lower location comparisons between 
lesions resected at surgery and those seen on SPECT images 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
It is immediately clear that only observer 1 has >50% of the lesions given at the 
same overall site, whilst all of the other observers as well as the combined 
results are <50%.  Observer 5 had the smallest proportion at the same overall 
site with 32%. 
Comparisons were then made of the given anterior/posterior location for each 
lesion and the results are shown in Table 6.27.  One of the samples resected at 
surgery had no anterior/posterior information given and so is excluded from the 
results in the table. 
Observer No. Same (%) No. Different (%) Total 
1 15 (94%) 1 (6%) 16 
2 9 (56%) 7 (44%) 16 
3 14 (78%) 4 (22%) 18 
4 10 (56%) 8 (44%) 18 
5 18 (56%) 14 (44%) 32 
Overall 66 (66%) 34 (34%) 100 
Table 6.27 - Results of comparison in anterior/posterior location between lesions resected 
at surgery and those seen on SPECT images 
Number and percentage of lesions seen in the same and different anterior/posterior location 
for each observer and combined for all observers. 
As for the left/right location, all the observers gave >50% of lesions at the same 
anterior/posterior location as they were found by the surgeon.  Observer 1 had 
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the highest proportion at 94% whilst the overall combined result for all the 
observers showed that almost 2/3 of the lesions were given at the same site. 
An overall comparison was then made of the location of each given lesion by 
combining all the results for the left/right, upper/lower and anterior/posterior 
comparisons.  The results are shown in Table 6.28. 
Observer No. Same (%) No. Different (%) Total 
1 10 (59%) 7 (41%) 17 
2 4 (24%) 13 (76%) 17 
3 7 (35%) 13 (65%) 20 
4 6 (32%) 13 (68%) 19 
5 6 (18%) 28 (82%) 34 
Overall 33 (31%) 74 (69%) 107 
Table 6.28 - Results of combined left/right, upper/lower and anterior/posterior location 
comparisons between lesions resected at surgery and those seen on SPECT images 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
Again, only observer 1 saw more than half of the lesions at the same place as the 
surgeon resected sampled whilst observer 5 saw only 18% at the same overall 
location. 
The sensitivity and specificity of true lesion detection were again calculated for 
each individual observer as well as for the overall combined results.  Table 6.29 
shows these calculated values along with the sensitivity and specificity for 
ultrasound imaging, to act as a comparison. 
Observer Sensitivity (%) Specificity (%) 
1 80 33 
2 57 25 
3 75 60 
4 85 0 
5 84 40 
Overall 77 31 
US 72 33 
Table 6.29 - Calculated sensitivity and specificity values for comparison of surgical and 
SPECT imaging results 
Percentage sensitivity and specificity values are given for each observer and for the 
combined results of all observers as well as for US imaging to provide a comparison 
The observers’ sensitivity and specificity values can be seen to be comparable to 
or better than those from ultrasound imaging, with the exception of observer 2 
having a sensitivity of just 57% and observer 4 having a 0% specificity value.  
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When these results are compared with those in Table 6.11, it can clearly be seen 
that the sensitivity is considerably improved when the observers are reviewing 
the SPECT images, meaning that more true lesions are seen.  However, the 
specificity is poorer, indicating that there are more false positive findings from 
the SPECT images and that the observers believe that image artefacts are in fact 
true lesions.  This is in keeping with the results of the direct comparison 
between Phases 1 and 2 of the observer study (see Section 5.5.1), where more 
lesions were seen on the SPECT images than on the planar. 
6.2.2.2 Ultrasound Results Comparison 
Table 6.30 shows the results of the comparison of the number of lesions seen on 
ultrasound imaging and the number seen on the SPECT images by each of the 
observers for each of the 25 patients.  It can be seen that there were very few 
occasions in which more lesions were seen on the ultrasound images than were 
reported by the observers from the SPECT imaging.  As for the comparison with 
the surgical results (Section 6.2.2.1), the largest category is that where the 
number of lesions seen was equal.  However, there were a significant number 
(42%) of cases in which fewer lesions were seen on ultrasound than were 
reported from the SPECT observer study. 
Observer US > S US < S US = S Total 
1 0 7 18 25 
2 2 7 16 25 
3 0 12 13 25 
4 0 8 17 25 
5 0 19 6 25 
Total 2 53 70 125 
Table 6.30 - Comparison of number of lesions seen on ultrasound and in phase 2 (SPECT) 
US>S = number of times more lesions were seen on ultrasound than on SPECT images, 
US<S = number of times fewer lesions were seen on ultrasound than on SPECT images, 
US=S = number of times same number of lesions were seen on ultrasound as on SPECT 
images. 
The results of applying the Wilcoxon Signed Ranks test to this data are shown in 
Table 6.31.  For 4 of the 5 observers as well as the combined data, p<0.05 and 
therefore a statistically significant difference in the number of lesions seen is 
demonstrated.  Observer 2 is the only observer for whom there is no statistically 
significant difference.  However, all estimated median and 95% CI values are ≤0, 
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meaning that there is a tendency to see more lesions on the SPECT images than 
are reported on ultrasound. 
Observer p-value Estimated Median 95% CI 
1 0.022 0.0 (-0.5, 0.0) 
2 0.155 0.0 (-0.5, 0.0) 
3 0.003 -0.5 (-1.0, 0.0) 
4 0.014 -0.5 (-0.5, 0.0) 
5 <0.001 -1.5 (-2.0, -1.0) 
Overall <0.001 -0.5 (-0.5, -0.5) 
Table 6.31 - Results from Wilcoxon Signed Ranks test on differences in number of lesions 
seen (ultrasound vs phase 2) 
Output from Minitab software applied to the differences in the number of lesions seen on 
ultrasound and those seen on SPECT imaging. 
The reported positive/negative status of each lesion was then compared and the 
results are given in Table 6.32.  As was the case in Table 6.22 when the surgical 
and SPECT reports were compared, there are >50% of the results in the “same” 
category for each of the observers.  On this occasion, observer 3 has the lowest 
proportion in this category with 59%, whilst observer 4 has the highest with 85%. 
Observer No. Same +/- (%) No. Different +/- (%) Total 
1 20 (77%) 6 (23%) 26 
2 18 (69%) 8 (31%) 26 
3 17 (59%) 12 (41%) 29 
4 23 (85%) 4 (15%) 27 
5 35 (71%) 14 (29%) 49 
Overall 113 (72%) 44 (28%) 157 
Table 6.32 - Results from comparison of positive/negative findings (ultrasound vs phase 2) 
Number of comparisons between the overall given positive/negative report for a lesion that 
were the same and different between those seen on ultrasound imaging and those seen on 
the SPECT images.  Percentages of the total in each category for each observer and overall 
are given in brackets. 
The Wilcoxon Signed Ranks test was then applied to the data and the results are 
given in Table 6.33.  As before, p<0.05 was taken to be the level of statistical 
significance.  On this occasion, only the results for observers 2 & 3 do not 
demonstrate statistical significance.  The estimated median and 95% CI values 
for all the observers are, however ≥0, suggesting that there are more reports 
given with the same positive/negative result than are given a different result. 
The left/right location comparison was then carried out and the results are 
shown in Table 6.34. 
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Observer p-value Estimated Median 95% CI 
1 0.017 1.0 (0.0, 1.0) 
2 0.089 0.0 (0.0, 1.0) 
3 0.424 0.0 (0.0, 1.0) 
4 0.001 1.0 (1.0, 1.0) 
5 0.009 1.0 (0.0, 1.0) 
Overall <0.001 1.0 (0.0, 1.0) 
Table 6.33 - Results from Wilcoxon Signed Ranks Test on positive/negative comparison 
(ultrasound vs phase 2) 
Output from statistical test applied to comparison between the positive/negative report 
findings from ultrasound imaging and those given from review of the SPECT images. 
Observer No. Same (%) No. Different (%) Total 
1 10 (71%) 4 (29%) 14 
2 10 (67%) 5 (33%) 15 
3 13 (76%) 4 (24%) 17 
4 11 (69%) 5 (31%) 16 
5 16 (64%) 9 (36%) 25 
Overall 60 (69%) 27 (31%) 87 
Table 6.34 - Results of comparison in left/right location between lesions seen on ultrasound 
and those seen on SPECT images 
Number and percentage of lesions seen in the same and different left/right location for each 
observer and combined for all observers. 
It can clearly be seen that in the majority of cases for each observer, the same 
left/right location was given for a lesion when compared to that reported from 
the ultrasound.  The lowest proportion given at the same location was 64% from 
observer 5, who once again also had the highest total number of comparisons 
and therefore reported more lesions than the other observers. 
Table 6.35 gives the results of the upper/lower location comparison.  Only 
observer 4 gave fewer lesions at the same location (47%) than at a different site 
when compared to the ultrasound report.  Observer 1 saw as many as 69% at the 
same location, meaning that there was once again a large variation between the 
results for the different observers. 
The combined results for the left/right and upper/lower comparisons are shown 
in Table 6.36.  Once again, observer 1 had the highest proportion of lesions 
given at the same overall location at 64% whilst observers 2 & 5 reported only 
40% at the same site as the ultrasound. 
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Observer No. Same (%) No. Different (%) Total 
1 9 (69%) 4 (31%) 13 
2 7 (50%) 7 (50%) 14 
3 9 (56%) 7 (44%) 16 
4 7 (47%) 8 (53%) 15 
5 12 (50%) 12 (50%) 24 
Overall 44 (54%) 38 (46%) 82 
Table 6.35 - Results of comparison in upper/lower location between lesions seen on 
ultrasound and those seen on SPECT images 
Number and percentage of lesions seen in the same and different upper/lower location for 
each observer and combined for all observers. 
Observer No. Same (%) No. Different (%) Total 
1 9 (64%) 5 (36%) 14 
2 6 (40%) 9 (60%) 15 
3 9 (53%) 8 (47%) 17 
4 8 (50%) 8 (50%) 16 
5 10 (40%) 15 (60%) 25 
Overall 42 (48%) 45 (52%) 87 
Table 6.36 - Results of combined left/right and upper/lower location comparisons between 
lesions seen on ultrasound and those seen on SPECT images 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
The given anterior/posterior locations were then compared and the results are 
shown in Table 6.37.  All the observers reported >50% of lesions at the same 
anterior/posterior location as was given by the ultrasound report.  However, 
there was again a wide variation between the observers with observer 1 giving as 
many as 93% at the same site whilst observer 4 had only 56% in this category. 
Observer No. Same (%) No. Different (%) Total 
1 13 (93%) 1 (7%) 14 
2 11 (73%) 4 (27%) 15 
3 14 (82%) 3 (18%) 17 
4 9 (56%) 7 (44%) 16 
5 16 (64%) 9 (36%) 25 
Overall 63 (72%) 24 (28%) 87 
Table 6.37 - Results of comparison in anterior/posterior location between lesions seen on 
ultrasound and those seen on SPECT images 
Number and percentage of lesions seen in the same and different anterior/posterior location 
for each observer and combined for all observers. 
The anterior/posterior comparison findings were then combined with those for 
the left/right and upper/lower comparisons and a comparison of the overall 
location in 3 dimensions was produced.  The results are given in Table 6.38. 
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Observer No. Same (%) No. Different (%) Total 
1 9 (64%) 5 (36%) 14 
2 5 (33%) 10 (67%) 15 
3 9 (53%) 8 (47%) 17 
4 5 (31%) 11 (69%) 16 
5 8 (32%) 17 (68%) 25 
Overall 36 (41%) 51 (59%) 87 
Table 6.38 - Results of combined left/right, upper/lower and anterior/posterior location 
comparisons between lesions seen on ultrasound and those seen on SPECT images 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
It can be seen that both observer 1 and observer 3 gave >50% of lesions at the 
same overall location as were reported from ultrasound scanning.  However, the 
other observers only gave around 30% of lesions at the same location. 
Table 6.39 shows the calculated sensitivity and specificity values for each 
individual observer and for all the observers combined when the ultrasound 
results are taken to be the comparison standard.  The results clearly show good 
sensitivity in general, with observer 4 having 100% sensitivity.  However, the 
specificity is more variable with observer 2 having a value of 73% whilst observer 
3 has just 36%.  When compared with the results in Table 6.19, the sensitivity 
shows a general improvement, whilst the specificity is poorer.  This is the same 
situation as was seen when the Phase 1 and 2 observer study results were 
compared with the surgical findings (Section 6.2.2.1), indicating that more true 
lesions are seen on the SPECT images than the planar but that there are also 
more false positive reports being given by the observers. 
Observer Sensitivity (%) Specificity (%) 
1 91 63 
2 60 73 
3 67 36 
4 100 38 
5 94 42 
Overall 81 48 
Table 6.39 - Calculated sensitivity and specificity values for comparison of US and SPECT 
imaging results 
Percentage sensitivity and specificity values are given for each observer and for the 
combined results of all observers 
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6.2.3 Phase 3 versus Surgical and US Findings Comparison 
6.2.3.1 Surgical Results Comparison 
For each of the 17 patients, the difference between the number of samples 
resected during parathyroidectomy and the number seen by each of the 5 
observers on the Sestamibi (planar + SPECT) images in phase 3 of the observer 
study was calculated.  Table 6.40 shows the results categorised in the same way 
as the previous analyses involving the results from phases 1 and 2 of the 
observer study. 
Observer Sur > M Sur < M Sur = M Total 
1 6 0 11 17 
2 9 0 8 17 
3 5 0 12 17 
4 7 2 8 17 
5 1 5 11 17 
Total 28 7 50 85 
Table 6.40 - Comparison of number of samples resected at surgery and number of lesions 
seen in phase 3 (Sestamibi only) 
Sur>M = number of times more lesions were resected than were seen on Sestamibi images, 
Sur<M = number of times fewer lesions were resected than were seen on Sestamibi images, 
Sur=M = number of times same number of lesions were resected as were seen on Sestamibi 
images. 
The results show that there were only a very small number of occasions in which 
there were more lesions seen on the Sestamibi images than were resected at 
surgery, whilst there were 4 times as many occasions on which there were fewer 
lesions seen than were sampled.  The largest category is once again that in 
which there were equal numbers of surgical samples and lesions reported from 
the images. 
Table 6.41 shows the results of the non-parametric Wilcoxon Signed Ranks test 
being applied to these data.  The results for 2 of the observers (1 & 2) show 
statistically significant differences with p<0.05 but this is not the case for the 
other 3 observers.  The result of the test applied to the data from all the 
observers is also statistically significant.  Interestingly, only observer 5 has a 95% 
CI that is ≤0, which indicates that this observer generally saw more lesions on 
the Sestamibi images than were sampled at surgery, whereas the opposite was 
true for all the other observers. 
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Observer p-value Estimated Median 95% CI 
1 0.036 0.5 (0.0, 0.5) 
2 0.009 0.5 (0.0, 1.0) 
3 0.059 0.0 (0.0, 0.5) 
4 0.155 0.5 (0.0, 0.5) 
5 0.173 0.0 (-0.5, 0.0) 
Overall 0.001 0.5 (0.0, 0.5) 
Table 6.41 - Results from Wilcoxon Signed Ranks test on differences in number of lesions 
seen (surgery vs phase 3) 
Output from Minitab software applied to the differences in the number of lesions resected at 
surgery and the number seen on Sestamibi only imaging. 
The reported positive/negative results for each sample resected and each lesion 
seen on phase 3 of the observer study were then compared and the results are 
shown in Table 6.42. 
Observer No. Same +/- (%) No. Different +/- (%) Total 
1 7 (35%) 13 (65%) 20 
2 6 (30%) 14 (70%) 20 
3 9 (45%) 11 (55%) 20 
4 13 (59%) 9 (41%) 22 
5 20 (69%) 9 (31%) 29 
Overall 55 (49%) 56 (51%) 111 
Table 6.42 - Results from comparison of positive/negative findings (surgery vs phase 3) 
Number of comparisons between the overall given positive/negative report for a lesion that 
were the same and different between the surgically resected lesions and those seen on the 
Sestamibi only images.  Percentages of the total in each category for each observer and 
overall are given in brackets. 
In contrast to the results for the comparisons of surgical results with those from 
phases 1 and 2 of the observer study, 3 of the individual observers as well as the 
combined result for all the observers have <50% in the “same” category.  Given 
that 18 of the 20 samples from surgery were given a positive histological report 
for parathyroid adenoma or hyperplasia, this suggests that the observers were 
either not seeing some true lesions on the Sestamibi images or that they are not 
confident that the lesion they are seeing is a true adenoma and so are reporting 
it as equivocal. 
The Wilcoxon Signed Ranks test was then applied to these data and the results 
are given in Table 6.43.  None of the results are statistically significant as p>0.05 
in every case.  However, the 95% CI values for observers 1-3 are all ≤0 whilst 
those for observers 4 & 5 are ≥0. This supports the results in Table 6.42 by 
showing that observers 1-3 tend to give a different report from the surgical 
report whilst observers 4 & 5 generally give the same report. 
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Observer p-value Estimated Median 95% CI 
1 0.247 0.0 (-1.0, 0.0) 
2 0.121 -0.5 (-1.0, 0.0) 
3 0.709 0.0 (-1.0, 0.0) 
4 0.465 0.0 (0.0, 1.0) 
5 0.076 0.0 (0.0, 1.0) 
Overall 0.936 0.0 (0.0, 0.0) 
Table 6.43 - Results from Wilcoxon Signed Ranks Test on positive/negative comparison 
(surgery vs phase 3) 
Output from statistical test applied to comparison between the positive/negative report 
findings for surgical results and those given from review of the Sestamibi only images. 
A comparison of the given location of each lesion for each patient was then 
carried out in the same way as has been previously discussed.  The results for 
the left/right comparison between the surgically resected samples and those 
seen on Sestamibi images are shown in Table 6.44.  As has been the case 
previously, observer 5 has the highest number of comparisons, meaning that this 
observer generally saw a greater number of lesions on the Sestamibi images than 
did the other observers.  It can also be seen from the results that observer 2 saw 
the smallest proportion of lesions at the same left/right position as those 
sampled at surgery at only 35%.  All the other observers saw >50% at the same 
position, with observer 1 having the highest fraction at 76%. 
Observer No. Same (%) No. Different (%) Total 
1 13 (76%) 4 (24%) 17 
2 6 (35%) 11 (65%) 17 
3 12 (71%) 5 (29%) 17 
4 12 (63%) 7 (37%) 19 
5 18 (75%) 6 (25%) 24 
Overall 61 (65%) 33 (35%) 94 
Table 6.44 - Results of comparison in left/right location between lesions resected at surgery 
and those seen on Sestamibi only images 
Number and percentage of lesions seen in the same and different left/right location for each 
observer and combined for all observers. 
The results of the upper/lower location comparison are shown in Table 6.45.  In 
this instance, only observer 3 gave the same upper/lower location as the surgical 
report in more than half of cases (53%).  The lowest proportion of reports at the 
same site was given by observer 2 with only 29%. 
The left/right and upper/lower comparisons were then combined and the results 
are shown in Table 6.46.  Once again, only observer 3 saw >50% of lesions on the 
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Sestamibi images at the same overall location as those which were sampled at 
surgery. 
Observer No. Same (%) No. Different (%) Total 
1 8 (47%) 9 (53%) 17 
2 5 (29%) 12 (71%) 17 
3 9 (53%) 8 (47%) 17 
4 9 (47%) 10 (53%) 19 
5 10 (42%) 14 (58%) 24 
Overall 41 (44%) 53 (56%) 94 
Table 6.45 - Results of comparison in upper/lower location between lesions resected at 
surgery and those seen on Sestamibi only images 
Number and percentage of lesions seen in the same and different upper/lower location for 
each observer and combined for all observers. 
Observer No. Same (%) No. Different (%) Total 
1 7 (41%) 10 (59%) 17 
2 4 (24%) 13 (76%) 17 
3 9 (53%) 8 (47%) 17 
4 8 (42%) 11 (58%) 19 
5 8 (33%) 16 (67%) 24 
Overall 36 (38%) 58 (62%) 94 
Table 6.46 - Results of combined left/right and upper/lower location comparisons between 
lesions resected at surgery and those seen on Sestamibi only images 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
As SPECT image data was included in this phase of the study, a comparison was 
also made of the reported anterior/posterior location of each lesion, and the 
results are given in Table 6.47.  There are significant variations in the results for 
the different observers with observer 1 having the same proportion (81%) given 
at the same location as observer 2 has given at a different location.  The overall 
combined results for all the observers show little difference between the two 
categories. 
Observer No. Same (%) No. Different (%) Total 
1 13 (81%) 3 (19%) 16 
2 3 (19%) 13 (81%) 16 
3 11 (69%) 5 (31%) 16 
4 6 (33%) 12 (67%) 18 
5 15 (68%) 7 (32%) 22 
Overall 48 (54%) 40 (46%) 88 
Table 6.47 - Results of comparison in anterior/posterior location between lesions resected 
at surgery and those seen on Sestamibi only images 
Number and percentage of lesions seen in the same and different anterior/posterior location 
for each observer and combined for all observers. 
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The final analysis on the location data was to combine the left/right, 
upper/lower and anterior/posterior comparison information to give an overall 
location comparison in 3 dimensions for each reported lesion.  The results are 
shown in Table 6.48. 
Observer No. Same (%) No. Different (%) Total 
1 6 (35%) 11 (65%) 17 
2 2 (12%) 15 (88%) 17 
3 7 (41%) 10 (59%) 17 
4 4 (21%) 15 (79%) 19 
5 6 (25%) 18 (75%) 24 
Overall 25 (27%) 69 (73%) 94 
Table 6.48 - Results of combined left/right, upper/lower and anterior/posterior location 
comparisons between lesions resected at surgery and those seen on Sestamibi only images 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
It is clear from these results that, in general, there are a much larger number of 
cases in which the location given from Sestamibi images is different from that 
given in the surgical report.  This suggests that there is either insufficient 
information available to the observers without the 123I-iodide and subtraction 
images or that there is poor differentiation of true lesions on the Sestamibi 
images. 
The given positive/negative findings and left/right locations for each lesion were 
then used to calculate the sensitivity and specificity of lesion detection for each 
of the observers and for the overall combined results.  The results are shown in 
Table 6.49.  The sensitivity and specificity of the ultrasound imaging results is 
also shown to provide a comparison between the two imaging methods. 
Observer Sensitivity (%) Specificity (%) 
1 25 100 
2 25 100 
3 44 100 
4 57 20 
5 72 0 
Overall 45 29 
US 72 33 
Table 6.49- Calculated sensitivity and specificity values for comparison of surgical and 
Sestamibi only imaging 
Percentage sensitivity and specificity values are given for each observer and for the 
combined results of all observers as well as for US imaging to provide a comparison 
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Both the sensitivity and specificity are very variable between the different 
observers with a higher sensitivity tending to be accompanied by a low 
specificity and vice versa.  For example, observer 5 has a comparable sensitivity 
to ultrasound imaging of 72% but a specificity of 0%.  In contrast, observers 1 & 2 
have poor sensitivity at just 25% but have 100% specificity.  These results 
indicate that observers 1 & 2 were less likely to designate a possible lesion seen 
on the 99mTc-Sestamibi-only images as positive and, in so doing, gave no false 
positive reviews but also missed true positive lesions.  Observer 5, however, 
tended to give a positive result to all lesions seen, meaning that the sensitivity 
was high but the specificity was low because of many false positive reports. 
The tradeoff between sensitivity and specificity can be characterised by a 
receiver operating characteristic (ROC) curve.  This is a plot of sensitivity 
against 1-specificity and demonstrates how the sensitivity and specificity vary 
relative to one another as the decision threshold varies.  For example, an 
operator using a conservative measure of a positive lesion would achieve good 
specificity due to few false positive results but this would result in poorer 
sensitivity due to true positive lesions being classified as false negative.  In 
contrast, an operator using a liberal measure of a positive lesion would have 
good sensitivity but poorer specificity.  Thus, from the results in Table 6.49, it 
can be seen that observers 1-3 were using a conservative threshold, whilst 
observers 4 & 5 were using a more liberal measure of a positive lesion. 
The sensitivity and specificity results for phase 3 of the observer study were 
much more variable than those for phases 1 & 2, which are given in Table 6.11 
and Table 6.29, respectively.  The observers openly stated that they were not 
comfortable reviewing the 99mTc-Sestamibi images in the absence of the 123I-
iodide images, which provided an indication of the position and shape of the 
thyroid gland as well as subtraction images, and so this is not a surprising 
finding. 
6.2.3.2 Ultrasound Results Comparison 
The difference between the number of lesions seen by each observer on phase 3 
of the observer study and that reported from ultrasound scanning was calculated 
for each of the 25 patients.  The results were then categorised in the same 
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manner as previously and the results are shown in Table 6.50.  The Wilcoxon 
Signed Ranks test was also applied to these data and the results of this analysis 
are shown in Table 6.51. 
The results show a more even spread between the categories than was seen 
when the surgical results were compared to those from phase 3 of the observer 
study.  The largest category is once again that in which the number of lesions 
seen by the observers is the same as that seen on ultrasound scanning but the 
other two categories both have a significant number of entries.  There were, 
however, more occasions in which the observer saw more lesions on the 
Sestamibi only images than were reported from ultrasound than when the 
opposite was the case.  In particular, observer 5 had more observations in this 
category than in either of the others. 
Observer US > M US < M US = M Total 
1 5 9 11 25 
2 8 3 14 25 
3 5 8 12 25 
4 4 7 14 25 
5 2 14 9 25 
Total 24 41 60 125 
Table 6.50 - Comparison of number of lesions seen on ultrasound and in phase 3 (Sestamibi 
only) 
US>M = number of times more lesions were seen on ultrasound than on Sestamibi images, 
US<M = number of times fewer lesions were seen on ultrasound than on Sestamibi images, 
US=M = number of times same number of lesions were seen on ultrasound as on Sestamibi 
images. 
Observer p-value Estimated Median 95% CI 
1 0.363 0.0 (-0.5, 0.0) 
2 0.197 0.0 (0.0, 0.5) 
3 0.485 0.0 (-0.5, 0.0) 
4 0.351 0.0 (-0.5, 0.0) 
5 0.004 -0.5 (-1.0, -0.5) 
Overall 0.021 0.0 (-0.5, 0.0) 
Table 6.51 - Results from Wilcoxon Signed Ranks test on differences in number of lesions 
seen (ultrasound vs phase 3) 
Output from Minitab software applied to the differences in the number of lesions seen on 
ultrasound and those seen on Sestamibi only imaging. 
The results of the Wilcoxon Signed Ranks test support those given in Table 6.50 
in that only the results from observer 5 show a statistically significant difference 
with p<0.05.  As expected, the estimated median and 95% CI for this observer 
are both <0, indicating that more lesions were seen on the Sestamibi images 
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than were highlighted in the ultrasound report.  The result from the statistical 
test applied to the data from all 5 observers combined is also statistically 
significant with p<0.05, which is most likely due to the increased power of the 
test when a larger sample size is used. 
Table 6.52 gives the results of the comparison between the positive/negative 
reports from ultrasound and Sestamibi imaging.  It can be seen that only 
observer 1 has <50% in the “same” category at 36%, whilst all the others have 
>50% in this category with the highest being 64% for observer 3. 
Observer No. Same +/- (%) No. Different +/- (%) Total 
1 9 (36%) 16 (64%) 25 
2 14 (56%) 11 (44%) 25 
3 16 (64%) 9 (36%) 25 
4 14 (54%) 12 (46%) 26 
5 19 (54%) 16 (46%) 35 
Overall 72 (53%) 64 (47%) 136 
Table 6.52 - Results from comparison of positive/negative findings (ultrasound vs phase 3) 
Number of comparisons between the overall given positive/negative report for a lesion that 
were the same and different between those seen on ultrasound imaging and those seen on 
the Sestamibi only images.  Percentages of the total in each category for each observer and 
overall are given in brackets. 
Once again, the Wilcoxon Signed Ranks test was applied to these data and the 
results are shown in Table 6.53.  In this case, there were no statistically 
significant results with p>0.05 in all cases.  The 95% CI for observer 1 is ≤0, 
which is as expected, given the findings in Table 6.52. 
Observer p-value Estimated Median 95% CI 
1 0.226 0.0 (-1.0, 0.0) 
2 0.609 0.0 (0.0, 1.0) 
3 0.226 0.0 (0.0, 1.0) 
4 0.741 0.0 (0.0, 1.0) 
5 0.664 0.0 (0.0, 0.0) 
Overall 0.552 0.0 (0.0, 0.0) 
Table 6.53 - Results from Wilcoxon Signed Ranks Test on positive/negative comparison 
(ultrasound vs phase 3) 
Output from statistical test applied to comparison between the positive/negative report 
findings from ultrasound imaging and those given from review of the Sestamibi only 
images. 
The same comparisons were then made of the reported locations of each lesion 
from the ultrasound images and by the observers from the Sestamibi images.  
The results of the left/right comparison are shown in Table 6.54 and it can be  
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Observer No. Same (%) No. Different (%) Total 
1 7 (50%) 7 (50%) 14 
2 4 (29%) 10 (71%) 14 
3 8 (57%) 6 (43%) 14 
4 8 (57%) 6 (43%) 14 
5 13 (68%) 6 (32%) 19 
Overall 40 (53%) 35 (47%) 75 
Table 6.54 - Results of comparison in left/right location between lesions seen on ultrasound 
and those seen on Sestamibi only images 
Number and percentage of lesions seen in the same and different left/right location for each 
observer and combined for all observers. 
seen that once again observer 2 has the lowest proportion in the “same” 
category at 29%, whilst all the others have ≥50% in this category. 
The same analysis was applied to the give upper/lower location of each observed 
lesion and the results are shown in Table 6.55.  As was the case when the 
surgical results were compared to those from phase 3 of the observer study, only 
observer 3 gave a higher proportion of lesions in the same upper/lower location 
than in a different position. 
Observer No. Same (%) No. Different (%) Total 
1 5 (39%) 8 (61%) 13 
2 4 (31%) 9 (69%) 13 
3 7 (54%) 6 (46%) 13 
4 4 (31%) 9 (69%) 13 
5 8 (44%) 10 (56%) 18 
Overall 28 (40%) 42 (60%) 70 
Table 6.55 - Results of comparison in upper/lower location between lesions seen on 
ultrasound and those seen on Sestamibi only images 
Number and percentage of lesions seen in the same and different upper/lower location for 
each observer and combined for all observers. 
The results of the combined analysis of the left/right and upper/lower locations 
are shown in Table 6.56.  As expected from the results in Table 6.54 and Table 
6.55, only observer 3 gave more lesions as being in the same combined location 
as being at a different site.  The lowest proportion of lesions reported at the 
same site from the Sestamibi images as were seen on ultrasound scanning was 
from observer 2 at just 29%. 
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Observer No. Same (%) No. Different (%) Total 
1 5 (36%) 9 (64%) 14 
2 4 (29%) 10 (71%) 14 
3 8 (57%) 6 (43%) 14 
4 5 (36%) 9 (64%) 14 
5 9 (47%) 10 (53%) 19 
Overall 31 (41%) 44 (59%) 75 
Table 6.56 - Results of combined left/right and upper/lower location comparisons between 
lesions seen on ultrasound and those seen on Sestamibi only images 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
A similar comparison was then carried out on the reported anterior/posterior 
location of each lesion and on an overall combined left/right, upper/lower and 
anterior/posterior location.  The results are shown in Table 6.57 and Table 6.58 
respectively. 
Observer No. Same (%) No. Different (%) Total 
1 9 (64%) 5 (36%) 14 
2 4 (29%) 10 (71%) 14 
3 9 (64%) 5 (36%) 14 
4 3 (21%) 11 (79%) 14 
5 10 (53%) 9 (47%) 19 
Overall 35 (47%) 40 (53%) 75 
Table 6.57 - Results of comparison in anterior/posterior location between lesions seen on 
ultrasound and those seen on Sestamibi only images 
Number and percentage of lesions seen in the same and different anterior/posterior location 
for each observer and combined for all observers. 
The results of the comparison of the anterior/posterior position are similar to 
those of the left/right comparison (Table 6.54) with the exception of observer 4 
seeing a very low proportion (21%) at the same location as was reported from 
ultrasound imaging. 
Observer No. Same (%) No. Different (%) Total 
1 5 (36%) 9 (64%) 14 
2 2 (14%) 12 (86%) 14 
3 8 (57%) 6 (43%) 14 
4 1 (7%) 13 (93%) 14 
5 6 (32%) 13 (68%) 19 
Overall 22 (29%) 53 (71%) 75 
Table 6.58 - Results of combined left/right, upper/lower and anterior/posterior location 
comparisons between lesions seen on ultrasound and those seen on Sestamibi only images 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
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Finally, the comparisons of the overall given location for the lesions shows that 
again, observer 3 is the only individual with >50% in the “same” category.  
Observer 4 saw only a single lesion (7%) at the same overall location as was 
reported from the ultrasound imaging, which is the lowest proportion seen on 
any of the location comparisons in this report. 
The sensitivity and specificity for each observer taking the ultrasound result as 
the comparison standard and considering only the given positive/negative and 
left/right findings are shown in Table 6.59. 
As was the case when the phase 3 findings were compared to the surgical results 
(see Table 6.49), there is considerable variation in the sensitivity and specificity 
for the different observers.  However, the sensitivity is generally low, indicating 
that there were a number of lesions seen on ultrasound imaging that were not 
noted by the observers on the 99mTc-Sestamibi planar + SPECT images.  The 
specificity values are better, but are still very variable with observer 3 
demonstrating high specificity at 82% whilst observer 5 was poor with a value of 
just 44%.  The variable results once again demonstrate that the observers were 
not confident in reviewing the 99mTc-Sestamibi images in the absence of the 123I-
iodide images. 
Observer Sensitivity (%) Specificity (%) 
1 8 55 
2 17 75 
3 46 82 
4 46 64 
5 53 44 
Overall 35 62 
Table 6.59- Calculated sensitivity and specificity values for comparison of US and Sestamibi 
only imaging results 
Percentage sensitivity and specificity values are given for each observer and for the 
combined results of all observers 
6.2.4 Phase 4 versus Surgical and US Findings Comparison 
6.2.4.1 Surgical Results Comparison 
The final comparison involving the findings from parathyroidectomy surgery on 
the study participants was carried out with the results of phase 4 (all images) of 
the observer study.  As before, the difference between the number of lesions 
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sampled at surgery and the number seen by each individual observer when 
reviewing all the available images together was calculated.  The results of the 
analysis are shown in Table 6.60. 
It is clear from the data that the largest category for each individual observer 
and also overall is that in which the same number of samples were taken at 
surgery as lesions were seen on the nuclear medicine images.  These account for 
67% of the total, indicating that there is good agreement between the number of 
lesions suggested on nuclear medicine planar + SPECT subtraction imaging and 
the number of suspicious samples noted by the surgeon. 
Observer Sur > A Sur < A Sur = A Total 
1 4 2 11 17 
2 4 0 13 17 
3 5 1 11 17 
4 3 3 11 17 
5 1 5 11 17 
Total 17 11 57 85 
Table 6.60 - Comparison of number of samples resected at surgery and number of lesions 
seen in phase 4 (all images) 
Sur>A = number of times more lesions were resected than were seen on review of all 
available images, Sur<A = number of times fewer lesions were resected than were seen on 
review of all available images, Sur=A = number of times same number of lesions were 
resected as were seen on review of all available images. 
Table 6.61 gives the results of the Wilcoxon Signed Ranks test that was applied 
to the difference data.  It is immediately apparent that there are no instances in 
which p<0.05, meaning that no statistically significant differences exist between 
the number of lesions resected and the number seen by the observers.  This 
supports the conclusions drawn from the data in Table 6.60. 
Observer p-value Estimated Median 95% CI 
1 0.402 0.0 (0.0, 0.5) 
2 0.100 0.0 (0.0, 1.0) 
3 0.142 0.0 (0.0, 0.5) 
4 1.000 0.0 (-0.5, 0.5) 
5 0.173 0.0 (-0.5, 0.0) 
Overall 0.139 0.0 (0.0, 0.0) 
Table 6.61 - Results from Wilcoxon Signed Ranks test on differences in number of lesions 
seen (surgery vs phase 4) 
Output from Minitab software applied to the differences in the number of lesions resected at 
surgery and the number seen on review of all images. 
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The positive/negative report information given for each lesion from histology 
after surgery and that given by the observers from the subtraction imaging were 
then compared, and the results are shown in Table 6.62.  All the observers gave 
a significant majority of reports that were the same as those from surgery, with 
observer 4 having the highest proportion in this category at 74%.  Once again, 
the tendency for observer 5 to report more lesions is demonstrated by the higher 
number of overall comparisons for this observer compared to the others. 
Observer No. Same +/- (%) No. Different +/- (%) Total 
1 14 (64%) 8 (36%) 22 
2 12 (60%) 8 (40%) 20 
3 14 (67%) 7 (33%) 21 
4 17 (74%) 6 (26%) 23 
5 18 (62%) 11 (38%) 29 
Overall 75 (65%) 40 (35%) 115 
Table 6.62 - Results from comparison of positive/negative findings (surgery vs phase 4) 
Number of comparisons between the overall given positive/negative report for a lesion that 
were the same and different between the surgically resected lesions and those seen when 
all images were reviewed together.  Percentages of the total in each category for each 
observer and overall are given in brackets. 
These data were then subjected to the non-parametric Wilcoxon Signed Ranks 
statistical test.  The results are shown in Table 6.63 and it can be seen that 
statistically significant differences exist only for observer 4 – who had the 
highest proportion in the “same” category – and the overall combined data for 
all 5 observers.  The 95% CI for each observer are, however, ≥0, indicating that 
there is a general tendency for the observers to give the same rather than a 
different positive/negative report when compared to the surgical findings.  Once 
again, this is as expected, given the findings shown in Table 6.62. 
Observer p-value Estimated Median 95% CI 
1 0.270 0.0 (0.0, 1.0) 
2 0.444 0.0 (0.0, 1.0) 
3 0.187 0.0 (0.0, 1.0) 
4 0.046 1.0 (0.0, 1.0) 
5 0.261 0.0 (0.0, 1.0) 
Overall 0.005 0.0 (0.0, 1.0) 
Table 6.63 - Results from Wilcoxon Signed Ranks Test on positive/negative comparison 
(surgery vs phase 4) 
Output from statistical test applied to comparison between the positive/negative report 
findings for surgical results and those given from review of all images. 
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A similar analysis to that carried out previously (see Sections 6.2.1.1, 6.2.2.1 & 
6.2.3.1) was then performed on the given information relating to the location of 
each lesion.  The results of the left/right comparison are shown in Table 6.64. 
For each observer, the majority of lesions were given to be at the same 
left/right location as those that were sampled at surgery.  The lowest proportion 
at the same site was reported by observer 5 with 65%. 
Observer No. Same (%) No. Different (%) Total 
1 14 (78%) 4 (22%) 18 
2 12 (71%) 5 (29%) 17 
3 13 (77%) 4 (23%) 17 
4 13 (68%) 6 (32%) 19 
5 15 (65%) 8 (35%) 23 
Overall 67 (71%) 27 (29%) 94 
Table 6.64 - Results of comparison in left/right location between lesions resected at surgery 
and those seen on review of all images 
Number and percentage of lesions seen in the same and different left/right location for each 
observer and combined for all observers. 
The same analysis was then carried out on the upper/lower position information 
and the results are shown in Table 6.65.  The results are more variable than 
those from the left/right comparison with observer 2 giving only 47% of reported 
lesions given at the same upper/lower site, whilst observers 1 & 5 saw 61% at 
the same position. 
Observer No. Same (%) No. Different (%) Total 
1 11 (61%) 7 (39%) 18 
2 8 (47%) 9 (53%) 17 
3 9 (53%) 8 (47%) 17 
4 11 (58%) 8 (42%) 19 
5 14 (61%) 9 (39%) 23 
Overall 53 (56%) 41 (44%) 94 
Table 6.65 - Results of comparison in upper/lower location between lesions resected at 
surgery and those seen on review of all images 
Number and percentage of lesions seen in the same and different upper/lower location for 
each observer and combined for all observers. 
The left/right and upper/lower comparisons were then combined and the results 
are shown in Table 6.66.  Again, there is considerable variation between the 
observers with observer 1 seeing as many as 56% of lesions at the same overall 
site but observer 4 giving only 37% at the same location.  It is interesting to note 
that observer 4 had proportions in the “same” category of >50% for each of the 
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left/right and upper/lower comparisons independently but a much lower 
fraction for the combined analysis.  This suggests that this observer tends to give 
one or other of these positions as the same as the surgical findings, but not both 
for an individual patient. 
Observer No. Same (%) No. Different (%) Total 
1 10 (56%) 8 (44%) 18 
2 8 (47%) 9 (53%) 17 
3 9 (53%) 8 (47%) 17 
4 7 (37%) 12 (63%) 19 
5 11 (48%) 12 (52%) 23 
Overall 45 (48%) 49 (52%) 94 
Table 6.66 - Results of combined left/right and upper/lower location comparisons between 
lesions resected at surgery and those seen on review of all images 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
As SPECT data was presented to the observers during phase 4 of the observer 
study, an analysis of the anterior/posterior position of each lesion was possible.  
The results of the comparison between the surgical position and that reported by 
the observers are shown in Table 6.67. 
Observer No. Same (%) No. Different (%) Total 
1 12 (71%) 5 (29%) 17 
2 8 (50%) 8 (50%) 16 
3 12 (75%) 4 (25%) 16 
4 14 (78%) 4 (22%) 18 
5 19 (86%) 3 (14%) 22 
Overall 65 (73%) 24 (27%) 89 
Table 6.67 - Results of comparison in anterior/posterior location between lesions resected 
at surgery and those seen on review of all images 
Number and percentage of lesions seen in the same and different anterior/posterior location 
for each observer and combined for all observers. 
The results show that each of the observers gave ≥50% of lesions at the same 
anterior/posterior position as was recorded in the surgical notes for each 
resected sample.  The highest proportion in the “same” category was for 
observer 5 with 86%, whist the lowest was for observer 2 with 50%. 
An overall comparison of given location was then carried out by combining all 
the information from the individual left/right, upper/lower and 
anterior/posterior comparisons.  The results of this analysis are shown in Table 
6.68. 
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Observer No. Same (%) No. Different (%) Total 
1 9 (50%) 9 (50%) 18 
2 5 (29%) 12 (71%) 17 
3 8 (47%) 9 (53%) 17 
4 5 (26%) 14 (74%) 19 
5 10 (44%) 13 (56%) 23 
Overall 37 (39%) 57 (61%) 94 
Table 6.68 - Results of combined left/right, upper/lower and anterior/posterior location 
comparisons between lesions resected at surgery and those seen on review of all images 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
Only observer 1 gave as many as 50% of lesions at the same overall location as 
the surgical report, whilst observer 4 saw only 26% at the same site.  Although 
the results from all the individual comparisons were positive, the combined 
results are somewhat poorer, again suggesting that the observers are often 
giving one position parameter as the same as the surgical report but the other 2 
parameters are rarely also the same for an individual patient. 
Table 6.69 shows the sensitivity and specificity values for each observer and for 
the combined results from all 5 observers.  The sensitivity and specificity of the 
ultrasound imaging results is also given for comparison. 
Observer Sensitivity (%) Specificity (%) 
1 67 50 
2 60 33 
3 67 25 
4 80 29 
5 69 13 
Overall 64 27 
US 72 33 
Table 6.69 - Calculated sensitivity and specificity values for comparison of surgical and all 
dual-isotope subtraction imaging 
Percentage sensitivity and specificity values are given for each observer and for the 
combined results of all observers as well as for US imaging to provide a comparison 
When compared with the sensitivity and specificity values for the other phases 
of the observer study (see Table 6.11, Table 6.29 & Table 6.49), it can be seen 
that the sensitivity values are generally less variable between the observers and 
are comparable to the result for ultrasound imaging.  The specificity values are, 
however, more variable with a range of 13% (observer 5) to 50% (observer 1).  
The sensitivity is generally slightly poorer than for phase 2 (SPECT only) but the 
specificity is improved for 3 of the 5 observers (see Table 6.29).  Once again, 
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observer 5 shows good sensitivity but the poorest specificity, highlighting this 
observer’s tendency to see more lesions than the others. 
6.2.4.2 Ultrasound Results Comparison 
The findings from the ultrasound scans and the observers’ reading of the phase 4 
images were then compared.  The results of the difference in the number of 
lesions seen are shown in Table 6.70, with all 25 patients who had ultrasound 
scanning taken into account.  The Wilcoxon Signed Ranks test was also applied to 
these data and the results are shown in Table 6.71. 
Observer US > A US < A US = A Total 
1 0 8 17 25 
2 2 3 20 25 
3 1 7 17 25 
4 0 10 15 25 
5 0 13 12 25 
Total 3 41 81 125 
Table 6.70 - Comparison of number of lesions seen on ultrasound and in phase 4 (all 
images) 
US>A = number of times more lesions were seen on ultrasound than on review of all 
available SPECT and planar images, US<A = number of times fewer lesions were seen on 
ultrasound than on review of all images, US=A = number of times same number of lesions 
were seen on ultrasound as on review of all images. 
It can immediately be seen that there are almost no occasions in which the 
observer saw fewer lesions on review of all the planar and SPECT images 
together than were reported from the ultrasound scan.  The largest category is 
that in which the same number of lesions were seen on each type of imaging, 
which is the case both overall and for 4 of the 5 observers.  Only observer 5 had 
more instances where more lesions were seen on the nuclear medicine images 
than the ultrasound.  This is in keeping with the findings throughout this study, 
whereby observer 5 tended to see more lesions than any of the other observers. 
The Wilcoxon Signed Ranks test demonstrates that statistically significant 
differences exist for 3 of the 5 observers (observers 1, 4 & 5) individually as well 
as for the combined data for all observers.  In each case, the estimated median 
and 95% CI returned by the statistical software are ≤0, meaning that there was a 
tendency for the observers to see more lesions in the phase 4 images than were 
reported from ultrasound. 
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Observer p-value Estimated Median 95% CI 
1 0.014 -0.5 (-0.5, 0.0) 
2 0.787 0.0 (0.0, 0.0) 
3 0.059 0.0 (-0.5, 0.0) 
4 0.006 -0.5 (-1.0, 0.0) 
5 0.002 -0.5 (-1.0, -0.5) 
Overall <0.001 -0.5 (-0.5, 0.0) 
Table 6.71 - Results from Wilcoxon Signed Ranks test on differences in number of lesions 
seen (ultrasound vs phase 4) 
Output from Minitab software applied to the differences in the number of lesions seen on 
ultrasound and those seen on review of all images. 
The final results in terms of the positive/negative report given for each lesion 
seen on ultrasound and planar + SPECT imaging were then compared.  The 
results are given in Table 6.72.  There is a clear distinction between the number 
of times a different report was given to the number of times the same result 
occurred, with the “same” category being significantly larger.  The highest 
proportion in this category was for observer 1 with 79%, whilst the lowest was 
for observers 2 & 5 with 72%.  The proportions given the same report here are 
slightly higher than those for the comparison of the lesions resected at surgery 
and those seen on the planar + SPECT images. 
Observer No. Same +/- (%) No. Different +/- (%) Total 
1 22 (79%) 6 (21%) 28 
2 18 (72%) 7 (28%) 25 
3 20 (77%) 6 (23%) 26 
4 24 (77%) 7 (23%) 31 
5 26 (72%) 10 (28%) 36 
Overall 110 (75%) 36 (25%) 146 
Table 6.72 - Results from comparison of positive/negative findings (ultrasound vs phase 4) 
Number of comparisons between the overall given positive/negative report for a lesion that 
were the same and different between those seen on ultrasound imaging and those seen on 
review of all images.  Percentages of the total in each category for each observer and 
overall are given in brackets. 
Once again, the Wilcoxon Signed Ranks test was applied to the data and the 
results are shown in Table 6.73.  In this case, only the result for observer 2 has 
p>0.05, meaning that all the others are statistically significant.  All the 
estimated median and 95% CI values are ≥0, meaning that more lesions are given 
the same positive/negative report than are given a different report.  These 
results support the conclusions drawn from the data in Table 6.72. 
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Observer p-value Estimated Median 95% CI 
1 0.009 1.0 (0.0, 1.0) 
2 0.056 1.0 (0.0, 1.0) 
3 0.017 1.0 (0.0, 1.0) 
4 0.008 1.0 (0.0, 1.0) 
5 0.020 1.0 (0.0, 1.0) 
Overall <0.001 1.0 (0.0, 1.0) 
Table 6.73 - Results from Wilcoxon Signed Ranks Test on positive/negative comparison 
(ultrasound vs phase 4) 
Output from statistical test applied to comparison between the positive/negative report 
findings from ultrasound imaging and those given from review of all images. 
The reported left/right position of each lesion from ultrasound and planar + 
SPECT images was then compared and the results are shown in Table 6.74.  More 
lesions were seen at the same position than at a different site by all the 
observers with observer 5 having the lowest proportion at 65%. 
Observer No. Same (%) No. Different (%) Total 
1 11 (73%) 4 (27%) 15 
2 10 (71%) 4 (29%) 14 
3 11 (79%) 3 (21%) 14 
4 11 (73%) 4 (27%) 15 
5 11 (65%) 6 (35%) 17 
Overall 54 (72%) 21 (28%) 75 
Table 6.74 - Results of comparison in left/right location between lesions seen on ultrasound 
and those seen on review of all images 
Number and percentage of lesions seen in the same and different left/right location for each 
observer and combined for all observers. 
The given upper/lower locations were then compared in the same way and the 
results are shown in Table 6.75.  Once again, more lesions were seen at the 
same position as that reported from ultrasound by all the observers, with the 
lowest proportion in this category being 61% for observer 3. 
Observer No. Same (%) No. Different (%) Total 
1 10 (71%) 4 (29%) 14 
2 10 (77%) 3 (23%) 13 
3 8 (61%) 5 (39%) 13 
4 11 (77%) 3 (23%) 14 
5 10 (62%) 6 (38%) 16 
Overall 49 (70%) 21 (30%) 70 
Table 6.75 - Results of comparison in upper/lower location between lesions seen on 
ultrasound and those seen on review of all images 
Number and percentage of lesions seen in the same and different upper/lower location for 
each observer and combined for all observers. 
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Table 6.76 shows the results of the combined left/right and upper/lower 
comparisons.  It is immediately clear that, on this occasion, all the observers 
saw >50% of lesions at the same overall site, which is considerably higher for 
some of the observers than the comparison with the surgical results presented in 
Table 6.66. 
Observer No. Same (%) No. Different (%) Total 
1 10 (67%) 5 (33%) 15 
2 9 (64%) 5 (36%) 14 
3 9 (64%) 5 (36%) 14 
4 10 (67%) 5 (33%) 15 
5 10 (59%) 7 (41%) 17 
Overall 48 (64%) 27 (36%) 75 
Table 6.76 - Results of combined left/right and upper/lower location comparisons between 
lesions seen on ultrasound and those seen on review of all images 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
As all the acquired SPECT data was included in phase 4 of the observer study, a 
comparison was also made of the given anterior/posterior location for each 
lesion on ultrasound and SPECT.  The results of this analysis are shown in Table 
6.77. 
Observer No. Same (%) No. Different (%) Total 
1 13 (87%) 2 (13%) 15 
2 11 (79%) 3 (21%) 14 
3 12 (86%) 2 (14%) 14 
4 12 (80%) 3 (20%) 15 
5 15 (88%) 2 (12%) 17 
Overall 63 (84%) 12 (16%) 75 
Table 6.77 - Results of comparison in anterior/posterior location between lesions seen on 
ultrasound and those seen on review of all images 
Number and percentage of lesions seen in the same and different anterior/posterior location 
for each observer and combined for all observers. 
As was the case for the left/right and upper/lower comparisons, a significantly 
higher proportion of lesions were seen at the same anterior/posterior location 
than were seen at a different position. 
These data were then combined with the left/right and upper/lower comparison 
results to give a comparison of the overall 3-dimensional location of each lesion 
and the results are given in Table 6.78.  For the first time in this analysis, >50% 
of the comparisons of the overall location of each lesion fell into the “same”  
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Observer No. Same (%) No. Different (%) Total 
1 10 (67%) 5 (33%) 15 
2 8 (57%) 6 (43%) 14 
3 9 (64%) 5 (36%) 14 
4 9 (60%) 6 (40%) 15 
5 10 (59%) 7 (41%) 17 
Overall 46 (61%) 29 (39%) 75 
Table 6.78 - Results of combined left/right, upper/lower and anterior/posterior location 
comparisons between lesions seen on ultrasound and those seen on review of all images 
Number and percentage of lesions seen in the same and different overall location for each 
observer and for the combined for all observers. 
category for each of the 5 observers.  This indicates that similar information is 
being gained from the anatomical ultrasound imaging and the functional nuclear 
medicine imaging when both subtraction planar and subtraction SPECT are 
considered by the reporting observer. 
The calculated sensitivity and specificity values for the observer findings 
compared to the ultrasound report as the comparison standard are shown in 
Table 6.79. 
Observer Sensitivity (%) Specificity (%) 
1 75 75 
2 62 75 
3 69 83 
4 100 45 
5 83 57 
Overall 73 64 
Table 6.79- Calculated sensitivity and specificity values for comparison of US and all dual-
isotope subtraction imaging 
Percentage sensitivity and specificity values are given for each observer and for the 
combined results of all observers 
The sensitivity is high for all observers, with observer 4 demonstrating a 
sensitivity of 100%.  However, the specificity is more variable with high 
sensitivity coupled to lower specificity again demonstrated.  As has been the 
case throughout this study, the sensitivity and specificity values for the 
comparison with ultrasound imaging are better than those for the comparison 
with the surgical findings (see Table 6.69).  However, this is not a surprising 
result, as the report from nuclear medicine imaging is almost always available 
before ultrasound imaging is undertaken, meaning that the anatomical 
ultrasound imaging is often heavily influenced by the functional nuclear 
medicine imaging. 
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6.2.5 Summary of Observer Study and Surgical Comparison 
Results 
In a similar way to Sections 5.4.6 & 5.5.7, graphical plots were created to 
summarise the findings of the comparison between the results of the observer 
study and the report from surgery.  In each case, differences in the number of 
lesions seen are quoted as the result from surgery minus the result from the 
observer study. 
A plot of the differences in the number of lesions seen between surgery and 
each phase of the observer study is shown in Figure 6.1.  In each case “more” 
indicates that more lesions were resected at surgery than were seen by the 
observers and “less” means that fewer lesions were removed than were reported 
from the images. 
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Figure 6.1 - Bar chart of differences in number of lesions 
Frequency of “more”, “same” and “less” findings for comparison of number of lesions 
removed at surgery versus the number reported on each phase of the observer study.  
Phase 1 = planar images only, Phase 2 = SPECT images only, Phase 3 = Sestamibi images 
only (planar & SPECT), Phase 4 = all images. 
It is immediately clear that the largest category in each case is “same”, meaning 
that the surgeon removed the same number of suspicious lesions as had been 
seen by the observers on the nuclear medicine images.  The highest overall 
Chapter 6  169 
number in this category occurred for phase 4 with the lowest for phase 1.  In 
addition, the results from phase 2 show a larger number in the “less” category 
than in “more”.  This indicates that there are more instances where fewer 
lesions were resected by the surgeon than had been seen by the observers on the 
SPECT images than instances where a greater number of lesions were resected 
than had been seen.  The opposite is true for all of the other phases.  This 
suggests that there was a degree of over-reporting by the observers when 
reviewing the SPECT only images, which was less prevalent on the other phases. 
The number of times that the same positive/negative result for adenoma was 
found after surgery as was given by the observers from the images in each phase 
of the study is shown in graphical form in Figure 6.2. 
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Figure 6.2 - Bar chart of comparisons in positive/negative findings 
Frequency of “same” and “different” findings for comparison of the positive/negative 
findings for each lesion resected at surgery compared to those seen on each phase of the 
observer study.  Phase 1 = planar images only, Phase 2 = SPECT images only, Phase 3 = 
Sestamibi images only (planar & SPECT), Phase 4 = all images. 
The chart clearly shows that the number of “same” and “different” findings for 
phases 1 & 3 are similar, whereas there are considerably more in the “same” 
category for phases 2 & 4.  The results for phase 2 demonstrate both the highest 
number in the “same” category and the lowest number in the “different” 
category.  Given that there were only two negative results reported from 
Chapter 6  170 
surgery, the results in the graph show that more true positive lesions were 
identified by the observers when the dual-isotope subtraction SPECT images 
were available for review than when they were not. 
A graphical comparison of the given left/right locations of the lesions resected 
at surgery and those seen on each phase of the observer study is shown in Figure 
6.3.  The given location of each lesion seen on the observer studies was defined 
as “same” or “different” with respect to the position of removed samples 
recorded in the surgical report. 
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Figure 6.3 - Bar chart of comparisons in left/right locations 
Frequency of “same” and “different” findings for comparison of the given left/right location 
for each lesion resected at surgery compared to those seen on each phase of the observer 
study.  Phase 1 = planar images only, Phase 2 = SPECT images only, Phase 3 = Sestamibi 
images only (planar & SPECT), Phase 4 = all images. 
The chart shows that on each phase of the study, the observers were seeing 
more lesions at the same left/right position than on the contra-lateral side when 
the results were compared to the surgical findings.  The highest number of 
“same” comparisons was for phase 2 of the observer study, whilst the lowest 
number was for phase 1.  The number of lesions given on the “different” side 
was roughly the same for phases 2, 3 & 4, with phase 4 having slightly the lowest 
value. 
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The overall location of each lesion seen on the observer study, taking into 
account the given left/right, upper/lower and anterior/posterior positions, was 
also compared to the surgical report.  The results are plotted in Figure 6.4.  
Once again, it should be noted that no anterior/posterior information was 
included in the assessment of results for phase 1 (planar only) of the observer 
study. 
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Figure 6.4 - Bar chart of comparisons in overall given location 
Frequency of “same” and “different” findings for comparison of the overall given location 
for each lesion resected at surgery compared to those seen on each phase of the observer 
study.  Phase 1 = planar images only, Phase 2 = SPECT images only, Phase 3 = Sestamibi 
images only (planar & SPECT), Phase 4 = all images. 
In contrast to the results displayed in Figure 6.3, every phase has a higher 
frequency of “different” results in relation to “same”.  The reason for these 
differences is most likely to be the different way in which the image observers 
and the surgeon define the position of a lesion.  The observers will always define 
a lesion’s location with respect to the thyroid gland, meaning that “upper” will 
relate to a lesion seen superior to the thyroid isthmus and “lower” will define a 
lesion inferior to the isthmus.  However, the surgeon will define the position of 
the resected parathyroid gland with respect to other glands seen at surgery, or 
possibly even some other anatomical landmark.  Given the significant variation 
in the location of parathyroid glands (see Section 1.1.2, Figure 1.5), this could 
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lead to the same gland being given a different location by the surgeon when 
compared to the image observer. 
Further and more detailed discussion of all the results in Chapters 5 & 6 is 
carried out in Chapter 7 of this thesis. 
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Chapter 7 – Parathyroid Study – Discussion, 
Conclusions and Suggestions for Further Work 
7.1 Discussion 
7.1.1 Study Participants 
All patients referred to the Nuclear Medicine Department at Glasgow Royal 
Infirmary (GRI) for parathyroid imaging between February 2006 and October 
2008 were invited to take part in this study.  The eventual 32 study participants 
were those patients who provided informed consent that they were willing to 
take part in the study.  The demographics show that there were more female 
participants than male (19:13), which is as expected due to the higher 
prevalence of parathyroid disorders among women (Sorva et al., 1992, Robin, 
1996, Jensen, 1999, Adami et al., 2002, Judson & Shaha, 2008, Rodgers et al., 
2008, Sathe et al., 2009).  All participants tolerated the SPECT scan acquisition 
well with a minimal level of movement artefact visible on only a small number 
of the acquisitions.   Only a single patient complained of slight claustrophobia 
but, after reassurance, was able to tolerate the acquisition to completion. 
7.1.2 SPECT Reconstructions 
The parameters chosen in this study for the reconstruction of the SPECT images 
were as a result of direct advice taken from the company supplying the 
reconstruction software and a trial-and-error process to optimise the final 
viewed images.  The software suppliers, Nuclear Diagnostics Ltd., recommended 
that the iterative Ordered Subsets Expectation Maximisation (OSEM) 
reconstruction algorithm be used in preference to the traditional filtered back-
projection (FBP) option.  Evidence in the literature suggests that the OSEM 
technique improves spatial resolution (Brambilla et al., 2005) and that 
reconstructed images of equal quality to those from FBP can be achieved with 
fewer acquisition projections or a lower number of acquired counts per 
projection (Takahashi et al., 2003).  The chosen number of subsets and 
iterations used for the reconstructions was also as a result of advice from 
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Nuclear Diagnostics Ltd.  They recommended that, from their experience, the 
number of subsets should be ¼ of the total number of acquisition frames (in this 
case 60, meaning 15 subsets were used) and that 4 iterations would allow 
convergence to an accurate representation of the true radionuclide distribution 
within the body without requiring excessive processing time.  These parameters 
were therefore adopted. 
The choice of post-reconstruction filter was largely as a result of trial-and-error.  
Each of the 9 different filters available with the reconstruction software was 
trialled with a number of different values of the variable parameters for each 
filter on a number of different patient image data sets (see Section 5.3 for a list 
of the filters and the variable parameters for each).  Those images felt by the 
researcher to provide a reasonable compromise between smoothness and 
excessive noise were then shown to some of the observers of this study (2 
clinicians and 2 clinical scientists) and they were asked to pick their preferred 
images in each case.  The final choice of filter used for all images in this study 
was therefore chosen by consensus of subjective opinion from several 
experienced members of staff on optimal image quality. 
The fact that the same post-reconstruction filter was chosen as the optimum for 
both the 99mTc-Sestamibi and 123I-iodide images was surprising.  The total counts 
in the 99mTc and 123I energy windows are very different due to the different 
injected activities and the relative affinity of organs in the neck region to each 
radiopharmaceutical.  The total counts in the 99mTc window were higher in 
almost all cases due to the higher level of background activity in other tissues of 
the neck but the counts in the thyroid gland itself was more variable for the two 
radiopharmaceuticals, with some patients demonstrating higher counts in the 
99mTc window, some showing higher counts in the 123I window and others showing 
similar counts in each.  Also, the target to background ratio of the thyroid gland 
in the two different energy windows are significantly different, with the ratio 
being low for 99mTc but very high for 123I.  It would therefore be expected that a 
different filter would be required to give the best contrast between the thyroid 
and the background activity.  However, the consensus opinion from the 
observers was that the same Hanning filter (cutoff 3.0 cycles/cm) was the best 
compromise for both sets of images and so this was used for all reconstructions. 
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7.1.3 General Observer Comments 
The 5 observers that took part in this study were two consultant nuclear 
medicine physicians, 1 consultant radiologist and 2 experienced clinical 
scientists in nuclear medicine physics.  None had viewed parathyroid SPECT 
images before this study and so all the observers required some time to become 
familiar with the new image data sets at the start of the study.  They all 
commented that the 99mTc-Sestamibi SPECT images in particular were difficult to 
interpret due to the high levels of non-specific uptake within the neck.  As the 
study progressed, however, they all became more comfortable and confident in 
reviewing the SPECT images and indeed by the end of the study, all commented 
that they preferred the SPECT images to be available as they felt they could 
better characterise any lesions seen on the planar images. 
All the observers also commented that they preferred the availability of the 123I-
iodide images in order to visualise the thyroid anatomy rather than viewing the 
99mTc-Sestamibi images alone.  This is most likely due to the fact that the 
standard protocol used at GRI is a dual-isotope planar subtraction technique and 
the observers are all used to presence of the 123I images.  This may have 
affected the results of this study slightly, but it is recognised that subtraction 
imaging can, on occasion, confirm the presence of lesions that are either 
equivocal or not visible on single-tracer imaging or the presence of thyroid 
disease (e.g. hot/cold thyroid nodule) that may be uncertain from imaging with 
99mTc-Sestamibi only (Jeanguillaume et al., 1997, Krausz et al., 2001, Profanter 
et al., 2003, Wong et al., 2009).  Imaging of the thyroid independently also 
reduces the risk of false-positive results, which can occur in the presence of a 
thyroid adenoma (Kresnik et al., 1997). 
When carrying out the final phase of the study, when all images were made 
available to the observers, they commented that there were some lesions that 
were not visible on the planar images that were very clear on the SPECT views.  
This indicates that there is some degree of under-reporting occurring with 
subtraction planar imaging that may be reduced with the introduction of 
subtraction SPECT imaging. 
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The number of lesions seen by each individual observer and in total was highest 
for phases 2 & 4 of the study, when the dual-isotope subtraction SPECT images 
were included in the review.  The lowest total number of lesions seen as well as 
the highest number of negative reports was found for phase 1, in which only 
planar images were available for review.  This demonstrates that more possible 
lesions are visible on the SPECT images than on planar alone, but does not in 
itself confirm that SPECT imaging is better as the extra lesions seen may be 
image artefacts and not true parathyroid adenomas. 
There was a clear difference in the total number of lesions reported by the 
individual observers throughout the study.  Observer 2 saw fewer lesions than all 
the others on every phase, whilst observer 5 saw more than all the others on 
every phase.  This demonstrates the highly subjective nature of image review, 
even amongst experienced nuclear medicine clinicians and scientists.  Observer 
5 had a tendency to report every potential lesion seen on the images, whereas, 
in contrast, observer 2 felt that many of the possible lesions were image 
artefacts and so ignored them.  Therefore, observer 5 had a probable tendency 
to over-report the images, whilst observer 2 had a tendency to under-report 
possible lesions. 
The observers also gave scores for image quality during each phase of the study.  
In general, the 99mTc-Sestamibi SPECT images gained the lowest scores for image 
quality and were also occasionally described as “poor” by the observers due to a 
lack of acquired counts in the images.  Improvements to image quality can be 
made by increasing the administered activity of 99mTc-Sestamibi to provide a 
greater activity concentration in the area of interest, by increasing the length of 
each SPECT acquisition frame beyond the 30s used in this study, or by using a 
combination of both of these options. 
7.1.4 Comparison of Phases of Observer Study 
The most striking finding of the observer study was that all the observers tended 
to see a larger number of lesions when SPECT imaging was available than when 
reviewing only planar images.  This is to be expected, since the planar images 
only give an anterior view whereas the SPECT images give a three-dimensional 
representation of the distribution of radiopharmaceutical in the neck area.  Any 
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lesion situated immediately posterior to the thyroid may therefore not be 
visualised on a planar view but the SPECT images include this area, allowing the 
lesion to be visualised.  However, the increase in the number of lesions reported 
by the observers may be due to image artefacts rather than true lesions and so 
the comparison with the surgical reports is necessary to determine the true 
clinical utility of the SPECT images. 
From the planar images, the observers gave positive reports for half of the 
lesions seen.  When reviewing the SPECT images in the absence of the planar 
views, however, a greater number of lesions were seen and a greater proportion 
of those lesions - 85% - were reported as positive.  A similar proportion at 79% 
were deemed positive when both planar and SPECT dual-isotope images were 
available for review with the proportion dropping to 64% when only the 99mTc-
Sestamibi images were reviewed.  The Wilcoxon Signed Ranks tests carried out 
on the data confirmed the increase in observer confidence when SPECT images 
were available for review with p<0.05 in the majority of cases.  The exception 
was in phase 3 with only Sestamibi images being available to the observers, 
when the expressed confidence levels were not significantly different from the 
review of planar images.  This strongly suggests that the dual-isotope subtraction 
SPECT is allowing the observers to more clearly see possible lesions on the 
images and therefore giving them more confidence in their reports. 
The scores for image quality were consistently higher for the 123I-iodide images, 
both planar and SPECT, than for the 99mTc-Sestamibi images.  This is to be 
expected, however, due to the high non-specific background activity that 
characterises Sestamibi uptake in the neck region whilst iodine is selectively 
taken up in the thyroid gland only.  The lowest image quality scores were given 
for 99mTc-Sestamibi SPECT images in phases 2 & 3 of the observer study.  In 
contrast, the highest overall image quality and subtraction usefulness scores 
were given in phase 4, when both planar and SPECT dual-isotope images were 
available to the observers for review.  This suggests that the combination of 
planar and SPECT dual-isotope images is the preferred system for reporting of 
parathyroid images by the observers in this study. 
It is also clear from the results in Chapter 5 that there was a wide variation in 
the number of lesions being reported by the 5 observers.  In particular, observer 
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5 consistently reported more lesions than each of the other observers.  This may 
represent over-reporting by this observer or increased caution by the others in 
order to prevent false-positive reports.  Observer 5 is an experienced clinical 
scientist and, although having many years’ experience of viewing parathyroid 
images, is not responsible for issuing reports for imaging studies in the 
department.  In contrast, observers 1, 2 & 3 are consultant clinicians who all 
routinely issue clinical reports for a wide variety of nuclear medicine 
investigations, including parathyroid imaging. 
In other areas considered in this study, there was often considerable variation 
between the results for each of the 5 observers.  This shows how subjective the 
reviewing and reporting of nuclear medicine images can be but is also certainly 
due in part to the fact that the observers were asked to review types of SPECT 
images which were entirely new to them and of which they had no experience.  
All commented towards the end of the study that they were becoming more 
comfortable with reviewing the dual-isotope subtraction images and so it is 
possible that the results from phase 2 were slightly affected by this general 
unfamiliarity.  In order to assess the magnitude of the effect, the observers were 
asked to review the phase 2 SPECT images a second time, after all the other 
phases of the study were complete.  The results of this 2nd review are discussed 
in Section 7.1.7 below. 
In all comparisons with planar images, a similar number of lesions were seen on 
the same side (i.e. left/right) as on the opposite side, indicating that the lesions 
seen on the planar images were not always the same as those seen when SPECT 
images were available.  The main reason for this is the significantly higher 
number of lesions seen on phases 2-4 of the study relative to phase 1, meaning 
that the comparisons being made are not always like-with-like and a single 
lesion seen on the planar images may have been compared to up to 4 lesions 
seen in a later phase of the study.  Unfortunately, there was no way to design 
the study to remove this effect as it would have required the researcher to make 
judgements as to when a lesion reported by an observer from different phases of 
the study was the same lesion or a completely different lesion or artefact.  This 
would have been an unacceptable level of subjective interference from one 
person on the results and so the method of comparing each individual lesion 
from each of the different phases of the observer study was used instead. 
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The number of lesions seen at the same upper/lower location was always lower 
than the number given at the same left/right site.  This is most likely due to the 
fact that the planar images give only a single-angled view of the location of the 
lesion relative to the thyroid gland.  The resultant image would be heavily 
influenced by any angulation of the gamma camera detector at the time of 
acquisition, which could lead to slight distortion in the final image.  The three-
dimensional nature of the SPECT images removes this dependency, meaning that 
a more accurate assessment of the location of a lesion with respect to the 
thyroid can be made. 
When the phases of the study involving the use of at least one set of SPECT 
images were compared to each other, a clear distinction emerged.  During phase 
3 of the study, when the planar and SPECT 99mTc-Sestamibi images were 
reviewed in the absence of any 123I-iodide images, fewer lesions were reported 
and the level of confidence expressed by the observers was lower than when 
iodine images were also available.  This is a confirmation of the general 
comments made by the observers, who all stated that they were least 
comfortable reviewing the images in phase 3 of the study.  Indeed, when a 
Wilcoxon Signed Ranks test was performed on the confidence levels expressed by 
the observers during the dual-isotope SPECT image review were compared to 
those from the Sestamibi-only review, values of p<<0.05 were found in every 
case.  The differences were less clear-cut when the Sestamibi-only review was 
compared with that involving all dual-isotope planar and SPECT images, but the 
tendency was still towards higher confidence levels being expressed when the 
123I-iodide images were available to the observers.  These findings are certainly 
partly attributable to the fact that all the observers in the study are used to 
having dual-isotope and subtraction images available to them in the reporting of 
parathyroid images.  However, the significant level of the differences indicates 
that, at least at this institution, a change in practice to single-isotope, dual-
phase imaging would not be a welcome step and would be likely to lead to a 
considerable increase in the number of equivocal reports being produced. 
In the comparison of phases 2 & 4, there was less difference between the 
numbers of lesions seen and the expressed confidence levels than was seen in 
the other comparisons.  This suggests that the observers were primarily using the 
SPECT images to report on phase 4 of the study, rather than relying heavily on 
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the planar views.  This is a surprising finding, since the observers’ current 
practice is to view planar images only, but it demonstrates that the observers 
found the amount of information on radiopharmaceutical distribution that is 
displayed in the SPECT images very useful in making decisions on the presence or 
otherwise of true parathyroid adenomas on the images. 
When considering the given left/right location of each lesion, the number of 
times the same side was given was highest in the comparison of phases 2 & 4, 
with all observers giving >60% of lesions on the same side with the exception of 
observer 5, whose results are likely to be influenced by the larger number of 
lesions this observer reported on all phases, as discussed above.  This once again 
confirms that the observers were relying heavily on the SPECT images for 
locating lesions when all planar and SPECT images were available to them during 
phase 4.  Both the comparisons involving the Sestamibi-only images with the 
other SPECT phases resulted in a similar number of lesions reported on the same 
side at slightly more than 50% in all cases with the exception of observer 1 in the 
comparison of phases 3 & 4, who gave just under 50% at the same left/right 
location.  These results suggest that there are still a significant number of 
occasions on which a different lesion is being reported from each of the two sets 
of images involved in the comparison. 
The given upper/lower and anterior/posterior locations for each of phases 2-4 of 
the observer study were also compared.  The results clearly show that, in these 
two planes, the same location was given considerably less frequently than was 
the case for the left/right location.  This is a slightly surprising result and 
indicates that the presence or absence of 123I-iodine and/or planar images had a 
significant impact on the exact reported location of each lesion.  The fact that 
more lesions were seen on phase 2 of the study than on the other phases may 
also be a factor since, as was the case when comparisons were made with the 
findings from the planar images, more than one lesion reported from phases 3 & 
4 will have been compared to a single lesion noted on phase 2, as was discussed 
in more detail above. 
In summary, the comparisons of the results from the different phases of the 
observer study demonstrate that the inclusion of SPECT images in nuclear 
medicine parathyroid examinations results in a larger number of lesions being 
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reported and an increase in the confidence level that these lesions represent 
true parathyroid adenomas.  Also, the inclusion of dual-isotope subtraction 
SPECT images increases the confidence level of the observers over the situation 
where only 99mTc-Sestamibi images were made available.  The most similar 
results were seen when phases 2 & 4 of the study were compared, indicating 
that the observers were relying heavily on the information from the SPECT 
images during phase 4, when both planar and SPECT images were available.  The 
given location of lesions often differed for a single patient data set between 
different phases of the study, although this is partly due to the comparison 
method used here, as discussed above.  However, the most similar results were 
once again seen between phases 2 & 4, with an overall figure of 60% of lesions 
seen at the same left/right location on the two phases. 
7.1.5 Comparison of Surgical and Ultrasound Findings 
Surgery is the primary curative method of choice in cases of hyperparathyroidism 
(Serchuk et al., 1997, Thomas & Wishart, 2003, Pelizzo et al., 2008, Rodgers et 
al., 2008) and the ability of an experienced endocrine surgeon to visually detect 
and then remove a parathyroid adenoma during bi-lateral neck exploration has 
been the main technique used for many years, with a high success rate of 95% or 
more (van Heerden & Grant, 1991, Udén et al., 1992, Weber et al., 2000, 
Thomas & Wishart, 2003, Russell et al., 2006, Pelizzo et al., 2008), with post-
surgical histology definitively determining the presence or otherwise of a 
parathyroid adenoma.  However, minimally invasive parathyroidectomy is 
becoming increasingly common (Greene et al., 2009), as it requires only a small, 
unilateral incision to be made and results in shorter surgery, a shorter hospital 
stay and lower morbidity rate post-surgery (Bergenfelz et al., 2002, Adler et al., 
2008 & 2009) with no significant decrease in the curative effect of the surgery 
(Sidhu et al., 2003, Russell et al., 2006, Westerdahl & Bergenfelz, 2007). 
In order to perform unilateral surgery, it is necessary for the surgeon to have 
some information on the location of the suspected parathyroid adenoma and this 
is provided by pre-surgical imaging studies (Quiros et al., 2004).  Both 
anatomical ultrasound and functional nuclear medicine imaging are available 
and patients may undergo both types of imaging prior to surgery.  Of the 32 
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participants in this study, a total of 13 patients had both ultrasound imaging and 
parathyroidectomy surgery.  The findings from ultrasound imaging were 
compared to those from histological analysis of surgically resected samples so as 
to provide a baseline with which to compare the various phases of the nuclear 
medicine observer study. 
Most commonly, a surgical sample resected from a site identified as that of a 
positive lesion on ultrasound imaging was confirmed to be a parathyroid 
adenoma or hyperplastic gland upon histological examination.  This was the case 
for 7 of the 13 patients.  However, there were also 3 examples of a negative 
ultrasound report being given for patients who had a positive sample removed at 
surgery as well as a patient with an ectopic parathyroid adenoma in the 
mediastinum, which was also not reported from ultrasound due to the 
difficulties in using this type of imaging in the mediastinum (Beierwaltes, 1991, 
Carlier et al., 2008).  The remaining 2 patients had positive samples resected at 
surgery from different sites than those suggested by the preoperative ultrasound 
imaging.  Overall, when taking into consideration the positive/negative report 
and given left/right location of each lesion, the sensitivity and specificity of 
ultrasound imaging were found to be 72% and 33% respectively for the study 
participants.  These figures are well below those reported by some other 
researchers, as discussed further in Section 7.1.9 below. 
7.1.6 Comparison of Observer Study with Surgical Findings 
In order to determine the true clinical utility of the various types of nuclear 
medicine images investigated for the present study, it was necessary to compare 
the results to those from surgery which, with histological analysis of resected 
samples, provides the true gold standard as to the presence or otherwise of a 
parathyroid adenoma. 
The results of all 4 phases of the observer study were compared to the surgical 
results, which were taken from the patients’ case notes.  Unfortunately for the 
purposes of this study, only 17 of the 32 participants (53%) have undergone 
parathyroidectomy surgery up to the present time.  This is partly due to the 
patient-pathway employed at GRI, whereby the results of imaging studies are 
taken into account in the decision making process for surgery.  Normally, only 
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patients with positive results from imaging investigations are referred on to the 
endocrine surgeons, whilst those with negative results tend to be managed 
clinically.  The literature indicates that this is a different referral process from 
that used at other institutions, whereby the patients are referred for localisation 
imaging only once the need for surgery has already been confirmed (e.g. Billotey 
et al., 1996a, Hindié et al., 1998, Sidhu et al., 2003).  The report from imaging 
then acts as a guide for the surgeon as to the most likely location for the 
parathyroid adenoma, rather than being used to definitively determine its 
presence or absence. 
The surgical findings of the 17 patients were, nonetheless, compared to the 
results of the various phases of the observer study, with the surgical results 
acting as the gold standard.  There was some variation in the results from 
individual observers, with the tendency for observer 5 to see more lesions than 
the others previously discussed, but general trends are still evident in the data.  
When the observers were presented only with planar views in phase 1 of the 
study, they tended to see fewer lesions than were resected at surgery.  This was 
also the case when only 99mTc-Sestamibi images were available to the observers 
in phase 3.  In contrast, when dual-isotope subtraction SPECT images were used 
in phases 2 & 4 of the study, there was no significant difference between the 
number of lesions seen by the observers and the number removed at surgery.  
The exception to this was observer 5 in phase 2 of the study, where the observer 
reported more lesions from the SPECT images than were resected by the 
endocrine surgeon, which is again evidence of this observer’s tendency to over-
report lesions on the images.  All of these results show, however, that there are 
a number of true parathyroid adenomas that are not being reported from the 
planar and Sestamibi-only images, but that the inclusion of dual-isotope 
subtraction SPECT allows visualisation of at least some of these lesions. 
When the given positive/negative reports from the observers were compared to 
the positive/negative histological results, a similar pattern appeared.  More of 
the lesions seen by the observers during phases 2 & 4 of the study were given the 
same positive/negative report as was given on histological examination of the 
resected gland than was the case for phases 1 & 3.  The results of the non-
parametric Wilcoxon Signed Ranks test applied to the data comparing the 
number of “same” and “different” positive/negative reports given underline 
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this.  No statistically significant differences were seen for any of the observers 
when the test was applied to the results from the review of the planar and 
Sestamibi-only images and no clear patterns were demonstrated in the 95% 
confidence intervals (95% CIs).  In contrast, the results from the SPECT and all 
images phases of the study demonstrated several cases of statistical significance 
(p<0.05) in the comparisons and a strong tendency for the number of “same” 
results to be higher than the number of “different”, demonstrated by the 95% 
CIs being >1. 
Comparisons were also made of the location of each lesion reported by the 
observers during each phase of the study and the location of each resected 
sample given by the endocrine surgeon.  The most important information for the 
surgeon wishing to perform minimally invasive surgery is whether the suspected 
parathyroid adenoma is on the left- or right-hand-side of the neck and so the 
focus of the comparison was on the given left/right location of each lesion. 
Generally speaking, more lesions were seen by the observers at the same 
left/right location that was recorded in the surgical notes than were seen on the 
contralateral aspect of the neck.  This is encouraging, as it indicates that the 
information being given to the surgeons to assist in performing minimally 
invasive surgery is reasonably accurate.  However, the results once again 
demonstrate that the same side was most often given when the observers were 
viewing dual-isotope subtraction SPECT images in phases 2 & 4 of the study, with 
little difference in the results when planar images were and were not included.  
The lowest numbers of lesions seen on the same side was for the planar images.  
This will be due in part to the fact that there were a number of occasions in 
which no lesion was seen on the planar images when, in fact, a sample was 
resected at surgery. 
A comparison was also made of the given upper/lower location relative to the 
thyroid gland of each observed lesion against each sample resected at surgery.  
In each phase of the observer study, the results were less consistent with those 
from surgery than was the case for the given left/right location of each lesion.  
The main reason for this is the difference in the way “upper” and “lower” are 
defined by the image observers and surgeons respectively.  An image observer 
will tend to report a lesion as “upper” if it lies at or above the thyroid isthmus 
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and “lower” if it lies below this level.  However, a surgeon will define a gland as 
“upper” or “lower” on the basis of other glands observed at surgery, which 
relate to the embryologic origin of the different glands (Taïeb et al, 2007).  It is 
therefore possible that a surgeon may find a gland that lies inferior to the 
thyroid isthmus but superior to another parathyroid gland and so would 
designate this as an “upper” gland, whereas a gland in this location on imaging 
would always be defined as a “lower” gland.  The two definitions are therefore 
very different and cannot be compared directly.  Since the lateral (left/right) 
position of the observed lesion is the most important factor for successful 
minimally invasive surgery, the upper/lower information can be helpful but is 
not absolutely necessary for the surgeon. 
The same is true of the anterior/posterior location information given for the 
phases of the observer study involving SPECT images.  Parathyroid glands most 
often lie posterior to the thyroid but ectopic glands are not uncommon (Berne & 
Levy, 1993, Moore & Agur, 2007, Rodgers et al., 2008) and so it is possible that 
an adenoma could lie anterior to the thyroid.  The anterior/posterior 
information was not given for all glands resected at surgery (see Table 6.1) and 
so comparisons with the observer study were made only for those samples where 
this information was available.  The results of the comparison showed wide 
variation between the observers with little clear pattern.  Again, however, the 
location definition used by the observers and surgeons were not necessarily the 
same and direct comparison is therefore not feasible. 
The sensitivity and specificity for each phase of the observer study were 
calculated using only the given positive/negative result for parathyroid adenoma 
and the left/right location of the observed lesion and comparing these to the 
surgical report for each patient.  The overall sensitivity and specificity values for 
each phase of the study are shown in Table 7.1, along with the calculated values 
for the comparison of the ultrasound imaging reports with the surgical reports. 
It is immediately clear from these results that the sensitivity is significantly 
higher when dual-isotope subtraction SPECT images are available to the 
observers.  The highest sensitivity value is for phase 2 of the observer study, 
when the dual-isotope subtraction SPECT images were presented in the absence 
of any planar images.  The lowest sensitivity is found for phase 3, when no 123I-
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iodide images were included, which again confirms the preference for the 
observers to have the thyroid images available to them.  The sensitivity for 
ultrasound imaging is lower than for SPECT imaging but is slightly better than for 
phase 4 of the study, when dual-isotope subtraction SPECT and planar images 
were both available. 
Study Phase Sensitivity (%) Specificity (%) 
1  (planar) 49 61 
2 (SPECT) 77 31 
3 (Sestamibi) 45 29 
4 (all images) 64 27 
Ultrasound 72 33 
Table 7.1 - Overall sensitivity and specificity values for comparison of results of observer 
study and ultrasound imaging with surgical results 
Combined sensitivity and specificity results for all 5 observers for each phase of the 
observer study and those from the ultrasound imaging reports relative to surgery 
The specificity values are low for ultrasound imaging and for phases 2-4 of the 
observer study, which is likely to be due to the fact that there were only 2 true 
negative results from surgery.  Since the specificity is strongly dependent on the 
true negative rate (see Equation 4.3), any slight differences between the 
observer study and surgical results will be magnified.  The relatively high 
specificity for phase 1 is due to the low number of positive results given by the 
observers overall, meaning that the false positive rate was very low. 
These overall results do, however, obscure variations between observers.  
Observer 5 tended to have high sensitivity but relatively low specificity due to 
the tendency to report larger numbers of lesions overall, as has been discussed 
previously.  In contrast, observers 1-3 tended to have lower sensitivity but 
higher specificity values, indicating that these observers are more cautious 
overall and are therefore less likely to report an artefact as being a positive 
lesion, but are also more likely to report a true lesion as negative. 
All of the results from the comparison of the surgical results with those from the 
observer study clearly show an improvement in the detection of parathyroid 
adenomas when dual-isotope subtraction SPECT imaging is utilised.  Also, there 
is an improvement in the left/right localisation of a true lesion when dual-
isotope SPECT is available.  There was little discernible difference between the 
phases of the study when dual-isotope subtraction SPECT was used alone and 
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when it was used in conjunction with dual-isotope subtraction planar imaging.  
The overall benefit when compared to planar imaging alone is, however, clear 
and it would therefore be recommended that the technique is employed 
routinely at GRI for parathyroid imaging. 
7.1.7 Second Review of Phase 2 SPECT Images 
As the observers had no previous experience of viewing dual-isotope subtraction 
SPECT images, it is possible that the results from phase 2 of the observer study 
were affected by this unfamiliarity.  The observers were therefore asked to 
review the phase 2 images a second time in order to determine the magnitude of 
this effect.  Unfortunately, only 3 of the original 5 observers – observers 2, 3 & 5 
– were available to take part in the second phase 2 review.  The same 32 patient 
image data sets, scoring sheets and methods were used as in the original review 
and the results were analysed in a similar fashion.  This second review took 
place around 12 months after the other reviews were complete, by which time 
each of the observers had obtained around 18 months worth of experience in 
reading dual-isotope subtraction SPECT parathyroid images. 
In total, 81 lesions were seen by the 3 observers with 29 (36%) being classed as 
definitely positive for parathyroid adenoma, 17 (21%) felt to be suggestive and 
35 (43%) being defined as equivocal.  In total, 24 (25%) of the 96 reviews were 
reported as negative.  A comparison of the number of lesions seen by each of the 
3 observers on the first and second review of the phase 2 images is shown in 
Figure 7.1.  It can clearly be seen that all of the observers reported fewer 
lesions seen on the second review compared to the first.  The largest difference 
was for observer 5, who reported 64 lesions from the first review and only 34 
from the second.  This observer commented that on the first review, they 
reported a large number of equivocal lesions that they were more confident 
were simply artefacts on the second review.  In contrast, the number of lesions 
seen by observer 2 differed by only 1 (24 to 23), indicating a greater degree of 
consistency by this observer on the 2nd review. 
The sensitivity and specificity for comparison with the surgical findings were also 
calculated for the second SPECT review and are shown in Table 7.2, alongside 
the results from the first phase 2 review.  Once again, only the given 
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positive/negative status of each lesion and its given left/right location were 
taken into account in the calculation of the sensitivity and specificity.  The 
quoted overall sensitivity and specificity for the original review are for these 3 
observers only, with observers 1 & 4 excluded, and so are slightly different to 
those quoted in Table 6.29. 
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Figure 7.1 - Comparison of lesions seen on first and second reviews of SPECT data 
Bar chart showing the total number of lesions seen by each observer on the first (blue) and 
second (purple) reviews of the phase 2 dual-isotope subtraction SPECT images. 
Observer Sensitivity 1st 
review (%) 
Sensitivity 2nd 
review (%) 
Specificity 1st 
review (%) 
Specificity 2nd 
review (%) 
2 57 57 25 25 
3 75 60 60 75 
5 84 67 40 50 
Overall 73 61 42 50 
Table 7.2 - Calculated sensitivity and specificity relative to surgical findings for first and 
second SPECT image reviews 
Sensitivity and specificity calculated for each individual observer and overall relative to the 
surgical and histological reports for the 1st and 2nd phase 2 SPECT image review. 
The sensitivity and specificity for observer 2 remained the same on the second 
review of the dual-isotope subtraction SPECT images, confirming this observer’s 
consistency.  However, the results for observers 3 & 5, as well as the overall 
results, demonstrate a reduced sensitivity and increased specificity on the 
second review.  The increased specificity is to be expected since, as the 
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observers become more comfortable with reviewing the SPECT images, they will 
become more adept at distinguishing artefacts from true lesions.  However, the 
reduction in sensitivity was not expected and is the result of some lesions that 
were previously correctly reported as positive now being felt to be artefacts. 
Given the fact that patients at GRI are referred for imaging prior to any decision 
on surgery being made, the specificity is the more important measure, as 
discussed in Section 3.1.1.  Although the overall specificity remains relatively 
low at 50%, the increase in specificity on the second review confirms that the 
observers are becoming more comfortable and confident in reading the dual-
isotope subtraction SPECT images over time.  Unfortunately, as noted previously, 
the small number of true negative lesions at surgery heavily influences the 
specificity and so it is not a reliable measure here.  However, the overall 
sensitivity on the second review remains as good as any of the other phases of 
the observer study, meaning that the true positive rate remains high and many 
parathyroid adenomas are being visualised on the images.  The relatively high 
sensitivity and increase in specificity on the second review confirms that dual-
isotope subtraction SPECT imaging provides an improvement in parathyroid 
adenoma localisation over other nuclear medicine imaging methods. 
7.1.8 Comparison of Observer Study with Ultrasound Findings 
A total of 25 of the 32 study participants (78%) also had ultrasound imaging of 
the neck as an aid to localising any existing parathyroid adenomas.  The results 
of the observer study were compared to the ultrasound results in order to 
determine any significant differences between the imaging modalities in 
detecting parathyroid adenomas.  The comparison methods used were the same 
as those for comparing the observer study results with those from surgery, 
although on this occasion the reported ultrasound results were taken as the 
comparison standard. 
In general, the results of the observer study were more similar to those of the 
ultrasound scanning than they were to those from surgery.  At first glance, this 
may seem like a surprising result since ultrasound is an anatomical imaging 
modality whereas nuclear medicine gives images of physiological function.  
However, most of the participants that had an ultrasound scan of the neck for 
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suspected parathyroid adenoma were referred for the scan after having nuclear 
medicine imaging in order to confirm a possible or likely lesion seen on the 
planar dual-isotope subtraction images.  The operator performing the ultrasound 
scan is aware of the reported result from the functional nuclear medicine 
imaging and so may be influenced.  As a result, the two imaging modalities are 
not totally independent.  The sensitivity and specificity of ultrasound scanning 
were also well below 100% - at 72% and 33%, respectively – and so using the 
ultrasound report as a gold standard is not truly accurate, but nevertheless gives 
an interesting comparison of the results from the two imaging modalities. 
In the comparison of the number of lesions seen on ultrasound imaging and each 
of the 4 phases of the observer study, there was generally little difference to be 
seen.  Indeed, for each of the 4 phases, there were more instances where the 
same number of lesions was reported than a different number.  When the results 
from phase 1 of the observer study were used in the comparison, there was a 
general tendency for more lesions to be seen on ultrasound than on planar 
subtraction nuclear medicine imaging.  In contrast, the opposite was true when 
the phase 2 results were compared to ultrasound, with statistically significant 
differences in the number of lesions seen demonstrated for 4 of the 5 observers 
on application of the Wilcoxon Signed Ranks test to the data.  The 95% CI for the 
difference in number of lesions seen for all 5 observers was ≤0, indicating that 
more lesions were being reported from the subtraction SPECT images than from 
ultrasound. 
Phase 3 of the study gave the least significant differences between the reports 
from ultrasound and nuclear medicine imaging.  There was a slight tendency for 
more lesions to be seen on the Sestamibi-only images, although the results were 
only statistically significant for observer 5 and the overall total.  As has been 
mentioned previously, observer 5 was inclined to report more lesions than the 
other observers throughout this process and so this result is not surprising.  The 
comparison of the results of phase 4 of the observer study with the ultrasound 
reports showed a more significant trend towards the observers seeing more 
lesions when all the nuclear medicine images were available to them.  For 3 of 
the 5 observers as well as the overall combined results, a statistically significant 
difference in the number of lesions seen was demonstrated and the 95% CIs all 
being ≤0 shows that the observers tended to see more lesions on the combined 
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planar and SPECT subtraction nuclear medicine images than were reported at 
ultrasound scanning.  These results all suggest either a tendency for over-
reporting of lesions from nuclear medicine images or a lack of sensitivity on 
ultrasound imaging. 
The given positive/negative results from the ultrasound scanning report were 
then compared to those from the 4 phases of the observer study and a similar 
pattern to that seen on comparison of the surgical and observer study results 
was observed.  For the results of phases 1 & 3 of the study, there were no 
significant differences found, with the same positive/negative report being given 
in most cases.  However, phases 2 & 4 of the observer study showed different 
reports being given in many cases, with most observers individually as well as 
the combined totals showing a statistically significant difference (p<0.05) on 
application of the Wilcoxon Signed Ranks test.  The fact that the 95% CIs are all 
≥0 indicates that the nuclear medicine observers are more inclined to report a 
lesion as positive than is the case on the ultrasound reports. 
As was the case when the observer study results were compared with the 
surgical findings, comparisons were also made of the reported location of each 
lesion during each phase of the observer study and the site of each lesion given 
in the ultrasound report.  As before, the main focus of the comparison was on 
the given left/right location of each lesion (see Section 7.1.6 above), although 
the upper/lower and anterior/posterior locations were also considered. 
The results of the left/right location comparison showed that in the majority of 
cases in all 4 phases of the observer study, the same left/right site was given as 
had been reported from ultrasound.  Only observer 2 saw more lesions at a 
different site from ultrasound imaging than at the same site, and then only in 
phases 1 (planar) and 3 (Sestamibi-only).  This again demonstrates the 
similarities between the findings from the 2 types of preoperative imaging, 
despite the fact that ultrasound is an anatomical imaging modality whilst 
nuclear medicine produces functional images. 
As discussed in Section 7.1.6 above, the definitions of “upper”, “lower”, 
“anterior” and “posterior” as applied to a parathyroid lesion can differ between 
an observer reviewing an imaging study and an endocrine surgeon resecting 
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suspicious samples during parathyroidectomy.  However, these differences do 
not exist when considering a comparison of different types of imaging since all 
location definitions will be given relative to the observed thyroid gland.  It was 
therefore expected that the comparisons of the given upper/lower and 
anterior/posterior sites for each lesions on ultrasound and the various phases of 
the observer study would be more similar than when the observer study results 
were compared with surgery. 
This was, however, not the case for all phases.  The results were very variable 
between observers but general overall trends could be determined.  The 
comparison of phase 1 with the ultrasound findings included only the 
upper/lower information as it is not possible to determine the anterior/posterior 
position of a lesion from an anterior planar projection image.  The numbers of 
lesions seen at the same and different upper/lower locations were similar with 
no obvious trend seen.  Phase 2 gave similar results for the upper/lower 
comparison, although there was a slight tendency for more lesions to be given at 
the same location than at a different site.  In complete contrast, the 
anterior/posterior comparison results for phase 2 clearly showed more lesions 
being given at the same site than at a different position for all observers, with 
observer 1 giving as many as 93% at the same location as was reported at 
ultrasound. 
The results for phase 3 were less clear cut with generally slightly fewer lesions 
being given at the same upper/lower location from Sestamibi-only images as 
from ultrasound.  The results for the anterior/posterior comparison were very 
variable with 3 of the 5 observers seeing more lesions at the same site, whilst 
the others saw more at a different position.  This again demonstrates that the 
observers were not entirely comfortable reporting from the Sestamibi-only 
images and preferred to have 123I-iodide images available to give a clear image 
of thyroid uptake.  Phase 4 was the only part of the observer study that gave the 
expected results for the upper/lower and anterior/posterior location 
comparisons, with all observers reporting more lesions at the same site that at a 
different position when compared to the findings of ultrasound imaging.  This 
suggests that the combination of planar and SPECT subtraction images gives the 
most consistent location information when compared to ultrasound than do any 
of the other combinations of nuclear medicine images. 
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The overall sensitivity and specificity values for the comparison of the various 
phases of the observer study with the ultrasound results are shown in Table 7.3.  
When compared to those in Table 7.1, it is immediately clear that the sensitivity 
and particularly the specificity are higher when taken relative to ultrasound 
rather than the surgical results.  This is to be expected since, as discussed 
above, the ultrasound and nuclear medicine imaging for parathyroid disease at 
GRI are not totally independent. 
Study Phase Sensitivity (%) Specificity (%) 
1  (planar) 46 72 
2 (SPECT) 81 48 
3 (Sestamibi) 35 62 
4 (all images) 73 64 
Table 7.3 - Overall sensitivity and specificity values for comparison of results of observer 
study with ultrasound imaging results 
Combined sensitivity and specificity results for all 5 observers for each phase of the 
observer study compared with those from the ultrasound imaging reports 
The results also demonstrate that the sensitivity is once again higher for those 
phases of the observer study that included dual-isotope subtraction SPECT 
images than for those phases that did not.  The highest sensitivity, as was the 
case for the comparison with the surgical results, was for phase 2, but this was 
combined with the lowest specificity.  In contrast, both phases 1 & 3 had low 
sensitivity but higher specificity.  The results for phase 4 show relatively high 
sensitivity and specificity, suggesting that the combination of dual-isotope 
subtraction planar and SPECT images gives results most similar to those from 
ultrasound imaging. 
7.1.9 Comparison with Results from Other Researchers 
A detailed description of the history of nuclear medicine imaging of the 
parathyroid glands and the many available radiopharmaceuticals and techniques 
is given in Section 1.3.2 of this thesis.  A 1998 review of the available literature 
(Pattou et al., 1998) clearly demonstrated the large number of different 
techniques in use and the relative success with which they were used at 
different centres.  The measured sensitivity in parathyroid adenoma detection 
from a large number of studies was collated and the results showed wide 
variation, with a range of 55% - 100%, for planar imaging techniques.  Indeed, 
the first study into the use of the 99mTc-Sestamibi dual-phase technique 
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(Taillefer et al., 1992) found a sensitivity of 90%, whilst a much later study using 
the same technique reported a sensitivity of just 55% (Neumann et al., 1997a & 
1997b). 
The main premise behind the dual-phase technique – that the washout rate of 
Sestamibi from a parathyroid adenoma is slower than that of thyroid tissue – has 
also been shown to be non-universal (Calendini-Viallet, 1997, Krausz et al., 
2001).  Further work has demonstrated increased sensitivity from dual-isotope 
techniques when compared to the use of dual-phase washout (Hindié et al., 
1998, Leslie et al., 2002, Wakamatsu et al., 2003) and a sensitivity of 100% in 
relation to preoperative localisation of a single diseased gland prior to unilateral 
surgery has been reported with dual-isotope planar imaging (Hindié et al., 
2000).  Pattou’s review (1998) also demonstrated a tendency for increased 
sensitivity when 123I was used to define the thyroid gland in subtraction imaging, 
as opposed to the use of 99mTc-pertechnetate.  This has been confirmed by more 
recent work (Kettle & O’Doherty, 2006). 
The findings of the present study show much lower sensitivity values than most 
of the analysis presented in the literature, with the sensitivity varying between 
46% and 60% for the 5 observers reviewing dual-isotope subtraction planar 
images.  These values are, however, comparable with the 55% found by 
Neumann (Neumann et al., 1997a & 1997b), who used the same parameters to 
determine the sensitivity.  Other studies are less clear on how sensitivity is 
defined and so may be measuring a different quantity and a direct comparison 
may not be valid.  Another factor which could affect the sensitivity of this study 
is the standard referral pattern at GRI.  As previously noted, at other centres, 
patients undergo imaging only after the need for surgery has been confirmed, 
whereas the results of imaging at GRI will affect the clinical decision on whether 
or not to operate.  The clinicians reporting images at other centres are therefore 
simply providing guidance to the surgeon as to the most likely position of an 
adenoma or hyperplastic parathyroid gland.  In contrast, at GRI the purpose of 
imaging is to confirm the presence of an overactive gland to assess the 
requirement for surgery.  Clinicians at other centres are therefore more likely to 
class a lesion as positive than would be the case at GRI, meaning that the 
sensitivity for parathyroid imaging at other centres is higher than at GRI. 
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Differences in the detection rates of lesions between primary and secondary 
hyperparathyroidism and between single- and multi-gland disease have also been 
demonstrated by a number of groups.  For example, one group found a 
sensitivity of 96.2% for adenoma detection in primary hyperparathyroidism, but 
just 48.5% in secondary hyperparathyroidism (Suehiro & Fukuchi, 1992).  Another 
group determined a sensitivity of 89% for the detection of single adenomas but 
only 47% for hyperplastic glands (Chen et al., 1997).  However, another study 
found good sensitivity for the detection of hyperplasia at 96% (Gordon et al., 
2002).  The size of the adenoma has also been found to affect the sensitivity of 
imaging with 99mTc-Sestamibi, with sensitivity for detection of large and small 
adenomas of 81% and 56% respectively, although the mechanism for this is not 
well understood (Moka et al., 2000b). 
There was no segregation between participants with primary and secondary 
hyperparathyroidism or between single- and multi-gland disease in the present 
study due to the relatively small sample size available.  However, the inclusion 
of all participants in a single group is likely to be contributing to the relatively 
low sensitivity found in this study when compared to others in the literature.  
Indeed, the sensitivity found here for planar imaging is not dissimilar to that 
found in studies where no distinction was made between groups of patients (e.g. 
Thomas et al., 2009). 
Three-dimensional single-isotope SPECT imaging with 99mTc-Sestamibi has also 
been studied widely, again with varying reported sensitivity.  Some groups found 
that the use of SPECT increased sensitivity significantly over planar imaging 
(Billotey et al., 1996a & 1996b, Moka et al., 2000b, Lorberboym et al., 2003, 
Schachter et al., 2004, Spanu et al., 2004, Slater & Gleeson, 2005, Ansquer et 
al., 2008, Carlier et al., 2008, Thomas et al., 2009), whilst others found little or 
no improvement (Torres et al., 1996, Chen et al., 1997, Ho Shon et al., 2008, 
Nichols et al., 2008).  The quoted sensitivities for 99mTc-Sestamibi SPECT imaging 
in these studies range from 54% (Ho Shon et al., 2008) to 98% (Spanu et al., 
2004) with the majority being well above 80%.  It should be noted, however, that 
some of these studies differentiate between different types of parathyroid 
disease whereas others, which tend to have lower overall sensitivity, do not.  
Also, some studies involved the reviewing of SPECT images only, whilst others 
used a combination of 99mTc-Sestamibi SPECT and planar images. 
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This study found sensitivity values for 99mTc-Sestamibi planar + SPECT imaging of 
between 25% and 72% for the 5 observers.  Although the values found in different 
studies in the literature have a similar overall range, the sensitivities found here 
are generally lower than these other studies.  This is most likely due to the fact 
that the routine practice at GRI is to perform dual-isotope imaging and so the 
observers are unused to reviewing Sestamibi images without the accompanying 
123I-iodide thyroid images.  This unfamiliarity resulted in a lack of confidence 
from the observers in defining possible lesions as positive, leading to a 
significant reduction in the sensitivity. 
Numerous comparisons have also been made of the relative sensitivities of 
nuclear medicine and ultrasound imaging.  Again, there are differences of 
opinion, with some groups finding ultrasound to be equally or more sensitive 
when compared to planar imaging (Wakamatsu et al., 2001 & 2003, Berber et 
al., 2008, Siperstein et al., 2008, Wong et al., 2009), whilst others found it to be 
less sensitive (Heller et al., 1993) and still others concluded that a combined 
imaging protocol provided the maximum useful clinical information (Kara Gedik 
et al., 2008).  Comparisons have also been made with SPECT imaging, once more 
with conflicting results.  One study found that ultrasound had a significantly 
higher sensitivity at 74% than SPECT at 58% (Tublin et al., 2009), whereas others 
found SPECT to provide improved sensitivity over ultrasound at 91% to 71% (Hara 
et al., 2007), 82% to 51% (Carlier et al., 2008) and 75% to 56% (Quiros et al., 
2004).  The present study found a comparable sensitivity from ultrasound 
imaging at 72%, although this was considerably higher than the sensitivity for 
99mTc-Sestamibi planar + SPECT imaging, for the reasons discussed in the 
preceding paragraph. 
Despite there being a large number of publications relating to the use of SPECT 
in nuclear medicine parathyroid imaging, the research group led by Donald R. 
Neumann in Cleveland, Ohio, is the only team to have published work focussing 
on dual-isotope subtraction SPECT using 99mTc-Sestamibi and 123I-iodide in the 
investigation of parathyroid disease.  This group has published several studies on 
the topic (Neumann et al., 1997b, 1998, 2000, 2008), with each study focussing 
on a different patient sample.  For example, the work published in 1997 
considered only patients with primary hyperparathyroidism and found an overall 
sensitivity of 88% in the detection of hyperfunctioning parathyroid glands.  The 
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1998 study concerned only patients with secondary hyperparathyroidism, none of 
whom had previously undergone parathyroidectomy surgery.  On this occasion, 
the sensitivity of the dual-isotope SPECT was found to be slightly lower at 77%.  
When only reoperative patients were considered in the 2000 paper, the 
sensitivity in this group was found to be 100%.  A further study in 2008 once 
again included only patients with primary hyperparathyroidism, although this 
was a larger sample size than in the 1997 work.  The sensitivity reported from 
the 1998 Neumann study was 71% and the criteria for determining sensitivity 
were the same as those used in this study. 
The present study included all these categories of patients, with primary and 
secondary hyperparathyroidism and reoperative patients all represented.  The 
sensitivity for dual-isotope SPECT alone ranged from 57% to 85% for the 5 
observers, whilst that for dual-isotope planar and SPECT together ranged from 
60% to 80%.  These values are consistent with those found in the larger sample 
size study performed by Neumann et al in 2008, which were calculated using the 
same conditions.  This confirms that the results of this study are valid and that 
the significant increase in sensitivity seen when dual-isotope SPECT images are 
included in the observer review demonstrates a true improvement. 
Multi-modality imaging systems are now becoming more common in many 
centres, and the introduction of SPECT/CT into routine use has provided a new 
avenue for the investigation of parathyroid disease.  Various groups have utilised 
99mTc-Sestamibi SPECT/CT and have found improvements in sensitivity and 
particularly in specificity in patients who have an ectopic parathyroid adenoma 
or who have previously undergone neck surgery (Even-Sapir et al., 2001, Gayed, 
et al., 2005, Krausz, et al., 2006, Lavely et al., 2007, Papathanassiou et al., 
2008, Akram et al., 2009).  Once again, only one group has considered dual-
isotope subtraction SPECT/CT (Neumann et al., 2008) and found a similar 
sensitivity when compared with dual-isotope SPECT at 70% vs 71%, but a 
significantly increased specificity at 96% vs 48%.  A SPECT/CT system is now in 
place at GRI but, unfortunately, was not available in time for any work in this 
area to be included in this thesis.  However, work has now begun in the 
department to evaluate the utility of dual-isotope subtraction SPECT/CT for 
parathyroid imaging. 
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7.1.10 Results with Equivocal Reports Taken as Positive 
The different referral pattern for imaging used at GRI compared to many other 
institutions for patients with hyperparathyroidism and how this may affect the 
reports given by the nuclear medicine clinicians was outlined in Section 3.1.1.  It 
is acknowledged that, at GRI, there is a greater likelihood of images being 
reported as equivocal or negative than at many other centres in order to prevent 
patients undergoing unnecessary surgery.  In this study, equivocal reports from 
the observers were regarded as being negative as there was no definitive 
localisation of an adenoma.  However, the observers were still seeing something 
they regarded as suspicious on these images, and it is possible that such 
investigations would be treated as positive at another institution where the 
patient would be undergoing surgery regardless of imaging results, and that this 
may account for the differences in sensitivity found in this study when compared 
to those published in the literature, as discussed in Section 7.1.9 above.  In 
order to assess how this may affect the results of the observer study, the 
analysis was repeated taking all equivocal results to be positive. 
Figure 7.2 shows a comparison of the total number of lesions regarded as 
positive for adenoma on each phase of the observer study when equivocal results 
were taken as being firstly negative and then positive.  It is clear that the 
number of positive lesions seen on all 4 phases increases significantly when an 
equivocal report is regarded as positive.  This is to be expected as there were 
equivocal results given by the observers on all the phases.  The greatest 
percentage increase in the number of positive lesions was for phase 3 at 87%.  
This confirms that there was a high proportion of equivocal results for this 
phase, due to the observers’ discomfort with reviewing 99mTc-Sestamibi images 
in the absence of the 123I-iodide thyroid images. 
Chapter 7  199 
0
40
80
120
160
200
Phase 1 Phase 2 Phase 3 Phase 4
N
o
.
 
Le
s
io
n
s 
Po
si
tiv
e
Equivocal -ve
Equivocal +ve
 
Figure 7.2 - Comparison of number of positive lesions seen when equivocal taken as 
negative and positive 
Bar chart showing the number of lesions given as positive for adenoma by the observers on 
each of the 4 phases of the observer study (Phase 1 = planar, Phase 2 = SPECT, Phase 3 = 
Sestamibi only, Phase 4 = all images) when equivocal reports were regarded as negative 
(blue) and positive (purple). 
The given positive/negative report from histological assessment of each gland 
resected at surgery was then compared to the positive/negative findings from 
the observer study.  Figure 7.3 shows a comparison of the number of times the 
same positive/negative report was given from surgery and imaging when the 
equivocal results from the observers were taken to be firstly negative and then 
positive.  The number of times the same conclusion on the status of a gland was 
reached can clearly be seen to be higher on every phase when the equivocal 
reports were taken to be positive for the presence of an adenoma. 
These findings suggest that regarding lesions reported as equivocal by the 
observers to be positive for the presence of parathyroid adenoma can 
significantly affect the results of the comparison of imaging findings with 
surgical findings.  In order to further assess this effect, the sensitivity and 
specificity for each phase of the study was re-calculated taking equivocal 
reports as positive and the results were compared to the original values given in 
Table 7.1.  As before, only the given positive/negative and left/right findings 
were used to calculate the sensitivity and specificity, and the results are shown 
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in Table 7.4, with those from the original analysis with equivocal taken as 
negative also shown for comparison. 
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Figure 7.3 - Comparison of number of same positive/negative reports when equivocal taken 
as negative and then positive 
Bar chart showing the number of times the same positive/negative report was given for 
each gland removed at surgery as compared to each lesion reported by the observers on 
the 4 phases of the observer study (Phase 1 = planar, Phase 2 = SPECT, Phase 3 = 
Sestamibi only, Phase 4 = all images) when equivocal reports were regarded as negative 
(blue) and positive (purple). 
Study Phase Sensitivity (%) 
Equi -ve 
Sensitivity (%) 
Equi +ve 
Specificity 
(%) Equi -ve 
Specificity 
(%) Equi +ve 
1  (planar) 49 67 61 25 
2 (SPECT) 77 87 31 3 
3 (Sestamibi) 45 69 29 9 
4 (all images) 64 82 27 8 
Table 7.4 - Sensitivity and specificity results for equivocal taken as negative and positive 
Calculated overall sensitivity and specificity relative to the surgical gold standard for each 
phase of the observer study firstly taking equivocal reports as negative (Equi –ve) and then 
positive (Equi +ve). 
The calculated sensitivity and specificity values in Table 7.4 clearly show that 
taking equivocal reports as positive leads to a significant increase in the 
sensitivity but with an associated decrease in the specificity.  The former is due 
to an increase in the true positive rate for lesions that were previously classed 
as false negative, whereas the latter is due to an increase in the number of false 
positive reports that were previously true negatives.  The sensitivity values when 
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taking equivocal reports as positive, particularly for phases 2 & 4 which included 
the dual-isotope subtraction SPECT images at 87% and 82% respectively, are 
more similar to the values found by other research groups, as discussed in 
Section 7.1.9 above.  Although the specificity is very poor, it is important to 
note that, as discussed previously, the specificity is highly dependent on the 
true negative rate.  Since there were only 2 true negatives recorded at surgery, 
the calculated specificity values are likely to be unreliable. 
These results confirm that the standard patient pathway and referral pattern 
used at GRI has a strong influence on the way that imaging studies are reported.  
Lesions which may be reported as positive at other centres that use a different 
referral pattern are given as equivocal at GRI.  Taking these equivocal reports to 
be positive gives similar sensitivity values to those seen in studies carried out at 
other institutions.  However, the specificity is considerably reduced due to an 
increase in the number of false positive reports.  In a situation where it has 
already been confirmed that the patient will undergo surgery, a false positive 
report is of little consequence as the surgeon will simply look elsewhere in the 
neck if a suspicious gland is not seen at the location suggested by the imaging 
report.  In contrast, if the decision to perform surgery is dependent on the result 
of the imaging investigation, a false positive report could lead to unnecessary 
surgery being carried out and so is therefore undesirable.  Should the referral 
pattern at GRI change in the future, it will be necessary for the nuclear 
medicine clinicians to modify their reporting techniques to reflect the different 
emphasis required from the results. 
7.2 Conclusions 
The inclusion of dual-isotope subtraction SPECT images in the investigation of 
parathyroid disease gave an increase in the number of observed lesions over the 
use of planar imaging alone.  This was coupled with an increase in the 
confidence level expressed by the observers taking part in the study.  Single 
isotope 99mTc-Sestamibi imaging including both planar and SPECT imaging 
provided no significant benefit over dual-isotope planar imaging for the 
observers.  This is mainly due to the fact that standard practice at GRI is to 
carry out dual-isotope subtraction imaging, and so the observers involved in this 
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study are not comfortable reporting parathyroid studies without the presence of 
123I-iodide thyroid images. 
Surgical findings represent the gold standard for parathyroid studies, since 
histology is the only way to confirm or deny the presence of a true parathyroid 
adenoma or hyperplastic gland.  The phases of the observer study that included 
dual-isotope subtraction SPECT showed an increase in sensitivity for detecting 
true parathyroid adenomas at the correct lateral location in the neck over the 
other phases.  This indicates that dual-isotope subtraction SPECT is the 
preferred method of those considered in this study for parathyroid imaging. 
The sensitivity and specificity values found during this study were lower than 
those found in the literature.  The reason for this is not entirely clear but may 
be due to the methods for determining sensitivity used by other groups.  Also, 
some of the other studies included information from surgery about parathyroid 
glands that were not resected, giving a larger number of true negative results 
that would influence the specificity particularly.  However, the increase in 
sensitivity with dual-isotope subtraction SPECT over planar imaging is sufficiently 
significant to conclude that this is the method of choice for pre-operative 
localisation of parathyroid lesions. 
The results of the comparison between ultrasound imaging and the various 
phases of the observer study are affected by the fact that, due to standard 
practice at GRI, the two modalities are not entirely independent for parathyroid 
imaging.  However, it was demonstrated that the inclusion of dual-isotope 
subtraction SPECT images increases the sensitivity relative to ultrasound 
imaging, as was the case for the comparison with the surgical findings. 
Since the work for this study was carried out, the standard protocol for 
parathyroid imaging in the Department of Nuclear Medicine at GRI has been 
altered to include dual-isotope subtraction SPECT.  The clinicians felt strongly 
that the results of this study demonstrated that there were clear benefits in 
terms of the accuracy of reporting to be gained from including SPECT imaging.  
Since late 2008, all patients presenting for parathyroid imaging in the 
department have therefore undergone dual-isotope subtraction SPECT at 15 
minutes post-injection of 99mTc-Sestamibi and dual-isotope subtraction planar 
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imaging 2 hours later.  All patients are now administered with a standard 
activity of 900MBq of 99mTc-Sestamibi, which is considerably higher than the 
average of 621.9MBq administered to the participants of this study, as well as 
20MBq 123I-iodide for the dual-isotope acquisition.  The acquisition time for each 
frame of the SPECT image acquisition has also been increased from 30s to 40s to 
provide a higher total number of counts and therefore better image quality than 
was available for this study.  Indeed, the second review of the phase 2 SPECT 
data (Section 7.1.7) took place after this change in routine practice had been 
implemented, and the observers all commented on the relatively poor image 
quality of the images for this study in comparison to those now routinely 
acquired according to the new standard procedure.  The clinicians are therefore 
confident that this new protocol allows them to provide the maximum level of 
useful clinical information to both the referring clinicians and the endocrine 
surgeons. 
7.3 Suggestions for Further Work 
The relatively small number of participants who underwent parathyroidectomy 
surgery is the main weakness of this study.  The main reason for this problem 
occurring is the way the standard patient pathway is laid out at GRI, meaning 
that a patient with negative imaging results will most often be managed 
clinically and not undergo surgery.  A researcher carrying out a prospective 
imaging study can therefore not be certain that any individual patient will be 
referred for surgery after imaging.  This problem could be overcome either by 
collecting patient image data over a longer time period, resulting in a larger 
number of participants and more surgical examples, or by extending the study to 
other centres to include a larger number of patients, some of whom will undergo 
surgery regardless of the results of imaging examinations. 
The work of the group led by Neumann (Neumann, 1992, Neumann et al., 1997b, 
1998, 2000, 2008) was carried out with segregation of the different types of 
hyperparathyroidism, whereas this study included patients with all types of 
hyperparathyroidism, although primary hyperparathyroidism was most common.  
Neumann and his team found differences in the detection sensitivity and 
specificity between patients with primary and secondary hyperparathyroidism 
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(Neumann et al., 1997b, 1998, 2000), with lesions due to secondary 
hyperparathyroidism being generally harder to detect than primary parathyroid 
adenomas.  The inclusion of participants with both types of disease in this study 
may have influenced the results slightly and so, if a larger sample was to be 
taken to extend this work, segregation of participants would be recommended.  
The results could then be more directly compared to those from Neumann’s 
various studies published in the literature. 
Another problem encountered in this study was the lack of true negative results 
from surgery, which is mainly attributable to the high specificity of the 
experienced endocrine surgeon in identifying parathyroid adenomas or 
hyperplastic glands and the fact that the decision to send a patient for surgery is 
based on the results of imaging studies.  This meant, however, that the 
specificity results from the comparison of the observer study findings with those 
from surgery are somewhat unreliable, as the specificity is so heavily dependent 
on the true negative rate.  Again, a larger study sample would go some way to 
improving the situation, but it is recognised that the problem is likely to remain 
to some extent because of the aforementioned high specificity of the endocrine 
surgeons. 
There were also sometimes significant differences in the results for each of the 
individual observers.  Further work involving consensus reporting by two or more 
observers may be useful in determining why these differences exist and if 
improvements to the sensitivity and/or specificity can be made.  Standard 
practice at GRI is for an individual consultant physician or radiologist (observers 
1-3) to report images, usually in the presence of an experienced nuclear 
medicine clinical scientist (observers 4 & 5). 
A further development that would be interesting to study would be the use of 
dual-isotope subtraction SPECT/CT in parathyroid imaging.  Indeed, the group 
led by Neumann has carried out some preliminary work on this topic (Neumann 
et al., 2008), which suggests that the inclusion of the registered CT data in 
conjunction with 123I/99mTc-Sestamibi subtraction SPECT increases the specificity 
of parathyroid imaging.  As mentioned previously, the department at GRI is now 
using dual-isotope subtraction SPECT routinely but also now has a SPECT/CT 
system and work is now being carried out to assess the utility of SPECT/CT for 
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parathyroid patients.  This work is not well enough advanced to be discussed 
here, but it is hoped that a sufficient body of data will be built up to allow 
reasonable assessments of the relative merits of imaging with and without CT to 
be made. 
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Chapter 8 – Thyroid Uptake Calculations from 
SPECT Images 
8.1 Introduction 
8.1.1 Nuclear Medicine Thyroid Studies 
It has been known for many years that the thyroid gland is responsible for the 
production of various hormones which regulate metabolism (Martini, 2001, Moore 
& Agur, 2007).  These hormones contain iodine as an important component and 
it was quickly realised that iodine from the bloodstream accumulates in the 
thyroid via an ion-concentrating mechanism.  The thyroid then metabolises 
trapped iodide ions to create the thyroid hormones.  Since the introduction of 
nuclear medicine imaging, this tendency to accumulate iodine has been utilised 
to assess the function of the thyroid gland.  Although ultrasound imaging is still 
used extensively to assess the anatomy and morphology of the thyroid, it cannot 
provide functional information in the way that nuclear medicine is able to (Sharp 
et al, 1998). 
Initial work on nuclear medicine studies of the thyroid was carried out using the 
fission product 131I-iodide and a scintillation detector connected to a multi-
channel analyser to measure the total counts detected and hence calculate a 
percentage uptake value for the thyroid.  However, 131I has a long half-life of 
8.04 days and produces beta radiation as well as high energy gamma emissions 
(364keV).  Patients therefore received a high radiation dose, particularly to the 
thyroid itself, and the gamma photons produced were of a higher energy than is 
ideal for detection.  The radiation burden for the patient could be reduced by 
chemically blocking the metabolism of iodine in the thyroid using drugs such as 
methimazole or propylthiouracil (Andros et al, 1965, Esser et al, 1973), but the 
problems with detection of the emitted photons remained.  Images could be 
acquired using a rectilinear scanner or a gamma camera, but the quality was 
poor. 
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The radioactive iodine uptake (RAIU) measurement quickly became an important 
tool in the diagnosis of thyroid disorders as it gave a direct measure of the 
thyroid function.  However, good quality images of the gland were also becoming 
increasingly important to clinicians, especially in cases of nodular thyroids 
(Sharp et al, 1998).  The functional nuclear medicine images were able to 
distinguish between nodules that had increased function relative to the 
surrounding thyroid tissue (“hot” nodules) and those that had decreased function 
(“cold” nodules).  Other thyroid diseases also produce characteristic abnormal 
patterns (Smith & Oates, 2004) which can aid in diagnosis.  Isotopes that would 
give higher quality images than 131I were therefore sought. 
Other radioactive isotopes of iodine, such as 123I and 125I, soon became available 
and were considered as possible replacements for 131I in thyroid studies.  
However, although 123I has an acceptably short half-life of 13 hours and a gamma 
emission in the ideal energy range for scintillation detection and hence gamma 
camera imaging at 159keV, it can only be produced by a cyclotron and is 
therefore considerably more expensive than products containing 99mTc as the 
radioisotope.  Similarly, although 125I is reactor produced and is therefore less 
expensive, it also has disadvantages as it has a very long half-life of 59.9 days 
and low gamma energy of 27 – 36keV (Delacroix et al, 2002) and so again will 
give a large radiation dose to the patient with poor detection capabilities. 
By the mid-1960s, it had been discovered that the pertechnetate ion was also 
concentrated in the thyroid gland (Andros et al, 1965).  In fact, the initial 
distribution of pertechnetate throughout the body is similar to that of iodine, 
with concentration in the thyroid, the salivary glands and the stomach.  
Although the thyroid does not metabolise the pertechnetate, it appears to 
accumulate the ion using the same ion-concentrating mechanism that takes 
iodine into the gland (Andros et al, 1965), giving uptake results similar to those 
found with a blocked thyroid gland, but the exact mechanism for pertechnetate 
trapping within the thyroid remains unknown (Sharp et al, 1998).  The 
radioactive isotope 99mTc was already commonly used in nuclear medicine 
because of its short half-life and ideal gamma photon energy of 140keV for 
detection using a scintillation device, and so radioactive pertechnetate was easy 
to acquire.  Indeed, the standard eluate from a 99mTc generator flushed with 
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sterile saline is sodium pertechnetate and so substantial amounts of this 
radiopharmaceutical can be readily and cheaply obtained. 
Although 99mTc-pertechnetate has been used in nuclear medicine studies for 
many years, there are relatively few models that describe the distribution of the 
radiopharmaceutical in the body.  Several authors have described 
compartmental models of pertechnetate distribution and uptake within the 
thyroid (Andros et al, 1965, Atkins & Richards, 1968, Shimmins et al, 1968, Hays 
& Berman, 1977, Hays, 1978, Hilditch & Alexander, 1980, Okada et al, 2003) 
with various methods of introducing pertechnetate into the body and measuring 
its distribution. 
In 1988, the International Commission on Radiological Protection published a 
report (ICRP, 1988) giving biokinetic data for a wide range of commonly used 
radiopharmaceuticals.  For 99mTc-pertechnetate, the model for uptake in the 
thyroid takes the form of a bi-exponential with one rapid washout component of 
half-life 60 minutes and another, much slower, washout component of half-life 
600 minutes.  The rapid component accounts for 85% of the washout, whilst the 
slower component accounts for 15%.  The model therefore takes the 
mathematical form: 
( ) ( )( )600/60/0 15.085.0 tt eeAA −− +=  
Equation 8.1 
 
where A is the activity in the thyroid gland at time t, A0 is the initial activity in 
the thyroid and t is the time since injection of the 99mTc-pertechnetate in 
minutes.  The model assumes that the thyroid accumulates a total of 2% of the 
initial injected activity and therefore this is the value for A0.  The uptake of the 
thyroid gland as a percentage of the initial injected activity can therefore be 
calculated at any subsequent time t using the model. 
8.1.2 The Thyroid Uptake Measurement 
The percentage uptake of radioactive iodine or pertechnetate is a useful 
diagnostic aid in thyroid diseases.  Although it is not normally used as a 
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definitive diagnosis for hypo- or hyperthyroidism – biochemical markers of the 
levels of thyroid hormone in the blood are more accurate – the uptake is often 
used to differentiate different types of disease; for example, it is often used to 
distinguish between Graves’ disease and other hyperthyroid conditions (Sharp et 
al, 1998). 
A measurement of uptake of radioactive iodine rapidly became commonplace for 
patients with thyroid disorders after the introduction of routine nuclear 
medicine investigations in the 1960s.  The patient was given an oral or 
intravenous administration containing 131I (or later 123I or 125I) in the form of 
sodium iodide.  The uptake measurement would then be carried out 24 hours 
later, when the uptake in the thyroid gland was approximately at its peak.  The 
introduction of 99mTc-pertechnetate for thyroid imaging allowed the uptake to 
be measured in a same-day procedure, meaning that the patient was not 
required to attend for 2 appointments on consecutive days (Wagner et al, 1999). 
For many years, the uptake measurement was carried out using a dedicated 
counter system.  A single sodium iodide scintillation crystal of typically 5cm 
diameter was optically linked to a photomultiplier tube, which was in turn 
connected to a multichannel analyser (Sharp et al, 1998).  In front of the crystal, 
a tapering lead collimator would be mounted to prevent extraneous counts from 
being measured in the detection system.  The counter would be positioned a set 
distance from the neck of the patient and the counts in the neck area over a set 
period of time would be noted.  The distance between the patient and the 
counter and also the acquisition time varied between institutions (e.g. Andros et 
al, 1976, Atkins & Richards, 1968, Hays & Berman, 1977) but the technique was 
consistent at each individual institution.  A standard of known activity was also 
counted in the same geometry in order to perform an absolute calculation of the 
percentage uptake in the thyroid.  The standard activity was placed in a special 
neck phantom to simulate the attenuation of the gamma photons by the soft 
tissues of the neck between the thyroid gland and the detector. 
Since the counter positioned over the neck would record counts that were not in 
the thyroid but were present in the extrathyroidal blood pool or other spaces, a 
background subtraction was required to obtain the true thyroid counts.  Uptake 
measurements with radioactive iodine commonly used a second counter placed 
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over the thigh to measure the blood pool activity (Atkins & Richards, 1968, Sharp 
et al, 1998).  However, initial measurements with pertechnetate found some 
difficulties with this technique, primarily due to the fact that the pertechnetate 
uptake must be carried out soon after injection as the pertechnetate is not 
organically bound in the thyroid and so is rapidly lost from the gland (Shimmins 
et al, 1969).  This leads to a high background activity in the neck and a poorer 
target: background ratio than is achieved with iodine (Andros et al, 1976, Hays, 
1978). 
In order to overcome these problems, some groups began to acquire scanning 
images of the neck using a rectilinear scanner (Atkins & Richards, 1968, 
Shimmins et al, 1968 & 1969 Andros et al, 1976) or a multicrystal camera (Hays, 
1978).  The thyroid could then be visualised along with the activity surrounding 
it.  A region of interest (ROI) could be applied around the thyroid, excluding 
most of the extrathyroidal activity.  The counts within the ROI were then used to 
perform the uptake calculation.  Background subtraction was still performed, 
but an ROI below the thyroid was used, rather than the thigh as was previously 
the case.  The ROI below the thyroid would give a better estimation of the 
extrathyroidal activity in the neck whilst ensuring that the salivary glands – 
which also concentrate iodine and pertechnetate – were outwith the region. 
From the early 1970s onwards, the gamma camera became more commonly used 
for the pertechnetate uptake measurement (Esser et al, 1973).  The main 
advantage of the gamma camera was that good quality images of the thyroid 
could be acquired simultaneously, reducing the total examination time 
considerably.  This technique does, however, require a larger activity to be 
given to the patient to ensure a sufficiently high count rate for imaging (Wagner 
et al, 1999).  The uptake measurement is carried out by taking the counts in a 
thyroid ROI and a background ROI placed below the thyroid.  A standard image 
must still be acquired to allow the absolute quantification to be carried out 
(Vahjen et al, 1992). 
Several studies have been performed to determine the best time post-injection 
at which to carry out the uptake measurement.  Atkins & Richards (1968) 
suggested that an uptake measurement at 20 minutes post-injection would give 
a result similar to a 24 hour iodine uptake.  Esser et al (1973) created uptake 
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curves over a 30 minute period after injection and were unable to find any 
pattern linking the shape of the uptake curve with the underlying disease type.  
However, they noted that an uptake measurement at 20 minutes post-injection 
would give a result within 94.5% of the maximum value, on average.  The uptake 
measurement is now routinely carried out at 20 minutes in most institutions, 
including Glasgow Royal Infirmary (GRI). 
As mentioned previously, different institutions will use different geometries for 
acquiring the information for the uptake measurement.  However, it is 
important that each institution is consistent in its own measurements, so that 
uptake values can be directly compared between patients and also between 
similar measurements carried out on the same patient at different time points.  
The normal range must also be defined independently by each institution as the 
measurement geometry and the phantom used for the standard acquisition can 
have a significant effect on the final result (Vahjen et al, 1992). 
8.1.3 Glasgow Royal Infirmary Thyroid Clinic 
The Nuclear Medicine department at GRI runs a thyroid clinic each Monday 
afternoon.  Patients with known or suspected thyroid disease are referred to the 
clinic for imaging and an assessment by a nuclear medicine physician.  Around 10 
– 12 patients attend the clinic each week. 
When a patient attends the clinic, they firstly undergo thyroid imaging with an 
associated uptake measurement.  The patient is given an intravenous (IV) 
injection of 99mTc-pertechnetate and is imaged 20 minutes later.  The first image 
is a 60 second (s) anterior planar view of the neck, with the patient at a 
standard distance from the face of the gamma camera collimator, which is used 
to calculate the percentage uptake of pertechnetate in the thyroid (see Section 
8.2.2 for details of the uptake calculation).  A second image with a marker 
denoting the sternal notch is then acquired, which gives the reporting physician 
information on the anatomical location of the thyroid and any unusual features 
within or around the gland.  The third and final image is acquired for 5 minutes 
and encompasses a wider field of view to include the chest area and highlight 
any ectopic thyroid tissue or other abnormality. 
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After imaging, the patient is assessed by a consultant nuclear medicine 
physician.  The physician reviews the images as well as the patient’s clinical 
history and symptoms in order to diagnose any disease that is present and to 
determine the best course of treatment.  Around 25 – 30% of the patients 
attending the clinic require radio-iodine treatment for thyrotoxicosis and will 
return to the department at a later date to be administered 131I-iodide as a drink 
by one of the physicists. 
An average clinic appointment will last for around 45 minutes, although the 
length of time can vary.  For this study, patients were asked to remain in the 
department for a further 30 minutes after consulting the physician so that a 
SPECT acquisition could be carried out. 
8.2 Materials and Methods 
8.2.1 Study participants 
The study received approval from the local research ethics committee (LREC) at 
GRI in combination with the parathyroid study discussed previously.  Further 
details of the ethics application and approval granted can be found in Section 
3.1.3.1 and Appendix A of this thesis. 
All patients referred to the thyroid clinic between February 2006 and October 
2008 were sent a copy of the patient information sheet and consent form for the 
study (see Appendix B).  Patients who expressed an interest in the study were 
given the opportunity to speak to the principal researcher or another member of 
staff privately.  Those who were willing to take part were then asked to sign the 
consent form.  Time constraints on the clinical service in the department meant 
that the number of study patients that could be accommodated each week 
ranged from 0 to a maximum of 3.  Once the maximum number of patients for a 
session had consented to take part, consent was not sought from any others, 
even if they had initially expressed an interest in taking part. 
The SPECT acquisitions were performed after the patients had completed their 
appointments in the thyroid clinic in order to prevent disruption to the routine 
provision of the clinic service.  As waiting times between planar imaging and the 
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consultation with a clinician as well as the length of the consultation for each 
patient varied, this resulted in a wide spread of times between injection and 
SPECT scanning.  In contrast, the injection to planar scanning time was constant 
at as close to 20 minutes as possible, as per the departmental protocol for the 
thyroid clinic. 
A total of 60 patients initially gave consent to take part in the study.  However, 
time constraints within the thyroid clinic meant that 3 of the patients did not 
undergo SPECT scanning.  Therefore, 57 thyroid SPECT acquisitions were 
performed. 
From February 2006 to April 2007, each patient attending the thyroid clinic 
received an intravenous injection of around 180MBq 99mTc-sodium pertechnetate 
20 minutes prior to planar imaging.  This injected activity is considerably higher 
than the usual limit of 80MBq set by the Administration of Radioactive 
Substances Advisory Committee (ARSAC).  However, specific approval had been 
given by ARSAC to the department at GRI to give the higher activity, provided 
that a drink of 20mg sodium perchlorate solution was given to each patient after 
imaging to wash the pertechnetate out of the thyroid gland and reduce the 
radiation dose to the same level as that for an administration of 80MBq.  From 
May 2007 onwards, each patient received an intravenous injection of 80MBq 
99mTc-sodium pertechnetate, which is the ARSAC limit for thyroid imaging.  Of 
the study participants, 37 therefore received an injected activity of 180MBq and 
20 received an injected activity of 80MBq.  Those participants scanned before 
May 2007 had their sodium perchlorate drink delayed for the 15 minute period 
required for the SPECT acquisition. 
The activity in the syringe before the injection and the residual activity in the 
syringe after injection were measured using a Capintec isotope calibrator and 
were recorded for all patients to allow an absolute measure of thyroid uptake to 
be calculated. 
8.2.2 Planar Uptake Measurements 
The thyroid uptake was calculated from an anterior planar image at 20 minutes 
post injection for every patient.  This is part of the standard protocol for 
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patients attending the thyroid clinic.  The patients are seated in front of a 
gamma camera with the neck a standard distance (12cm) from the face of a low 
energy, high resolution collimator.  A 60s anterior planar image is then taken.  A 
60s standard image of a known activity is also acquired in order to determine the 
sensitivity of the gamma camera in counts/s/MBq.  The percentage uptake of 
99mTc-pertechnetate in the thyroid gland is then calculated using a program 
supplied with the department’s HERMES computer system (Nuclear Diagnostics 
Ltd.), which applies a decay correction for the physical decay of the 99mTc 
between the time of injection and imaging. 
The departmental normal range for thyroid uptake is 0.5% - 4.0%.  If a patient 
has a calculated uptake of <0.5%, he or she is deemed to be hypothyroid.  
Similarly, patients with an uptake of >4% are classed as hyperthyroid. 
8.2.3 SPECT Acquisition 
All acquisitions were performed on a double headed Philips ADAC Forte gamma 
camera with the patient lying supine and using a head rest to ensure the head 
and neck remained still throughout the acquisition.  As for the parathyroid 
imaging, the camera heads were placed at a relative angle of 90o.  The initial 
SPECT acquisition protocol was established assuming an injected activity of 
180MBq.  The acquisition parameters were as follows: 1282 matrix, energy 
window at 140keV ± 10%, parallel hole high resolution (VXHR) collimators, 180o 
circular anterior rotation, 60 frames, 30s acquisition time per frame.  A roving 
zoom of a 30cm square centred on the thyroid gland was also applied to the 
acquired frames. 
The total imaging time for this protocol was felt to be long enough to allow 
reasonable counts to be acquired in each frame but short enough to be 
comfortable for the patients and to keep the risk of patient movement to a 
minimum. 
When the injected activity was reduced to 80MBq in May 2007, the acquisition 
time per frame was increased from 30s to 40s to ensure adequate counts per 
frame were maintained for each acquisition giving a total imaging time of 20 
minutes.  This increase in time per frame was not in proportion to the decrease 
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in administered activity for two main reasons.  The first was that it was felt 
unlikely that participants could lie still for significantly longer than 20 minutes, 
meaning that a longer scan time would lead to a considerable increase in the 
risk of motion artefacts in the SPECT images.  The second reason was that this 
study was being carried out in a working clinical department, meaning that 
gamma camera time was at a premium and long scanning times were not 
possible.  It was therefore felt that an increase in the acquisition time per frame 
from 30s to 40s would allow adequate counts to be acquired in each frame whilst 
keeping the total imaging time to an acceptable level. 
In order to carry out a calculation of the absolute uptake, it was necessary to 
acquire an acquisition of a standard of known activity for each patient 
acquisition and use the images to determine the sensitivity of the gamma 
camera in counts/s/MBq.  The thyroid phantom designed for this study (see 
Chapter 2 for further details) was used for the standard SPECT acquisition.  A 
known activity in the region of 10MBq of 99mTc-pertechnetate was added to the 
phantom’s thyroid insert and a SPECT acquisition was carried out using all the 
same parameters as for the patient acquisitions with the exception of the frame 
time.  This was reduced to 10s per frame, meaning a total acquisition time of 5 
minutes, to keep the imaging time to a minimum.  When multiple patient 
acquisitions were performed on one day, a single standard was acquired and 
applied to all the patient data sets for that day. 
Since the activity of 99mTc decays over time and also that the ICRP model of 
thyroid uptake (ICRP, 1988) depends upon time post injection, the time at which 
each SPECT acquisition began was noted.  The times at which the standard 
activity was measured and the standard SPECT acquisition commenced were also 
noted so that a decay correction for the total activity in the phantom at the 
time of acquisition could be carried out.  This would then allow an accurate 
measure of the gamma camera sensitivity to be made. 
8.2.4 SPECT Image Reconstruction 
All SPECT images – both patient and standard data - were reconstructed using 
the Ordered Subsets Expectation Maximisation (OSEM) iterative algorithm on the 
HERMES computer system.  The reconstruction was performed using 15 subsets 
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and 4 iterations with no scatter correction applied.  A post-reconstruction filter 
was then applied to smooth the data.  This filter was chosen after a trial-and-
error process to find a filter that gave the best compromise between sharpness 
and excessive image noise. 
A further reconstruction that included attenuation correction (AC) was carried 
out on 20 of the patient data sets.  The results of the uptake calculations from 
the two reconstructions could then be compared to determine if performing AC 
affects the uptake value.  A uniform attenuation correction of µ=0.12cm-1 was 
included in the iterative reconstruction algorithm.  Again, a post-reconstruction 
filter was applied to smooth the resulting SPECT images.  The images of the 
standard for each of the 20 patient data sets were also attenuation corrected 
before the uptake calculation was performed.  Since the thyroid lies very 
anterior in the neck with little overlying tissue to cause significant attenuation 
of the 140keV gamma photons from the 99mTc emission, performing the 
attenuation correction on the SPECT data was not expected to result in a 
significant difference in the calculated thyroid uptake.  However, large thyroid 
glands may have a degree of self-attenuation associated with them, which may 
lead to significantly different results when an attenuation correction is applied. 
8.2.5 Volume of Interest Definition 
In order to calculate the uptake, it was necessary to determine the total number 
of counts in the thyroid for both the patient and standard data by creating a 
volume of interest (VOI) outlining the thyroid gland on each set of SPECT images.  
Several possible methods of VOI definition were examined.  Ideally, the VOI 
would be defined as a whole from the full 3D data set using a threshold value, 
whereby all the pixels with a value greater than a certain percentage of the 
maximum counts are enclosed within the VOI.  However, when this was 
attempted with the available HERMES software, it was not possible to outline 
the thyroid satisfactorily.  An example data set with the poor VOI definition is 
shown in Figure 8.1, with the VOI shown in red on single reconstructed coronal 
(a), sagittal (b) and transverse (c) images.  It can clearly be seen that the 
thyroid as a whole is not correctly outlined.  When a lower threshold value was 
chosen, large amounts of background were included in the VOI, which is equally 
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unacceptable for an uptake calculation.  This was the case for all the patient 
data sets and so a different method of VOI definition was required. 
 
Figure 8.1 - Threshold VOI 
Automatic VOI (shown in red) created on thyroid SPECT images using a threshold 
technique. 
Instead of defining a full VOI, it is possible to achieve the same result by 
creating thyroid regions of interest (ROIs) on all the slices on which the thyroid is 
visible.  Various methods of ROI definition can be used, including seed, threshold 
or hand-drawn regions.  The seed method involves the selection of a “seed” 
pixel from which the ROI is grown along lines of equivalent counts until the 
necessary area is enclosed.  The threshold method is similar to that described 
above for the definition of a VOI.  The final method involves an operator 
manually drawing the ROI on each slice on which the thyroid is visible and so is 
more labour-intensive than the other methods.  It should also be noted that any 
of the 3D projections (coronal, sagittal and transverse) can be used to create 
these ROIs. 
The technique chosen for this study was to use the transverse slices to define 
the ROIs as it was felt that the thyroid was more readily distinguished from the 
background activity on this projection.  Each of the methods of ROI definition 
were then tested on a number of patient and standard data sets to see which 
would give the most acceptable results. 
An example ROI using the seed method is shown in Figure 8.2.  The ROI produced 
by this method is too large and includes a significant amount of background area 
as well as the thyroid gland itself.  If the ROI was grown to a lesser extent (i.e. 
not grown so far from the seed value), it would only encompass one thyroid lobe 
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and would also not be acceptable for the uptake calculation.  This seed method 
was therefore rejected. 
 
Figure 8.2 - Seed ROI 
Example of ROI produced on transverse SPECT slice using the seed method 
The threshold method, which allowed steps of 1% in the threshold value, was 
also investigated, and example ROIs defined using the method are shown in 
Figure 8.3.  The slice shown is the same slice from the same patient data set 
that is shown in Figure 8.2.  It can be seen that the higher threshold ROI (12%) 
only encloses one lobe of the thyroid whilst the lower threshold value (11%) 
produces an ROI that is too large and includes a significant area of background 
activity.  This situation occurred on several slices on most of the patient data 
sets and so the threshold method was also rejected as being unsuitable for this 
study. 
The major problem encountered with the seed and threshold values was the 
inability of the system to select both lobes of thyroid when they were separated 
on the image slice by an area of background activity.  Since the isthmus is small 
and is only visible on a limited number of slices, this situation occurs on the 
majority of slices.  It was therefore decided that, although more labour-
intensive, the hand-drawn method of ROI definition would be used.  An example 
of the ROI produced on the same image slice as those in Figure 8.2 and Figure 
8.3 is shown in Figure 8.4.  This ROI includes only the thyroid and does not 
encompass background activity. 
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Figure 8.3 - Threshold ROIs 
Two ROIs defined using the threshold method at 12% (yellow) and 11% (blue) of the 
maximum counts in the image 
 
Figure 8.4 - Hand-drawn ROI 
Example of ROI produced by an operator manually drawing around the image of the thyroid 
gland 
An ROI outlining the thyroid was therefore hand-drawn on every transverse 
image slice on which the thyroid was visible for each patient data set.  A 
background ROI was also applied to each slice so that background counts could 
be subtracted from those in the thyroid to give a more accurate value for each 
slice.  The background region was drawn once for each patient data set and then 
applied to each slice on which the thyroid was visible.  An example of a hand-
drawn thyroid ROI with a typical background ROI is shown in Figure 8.5.  Similar 
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ROIs were also drawn on all transverse slices of the standard image data on 
which the thyroid phantom was visible. 
 
Figure 8.5 - Typical thyroid and background ROIs 
Hand-drawn thyroid (red) and background (yellow) ROIs on a transverse image slice 
8.2.6 Thyroid Uptake Calculation 
The counts and total number of pixels in each ROI on each slice were stored 
electronically using the HERMES system.  The data were then exported from the 
HERMES computer to a PC and entered into a spreadsheet program (Microsoft 
Excel) for analysis.  A background correction, taking into account the relative 
areas of the thyroid and background ROIs, was performed on the counts in each 
thyroid ROI using the following equation: 
b
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Equation 8.2 
 
where Cbc is the background corrected counts, Ct is the total counts in the 
thyroid ROI, Cb is the total counts of the background ROI, At is the area (total 
number of pixels) of the thyroid ROI and Ab is the area of the background ROI.  
The background corrected counts on all slices were then summed to obtain the 
total number of counts in the thyroid gland – that is the counts in the thyroid 
VOI. 
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The same background correction was applied to the data from the standard 
acquisition and the total counts were again summed.  This value was then 
divided by the total acquisition time (5 minutes, 300s) and the known activity in 
the phantom at the time the SPECT acquisition was started, giving the sensitivity 
of the gamma camera in counts/s/MBq.  This value was then used along with the 
total counts from the patient thyroid VOI and the known time of the patient 
SPECT acquisition (15 minutes, 900s, or 20 minutes, 1200s) to give a total 
thyroid activity in MBq as follows: 
TS
CA tt
×
=  
Equation 8.3 
 
where At is the total activity in the thyroid in MBq, Ct is the total counts in the 
thyroid VOI, S is the gamma camera sensitivity in counts/s/MBq and T is the 
total acquisition time in seconds. 
The percentage uptake of 99mTc-pertechnetate was then calculated as: 
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Equation 8.4 
 
where U% is the percentage uptake in the thyroid, At is the activity in the thyroid 
calculated using Equation 8.3, As is the activity in the syringe prior to injection 
and Ar is the residual activity in the syringe after injection.  All activities were 
decay corrected to account for the time differences between the initial 
measurement of the activity prior to injection and the acquisition of the SPECT 
images.  An identical method was used to find the uptake value from the 
attenuation corrected SPECT images. 
An estimate of the error in the calculated SPECT uptake value was made by re-
analysing a total of 15 patient data sets.  The differences between the first and 
second uptake values were found and the error taken to be the standard 
deviation of these differences. 
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8.2.7 Uptake Calculation from Single SPECT Frame 
A further calculation of the uptake was made using a single anterior frame of the 
patient and standard SPECT acquisition data.  The acquisition frame was 30s long 
for the early participants in the study (prior to May 2007) and 40s for the later 
participants.  The analysis carried out was identical to that used to calculate the 
uptake from a planar image.  Since there was often a long time delay between 
injection and the SPECT scan due to the need for the patient to complete their 
thyroid clinic visit before the additional acquisition, it was hoped that this 
calculation would provide a more direct comparison between the uptake 
calculated from planar and SPECT images.  For the purposes of clarity, this value 
will be referred to as the “frame SPECT” uptake throughout the results and 
discussion sections. 
8.2.8 Comparison of Planar, SPECT, Attenuation Corrected 
SPECT and Model Uptake Values 
The ICRP model (ICRP, 1988) was used to determine an expected uptake value at 
the time of the SPECT acquisition using the measured planar uptake at a known 
time as the standard value.  That is, given the uptake value calculated from the 
planar images at around 20 minutes post injection, what would the model 
expect the uptake to be at the time of the SPECT acquisition?  The expected 
value was calculated as follows: 
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Equation 8.5 
 
where UE is the expected percentage uptake based on the model, Up is the 
percentage uptake calculated from the planar image, ts is the time of the SPECT 
acquisition in minutes post injection and tp is the time of the planar acquisition 
post injection, also in minutes. 
Comparisons of this expected value and the various calculated uptake values 
were then made using graphical plots produced using the spreadsheet program.  
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The method of least squares was used to find the best-fit straight line for each 
plot, with the equation: 
baxy +=  
Equation 8.6 
 
where a is the gradient and b is the intercept of the straight line. 
A statistical software program (Minitab v13) was also used to assess any 
statistically significant differences between the various uptake values calculated 
from the image data and the ICRP model.  Since, with each comparison, the data 
were not normally distributed, a non-parametric test was used.  The difference 
between the percentage uptake determined from alternative methods was 
calculated and a Wilcoxon Signed Ranks test was applied to the results, giving a 
p-value, an estimated median and a 95% confidence interval (CI) for the 
difference between the two uptake values being compared.  Statistical 
significance was taken to be a result with p<0.05. 
8.3 Results 
8.3.1 Patient Demographics and SPECT Imaging Times 
A total of 57 patients took part in the study, with 13 males (23%) and 44 females 
(77%).  The average age of the participants was 49.9±13.1 years (mean ± 1SD) 
with a range of 20 to 77 years.  From the results of the uptake calculated from 
the planar image as part of the visit to the thyroid clinic, 1 patient was classed 
as hypothyroid (uptake <0.5%), 31 patients were classed as euthyroid (uptake 
0.5% - 4.0%) and 25 were classed as hyperthyroid (uptake >4.0%). 
All planar scans were taken as close to 20 minutes post injection as possible, 
with an average time of 24.5 ± 8.0 minutes (mean ± 1SD) and a range of 5 - 42 
minutes.  The timing of the SPECT acquisition post injection varied more widely 
due to the differing times taken for patients to complete their visit to the 
thyroid clinic.  The average scan time was 71.5 ± 17.5 minutes post injection 
with a range of 40 – 106 minutes.  A histogram of the imaging times post 
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injection for both planar and SPECT acquisitions is shown in Figure 8.6.  The 
wider spread of the time at which the SPECT acquisitions were commenced is 
clearly seen. 
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Figure 8.6 - Histogram of imaging time post injection 
Histogram showing the time at which each acquisition commenced after injection of 99mTc-
pertechnetate 
8.3.2 SPECT Reconstruction 
Although the SPECT image data were to be used primarily for uptake 
measurements and not for clinical evaluation, it was necessary to define 
parameters for the SPECT reconstruction that gave acceptable image quality.  
The number of subsets and iterations (15 and 4 respectively) were chosen to give 
rapid convergence to the physiological distribution of activity.  After the 
iterative reconstruction was complete, the data were filtered to smooth the 
resultant images.  The following filters, with the option to vary certain 
parameters, which are listed in Section 5.3, are available from the HERMES 
system: Butterworth, Hanning, Low Pass, Metz and 3x3x3 smoothing.  All the 
filters were tested on a number of patient data sets.  For each type of filter, a 
number of different image data sets were produced after varying the optional 
parameters.  The goal was to produce images with the best compromise between 
sharpness and excessive image noise over a range of uptakes. 
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Figure 8.7 shows slices in 3 planes from a patient data set to which a post 
reconstruction filter that gives images which are too smooth has been applied.  
The structure of the thyroid cannot be defined from the images.  A sharper filter 
is therefore required to give images of acceptable quality. 
 
Figure 8.7 - Overly smoothed thyroid SPECT images 
Example of patient thyroid SPECT data that has been overly smoothed by the post 
reconstruction filter.  Figure shows coronal (top), transverse (middle) and sagittal (bottom) 
slices 
In contrast, the same slices are shown in Figure 8.8, but these were produced 
using a different filter which smoothed the images much less.  The resulting 
images are excessively noisy and so a filter giving a result between those shown 
in Figure 8.7 and Figure 8.8 was required. 
The same slices are shown again in Figure 8.9, showing the images produced 
when the best compromise post reconstruction filter is applied to the SPECT 
data.  The final choice of filter that was then applied to all data sets prior to the 
uptake calculation being performed was a Butterworth filter of order 5 and with 
a cut-off frequency of 2.5 cycles/cm.  The choice was made by asking 
experienced physicians and clinical scientists to review a number of SPECT image 
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Figure 8.8 - Overly sharp thyroid SPECT images 
Example of patient thyroid SPECT data that is too noisy after the application of the post 
reconstruction filter.  Slices are the same as those shown in Figure 8.7. 
 
Figure 8.9 - Best compromise thyroid SPECT images 
Example of patient thyroid SPECT data with the best compromise post reconstruction filter 
applied.  Slices are the same as those shown in Figure 8.7 and Figure 8.8. 
data sets with different post-reconstruction filters applied for each of several 
different patient acquisitions.  The reviewers were asked to assess which images 
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gave the best compromise between sharpness and excessive noise and the 
consensus view was taken to be the most appropriate filter for use in this study.  
The same filter was also applied to all the reconstructed standard data before 
the ROIs were defined for the sensitivity calculation. 
8.3.3 Comparison of Calculated and Modelled Uptake Values 
8.3.3.1 Basic Statistics 
A basic statistical analysis was carried out on each of the calculated uptake 
values to give some indication of any differences that may exist before a more 
thorough analysis was performed.  The mean, median, standard deviation, 
minimum, maximum and 1st and 3rd quartile values were assessed for each type 
of uptake calculation, and the results are shown in Table 8.1.  The data were 
then analysed in more detail, and the results are given in the following sections. 
It is apparent from these results that the mean percentage uptake as measured 
from SPECT imaging is higher than that measured from planar imaging or 
calculated from the ICRP model.  The minimum, maximum and standard 
deviation values are also higher for SPECT uptakes.  For each parameter 
considered, the ICRP model gave the lowest value, which was often significantly 
different from all the others. 
Uptake Type Mean % Median % SD % Min % Max % Q1 % Q3 % 
Planar 4.84 3.54 4.40 0.15 18.63 1.40 6.93 
SPECT 6.29 4.46 6.22 0.25 26.68 1.79 8.81 
Frame SPECT 6.39 4.63 5.89 0.20 25.59 1.71 9.45 
AC SPECT 6.45 2.12 9.79 0.97 36.65 1.21 6.90 
ICRP Model 2.71 1.76 2.55 0.08 11.10 0.86 3.49 
Table 8.1 - Basic descriptive statistics for thyroid uptake results calculated with different 
methods 
SD = standard deviation, min = minimum value, max = maximum value, Q1 = first quartile, 
Q3 = third quartile. 
8.3.3.2 Planar versus SPECT Uptake Values 
A spreadsheet program (Microsoft Excel) was used to produce plots to compare 
the various calculated uptake values.  As the uptake of pertechnetate within the 
thyroid gland is known to vary with time (Andros et al, 1965, Atkins & Richards, 
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1968, Shimmins et al, 1968, Hays & Berman, 1977, Hays, 1978, Hilditch & 
Alexander, 1980, ICRP, 1988, Okada et al, 2003), a direct comparison of the 
uptake values calculated from a planar image using the departmental standard 
method and a SPECT data set is not strictly valid.  Also, the values would not be 
expected to be exactly the same due to the fact that there will be some self-
attenuation of gamma rays within the thyroid gland.  This will have the greatest 
effect on the uptake calculated from a planar image as only a single projection 
is acquired.  SPECT reduces the effect by acquiring data from many different 
projections, meaning that the self-attenuation is minimised.  This effect would 
be expected to be most pronounced in a large gland due to the greater amoung 
of attenuating material present.  However, in order to give a rough indication of 
the accuracy of the SPECT method – that is, to ensure the method was giving 
results within the same ballpark – the calculated SPECT value for each patient 
was plotted against the calculated planar value.  The method of least squares 
was then used to find the best fit straight line to the data.  The results are 
shown in Figure 8.10, with the line of identity shown in pink.  All error bars 
denote ±1SD.  The thyroid uptake value calculated from the SPECT data can be 
seen to be generally higher than that calculated from the planar image as most 
of the points on the plot lie above the line of identity.  The data do, however, 
form a good straight line with r2 > 0.9 and gradient >1, which again indicates 
that the SPECT uptake tends to be higher than the planar uptake. 
The difference in the percentage uptake value calculated from the two sets of 
images (planar – SPECT) was also calculated.  The Wilcoxon Signed Ranks test 
was then applied to the difference values.  The test gave a statistically 
significant result with p<0.001, an estimated median of -0.86% and a 95% CI of (-
1.61%, -0.43%).  The negative estimated median and CI support the finding that 
the uptake value calculated from the SPECT images for the same patient tends 
to be higher than that calculated from the planar image. 
In order to determine if there was any relationship between the time difference 
between planar and SPECT image acquisition and the difference in the 
calculated uptake, the data were plotted and the result is shown in Figure 8.11.  
The plot shows no obvious trend towards an increasing or decreasing difference 
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in calculated uptake as the time difference between image acquisitions 
increases. 
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Figure 8.10 - Uptake from SPECT versus uptake from planar images 
Plot showing the uptake calculated from the SPECT data against the uptake from the 
anterior planar image with a straight line fit added.  The line of identity is shown in pink. 
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Figure 8.11 - Difference in calculated uptake (P - S) versus acquisition time difference 
Plot showing the difference between the uptake values calculated from the planar and 
SPECT images against the difference in acquisition start time post injection 
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8.3.3.3 Single SPECT Frame Uptake Values 
By extracting a single acquisition frame from the patient and standard SPECT 
data that was taken in an anterior position (with the gamma camera head at 0o), 
it was possible to calculate a “planar” uptake from the SPECT data.  This 
measurement of thyroid uptake would be made at the same time as the SPECT 
acquisition and so a direct comparison with the value calculated from the SPECT 
data can be made.  The single frame for the patient data set was acquired for a 
period of 30s (prior to May 2007) or 40s (May 2007 onwards) and the standard 
frame was 10s. 
A plot of the frame SPECT uptake against the planar uptake value is shown in 
Figure 8.12.  As with the plot of the SPECT against planar uptake values, the 
points all tend to lie above the line of identity, indicating that the frame SPECT 
uptake values are generally higher than those from the planar images. 
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Figure 8.12 - Uptake from frame SPECT versus uptake from planar images 
Plot showing the uptake calculated from the single anterior SPECT frame against the uptake 
from the anterior planar image with a straight line fit added.  The line of identity is shown in 
pink. 
The Wilcoxon Signed Ranks test applied to the difference between the uptake 
measured from the planar image and that from the frame SPECT image returned 
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a statistically significant result with p<0.001, an estimated median of -1.16% and 
a 95% CI of (-1.70%, -0.76%).  This again emphasises that the uptake calculated 
using counts from the frame SPECT image tends to be a higher value than that 
calculated from the planar image. 
As with the comparison of planar and SPECT uptake values, a plot was made of 
the difference between the calculated uptake from the planar and frame SPECT 
methods against the time difference between the image acquisitions.  The 
resultant plot is shown in Figure 8.13 and allows the affect of the time 
difference on the measured uptake to be assessed.  It can clearly be seen from 
the plot that there is no obvious trend in increasing or decreasing difference in 
the measured percentage uptake value with increasing time, meaning that the 
time of the measurement appears to have little effect on the result. 
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Figure 8.13 - Difference in calculated uptake (P - FS) versus acquisition time difference 
Plot showing the difference between the uptake values calculated from the planar and frame 
SPECT images against the difference in acquisition start time post injection 
When the frame SPECT uptake values were compared to those calculated from 
the full SPECT data, an altogether different result was obtained.  The resultant 
plot is shown in Figure 8.14, from which it can clearly be seen that all the points 
lie much closer to the line of identity with a more even spread above and below 
than is seen in Figure 8.12. 
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Figure 8.14 - Uptake from SPECT images versus uptake from frame SPECT image 
Plot showing the uptake calculated from the full reconstructed SPECT data set against the 
uptake from a single anterior SPECT frame with a straight line fit added.  The line of identity 
is shown in pink. 
The straight line fit determined from the method of least squares is very close to 
the line of identity (y = x).  The non-parametric Wilcoxon Signed ranks statistical 
test applied to the data gave p=0.61 with an estimated median of -0.04% and a 
95% CI of (-0.29%, 0.10%).  This indicates that no significant difference exists 
between the two uptake values calculated from planar and SPECT data acquired 
at the same time post injection.  This is in contrast to the comparison of the 
SPECT and planar uptakes.  The reason for this is not immediately clear, 
although possible causes include the shorter total acquisition time of the 
anterior SPECT frame (30s or 40s) relative to the 60s planar acquisition or an 
unexpected variation in the thyroid uptake over the period between the planar 
and SPECT acquisitions. 
8.3.3.4 Attenuation Corrected SPECT Uptake Values 
A total of 20 patient data sets were re-analysed after an attenuation correction 
was added to the reconstruction algorithm.  A simple Chang attenuation 
correction with a linear attenuation coefficient of µ = 0.120cm-1 was included in 
the iterative reconstruction after the patient outline had been traced to define 
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the attenuation correction volume.  The same process was then carried out on 
the attenuation corrected SPECT (AC SPECT) images as had already been 
performed on the non-AC SPECT data to calculate the thyroid uptake.  The 
resulting values were compared with those from the planar, SPECT and frame 
SPECT images.  It should be noted that the smaller sample of data used in this 
analysis means that the power of the statistical test is reduced when compared 
to its use for the larger sample of non-attenuation corrected image data. 
When compared with the uptake from the planar images, the AC SPECT uptake 
tended to give a higher value, as is demonstrated in the plot in Figure 8.15.  The 
Wilcoxon Signed Ranks Test performed on the difference between the planar and 
AC SPECT values supported this conclusion, giving p<0.001, an estimated median 
of -0.59% and a 95% CI of (-3.63%, -0.25%).  This is similar to the result obtained 
when the planar uptake was compared with that from the non-AC SPECT images. 
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Figure 8.15 - Uptake from AC SPECT images versus uptake from planar image 
Plot showing the uptake calculated from the attenuation corrected SPECT data set against 
the uptake from an anterior planar image with a straight line fit added.  The line of identity is 
shown in pink. 
Indeed, the gradient of the best-fit straight line of AC SPECT vs planar uptake is 
larger than that for SPECT vs planar uptake (1.93 vs 1.34).  This indicates that 
uptake calculated from the AC SPECT data is more different from the planar 
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uptake value than is the uptake calculated from the normal SPECT data.  A 
direct comparison of the AC SPECT and SPECT calculated uptake values was then 
made to assess the impact of the attenuation correction on the final thyroid 
uptake value. 
The plot of AC SPECT uptake vs SPECT uptake is shown in Figure 8.16, from 
which it can be seen that the uptake values are similar at low uptakes (lying 
close to the line of identity).  However, at the highest uptakes, the results 
diverge with the AC SPECT yielding a higher value, which would be expected if 
there was a degree of self-attenuation in the largest thyroids.  The Wilcoxon 
Signed Ranks test gave p=0.83 with an estimated median of 0.04% and a 95% CI 
of (-0.27%, 0.23%), meaning that no statistically significant differences exist 
between the two sets of uptake calculations. 
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Figure 8.16 - Uptake from AC SPECT images versus uptake from SPECT images 
Plot showing the uptake calculated from the attenuation corrected SPECT data set against 
the uptake from the SPECT data reconstructed without attenuation correction with a straight 
line fit added.  The line of identity is shown in pink. 
Finally, the AC SPECT data were compared to the frame SPECT uptake results to 
assess the differences between attenuation corrected SPECT and planar 
calculations carried out on data acquired at the same time post injection.  The 
plot produced from these data is shown in Figure 8.17.  As with the comparison 
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with the SPECT uptake values, all points lie close to the line of identity at low 
uptake values but at higher values, the AC SPECT gives a higher result from the 
calculation of the thyroid uptake. 
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Figure 8.17 - Uptake from AC SPECT images versus uptake from frame SPECT image 
Plot showing the uptake calculated from the attenuation corrected SPECT data set against 
the uptake from a single anterior SPECT frame with a straight line fit added.  The line of 
identity is shown in pink. 
The statistical analysis on the comparison of the AC SPECT and frame SPECT 
uptakes gave p=0.55, with an estimated median of 0.08% and a 95% CI of (-0.19, 
0.46).  No statistically significant difference was therefore found. 
8.3.3.5 ICRP Thyroid Uptake Model 
The ICRP model of thyroid uptake (ICRP, 1988) was used to calculate the 
expected uptake at the time of the SPECT acquisition given the uptake value 
calculated from the planar image at around 20 minutes post injection, using 
Equation 8.5.  The resultant percentage uptake value was compared with those 
calculated from the SPECT, frame SPECT and AC SPECT images.  The error in the 
expected uptake value was taken to be the difference between the value the 
model would give at the time post injection at which the SPECT data was 
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acquired and the value it would give at 20 minutes post injection, assuming the 
initial uptake was 0. 
The plot showing the comparison of the expected and measured SPECT uptake 
values is shown in Figure 8.18.  It can clearly be seen that the calculated value 
from the SPECT images is higher than that predicted by the ICRP model as most 
points lie above the line of identity, and the best-fit straight line has a gradient 
considerably greater than 1.  Indeed, the Wilcoxon Signed Ranks test supports 
this finding with p<0.001, an estimated median of 2.71% and a 95% CI of (1.93%, 
3.82%), indicating that a significant difference exists between the expected and 
calculated uptake values, with the SPECT uptake tending to be higher than the 
value expected from the model. 
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Figure 8.18 - Uptake from SPECT images versus expected SPECT uptake from ICRP model 
Plot showing the uptake calculated from the SPECT data set against the uptake predicted by 
the ICRP model with a straight line fit added.  The line of identity is shown in pink. 
The same analysis was applied to the differences between the calculated frame 
SPECT and AC SPECT uptake values and those predicted by the model.  The plots 
produced are shown in Figure 8.19 and Figure 8.20.  Again, it is clear that the 
thyroid uptake calculated from the image data, both for the frame SPECT and AC 
SPECT images, is higher than that predicted by the ICRP model, as the gradients 
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for both best-fit straight lines are much greater than 1 and most points on both 
plots lie above the line of identity. 
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Figure 8.19 - Uptake from frame SPECT image versus expected uptake from ICRP model 
Plot showing the uptake calculated from a single anterior SPECT frame against the uptake 
predicted by the ICRP model with a straight line fit added.  The line of identity is shown in 
pink. 
These findings are again strongly supported by the results of the statistical test.  
For the comparison of the frame SPECT and expected values, the test returned 
p<0.001, an estimated median of 3.14% and a 95% CI of (2.30%, 4.14%), meaning 
that the differences between the expected and calculated values are 
statistically significant and that the calculated uptake from the frame SPECT 
tends to be higher than the predicted uptake.  Similarly, the results of the 
statistical test for the difference between the AC SPECT and expected values 
showed statistical significance with p<0.001 and an estimated median of 1.77% 
and a 95% CI of (0.88%, 4.69%), both of which indicate that the AC SPECT gives a 
higher thyroid uptake than would be expected from the ICRP model. 
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Figure 8.20 - Uptake from AC SPECT images versus expected uptake from ICRP model 
Plot showing the uptake calculated from the attenuation corrected SPECT data set against 
the uptake predicted by the ICRP model with a straight line fit added.  The line of identity is 
shown in pink. 
8.3.3.6 Summary of Statistical Test Results 
A summary of the results of the Wilcoxon Signed Ranks test for each of the 
comparisons of thyroid uptake is given in Table 8.2.  The gradient of the best-fit 
straight line to the plotted data is also included in the table. 
Difference 
comparison 
p Estimated median 
difference (%) 
95% CI for 
difference (%) 
Gradient of 
best-fit line 
P – S <0.001 0.86 (-1.61, -0.43) 1.35 
P – FS <0.001 -1.16 (-1.70, -0.76) 1.30 
S – FS 0.61 -0.04 (-0.29, 0.10) 1.04 
P – ACS <0.001 -0.59 (-3.63, -0.25) 1.93 
S – ACS 0.83 0.04 (-0.27, 0.23) 1.30 
ACS – FS 0.55 0.08 (-0.19, 0.46) 1.34 
S – E <0.001 2.71 (1.93, 3.82) 2.30 
FS – E <0.001 3.14 (2.30, 4.14) 2.18 
ACS – E <0.001 1.77 (0.88, 4.69) 3.63 
Table 8.2 - Summary of results from Wilcoxon Signed Ranks statistical test applied to 
differences in calculated uptake from each alternative imaging method 
P = planar, S = SPECT, FS = frame SPECT, ACS = AC SPECT, E = expected from ICRP model 
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8.4 Discussion 
The ability to acquire 3-dimensional nuclear medicine SPECT images can be of 
considerable use in identifying lesions not visible on planar projections due to 
the ability to increase contrast by separating activity distributions in overlying 
and underlying structures on planar imaging (Sharp et al., 1998, Wagner et al., 
1999, Bruyant, 2002).  Quantitative or semi-quantitative measurements are 
often performed in nuclear medicine imaging (Sharp et al., 1998), giving a 
numerical value to some physiological function that is being imaged.  Combining 
SPECT and quantitative imaging could potentially result in more accurate 
quantitative measures of radiopharmaceutical uptake by ensuring that photons 
from all parts of the target organ are acquired as part of the image and hence 
are used in the uptake calculation. 
This study aimed to assess the practicality of measuring uptake of 99mTc-
pertechnetate in the thyroid gland using SPECT imaging and any differences that 
exist in the measured uptake from planar and SPECT imaging.  Both standard and 
attenuation-corrected SPECT images were considered, with a linear Chang 
attenuation correction with µ=0.12cm-1 being used.  Comparisons were also 
made of the measured SPECT uptake values against a model of thyroid uptake 
produced by the ICRP (ICRP, 1988) to determine the accuracy of the model. 
Ideally, the planar and SPECT images would be acquired at the same or a very 
similar time-point post-injection of 99mTc-pertechnetate due to the fact that 
pertechnetate uptake in the thyroid is known to vary over time (Andros et al, 
1965, Atkins & Richards, 1968, Shimmins et al, 1968, Hays & Berman, 1977, 
Hays, 1978, Hilditch & Alexander, 1980, ICRP, 1988, Okada et al, 2003).  
Unfortunately, this study had to be carried out within the demands of the 
routine clinical service of the department at GRI and so in most cases it was not 
possible to carry out SPECT imaging immediately after planar imaging.  Indeed, 
the time difference between the two acquisitions was usually greater than 30 
minutes and was over 1 hour in a number of cases, meaning that the time 
between injection and SPECT imaging was sometimes well over 60 minutes.  
Published data from the literature (Andros et al, 1965, Atkins & Richards, 1968, 
Shimmins et al, 1968, Hays & Berman, 1977, Hays, 1978, Hilditch & Alexander, 
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1980, ICRP, 1988, Okada et al, 2003) includes studies of thyroid uptake up to 
and including 60 minutes post-injection but no information could be found on 
uptake behaviour beyond this time.  It is therefore not possible to directly assess 
the impact of changing uptake on the results of this study.  Further work to 
determine the pattern of uptake over a longer time period is required to 
perform a full analysis on the data. 
The method of calculating thyroid uptake from SPECT images that was used in 
this study was very time-consuming and labour-intensive.  The whole analysis 
process from reconstructing the SPECT images and drawing regions of interest 
(ROIs) to analysing the counts within the ROIs in a spreadsheet took a minimum 
of 60 minutes for each individual patient.  This is an unrealistic time-frame for 
use in the clinical setting.  Allied to the fact that the acquisition time for the 
SPECT images was considerably longer than for the planar images used routinely 
for thyroid imaging at GRI, the SPECT method of uptake calculation is unlikely to 
be used on a routine basis.  However, this study has proved that it is possible to 
perform the measurement on patient data. 
The study produced some unexpected results, with the calculated uptake value 
between the planar and single SPECT frame images being significantly different – 
the uptake measured from the frame SPECT image tending to be higher than 
that from the planar.  Since the calculation method for the uptake from these 
types of image is essentially the same, some other effect must be responsible for 
the observed differences in measured uptake.  However, there was no significant 
trend observed in the difference in the calculated uptake value from these two 
sets of images with the time difference between the image acquisitions.  The 
reason for the observed differences is therefore unclear but could be related 
either to the different total acquisition time of the images or to the fact that 
the pertechnetate uptake had varied between the two acquisitions in an 
unknown way.  Further work is needed to clarify the situation. 
The same relationship was seen between the measured planar and SPECT 
uptakes, with the SPECT value tending to be higher.  This may be because the 
calculation method is significantly different or once again because of an 
unknown variation in uptake with time.  The frame SPECT and SPECT uptake 
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values were similar, however, which indicates that the cause is unlikely to be 
the different calculation method. 
The fact that the attenuation corrected SPECT images produced uptake values 
higher than those measured from the standard SPECT images was as expected.  
The application of linear attenuation correction provides an adjustment in the 
measured photon counts to account for the attenuation of photons originating 
from greater depth within the thyroid gland and therefore having to pass 
through a greater thickness of tissue before reaching the gamma camera 
detector.  Sections of the thyroid gland lying at greater depth within the neck 
therefore account for a greater proportion of the overall counts in the final 
attenuation corrected SPECT image than in the standard SPECT image and the 
measured uptake is correspondingly increased. 
The ICRP model of 99mTc-pertechnetate in the thyroid gland (ICRP, 1988) has 
been shown here to be inadequate to describe the change in uptake with time.  
It is a simple model of bi-exponential reduction with time but the measured 
uptake from the SPECT images in this study varied significantly from the 
expected values from the model based on the initial 20 minute planar uptake.  
Although using the planar uptake as a starting point is not entirely accurate, the 
true thyroid uptake at any given time is not known and so the 20 minute uptake 
was taken to be the standard as it was measured for all patients participating in 
the study. 
8.5 Conclusions and Suggestions for Further Work 
This work has demonstrated that it is possible to determine the percentage 
uptake of 99mTc-pertechnetate in the thyroid gland from 3-dimensional SPECT 
images.  However, the technique is both time-consuming and labour-intensive 
and so is unlikely to be implemented on a routine basis.  The standard method of 
calculating uptake from anterior planar images will continue to be used at GRI. 
This study has also shown that the ICRP model of 99mTc-pertechnetate uptake in 
the thyroid gland (ICRP, 1988) is not an accurate model, with significant 
differences existing between measured and expected uptake values from patient 
image data.  The model does not take into account the known increase to a 
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plateau level in the first 15-20 minutes post injection (Atkins & Richards, 1968, 
Esser et al., 1973, Meller & Becker, 2002), although it does include the fast and 
slow compartments modelled by Hays (Hays, 1978).  In order to more accurately 
test the model, a known uptake value would be required, which is not possible 
with patient data.  However, the results of this study suggest that the ICRP 
model should be used with caution. 
The observed differences between the measured uptakes from the various 
images used in this study could not be easily explained with the information 
available from this patient study.  The two main problems are the lack of 
knowledge of the true uptake in the thyroid gland at any given time and the 
unknown change in uptake over time.  The first of these can be studied using a 
phantom into which a known “uptake” activity has been introduced.  The second 
would require further acquisitions of patient data over an extended period of 
time post-injection of 99mTc-pertechnetate to determine the changing uptake. 
The phantom designed and built for this study (see Chapter 2) is an ideal 
instrument for assessing the measured uptake value when a known “uptake” is 
present.  Various acquisitions with the phantom were therefore performed to 
this end and the results are described in Chapter 9.  Unfortunately, acquiring 
data on thyroid uptake over an extended period post-injection of 99mTc-
pertechnetate was beyond the scope of this study but it is recommended that 
such work be carried out to fully assess the results presented here. 
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Chapter 9 – Accuracy of the Thyroid Uptake 
Calculation 
9.1 Introduction 
When measuring the uptake of a radioactive material in the thyroid gland, an 
absolute calculation is performed.  However, there will still be errors and 
uncertainties in the final calculated uptake due to the imaging conditions.  Since 
the sensitivity of the gamma camera is low due to the use of the collimator 
(Sharp et al, 1998), only a small fraction of the photons – around 1 in 10,000, or 
0.01% – emitted from the thyroid will be recorded in the resultant image.  Image 
statistics can therefore be poor, especially in cases of low thyroid uptake.  Since 
the uptake measurement relies on the number of counts within a region of 
interest (ROI) defining the thyroid, low counts leads to large uncertainties in the 
final calculation. 
For a planar image of the thyroid acquired in the anterior projection, only part 
of the gland is visualised directly.  Photons that arise in the posterior portion of 
the thyroid need to pass through more tissue (both the thyroid itself and 
overlying tissue) before reaching the gamma camera crystal than do those that 
originate in the anterior portion of the gland.  They are therefore attenuated 
more and the total number of counts recorded by the camera is reduced.  Since 
the thyroid lies very anterior in the neck and is thin in the anterior-posterior 
dimension at 1-2.5cm (ICRP, 1975), the effect of the attenuation will be small 
but it will still exist.  It may also be more significant for larger thyroids which 
may produce more self-attenuation due to greater thickness of thyroid tissue. 
The 3-dimensional (3D) reconstructions from a single photon emission computed 
tomography (SPECT) acquisition remove the problem of the posterior part of the 
gland not being visualised.  Image frames are collected from all angles around 
the patient and so counts from the posterior and lateral aspects of the thyroid 
are included directly in the acquisition.  However, because the counts still have 
to pass through a certain depth of tissue to reach the gamma camera crystal, the 
problem of attenuation remains.  SPECT images may therefore give better 
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visualisation of all parts of the thyroid gland but may not increase the accuracy 
of the uptake measurement. 
Performing an attenuation correction on the SPECT data should reduce the 
dependency of the number of counts recorded on the depth of the origin of the 
photons within the patient.  Various methods for attenuation correction exist 
(Webb et al., 1983, Sharp et al., 1998), ranging from a simple linear method 
that assumes uniform attenuation throughout the patient volume to the use of a 
CT acquisition to map the actual attenuation at all points in the image. 
In order to directly compare the accuracy of the different methods for 
calculating thyroid uptake, it is necessary to first know the true uptake.  Since it 
is never possible to know the true value for a patient, a phantom must be used 
to provide a simulation of a patient thyroid.  A known activity of a radioactive 
material corresponding to a particular “uptake” can be introduced into the 
phantom.  The phantom can then be imaged using a variety of different 
acquisition parameters and the uptake can be calculated from the resultant 
images.  A direct comparison of the calculated value from each set of image 
data can then be made with the known true uptake.  The relative accuracy of 
the different methods can then be assessed. 
9.2 Materials and Methods 
The new phantom custom designed and built for the work of this thesis (see 
Chapter 2 for further details) was used with its thyroid insert to directly 
compare the calculated thyroid uptake value from a variety of different image 
types.  Planar and SPECT acquisitions were performed with a variety of activities 
added to the phantom along with acquisitions of a standard activity in order to 
calculate the absolute “uptake” within the thyroid phantom. 
For each set of acquisitions, the main body of the phantom was filled with water 
and contained no radioactivity.  The three hollow chambers within the phantom 
– which can be filled with activity if necessary to simulate hot nodules – were 
also filled with water but no radioactivity.  In contrast, the main body of the 
thyroid insert was filled with water to which a known amount of activity had 
been added.  It was this activity which was used to simulate thyroid uptake. 
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A vial containing a known activity (around 100MBq) of 99mTc-pertechnetate in a 
10ml volume was used as the starting point for each measurement.  The exact 
activity in the vial was measured using the department’s Capintec isotope 
calibrator and the time of the measurement was noted.  This was taken to be 
the initial injected activity, as would be the case for a patient study.  A known 
volume (therefore corresponding to a known activity) was then drawn out of the 
vial and added to the main thyroid chamber of the phantom to simulate the 
uptake within the thyroid of a small percentage of the total injected activity.  
The residual activity in the syringe after injecting the pertechnetate into the 
phantom was measured and the time of this measurement was also noted.  The 
phantom therefore contained a known activity of 99mTc at a reference time.  The 
volume, and therefore percentage of the activity in the phantom, was varied for 
each set of acquisitions to simulate different thyroid uptakes within the range of 
0.7% to 20%, which is a typical range of thyroid percentage uptakes seen at 
Glasgow Royal Infirmary (GRI). 
A vial containing a known activity of 99mTc in the range 15MBq – 30MBq in a 10ml 
volume was used as a standard for each set of image acquisitions.  The activity 
in the vial was measured using the isotope calibrator and the activity and time 
of measurement were recorded.  The vial was then placed into the department’s 
standard phantom for thyroid imaging, which consists of a Perspex cylinder of 
diameter 15cm and a 3cm diameter slot for a vial which lies 0.5cm from the 
front face of the phantom, and planar and SPECT images were acquired.  These 
images could then be used to determine the sensitivity of the gamma camera (in 
counts/second/MBq) to allow an absolute measurement of the activity in the 
other phantom to be made. 
Planar images of the phantom and standard were acquired using the normal 
departmental protocol.  Each phantom was placed 12cm from the face of the 
LEHR collimator on the GE Camstar gamma camera in turn and a 60 second (s) 
image was acquired.  The percentage uptake in the thyroid phantom was then 
calculated using the analysis program provided on the HERMES computer system. 
Firstly, a region of interest (ROI) was drawn around the vial on the standard 
image and the counts within the ROI and the known activity in the vial at the 
time of measurement (decay corrected from the measurement made on the 
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isotope calibrator) were used to calculate the gamma camera sensitivity in 
counts/s/MBq. 
This sensitivity was then entered into the program, along with the activity 
initially measured in the vial prior to the phantom activity being drawn out of it 
(simulating the injected activity into the patient) and the residual activity in the 
syringe.  The time since the measurement of the vial activity was also entered to 
allow the program to perform a decay correction for the physical decay of the 
99mTc between the activity measurement and the image acquisition. 
Two ROIs were then drawn by hand on the image of the thyroid phantom.  The 
first outlined the image of the thyroid whilst the second was a background ROI 
drawn below the thyroid.  The program then used the counts in these ROIs to 
perform a background correction and to calculate the percentage “uptake” in 
the thyroid phantom insert at the time of imaging. 
A SPECT acquisition was also carried out for both the thyroid phantom and the 
standard.  The parameters used for the acquisition phantom images were 
identical to those used for patient acquisitions: VXHR collimators on the double-
headed Philips Forte gamma camera with the heads in the 90o orientation, 180o 
anterior circular acquisition, a 10% energy window centred on 140keV, 60x40s 
frames with a 3o rotation between frames, giving a total acquisition time of 20 
minutes and a 30cm square roving zoom applied. 
The standard images were acquired in exactly the same way except that the 
acquisition time for each frame was reduced to 10s, giving a total acquisition 
time of 5 minutes.  This was due to the fact that, on most occasions, the activity 
in the standard was considerably higher than that in the thyroid phantom and so 
an acceptable number of counts could be acquired in each frame in a shorter 
time.  Reducing the standard acquisition time also mimicked the procedure used 
for the patient thyroid uptake study (see Section 8.2.3) and kept the total time 
required for study acquisitions to a minimum so as to reduce the impact on the 
clinical work of the department. 
The SPECT images were then reconstructed using the same algorithm, 
parameters and post-reconstruction filter as those used for the patient thyroid 
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uptake study (Section 8.3.2).  Attenuation corrected images were also produced 
using a uniform linear attenuation coefficient of µ=0.12cm-1 to allow a direct 
comparison of the accuracy of the calculated uptake from SPECT data with and 
without an attenuation correction applied.  The final reconstructed SPECT 
images were in the transverse, coronal and sagittal planes. 
As with the patient SPECT images, ROIs were drawn by hand around the visible 
thyroid on the transverse slices of the reconstructed SPECT images for both the 
attenuation corrected (AC) and non-attenuation corrected data sets for both 
thyroid phantom and standard acquisitions.  A background ROI was also placed 
on each slice.  A file containing the counts in the two ROIs for each slice was 
exported to a spreadsheet program.  The “uptake” within the thyroid phantom 
was then calculated using Equation 8.2, Equation 8.3 & Equation 8.4. 
As was the case with the patient thyroid SPECT data, a “planar” uptake was also 
calculated from the anterior frame of the SPECT acquisition data.  The normal 
planar processing procedure using the HERMES system was followed to produce a 
“frame SPECT” uptake value. 
The calculated planar, frame SPECT, SPECT and AC SPECT uptake values were 
then compared to the known uptake by plotting the values on a graph and 
finding the best fit straight line to the data using the least squares method.  A 
non-parametric Wilcoxon Signed Ranks statistical test was also applied to the 
difference between the known and calculated uptake values to give a p-value, 
estimated median difference and a 95% confidence interval (CI) for the 
difference.  A p-value of <0.05 was taken to be statistically significant. 
An alternative to plotting one measured value against another would be to 
create Bland-Altman plots, whereby the difference between the two measured 
values is plotted against their mean.  This type of plot demonstrates any 
underlying trend in the differences changing as the actual measured value 
changes – for example, increasing differences with increasing measured value.  
However, in this case the straight line plots were chosen to allow a more direct 
comparison with the patient data discussed in Section 8.3. 
Chapter 9  248 
During the period of this study, a SPECT/CT system (Siemens Symbia T) was 
installed in the department at GRI.  A small number of acquisitions were 
performed on this system to allow a non-uniform attenuation correction to be 
carried out using the CT data to create a mu-map of densities.  Theoretically, 
this should give a more accurate attenuation correction than the uniform 
method applied to the data acquired on the dual-headed gamma camera and so 
should give a calculated percentage uptake which is closer to the known value.  
The SPECT acquisition parameters were similar to those used with the dual-
headed gamma camera except that the Symbia is able to perform a non-circular 
acquisition but has no roving zoom facility.  A non-circular acquisition with no 
zoom and all other parameters as listed above was therefore carried out for both 
the thyroid phantom and the standard. 
SPECT images were acquired simultaneously in a second energy window at 
108.5keV – 129.5keV, as shown in Figure 9.1, in order for scatter correction to 
be performed during reconstruction of the images.  This acquisition of data in a 
scatter window is standard practice for SPECT/CT acquisitions at GRI, although it 
is not used with the other gamma camera systems. 
 
Figure 9.1 - Energy spectrum of 99mTc acquisition showing image and scatter correction 
acquisition windows 
Gamma camera energy spectrum of 99mTc acquisition showing 99mTc image acquisition 
energy window A (red) and scatter correction energy window B (blue). 
The mu-map from the CT acquisition was then loaded into the HERMES OSEM 
SPECT reconstruction program along with the SPECT data and the non-linear 
attenuation correction was applied as part of the iterative reconstruction.  All 
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other reconstruction parameters were the same as those for the SPECT and AC 
SPECT reconstructions described above.  The same ROI analysis was carried out 
on the resultant transverse image slices in order to calculate the “uptake” of the 
thyroid phantom. 
A further CT attenuation corrected SPECT data set was also created using the 
Siemens Symbia system’s own software (MI Apps) to perform the SPECT 
reconstruction.  The Siemens FLASH3D iterative reconstruction method was used 
with both attenuation correction from the CT mu-map and scatter correction 
applied.  This method allows only a single type of post-reconstruction filter to be 
applied to the data, which is of the Gaussian form.  Several reconstructions were 
carried out with different filters applied in order to determine which gave 
images most similar in appearance to those from reconstructions on the HERMES 
system.  The parameters for the reconstruction were as follows: 15 subsets, 4 
iterations, Gaussian 5.0 filter.  The reconstructed images were then transferred 
to the HERMES system and the ROI analysis was carried out in the same way as 
for the other SPECT data. 
The results from the SPECT/CT acquisitions were then compared to the uptakes 
calculated from the planar, frame SPECT, SPECT and AC SPECT images as well as 
the known value. 
9.3 Results 
9.3.1 Comparison with Known “Uptake” Value 
Images were acquired of a total of 17 different “uptakes”, ranging from 0.78% to 
19.16%, simulating a range of observed patient uptake values.  A plot of the 
measured percentage uptake versus the known value was then created for the 
planar, frame SPECT, SPECT and AC SPECT uptakes and a straight line fit was 
performed on each set of data using the method of least squares.  The resultant 
graph is shown in Figure 9.2 with the line of identity shown in black.  
Theoretically, all points should lie upon this line of known uptake.  The error in 
the known uptake was taken to be ±5% of the uptake value and the error bars in 
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the measured uptakes represent ±1SD, calculated in the same way as for the 
patient data sets in Section 8.3.3. 
It is immediately clear that all of the points and best fit straight lines lie below 
the line of identity, indicating that all the methods of measuring the percentage 
uptake tend to underestimate the true uptake value.  All the lines lie close 
together with gradients of between 0.70 and 0.78, suggesting that there is little 
true difference between the uptake calculated using each of the different 
methods.  The quoted r2 values from each of the straight line fits are all >0.96, 
suggesting that each data set does correspond to a straight line with gradient <1. 
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Figure 9.2- Measured uptake versus known uptake for phantom acquisitions 
Plot of measured uptake from planar (blue), frame SPECT (pink), non-attenuation corrected 
SPECT (green) and attenuation corrected SPECT (red) against known uptake in the 
phantom.  The line of identity is shown in black and the equations of the best fit straight 
lines are shown in the corresponding colour to the data points. 
The line lying closest to the line of identity is that representing the uptake 
calculated from the attenuation corrected SPECT images.  This would be 
expected as the attenuation correction should provide some correction for the 
reduction in counts from the deeper-lying parts of the thyroid gland and so give 
a more quantitatively accurate result.  In contrast, the non-attenuation 
corrected SPECT images gave calculated uptake values furthest from the known 
value.  This is surprising as it was expected that the uptake from SPECT would 
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be more accurate than that from planar imaging due to the possibility of 
significant self-attenuation occurring on the planar images.  However, in each of 
the 17 analyses, the uptake calculated from the anterior planar view was higher 
than that calculated from the SPECT images. 
A statistical analysis was then carried out on these results using a dedicated 
software package (Minitab v13).  The difference between the known “uptake” 
and that measured from each of the different image data sets was calculated for 
each phantom acquisition and the non-parametric Wilcoxon Signed Ranks test 
was applied.  The test produces a p-value indicating the likelihood of the data 
corresponding to a data set with median value 0, an estimated median and a 95% 
confidence interval (CI).  The package gives the p-value to 3 decimal places and 
so if p<0.001, no exact figure is given.  Statistical significance was taken to be 
when p<0.05.  The results of this statistical analysis are shown in Table 9.1. 
 P Estimated Median 95% CI 
Known – Planar <0.001 2.10% (1.30%, 2.96%) 
Known – Frame SPECT <0.001 2.21% (1.31%, 3.11%) 
Known – SPECT <0.001 2.41% (1.45%, 3.40%) 
Known – AC SPECT <0.001 1.47% (0.78%, 2.47%) 
Table 9.1 - Results of Wilcoxon Signed Ranks statistical test applied to differences between 
known and calculated uptake values 
Results from applying statistical test to the differences between the known and calculated 
uptake values for each of the different types of image. 
The values in Table 9.1 verify the findings of the plot, with p<0.001 in each 
case, indicating that the results of the uptake analysis from each type of image 
data set are statistically significantly different from the known value.  The 
estimated median and 95% CI values are all >0, indicating that the known value 
is higher than that measured.  Also, the estimated median and 95% CI values are 
highest for “known – SPECT” and lowest for the “known – AC SPECT”, which is as 
expected, given that the plotted best fit straight lines for these data sets are 
furthest from and closest to the line of identity respectively. 
9.3.2 Direct Comparison of Calculated Uptake Values 
Since the analysis performed on patient data (see Section 8.3.3) had no known 
uptake to provide a comparison, the measured values were compared directly to 
each other.  A similar comparison was made with the data from the phantom 
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acquisitions in order to determine if the same differences between the uptakes 
calculated from different image data sets existed.  Plots were created to 
compare the calculated uptake values from each method of analysis.  These 
plots are shown in Figure 9.3 to Figure 9.8 with the line of identity shown in 
black on each plot and the equation of the best fit straight line to the data 
obtained by the method of least squares also given.  A Wilcoxon Signed Ranks 
test was also applied to the differences in calculated values from the different 
image data sets, giving a p-value, estimated median and 95% CI.  Once again, a 
result of p<0.05 was taken to be statistically significant. 
The plot shown in Figure 9.3 demonstrates that the measured uptake from the 
frame SPECT and planar images is similar, with the best-fit straight line lying 
close to the line of identity.  The high value of r2 indicates that the data are a 
good fit to a straight line.  This result is as expected, since the same analysis 
program is used to calculate the uptake and both images were acquired from a 
single fill of the phantom, meaning that the true “uptake” was identical in both 
cases.  This result does, however, differ significantly from that demonstrated in 
Chapter 8 when patient image data was considered (see Figure 8.12).  In that 
case, the frame SPECT method gave an uptake result considerably higher than 
the technique using planar imaging. 
The Wilcoxon Signed Ranks test gave a result of p=0.003, estimated median of 
0.07% and a 95% CI of (0.03%, 0.23%).  Although this is a statistically significant 
result, the estimated mean and 95% CI values are «1% and so would not result in 
a clinically significant difference in the final calculated value.  The reasons for 
the difference between these results from phantom data and those from patient 
acquisitions is not immediately clear but may be primarily related to the 
variation in uptake over time in a real thyroid, whereas the “uptake” in the 
phantom remains constant. 
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Figure 9.3 - Plot of uptake from frame SPECT image versus uptake from planar image 
The line of identity is shown in black and the best fit straight line to the data is shown in 
blue with its equation and the r2value from the method of least squares also displayed. 
Similarly, the plot of SPECT uptake versus planar uptake shown in Figure 9.4 
shows the data lying close to the line of identity and demonstrating a good 
straight line fit.  As in Figure 9.3, there is a slight tendency for the planar 
uptake value to be higher, which again is in contrast to the situation found when 
patient image data was considered (see Figure 8.10). 
Applying the Wilcoxon Signed Ranks test to the data returned the following 
results: p<0.001, estimated median of 0.25% and 95% CI of (0.14%, 0.46%).  As for 
the difference between the planar and frame SPECT uptakes discussed above, 
although this is a statistically significant result, the magnitude of the estimated 
median and 95% CI values are «1% and so would not be of significance in the 
clinical situation.  The positive values also confirm the tendency for the planar 
result to be slightly higher than the SPECT uptake, which again is in contrast 
with the results from the patient image data. 
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Figure 9.4 - Plot of uptake from SPECT images versus uptake from planar image 
The line of identity is shown in black and the best fit straight line to the data is shown in 
blue with its equation and the r2value from the method of least squares also displayed. 
Figure 9.5 shows a plot of the calculated uptake from the SPECT images versus 
that from the frame SPECT image.  On this occasion, the best-fit straight line is 
very close to the line of identity with a gradient of 0.97 and an intercept very 
close to 0.  This is similar to the result found from the patient data shown in 
Figure 8.14, although in that instance, the SPECT uptake tended to be slightly 
higher than the frame SPECT, whilst the opposite is true for the phantom data.  
The fact that these two uptake values are similar is to be expected as they are 
from the same raw acquisition data, meaning that there are no differences in 
the gamma camera or acquisition time to be taken into account. 
Surprisingly, the Wilcoxon Signed Ranks test returned a statistically significant 
result for these data with p<0.001, estimated median of 0.17% and 95% CI of 
(0.09%, 0.28%).  The result from the test applied to the patient data was not 
statistically significant with p=0.61.  However, the very low estimated median 
and 95% CI values would once again be of no significance in the clinical setting. 
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Figure 9.5 - Plot of uptake from SPECT images versus uptake from frame SPECT image 
The line of identity is shown in black and the best fit straight line to the data is shown in 
blue with its equation and the r2value from the method of least squares also displayed. 
As with the previous comparisons described above, the plot of uptake calculated 
from attenuation corrected SPECT images versus that from the planar image in 
Figure 9.6 shows the data lying close to the line of identity.  Once again, the 
best-fit straight line has a high r2 value and a gradient close to 1.  When the 
same analysis was carried out on the results from the patient image data (see 
Figure 8.15), there was an obvious tendency for the AC SPECT uptake to be 
considerably higher than that from the planar analysis.  On that occasion, the 
difference was statistically significant with p<0.001.  The results from the 
phantom data were also demonstrated to be statistically significant with 
p=0.047, an estimated median of -0.36% and 95% CI of (-0.77%, -0.02%). 
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Figure 9.6 - Plot of uptake from attenuation corrected SPECT images versus uptake from 
planar image 
The line of identity is shown in black and the best fit straight line to the data is shown in 
blue with its equation and the r2value from the method of least squares also displayed. 
As was the case with the previous plots of the data from measurements of 
phantom “uptake”, the plot of AC SPECT uptake versus frame SPECT uptake in 
Figure 9.7 shows the data being much closer to the line of identity than was the 
case for the corresponding comparison of data from patient images shown in 
Figure 8.17.  The phantom data are again a good fit to a straight line (r2>0.95) 
with a gradient of close to 1.  The patient data demonstrated a tendency for the 
AC SPECT uptake value to be considerably higher than that from the frame 
SPECT image. 
For this comparison of phantom data, the Wilcoxon Signed Ranks test returned 
the following results: p=0.029, estimated median of -0.45% and 95% CI of  
(-0.98%, -0.09%).  The difference in calculated uptake is therefore statistically 
significant but, as before, the magnitude of the differences would not be of 
clinical significance. 
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Figure 9.7 - Plot of uptake from attenuation corrected SPECT images versus uptake from 
frame SPECT image 
The line of identity is shown in black and the best fit straight line to the data is shown in 
blue with its equation and the r2value from the method of least squares also displayed. 
The final comparison of the measured “uptake” of the phantom considered the 
SPECT and AC SPECT data and the resultant plot is shown in Figure 9.8.  Of all 
the straight-line fit analyses carried out in these comparisons, this final result is 
the furthest from the line of identity, with a gradient of 1.11.  This indicates 
that the uptake value calculated from the AC SPECT images tends to be higher 
than that calculated from the non-attenuation corrected SPECT data.  This 
supports the findings of the plot in Figure 9.2, where the results from the SPECT 
images lay furthest from the line of identity, whilst those for the AC SPECT data 
were closest.  It is also an expected result as the attenuation correction should 
account for the reduction in counts at the gamma camera caused by variations in 
the depth of origin of the gamma photons.  A similar result was seen with the 
patient data (see Figure 8.16), although the gradient of the best fit straight line 
was larger at 1.30. 
The Wilcoxon Signed Ranks test applied to the data gave p=0.007, estimated 
median of -0.61% and 95% CI of (-1.26%, -0.20%), meaning that the difference 
was again statistically significant. 
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Figure 9.8 - Plot of uptake from attenuation corrected SPECT images versus uptake from 
SPECT images 
The line of identity is shown in black and the best fit straight line to the data is shown in 
blue with its equation and the r2value from the method of least squares also displayed. 
The above comparisons all demonstrate that the uptake values calculated from 
the various different images acquired of a phantom are much closer than are 
those calculated from patient data.  This is to be expected to an extent, as the 
phantom is an idealised situation and not truly physiological.  However, the main 
reason for the differences is most likely to be the variation in uptake of a real 
thyroid gland over time, which is not the case in a phantom where the “uptake” 
remains fixed so long as radioactive decay of the 99mTc is taken into account. 
9.3.3 CT Attenuation Corrected Uptake Values 
A total of 3 SPECT/CT acquisitions of the thyroid phantom were carried out in 
order to assess the accuracy of the uptake measurement from images that were 
reconstructed using a CT mu-map for attenuation correction.  All of the 
SPECT/CT acquisitions were carried out at the same time as one of the sets of 
planar and SPECT data acquisition discussed in Sections 9.3.1 & 9.3.2 above.  
This was to ensure that a direct comparison could be made with the uptake 
calculated from the planar image, the non-attenuation corrected SPECT images, 
the linear attenuation corrected images and the known “uptake” value. 
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Two different SPECT/CT uptake values were calculated, corresponding to the 
reconstruction of the data using the HERMES system and the reconstruction using 
the Siemens Syngo software.  Both are iterative techniques using the CT mu-map 
as the basis for the attenuation correction of the reconstructed images but the 
Siemens method also includes a correction for scattered photons in the acquired 
images.  The data were analysed on the HERMES system in the same way as has 
been described previously. 
The results of the various uptake calculations on the 3 sets of phantom 
acquisitions are shown in Table 9.2.  It is immediately clear that the uptakes 
calculated from the CT attenuation corrected data sets are considerably higher 
than those measured from the other images.  They are also higher than the 
known values in all cases, with the images including both scatter correction and 
CT attenuation correction being the highest in general. 
Known 
(%) 
Planar 
(%) 
Frame 
SPECT (%) 
SPECT 
(%) 
AC SPECT 
(%) 
SPECT + 
CTAC (%) 
SPECT + SC 
+ CTAC (%) 
2.89 2.36 2.29 2.22 2.55 3.45 5.63 
11.09 9.87 9.68 9.36 8.70 15.89 15.60 
13.28 7.96 7.93 7.60 7.19 19.36 21.43 
Table 9.2 - Results of uptake measurements on 3 phantom acquisitions that included 
SPECT/CT 
Known = actual “uptake” in phantom, Planar = uptake measured from planar image 
acquisition, Frame SPECT = uptake from anterior frame of SPECT acquisition, SPECT = 
uptake from reconstructed SPECT images not including attenuation correction, AC SPECT = 
uptake from reconstructed SPECT images with linear attenuation correction applied, SPECT 
+ CTAC = uptake from HERMES reconstructed SPECT/CT data including attenuation 
correction from CT mu-map, SPECT + SC + CTAC = uptake from Siemens reconstructed 
SPECT/CT data including scatter correction and attenuation correction from CT mu-map. 
Since attenuation correction carried out using the CT mu-map will give the most 
accurate correction for attenuation of counts prior to reaching the gamma 
camera detector, the fact that the uptake results from these data sets are 
highest of all is to be expected.  However, they are considerably higher than the 
true “uptake” present in the phantom at the time of acquisition, meaning that 
this method may be over compensating for the effects of attenuation in the 
phantom image data sets.  Unfortunately, the results data set was too small to 
successfully apply the Wilcoxon Signed Ranks test and so further acquisitions and 
analyses will be required to fully investigate the effect of CT attenuation 
correction on the uptake measurement. 
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9.4 Discussion 
Since it is never possible to know an exact value for the “true” uptake of 
radiopharmaceutical in an organ, phantom studies must be used in order to 
assess the accuracy of different uptake measurement techniques.  In this case, a 
total of 6 different image data sets involving both planar and SPECT images were 
used to perform an uptake calculation and the results were compared.  The 
phantom used was constructed of tissue-like Perspex and filled with water in 
order to simulate the attenuation properties of the neck. 
The main bulk of the analysis involved 17 data acquisitions and the use of 4 of 
these techniques: anterior planar image, anterior frame of a SPECT acquisition, 
reconstructed SPECT images with no attenuation correction applied and 
reconstructed SPECT images with the application of a uniform linear attenuation 
correction.  Analysis was also carried out on a further 3 image data sets acquired 
on a SPECT/CT system and reconstructed incorporating the CT mu-map data in 
order to perform a more sophisticated, non-uniform, attenuation correction than 
the linear technique. 
For each of the measurement techniques used in the main set of acquisitions, 
the calculated uptakes lay along a straight line with gradient <1, indicating that 
the measured uptake tends to be lower than the true value for all techniques.  
This would not, however, have a significant clinical effect as the normal range is 
based upon measured uptakes without the true value being known.  As 
expected, the uptake values calculated from the uniform attenuation corrected 
SPECT images were the closest to the known phantom “uptake”.  This is due to 
the fact that there will always be some attenuation of photons between the 
point of origin in the phantom and the surface of the gamma camera detector, 
which the attenuation correction seeks to rectify.  Since the materials in the 
phantom (Perspex and water) have similar attenuation properties at 140keV, 
(Hubbell & Seltzer, 1996), this linear correction will be reasonably accurate. 
Also, when compared directly to one another, the results of the uptake 
calculations from each set of images are similar and, although the differences 
are statistically significant according to the Wilcoxon Signed Ranks test, the 
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magnitudes of the differences are small (<1%) and would not be significant in a 
clinical situation. 
However, when the results of this phantom study are compared to those from 
the patient study described in Chapter 8, it is immediately clear that significant 
differences exist.  The comparisons of the different calculated uptake values in 
the patient data lie much further from the line of identity than do those in the 
phantom study.  In particular, the planar and frame SPECT data from the patient 
study are significantly more different than is the case for the same data sets 
from the phantom study. 
Although the phantom is an idealised situation and so does not fully replicate the 
physiological uptake or imaging conditions of a true thyroid, the extent of the 
differences in results from the patient and phantom studies was not expected.  
The most likely explanation for the differences is the fact that the uptake of 
99mTc-pertechnetate in a real thyroid gland does not stay constant over time 
(Andros et al, 1965, Shimmins et al, 1968, Esser et al, 1973, Atkins & Richards, 
1968, Meller & Becker, 2002) whilst that in the phantom remains constant, so 
long as the effects of radioactive decay are taken into account. 
Although work has been carried out by several groups to assess the changing 
99mTc-pertechnetate uptake in the thyroid up to around 60 minutes post-
injection (Andros et al, 1965, Shimmins et al, 1968, Esser et al, 1973, Atkins & 
Richards, 1968, Meller & Becker, 2002), there is little evidence in the literature 
of the pattern of uptake being studied beyond this time.  As the maximum time 
of SPECT imaging post-injection was 106 minutes, with a mean of 72 minutes, it 
is not known how the uptake will have varied in the glands of the patients in the 
study between the planar and SPECT image acquisitions.  Further work is 
therefore required to either assess the changing uptake over a longer period of 
time or to ensure that planar and SPECT imaging are carried out as close 
together as is possible to minimise any uptake change. 
However, since the method used in this study for calculating thyroid percentage 
uptake from SPECT images was both time-consuming and labour-intensive, it is 
unlikely to be used in routine practice.  The suggested further work is therefore 
unnecessary at this time.  However, if automated methods of region of interest 
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(ROI) definition are improved over time, it may be possible to reduce the 
analysis time for SPECT uptakes and therefore make the method more 
practicable.  Should this occur, work on determining the change in thyroid 
uptake of 99mTc-pertechnetate over an extended period of time would be 
worthwhile in order to validate the findings of this study. 
The greater availability in recent years of SPECT/CT systems gives the 
opportunity to carry out non-uniform attenuation correction using a CT mu-map 
image to give a more accurate indication of the attenuation coefficient at each 
point in the acquired image data set.  This should therefore produce images 
which are more physiologically accurate and therefore give a more accurate 
measurement of the uptake in an organ. 
In this case, only a small number of acquisitions were performed using a 
SPECT/CT system as it did not become available until some time after the 
project had started.  These preliminary results indicate that the uptake 
measured from CT attenuation corrected images is higher than that measured 
from planar, non-attenuation corrected SPECT images or SPECT images with a 
linear attenuation applied.  The calculated uptakes are, however, also 
considerably higher than the known values, indicating that the CT attenuation 
correction tends to over-compensate for the effects of attenuation in the 
phantom.  More phantom acquisitions and analysis are required in order to fully 
assess the affect of the CT attenuation correction on the calculated uptake. 
9.5 Conclusions and Suggestions for Further Work 
This phantom study has demonstrated that the measured uptake of 99mTc from 
planar and SPECT imaging tends to be lower than the true, known value.  The 
results from performing uptake analysis on planar images, a single anterior 
frame from the SPECT acquisition, reconstructed SPECT images and 
reconstructed SPECT images with a uniform linear attenuation correction applied 
are similar, with no differences that would be of clinical significance 
demonstrated. 
This is in contrast to a similar analysis performed on patient image data (see 
Chapter 8), where more marked differences between the calculated uptake 
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values were seen.  This is most likely to be due to the time differences between 
planar and SPECT imaging of patients, during which time the uptake of 99mTc-
pertechnetate may have varied significantly in the thyroid. 
The preliminary results of the application of CT attenuation correction to the 
SPECT data from acquisitions on a SPECT/CT system indicate that there tends to 
be an over-compensation for the effects of attenuation and the resultant uptake 
calculated from the images is higher than the known value. 
In order to further assess the differences between the results from the patient 
and phantom studies, either further acquisition of patient data with a minimal 
time difference between planar and SPECT acquisitions is required, or it is 
necessary to carry out a study to assess the change in 99mTc-pertechnetate in the 
thyroid gland over an extended period of time.  However, since the method of 
calculating the uptake from SPECT images used in this study is time-consuming 
and labour-intensive, it is not expected that this work will be carried out unless 
a more rapid method of analysis involving automatic region of interest definition 
is found. 
Further phantom acquisitions to consider the role of CT attenuation correction in 
uptake measurements would be interesting, however, and the preliminary 
results from this study suggest that this would be worthwhile. 
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Chapter 10 – Summary of Findings 
This thesis describes the findings of two independent pieces of work carried out 
in the Department of Nuclear Medicine at Glasgow Royal Infirmary (GRI) – the 
first being a study into the use of dual-isotope subtraction SPECT in the imaging 
of the parathyroid glands and the second being a study into the use of SPECT 
imaging to calculate the uptake of the thyroid gland.  The former intended to 
determine the clinical utility of dual-isotope subtraction SPECT for localising 
parathyroid adenomas prior to surgery and is described in Chapters 3 - 7 of this 
thesis.  The latter made a comparison of the calculated uptake from planar and 
SPECT imaging to assess any differences and to determine if the SPECT 
technique could be used in routine clinical practice and is described in Chapters 
8 & 9 of this thesis. 
A custom designed and built thyroid/parathyroid phantom (see Chapter 2 of this 
thesis for further details) was used initially to determine if SPECT imaging of the 
thyroid and parathyroid glands was feasible and to establish suitable image 
acquisition parameters for each of the studies.  The phantom demonstrated that 
the SPECT imaging was feasible and that a 180o anterior acquisition with 60 x 30s 
frames using a parallel hole low energy high resolution collimator would give 
acceptable images for both thyroid and parathyroid imaging. 
An observer study with the findings compared to surgical reports was used to 
assess dual-isotope subtraction SPECT imaging for localisation of parathyroid 
adenomas.  A total of 5 observers took part in the study, 3 being the 
department’s consultant clinicians and 2 being experienced nuclear medicine 
clinical scientists.  The results of the study demonstrated a clear increase in 
sensitivity for detection of true parathyroid lesions (surgery being the gold 
standard) when dual-isotope subtraction SPECT images were included for review. 
These findings have led to a change in clinical practice at GRI, with all patients 
referred for parathyroid imaging now undergoing dual-isotope subtraction SPECT 
on a routine basis.  Indeed, the SPECT image acquisition has replaced the first 
set of planar images which formed part of the previous routine imaging 
procedure (see Section 3.1.2 of this thesis for a description of the previous 
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procedure).  The acquisition parameters have been modified slightly to improve 
the quality of the 99mTc-Sestamibi SPECT images by increasing the injected 
activity for each patient to the ARSAC limit of 900MBq and by increasing the 
acquisition time for each SPECT frame from 30s to 40s.  These changes result in 
a higher total count acquisition for each SPECT frame and therefore 
reconstructed SPECT images with lower noise.  The observers who took part in 
this study have commented on the improved image quality that resulted from 
these changes. 
The recent availability of SPECT/CT in the department has led to further studies 
to assess the clinical utility of including a registered CT acquisition alongside the 
dual-isotope subtraction SPECT as standard for parathyroid imaging.  This work 
was not far enough advanced to form part of this thesis, but a full assessment of 
the relative utility of SPECT/CT will be made in the future. 
In contrast to the parathyroid work, the study into the use of SPECT imaging for 
calculating thyroid uptake has not led to any change in clinical practice at GRI.  
The findings were inconclusive, with differences being demonstrated between 
the calculated uptake values from planar and SPECT patient images that could 
not be easily explained.  Further work carried out using the thyroid phantom 
designed for this study demonstrated no significant difference between the 
calculated planar and SPECT uptakes.  This suggests that there is some 
physiological reason for the differences seen in the patient data that has not 
been taken into account.  The most likely explanation is a change in the amount 
of 99mTc-pertechnetate present in the thyroid gland between the time that 
planar and SPECT imaging was carried out.  However, no information on the 
uptake pattern of pertechnetate beyond 60 minutes is available in the literature 
and so no further explanation of the results is possible at present. 
Although further work could be carried out to assess the physiological 
differences in uptake over time, the method used in this study for calculating 
thyroid uptake from SPECT images was too cumbersome and time-consuming to 
be used routinely.  Therefore no change to clinical practice at GRI as a result of 
this study is expected and thyroid uptake will continue to be calculated from 
planar images. 
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This study has therefore resulted in a change of clinical practice for parathyroid 
imaging at GRI, with the introduction of dual-isotope subtraction SPECT 
routinely.  Thyroid imaging remains unchanged, however, with the thyroid 
uptake being calculated from planar images. 
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Appendix B – Patient Information Sheet & Consent 
Form 
 
Glasgow Royal Infirmary 
Nuclear Medicine Department 
 
 
Invitation to participate in a research study: 
 
The use of three-dimensional nuclear medicine images for thyroid and 
parathyroid disorders. 
 
 
You are being invited to take part in a research study.  Before you decide whether 
or not you wish to take part, it is important for you to understand why the research 
is being done and what it will involve.  Please take time to read the following 
information carefully and discuss it with others if you wish.  Ask us if there is 
anything that is not clear or if you would like more information.  Take time to 
decide whether or not you wish to take part. 
 
Thank you for taking the time to read this information sheet. 
 
 
What is the purpose of the study? 
 
This study has been designed to test a new method of taking nuclear medicine 
images for patients with possible thyroid and parathyroid disorders.  The study will 
involve an extra scan being taken when you come for your nuclear medicine 
appointment.  This extra scan will take up to 30 minutes to complete.  The 
information from this extra scan will allow a 3-dimensional (3D) picture of your 
thyroid/parathyroids to be created alongside the usual 2-dimensional (2D) images 
we collect.  This 3D picture might give the doctors clearer information about your 
thyroid/parathyroids.  This study has been set up to see how useful this extra 
information would be and if we should be collecting the 3D pictures for all patients 
coming to the department for thyroid and parathyroid scans. 
 
 
Why have I been chosen? 
 
You have been chosen to be a participant in this study because your doctor has 
asked that you have a scan of your thyroid gland or your parathyroid glands here 
at the Nuclear Medicine Department, Glasgow Royal Infirmary (GRI).  All patients 
referred to this department for these scans are being invited to take part in the 
study and will receive this information leaflet. 
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Do I have to take part? 
 
It is up to you to decide whether or not to take part.  If you decide that you are 
happy to take part, you may be asked to sign a consent form.  Not all patients 
receiving this leaflet will be asked to take part when they arrive in the department 
due to time constraints on our equipment.  Unless you have signed the consent 
form, the extra scan will not be carried out.  If you decide to take part you are still 
free to withdraw at any time and without giving a reason.  A decision to withdraw at 
any time, or a decision not to take part, will not affect the standard of care you 
receive.  If you do take part in the study, you will be given a copy of this 
information leaflet and a copy of the signed consent form to keep. 
 
 
What will happen to me if I take part? 
 
If you take part in the study you will have one extra scan taken when you come for 
your appointment.  This will mean you have to lie still on your back on the 
scanning couch for a maximum of 30 minutes.  After you have had all your scans, 
there is nothing else you need to do for this study.  The investigators will then use 
the information from the extra scan to carry out the rest of the work for the study. 
 
 
What do I have to do? 
 
All you will need to do to take part in this study is to sign the consent form when 
you arrive at the department and then lie on the scanner bed for up to 30 minutes 
while an extra scan of your thyroid gland or parathyroid glands is taken.  You will 
not be given any extra injections above those you will already be getting for your 
routine test.  There will be no changes for you to make to any medication you are 
taking or your diet other than those that are recommended by your doctor for your 
routine treatment. 
 
 
What are the side effects of taking part? 
 
There will be no side effects to you from taking part in this study.  The study only 
involves one extra scan being taken and you will not be given any other injections 
or medications as part of the study.  You will not be asked to stop taking any 
medication or make any other changes to your lifestyle for the purposes of this 
study. 
 
 
What are the possible disadvantages and risks of taking part? 
 
There are no real disadvantages or risks to you from taking part in the study.  You 
will not be required to have any other injections or take any other medication.  You 
will receive a small radiation dose from the standard test that your doctor has 
referred you here for, but this study will not result in an increased radiation dose.  
The only requirement is for you to lie still on your back on a scanning couch for up 
to 30 minutes while the extra scan data is acquired. 
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What are the possible benefits of taking part? 
 
The information from the extra scan will be available to the Nuclear Medicine 
consultant doctors, who will look at the results as well as those from the standard 
scans you will have.  We are not certain at this stage if the information we obtain 
from the extra study scan will be beneficial for your treatment or not. 
 
 
What if something goes wrong? 
 
There will be very little excess risk to you from taking part in this study as you will 
not be receiving any extra radiation dose or medication, nor will any of your 
medication be withheld for the purposes of this study. 
 
If you are unhappy with the level of service provided to you by the Nuclear 
Medicine Department, you make speak to any member of staff who will try to 
resolve the matter.  If, however, you have any complaints about your treatment 
that you feel cannot be resolved by the staff within the department, there is a 
hospital complaints procedure that you can follow.  If you wish to make a formal 
complaint, please contact the Patient Liaison Officer at Glasgow Royal Infirmary: 
 
  Anne Snape 
  Patient Liaison Department 
  Glasgow Royal Infirmary 
  84 Castle Street 
  Glasgow 
  G4 0SF 
  Tel: 0141 211 5112 
  E-mail: Anne.Snape@NorthGlasgow.Scot.NHS.UK 
 
 
Will my part in this study be kept confidential? 
 
All information which is collected about you during the course of the research will 
be kept strictly confidential.  Any information about you which leaves the hospital 
will have your name, address and any other personal details removed so that you 
cannot be recognised from it. 
 
 
What will happen to the results of the research study? 
 
The results from this study will be published in peer-reviewed journals.  All 
personal information about you will be removed before the results are published so 
that no-one can identify you from the publications. 
 
 
Who is organising and funding the research? 
 
The research is being organised by the staff in the Department of Nuclear 
Medicine, Glasgow Royal Infirmary.  At present, no external funding has been 
secured for the study. 
 
 
Appendix B  273 
Who has reviewed the study? 
 
The study has been reviewed by the Local Research Ethics Committee at 
Glasgow Royal Infirmary. 
 
 
Contact for Further Information 
 
If you have any questions about taking part in this study, please do not hesitate to 
contact us by post, telephone or e-mail using the details below: 
 
 Mrs. Jen Dennis 
 Department of Nuclear Medicine 
 Queen Elizabeth Building 
 Glasgow Royal Infirmary 
 16 Alexandra Parade 
 Glasgow 
 G31 2ER 
 
Tel: 0141 211 4762 (Nuclear Medicine Reception) 
 
E-mail: jen.dennis@northglasgow.scot.nhs.uk 
 
 
Thank you very much for taking the time to read this leaflet. 
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Glasgow Royal Infirmary 
Nuclear Medicine Department 
 
 
Study Number: 
Patient Identification Number for this trial: 
 
CONSENT FORM 
 
Title of Project:  The use of three-dimensional nuclear medicine images for 
thyroid and parathyroid disorders. 
 
 
Name of Researcher:  Mrs Jennifer L Dennis 
 
 
 
         Please initial box 
 
1. I confirm that I have read and understand the information sheet dated  
      June 2005 (version 1) for the above study and have had the opportunity 
       to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to    
 withdraw at any time, without giving any reason, without my medical  
 care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked    
 at by healthcare professionals where it is relevant to my taking part in  
       this research.  I give permission for these individuals to have access 
       to my records. 
 
4.    I agree to take part in the above study.       
 
 
 
           
Name of Patient    Date   Signature 
 
    
Name of Person taking consent Date   Signature 
(if different from researcher) 
 
   
Researcher     Date   Signature 
 
 
1 for patient; 1 for researcher; 1 to be kept with hospital notes 
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